TITLE	O
:	O
Characterization	O
of	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
by	O
analysis	O
of	O
haemagglutination	O
-	O
deficient	O
mutants	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
agglutinates	O
erythrocytes	O
of	O
several	O
species	O
by	O
virtue	O
of	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
of	O
the	O
surface	O
protein	O
S	O
.	O
We	O
have	O
isolated	O
and	O
characterized	O
five	O
haemagglutination	O
-	O
defective	O
(	O
HAD	O
)	O
mutants	O
.	O

If	O
the	O
binding	B-FUNC
of	O
sialylated	O
macromolecules	O
was	O
prevented	O
by	O
neuraminidase	O
treatment	O
,	O
the	O
parental	O
virus	O
was	O
as	O
sensitive	O
to	O
octylglucoside	O
as	O
were	O
the	O
HAD	O
mutants	O
.	O

We	O
discuss	O
the	O
possibility	O
that	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
helps	O
TGEV	O
to	O
resist	O
detergent	O
-	O
like	O
substances	O
encountered	O
during	O
the	O
gastrointestinal	O
passage	O
and	O
thus	O
facilitates	O
the	O
infection	O
of	O
the	O
intestinal	O
epithelium	O
.	O

Even	O
when	O
feline	O
macrophages	O
were	O
pretreated	O
with	O
MAb	O
FK50	O
-	O
4	O
prior	O
to	O
FIPV	O
inoculation	O
,	O
this	O
antibody	B-FUNC
prevented	O
FIPV	O
infection	O
.	O

TITLE	O
:	O
Contributions	O
of	O
Fas	O
-	O
Fas	O
ligand	B-FUNC
interactions	O
to	O
the	O
pathogenesis	O
of	O
mouse	O
hepatitis	O
virus	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Treatment	O
with	O
the	O
anti	O
-	O
CD18	O
monoclonal	O
antibody	B-FUNC
reduced	O
mortality	O
by	O
approximately	O
40	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Detection	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
by	O
immunohistochemistry	O
with	O
recombinant	O
antibody	B-FUNC
produced	O
in	O
phages	O
.	O

An	O
immunohistochemical	O
method	O
using	O
a	O
new	O
recombinant	O
antibody	B-FUNC
produced	O
by	O
a	O
phage	O
antibody	B-FUNC
system	O
(	O
PAS16	O
)	O
kit	B-FUNC
was	O
investigated	O
and	O
compared	O
with	O
that	O
using	O
a	O
monoclonal	O
antibody	B-FUNC
for	O
PEDV	O
detection	O
in	O
PEDV	O
-	O
infected	O
piglets	O
.	O

The	O
positive	O
signals	O
with	O
the	O
recombinant	O
PAS16	O
antibody	B-FUNC
were	O
similar	O
to	O
those	O
with	O
the	O
monoclonal	O
antibody	B-FUNC
.	O

RESULTS	O
:	O
A	O
significant	O
increase	O
in	O
hepatic	O
enzymes	O
and	O
MPO	B-FUNC
activity	O
was	O
induced	O
by	O
AP	O
and	O
mirrored	O
by	O
intraperitoneal	O
elastase	O
.	O

Studies	O
which	O
used	O
HVS	B-FUNC
have	O
shown	O
some	O
benefits	O
in	O
short	O
term	O
measures	O
of	O
CLD	O
without	O
an	O
in	O

Thus	O
,	O
the	O
direct	O
use	O
of	O
phage	O
-	O
displayed	O
peptides	O
to	O
evaluate	O
protective	O
antiviral	O
immune	O
responses	O
complements	O
their	O
use	O
to	O
characterize	O
antibody	B-FUNC
-	O
binding	B-FUNC
epitopes	O
.	O

ACS	B-FUNC
is	O
a	O
potentially	O
lethal	O
complication	O
of	O
severe	O
trauma	O
and	O
shock	O
in	O
children	O
.	O

ABSTRACT	O
:	O
Direct	O
automated	O
cycle	O
sequencing	O
(	O
DACS	B-FUNC
)	O
of	O
a	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
product	O
of	O
the	O
S	O
-	O
1	O
subunit	O
of	O
the	O
spike	O
peplomer	O
gene	O
was	O
used	O
to	O
identify	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
serotypes	O
.	O

Virus	O
-	O
receptor	B-FUNC
binding	I-FUNC
tests	O
failed	O
to	O
demonstrate	O
a	O
difference	O
between	O
the	O
abilities	O
of	O
wt	O
and	O
srr18	O
to	O
bind	B-FUNC
MHVR2	O
.	O

A	O
component	O
of	O
pancreatic	O
ascites	O
other	O
than	O
endotoxin	O
,	O
bacteria	O
,	O
or	O
cytokines	O
(	O
IL	O
-	O
1beta	O
,	O
TNF	O
,	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
,	O
or	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
is	O
capable	O
of	O
inducing	O
ARDS	O
in	O
healthy	O
animals	O
.	O

Inhibition	O
of	O
p38	B-FUNC
mitogen	O
activated	O
kinase	O
decreases	O
the	O
pulmonary	O
injury	O
through	O
attenuated	O
production	O
of	O
TNF	O
-	O
alpha	O
and	O
NO	O
suggesting	O
a	O
primary	O
role	O
for	O
these	O
mediators	O
in	O
pancreatitis	O
-	O
induced	O
ARDS	O
.	O

Pre	O
-	O
existing	O
antibody	B-FUNC
titres	O
(	O
as	O
a	O
result	O
of	O
natural	O
infection	O
)	O
in	O
the	O
serum	O
of	O
these	O
animals	O
were	O
found	O
to	O
be	O
significantly	O
increased	O
as	O
a	O
result	O
of	O
a	O
single	O
shot	O
vaccination	O
carried	O
out	O
between	O
2	O
and	O
12	O
weeks	O
before	O
calving	O
.	O

This	O
was	O
reflected	O
in	O
a	O
similar	O
increase	O
in	O
the	O
titre	O
and	O
duration	O
of	O
specific	O
antibody	B-FUNC
in	O
milk	O
and	O
colostrum	O
that	O
was	O
passed	O
on	O
to	O
the	O
calves	O
.	O

The	O
assay	O
is	O
used	O
to	O
monitor	O
the	O
response	O
to	O
vaccination	O
,	O
but	O
field	O
challenge	O
can	O
only	O
be	O
detected	O
if	O
flock	O
antibody	B-FUNC
status	O
is	O
monitored	O
continually	O
.	O

In	O
contrast	O
,	O
the	O
18	O
clinically	O
normal	O
and	O
RBCV	O
isolation	O
-	O
negative	O
cattle	O
had	O
high	O
hemagglutinin	O
inhibition	O
antibody	B-FUNC
titers	O
to	O
RBCV	O
from	O
the	O
beginning	O
,	O
while	O
their	O
antibody	B-FUNC
responses	O
to	O
P	O
.	O
haemolytica	O
antigens	O
were	O
delayed	O
.	O

At	O
time	O
of	O
arrival	O
,	O
508	O
of	O
814	O
(	O
62	O
.	O
4	O
%)	O
cattle	O
had	O
low	O
(<	O
50	O
)	O
or	O
undetectable	O
BCV	O
antibody	B-FUNC
titers	O
.	O

Serum	O
samples	O
were	O
obtained	O
at	O
arrival	O
and	O
again	O
28	O
days	O
after	O
arrival	O
and	O
tested	O
for	O
antibodies	O
to	O
BCV	O
,	O
using	O
an	O
antibody	B-FUNC
-	O
detection	O
ELISA	O
.	O

Sera	B-FUNC
were	O
tested	O
for	O
antibodies	O
to	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
swine	O
influenza	O
virus	O
(	O
SIV	O
),	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
pseudorabies	O
virus	O
,	O
Mycoplasma	O
hyopneumoniae	O
,	O
and	O
Actinobacillus	O
pleuropneumoniae	O
.	O

However	O
,	O
at	O
16	O
and	O
24	O
weeks	O
of	O
age	O
,	O
a	O
higher	O
antibody	B-FUNC
titer	O
was	O
consistently	O
associated	O
with	O
a	O
lower	O
ADG	O
.	O

Of	O
the	O
325	O
sera	B-FUNC
from	O
the	O
field	O
,	O
175	O
were	O
positive	O
for	O
TCV	O
by	O
immunofluorescent	O
antibody	B-FUNC
(	O
IFA	O
)	O
assay	O
.	O

The	O
ELISA	O
values	O
of	O
all	O
45	O
normal	O
turkey	O
sera	B-FUNC
were	O
completely	O
separated	O
from	O
that	O
of	O
IFA	O
-	O
positive	O
sera	B-FUNC
.	O

Reactivity	O
of	O
anti	O
-	O
rotavirus	O
,	O
anti	O
-	O
reovirus	O
,	O
anti	O
-	O
adenovirus	O
,	O
or	O
anti	O
-	O
enterovirus	O
antibodies	O
with	O
the	O
IBV	O
antigens	O
coated	O
in	O
the	O
commercially	O
available	O
ELISA	O
plates	O
coated	O
with	O
IBV	O
antigens	O
could	O
be	O
utilized	O
for	O
detection	O
of	O
antibodies	O
to	O
TCV	O
in	O
antibody	B-FUNC
-	O
capture	O
ELISA	O
.	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
in	O
a	O
polymyositis	O
patient	O
with	O
the	O
anti	O
-	O
Jo	O
-	O
1	O
antibody	B-FUNC
.	O

Both	O
in	O
vivo	O
and	O
in	O
vitro	O
assays	O
were	O
used	O
to	O
study	O
binding	B-FUNC
of	O
BCV	O
and	O
MHV	O
N	O
proteins	O
to	O
viral	O
and	O
nonviral	O
RNAs	O
.	O

Filter	O
binding	B-FUNC
was	O
used	O
to	O
map	O
N	O
-	O
binding	B-FUNC
sites	O
within	O
Drep	O
,	O
a	O
BCV	O
-	O
defective	O
genome	O
that	O
is	O
replicated	O
and	O
packaged	O
in	O
the	O
presence	O
of	O
helper	O
virus	O
.	O

This	O
is	O
the	O
first	O
identification	O
of	O
N	O
-	O
binding	B-FUNC
sequences	O
for	O
BCV	O
.	O

TITLE	O
:	O
Temperature	O
-	O
sensitive	O
acetylesterase	B-FUNC
activity	I-FUNC
of	O
haemagglutinin	O
-	O
esterase	O
specified	O
by	O
respiratory	O
bovine	O
coronaviruses	O
.	O

However	O
,	O
when	O
neuraminidase	O
-	O
treated	O
virions	O
or	O
mutants	O
with	O
a	O
defective	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
were	O
analyzed	O
,	O
the	O
S	O
protein	O
remained	O
in	O
the	O
supernatant	O
rather	O
than	O
in	O
the	O
pellet	O
fraction	O
.	O

Severe	O
or	O
longlasting	O
exacerbations	O
of	O
a	O
chronic	O
obstructive	O
bronchitis	O
,	O
severe	O
and	O
rapidly	O
progressive	O
bronchial	O
asthma	O
or	O
infection	O
associated	O
with	O
bronchiectasis	O
in	O
an	O
underlying	O
antibody	B-FUNC
deficiency	O
syndrome	O
,	O
primary	O
ciliary	O
dyskinesia	O
and	O
mucoviscidosis	O
.	O

In	O
addition	O
,	O
anti	O
-	O
Mig	O
treatment	O
resulted	O
in	O
a	O
significant	O
decrease	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
levels	O
of	O
IFN	O
-	O
gamma	O
and	O
IFN	O
-	O
beta	O
that	O
coincided	O
with	O
increased	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
expression	O
of	O
the	O
anti	O
-	O
inflammatory	O
Th2	O
cytokine	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
within	O
the	O
CNS	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
hepatitis	O
C	O
virus	O
NS3	O
protease	B-FUNC
activity	I-FUNC
by	O
product	O
-	O
based	O
peptides	O
is	O
dependent	O
on	O
helicase	O
domain	O
.	O

Infection	O
was	O
confirmed	O
with	O
a	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
test	O
and	O
by	O
immunohistochemical	O
demonstration	O
of	O
coronavirus	O
antigen	O
in	O
the	O
affected	O
tissues	O
,	O
including	O
the	O
left	O
testicle	O
.	O

In	O
mammals	O
,	O
passive	O
immunity	O
is	O
provided	O
by	O
neutralizing	O
antibodies	O
passed	O
to	O
the	O
offspring	O
via	O
the	O
placenta	O
or	O
the	O
milk	O
as	O
immunoglobulin	B-FUNC
G	O
and	O
secreted	O
immunoglobulin	B-FUNC
A	O
.	O
With	O
the	O
long	O
-	O
term	O
goal	O
of	O
producing	O
virus	O
-	O
resistant	O
livestock	O
,	O
we	O
have	O
generated	O
mice	O
carrying	O
transgenes	O
that	O
encode	O
the	O
light	O
and	O
heavy	O
chains	O
of	O
an	O
antibody	B-FUNC
that	O
is	O
able	O
to	O
neutralize	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
-	O
JHM	O
).	O

The	O
following	O
laboratory	O
parameters	O
were	O
abnormal	O
:	O
sedimentation	O
rate	O
64	O
/	O
70	O
mmHg	O
,	O
CD4	O
+	O
cells	O
462	O
/	O
ml	O
,	O
CD4	O
/	O
CD8	O
ratio	O
0	O
.	O
3	O
,	O
serum	O
CRP	O
16	O
mg	O
/	O
l	O
,	O
antistreptolysin	O
titre	O
542	O
kU	O
/	O
l	O
,	O
complement	O
C3	O
<	O
0	O
.	O
1	O
g	O
/	O
l	O
,	O
GPT	B-FUNC
37	O
U	O
/	O
l	O
,	O
albumin	O
49	O
.	O
5	O
%	O
and	O
gamma	O
-	O
globulin	O
28	O
.	O
5	O
%,	O
in	O
urine	O
,	O
leukocytes	O
25	O
/	O
microliter	O
and	O
protein	O
0	O
.	O
25	O
g	O
/	O
l	O
.	O

A	O
cis	O
-	O
acting	O
element	O
previously	O
identified	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
binds	B-FUNC
to	O
trans	O
-	O
acting	O
host	O
factors	O
from	O
mouse	O
fibroblasts	O
and	O
forms	O
at	O
least	O
three	O
RNA	O
-	O
protein	O
complexes	O
.	O

CONCLUSIONS	O
:	O
It	O
would	O
appear	O
that	O
serum	O
TNF	O
-	O
alpha	O
has	O
little	O
impact	O
on	O
the	O
pathogenesis	O
of	O
ALI	O
after	O
EL	O
,	O
whereas	O
serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
may	O
be	O
more	O
important	O
.	O

Sera	B-FUNC
collected	O
from	O
both	O
diarrhoeal	O
and	O
non	O
-	O
diarrhoeal	O
dogs	O
from	O
various	O
populations	O
throughout	O
Australia	O
were	O
tested	O
for	O
these	O
antibodies	O
to	O
CCV	O
.	O

A	O
total	O
of	O
64	O
patients	O
of	O
Plasmodium	O
falciprum	O
infections	O
were	O
admitted	O
to	O
the	O
District	O
Hospital	O
,	O
Ukhrul	O
,	O
during	O
the	O
period	O
of	O
1st	O
May	O
1996	O
to	O
15th	O
June	O
1999	O
;	O
9	O
.	O
37	O
%	O
patients	O
do	O
not	O
develop	O
complication	O
while	O
the	O
rest	B-FUNC
90	O
.	O
63	O
%	O
developed	O
one	O
or	O
more	O
complications	O
.	O

Moreover	O
L	O
-	O
Arginine	O
,	O
the	O
precursor	O
for	O
the	O
formation	O
of	O
endogenous	O
NO	O
,	O
has	O
been	O
found	O
to	O
be	O
deficient	O
in	O
neonates	O
with	O
PPHN	O
,	O
so	O
we	O
speculated	O
that	O
by	O
inhibiting	O
phosphodiesterase	B-FUNC
and	O
administrating	O
L	O
-	O
Arginine	O
smooth	O
muscle	O
relaxation	O
occurred	O
,	O
and	O
consequent	O
weaning	O
from	O
iNO	O
was	O
achieved	O
.	O

Furthermore	O
,	O
hnRNP	O
A1	O
and	O
PTB	O
,	O
both	O
of	O
which	O
also	O
bind	B-FUNC
to	O
the	O
complementary	O
strands	O
at	O
the	O
5	O
'	O
end	O
of	O
MHV	O
RNA	O
,	O
together	O
mediate	O
the	O
formation	O
of	O
an	O
RNP	O
complex	O
involving	O
the	O
5	O
'-	O
and	O
3	O
'-	O
end	O
fragments	O
of	O
MHV	O
RNA	O
in	O
vitro	O
.	O

TITLE	O
:	O
Maternal	O
antibody	B-FUNC
to	O
infectious	O
bronchitis	O
virus	O
:	O
its	O
role	O
in	O
protection	O
against	O
infection	O
and	O
development	O
of	O
active	O
immunity	O
to	O
vaccine	O
.	O

In	O
addition	O
,	O
Mab	O
+	O
chickens	O
had	O
a	O
weaker	O
virus	O
-	O
neutralizing	O
antibody	B-FUNC
response	O
to	O
a	O
second	O
IBV	O
vaccination	O
compared	O
to	O
Mab	O
-	O
birds	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

All	O
cattle	O
developed	O
high	O
IgM	O
antibody	B-FUNC
responses	O
and	O
long	O
-	O
lasting	O
IgA	O
antibody	B-FUNC
responses	O
both	O
systemically	O
and	O
locally	O
.	O

Prolonged	O
IgM	O
antibody	B-FUNC
responses	O
were	O
detected	O
in	O
serum	O
and	O
milk	O
,	O
while	O
those	O
in	O
nasal	O
secretions	O
were	O
much	O
shorter	O
.	O

ABSTRACT	O
:	O
Eleven	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
isolates	O
foreign	O
to	O
the	O
United	O
States	O
were	O
analyzed	O
by	O
using	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)/	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
and	O
S1	O
glycoprotein	O
gene	O
sequencing	O
.	O

The	O
lungs	O
of	O
the	O
SNO	B-FUNC
group	O
had	O
significantly	O
alleviated	O
edema	O
and	O
neutrophil	O
infiltration	O
compared	O
with	O
the	O
P	O
-	O
Control	O
.	O

The	O
causes	O
of	O
early	O
posttransplant	O
death	O
in	O
our	O
patient	O
group	O
included	O
infections	O
,	O
antibody	B-FUNC
-	O
mediated	O
rejection	O
,	O
hypoxic	O
-	O
ischemic	O
encephalopathy	O
secondary	O
to	O
cardiac	O
arrest	O
,	O
pulmonary	O
venous	O
thrombosis	O
,	O
and	O
ischemic	O
reperfusion	O
injury	O
.	O

In	O
experiment	O
1	O
,	O
four	O
2	O
-	O
day	O
-	O
old	O
piglets	O
fed	O
HCC	O
containing	O
an	O
antibody	B-FUNC
titer	O
of	O
1	O
:	O
512	O
and	O
another	O
four	O
piglets	O
fed	O
unimmune	O
cow	O
colostrum	O
(	O
UCC	O
)	O
were	O
orally	O
inoculated	O
with	O
10LD50	O
of	O
PED	O
virus	O
.	O

These	O
results	O
show	O
that	O
sequence	O
elements	O
downstream	O
of	O
the	O
noncanonical	O
site	O
can	O
dramatically	O
influence	O
the	O
choice	O
of	O
fusion	O
sites	O
for	O
synthesis	O
of	O
mRNA	O
5	O
and	O
are	O
interpreted	O
as	O
being	O
most	O
consistent	O
with	O
a	O
mechanism	O
of	O
similarity	O
-	O
assisted	O
RdRp	B-FUNC
strand	O
switching	O
during	O
minus	O
-	O
strand	O
synthesis	O
.	O

One	O
monoclonal	O
antibody	B-FUNC
,	O
5G1	O
,	O
had	O
a	O
high	O
neutralizing	O
titer	O
,	O
and	O
the	O
other	O
,	O
6C4	O
,	O
was	O
more	O
effective	O
in	O
neutralizing	O
and	O
binding	B-FUNC
to	O
virulent	O
TGEV	O
than	O
to	O
attenuated	O
TGEVs	O
.	O

Neutralizing	O
antibody	B-FUNC
titers	O
to	O
BCV	O
and	O
BVDV	O
were	O
determined	O
for	O
852	O
animals	O
from	O
3	O
Ontario	O
feedlots	O
.	O

Sequence	O
analysis	O
of	O
the	O
samples	O
revealed	O
silent	O
nucleotide	O
substitutions	O
in	O
the	O
binding	B-FUNC
site	O
of	O
the	O
internal	O
primer	O
used	O
for	O
the	O
n	O
-	O
PCR	O
.	O

These	O
studies	O
have	O
indicated	O
that	O
adhesion	O
molecules	O
such	O
as	O
intracellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
),	O
neutrophils	O
,	O
platelet	O
activating	O
factor	O
(	O
PAF	O
),	O
substance	O
P	O
,	O
and	O
chemokines	O
acting	O
via	O
the	O
CCR	B-FUNC
-	O
1	O
chemokine	O
receptor	O
play	O
a	O
pro	O
-	O
inflammatory	O
role	O
while	O
complement	O
factor	O
C5a	O
plays	O
an	O
anti	O
-	O
inflammatory	O
role	O
in	O
pancreatitis	O
and	O
lung	O
injury	O
.	O

Substitution	O
of	O
pAPN	O
amino	O
acids	O
283	O
to	O
290	O
into	O
hAPN	O
for	O
the	O
corresponding	O
amino	O
acids	O
288	O
to	O
295	O
introduced	O
an	O
N	O
-	O
glycosylation	O
sequon	O
at	O
amino	O
acids	O
291	O
to	O
293	O
that	O
blocked	O
HCoV	O
-	O
229E	O
receptor	B-FUNC
activity	I-FUNC
of	O
hAPN	O
.	O

Economic	O
losses	O
associated	O
with	O
IBV	O
infections	O
in	O
the	O
broilers	O
occurred	O
predominantly	O
in	O
flocks	O
hatched	O
with	O
low	O
and	O
erratic	O
maternal	O
antibody	B-FUNC
titers	O
.	O

Vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	O
)	O
is	O
upregulated	O
only	O
in	O
susceptible	O
mice	O
during	O
the	O
secondary	O
(	O
retinal	O
degeneration	O
)	O
phase	O
.	O

The	O
IgM	O
isotype	O
antibody	B-FUNC
response	O
to	O
TCV	O
was	O
1	O
.	O
40	O
and	O
0	O
.	O
91	O
at	O
7	O
and	O
14	O
d	O
PI	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-FUNC
is	O
one	O
of	O
the	O
viral	O
proteinases	O
responsible	O
for	O
processing	O
of	O
the	O
1a	O
and	O
1a	O
/	O
1b	O
polyproteins	O
to	O
multiple	O
mature	O
products	O
.	O

In	O
this	O
group	O
of	O
trials	O
HFOV	O
is	O
associated	O
with	O
a	O
strong	O
trend	O
for	O
an	O
increased	O
rate	O
of	O
gross	O
pulmonary	O
ALS	O
(	O
four	O
trials	O
,	O
summary	O
RR	O
1	O
.	O
54	O
(	O
0	O
.	O
98	O
,	O
2	O
.	O
42	O
)]	O
In	O
the	O
subgroup	O
of	O
two	O
trials	O
(	O
HIFI	O
1989	O
,	O
Rettwitz	O
-	O
Volk	O
1998	O
)	O
not	O
using	O
a	O
HVS	B-FUNC
there	O
is	O
no	O
effect	O
of	O
HFOV	O
on	O
the	O
rate	O
of	O
CLD	O
;	O
however	O
,	O
there	O
is	O
an	O
increase	O
in	O
the	O
rate	O
of	O
periventricular	O
leukomalacia	O
(	O
PVL	O
)	O
[	O
summary	O
RR	O
1	O
.	O
64	O
(	O
1	O
.	O
02	O
,	O
2	O
.	O
64	O
).	O

Destruction	O
of	O
base	B-FUNC
pairing	I-FUNC
between	O
positions	O
96	O
to	O
99	O
and	O
116	O
to	O
113	O
also	O
decreased	O
DI	O
RNA	O
replication	O
.	O

The	O
existence	O
of	O
a	O
population	O
of	O
M	O
molecules	O
adopting	O
a	O
Nexo	O
-	O
Cexo	O
topology	O
in	O
the	O
virion	O
envelope	O
was	O
demonstrated	O
by	O
(	O
i	O
)	O
immunopurification	O
of	O
(	O
35	O
)	O
S	O
-	O
labeled	O
TGEV	O
virions	O
using	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
specific	O
for	O
the	O
M	O
protein	O
carboxy	O
terminus	O
(	O
this	O
immunopurification	O
was	O
inhibited	O
only	O
by	O
deletion	O
mutant	O
M	O
proteins	O
that	O
maintained	O
an	O
intact	O
carboxy	O
terminus	O
),	O
(	O
ii	O
)	O
direct	O
binding	B-FUNC
of	O
M	O
-	O
specific	O
MAbs	O
to	O
the	O
virus	O
surface	O
,	O
and	O
(	O
iii	O
)	O
mass	O
spectrometry	O
analysis	O
of	O
peptides	O
released	O
from	O
trypsin	O
-	O
treated	O
virions	O
.	O

Hypoxia	O
downregulated	O
a	O
range	O
of	O
other	O
proinflammatory	O
mediators	O
,	O
including	O
MCP	B-FUNC
-	O
1	O
and	O
TNF	O
-	O
alpha	O
.	O

A	O
convergent	O
synthetic	O
strategy	O
was	O
employed	O
,	O
whereby	O
the	O
SCK	O
nanoparticles	O
and	O
the	O
PTD	B-FUNC
were	O
prepared	O
independently	O
and	O
then	O
coupled	O
together	O
during	O
immobilization	O
of	O
the	O
PTD	B-FUNC
component	O
on	O
a	O
solid	O
support	O
.	O

Covalent	O
labeling	O
of	O
the	O
SCK	O
precursor	O
with	O
fluorescein	O
-	O
5	O
-	O
thiosemicarbazide	O
provided	O
fluorescently	O
tagged	O
PTD	B-FUNC
-	O
nanocage	O
nanobioconjugates	O
to	O
allow	O
for	O
their	O
detection	O
by	O
fluorescence	O
microscopy	O
.	O

Fluorescence	O
confocal	O
microscopy	O
of	O
isolated	O
bioconjugate	O
-	O
bound	O
CHO	B-FUNC
cells	O
indicated	O
that	O
the	O
bioconjugated	O
nanoparticles	O
were	O
primarily	O
located	O
near	O
the	O
cell	O
periphery	O
;	O
however	O
,	O
transduction	O
of	O
the	O
nanoparticle	O
into	O
the	O
cells	O
also	O
occurred	O
.	O

This	O
study	O
shows	O
that	O
DNA	O
vaccination	O
failed	O
to	O
protect	O
cats	O
against	O
FIP	O
and	O
that	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
may	O
yield	O
adverse	O
effects	O
when	O
used	O
as	O
a	O
cytokine	O
adjuvant	O
.	O

She	O
had	O
a	O
14	O
-	O
year	O
history	O
of	O
primary	O
biliary	O
cirrhosis	O
(	O
PBC	O
)	O
diagnosed	O
histologically	O
,	O
with	O
a	O
positive	O
test	O
for	O
anti	O
-	O
mitochondrial	O
antibodies	O
and	O
elevated	O
biliary	O
enzyme	B-FUNC
activity	I-FUNC
.	O

These	O
results	O
indicate	O
that	O
transmission	O
occurs	O
primarily	O
during	O
the	O
winter	O
months	O
,	O
antibody	B-FUNC
decay	O
is	O
quite	O
rapid	O
,	O
and	O
reexposure	O
during	O
the	O
summer	O
is	O
rare	O
.	O

Serum	O
sES	O
and	O
plasma	O
vWF	O
:	O
Ag	O
concentrations	O
were	O
measured	O
and	O
PaO2	O
/	O
FiO2	O
ratio	O
,	O
Lung	O
Injury	O
Score	O
(	O
LIS	B-FUNC
)	O
and	O
APACHE	O
II	O
ratio	O
were	O
calculated	O
at	O
the	O
admission	O
to	O
IC	O
,	O
after	O
24	O
h	O
and	O
on	O
2	O
,	O
3	O
,	O
5	O
,	O
7	O
,	O
10th	O
day	O
.	O

Together	O
with	O
these	O
observations	O
,	O
direct	O
binding	B-FUNC
of	O
soMHVR	O
to	O
the	O
virus	O
spike	O
(	O
S	O
)	O
glycoprotein	O
as	O
revealed	O
by	O
coimmunoprecipitation	O
demonstrated	O
that	O
the	O
effect	O
is	O
mediated	O
by	O
the	O
binding	B-FUNC
of	O
soMHVR	O
to	O
the	O
S	O
protein	O
.	O

At	O
least	O
three	O
coronavirus	O
strains	O
within	O
group	O
2	O
expressed	O
a	O
structural	O
protein	O
with	O
sialate	O
-	O
4	O
-	O
O	O
-	O
acetylesterase	B-FUNC
activity	I-FUNC
,	O
distinguishing	O
them	O
from	O
other	O
members	O
of	O
group	O
2	O
,	O
which	O
encode	O
an	O
enzyme	O
specific	O
for	O
5	O
-	O
N	O
-	O
acetyl	O
-	O
9	O
-	O
O	O
-	O
acetylneuraminic	O
acid	O
.	O

At	O
12	O
-	O
72	O
hpi	B-FUNC
,	O
however	O
,	O
the	O
VH	O
/	O
CD	O
ratio	O
of	O
all	O
infected	O
pigs	O
was	O
significantly	O
less	O
than	O
that	O
of	O
control	O
pigs	O
.	O

These	O
data	O
lead	O
us	O
to	O
conclude	O
that	O
both	O
the	O
catalytic	O
systems	O
and	O
substrate	O
-	O
binding	B-FUNC
pockets	O
of	O
coronavirus	O
main	O
proteases	O
differ	O
from	O
those	O
of	O
other	O
RNA	O
virus	O
3C	O
and	O
3C	O
-	O
like	O
proteases	O
.	O

ABSTRACT	O
:	O
Using	O
the	O
whole	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
for	O
detecting	O
the	O
antibody	B-FUNC
against	O
IBV	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
is	O
a	O
routine	O
work	O
in	O
poultry	O
industry	O
.	O

Using	O
this	O
approach	O
,	O
we	O
found	O
that	O
the	O
chimeric	O
virus	O
containing	O
the	O
BCV	O
S	O
protein	O
on	O
the	O
virion	O
surface	O
entered	O
and	O
replicated	O
in	O
HRT	O
-	O
18	O
cells	O
;	O
this	O
was	O
specifically	O
blocked	O
by	O
prior	O
treatment	O
of	O
the	O
virus	O
with	O
a	O
neutralizing	O
antibody	B-FUNC
specific	O
to	O
the	O
BCV	O
S	O
protein	O
,	O
indicating	O
that	O
the	O
BCV	O
S	O
protein	O
is	O
responsible	O
for	O
initiating	O
chimeric	O
virus	O
infection	O
.	O

CEACAM	O
binding	B-FUNC
also	O
induced	O
separation	O
of	O
S1	O
and	O
S2	O
.	O

TITLE	O
:	O
Further	O
in	O
vitro	O
characterization	O
of	O
mouse	O
hepatitis	O
virus	O
papain	O
-	O
like	O
proteinase	B-FUNC
1	O
:	O
cleavage	O
sequence	O
requirements	O
within	O
pp1a	O
.	O

Nasopharyngeal	O
secretion	O
obtained	O
at	O
onset	O
of	O
illness	O
was	O
cultured	O
for	O
bacterial	O
pathogens	O
of	O
otitis	O
media	O
using	O
selective	O
agars	O
and	O
tested	O
for	O
rhinovirus	O
,	O
coronavirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	O
A	O
and	O
B	O
,	O
and	O
parainfluenza	O
1	O
-	O
3	O
by	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
technology	O
.	O

Reconstituted	O
fgl2	O
catalyzed	O
the	O
cleavage	O
of	O
human	O
prothrombin	O
to	O
thrombin	O
with	O
kinetics	O
consistent	O
with	O
a	O
first	O
order	O
reaction	O
,	O
with	O
an	O
apparent	O
V	O
(	O
max	O
)	O
value	O
of	O
6	O
mol	O
/	O
min	O
/	O
mol	O
fgl2	O
and	O
an	O
apparent	O
K	O
(	O
m	O
)	O
value	O
for	O
prothrombin	O
of	O
8	O
.	O
3	O
microM	O
.	O
The	O
catalytic	B-FUNC
activity	I-FUNC
was	O
totally	O
dependent	O
on	O
calcium	O
,	O
and	O
factor	O
Va	O
(	O
500	O
nM	O
)	O
enhanced	O
the	O
catalytic	O
efficiency	O
of	O
fgl2	O
by	O
increasing	O
the	O
apparent	O
V	O
(	O
max	O
)	O
value	O
to	O
3670	O
mol	O
/	O
min	O
/	O
mol	O
fgl2	O
and	O
decreasing	O
the	O
apparent	O
K	O
(	O
m	O
)	O
value	O
for	O
prothrombin	O
to	O
7	O
.	O
2	O
microM	O
.	O
By	O
a	O
combination	O
of	O
site	O
-	O
directed	O
mutagenesis	O
and	O
production	O
of	O
truncated	O
proteins	O
,	O
it	O
was	O
clearly	O
shown	O
that	O
residue	O
Ser	O
(	O
89	O
)	O
was	O
critical	O
for	O
the	O
prothrombinase	O
activity	O
of	O
fgl2	O
.	O

In	O
this	O
work	O
we	O
provide	O
direct	O
evidence	O
that	O
fgl2	O
cleaves	O
prothrombin	O
to	O
thrombin	O
consistent	O
with	O
serine	B-FUNC
protease	I-FUNC
activity	I-FUNC
and	O
requires	O
calcium	O
,	O
phospholipids	O
,	O
and	O
factor	O
Va	O
for	O
its	O
full	O
activity	O
.	O

Furthermore	O
,	O
the	O
upstream	O
kinase	O
responsible	O
for	O
eIF4E	O
phosphorylation	O
,	O
MAPK	B-FUNC
-	O
interacting	O
kinase	O
1	O
,	O
was	O
also	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
MHV	O
infection	O
.	O

ABSTRACT	O
:	O
Reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
have	O
proved	O
useful	O
for	O
the	O
detection	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
rat	O
coronavirus	O
(	O
RCV	O
)	O
in	O
acutely	O
infected	O
animals	O
and	O
contaminated	O
biomaterials	O
.	O

Use	O
of	O
the	O
assay	O
detected	O
as	O
little	O
as	O
two	O
femtograms	O
of	O
in	O
vitro	O
transcribed	O
RNA	O
generated	O
from	O
cloned	O
amplicon	O
,	O
and	O
when	O
compared	O
directly	O
with	O
mouse	O
antibody	B-FUNC
production	O
tests	O
,	O
had	O
similar	O
sensitivity	O
at	O
detecting	O
MHV	O
-	O
A59	O
in	O
infected	O
cell	O
culture	O
lysates	O
.	O

In	O
mice	O
lacking	O
antibody	B-FUNC
receptors	O
or	O
complement	O
pathway	O
activity	O
,	O
virus	O
did	O
not	O
persist	O
yet	O
demyelination	O
was	O
similar	O
to	O
parental	O
mice	O
.	O

Predictors	O
of	O
death	O
included	O
total	O
SNAP	B-FUNC
score	O
,	O
individual	O
SNAP	B-FUNC
items	O
(	O
urine	O
output	O
,	O
pH	O
,	O
Oxygenation	O
Index	O
(	O
OI	O
)),	O
5	O
-	O
min	O
Apgar	O
,	O
gestational	O
age	O
>	O
40	O
wk	O
,	O
growth	O
restriction	O
,	O
and	O
ventilation	O
for	O
asphyxia	O
/	O
apnoea	O
.	O

The	O
remaining	O
two	O
isolates	O
,	O
N	O
-	O
M24	O
and	O
N	O
-	O
M39	O
,	O
that	O
did	O
not	O
react	O
with	O
Mass	O
-	O
specific	O
Mab	O
,	O
resisted	O
neutralization	O
by	O
Mass	O
-	O
specific	O
chicken	O
serum	O
,	O
and	O
were	O
neutralized	O
only	O
by	O
homologous	O
chicken	O
antibody	B-FUNC
were	O
identified	O
as	O
non	O
-	O
Mass	O
IBV	O
.	O

Reactivity	O
of	O
antibodies	O
to	O
unrelated	O
virus	O
,	O
rotavirus	O
,	O
reovirus	O
,	O
adenovirus	O
,	O
or	O
enterovirus	O
with	O
different	O
TCV	O
isolates	O
was	O
all	O
negative	O
,	O
except	O
positive	O
response	O
was	O
seen	O
between	O
enterovirus	O
antibody	B-FUNC
and	O
a	O
TCV	O
western	O
North	O
Carolina	O
isolate	O
,	O
suggesting	O
coinfection	O
of	O
turkeys	O
with	O
TCV	O
and	O
enterovirus	O
in	O
that	O
particular	O
case	O
.	O

ABSTRACT	O
:	O
The	O
early	O
cytokines	O
interferon	O
-	O
alpha	O
(	O
IFN	O
-	O
alpha	O
),	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
),	O
interleukin	O
-	O
1	O
,	O
-	O
6	O
and	O
-	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
,	O
-	O
6	O
,	O
-	O
8	O
)	O
are	O
produced	O
during	O
the	O
most	O
early	O
stage	O
of	O
an	O
infection	O
.	O

In	O
challenge	O
studies	O
of	O
SIV	O
-	O
vaccinated	O
pigs	O
,	O
levels	O
of	O
IFN	O
-	O
alpha	O
,	O
TNF	O
-	O
alpha	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
but	O
not	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
were	O
correlated	O
with	O
clinical	O
and	O
virological	O
protection	O
.	O

In	O
comparison	O
with	O
the	O
respective	O
single	O
inoculations	O
,	O
which	O
were	O
subclinical	O
,	O
there	O
was	O
a	O
true	O
potentiation	O
of	O
disease	O
and	O
production	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
.	O

TNF	O
-	O
alpha	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
were	O
best	O
correlated	O
with	O
disease	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
antibody	B-FUNC
response	O
to	O
canine	O
coronavirus	O
infection	O
in	O
dogs	O
by	O
Western	O
Blotting	O
analysis	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
by	O
Western	O
Blotting	O
the	O
antibody	B-FUNC
responses	O
against	O
the	O
three	O
major	O
structural	O
proteins	O
of	O
Canine	O
coronavirus	O
(	O
CCoV	O
)	O
in	O
dogs	O
naturally	O
infected	O
.	O

AMPhi	O
were	O
harvested	O
,	O
and	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
macrophage	O
inflammatory	O
protein	O
(	O
MIP	O
)-	O
2	O
release	O
and	O
serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
TNF	O
-	O
alpha	O
levels	O
were	O
measured	O
at	O
5	O
h	O
after	O
HCLP	O
.	O

Serum	O
TNF	O
-	O
alpha	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
and	O
spontaneous	O
AMPhi	O
TNF	O
-	O
alpha	O
and	O
MIP	O
-	O
2	O
release	O
were	O
elevated	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
after	O
HCLP	O
,	O
concomitantly	O
with	O
the	O
development	O
of	O
lung	O
edema	O
and	O
leukocyte	O
activation	O
.	O

The	O
underlying	O
pathological	O
events	O
were	O
respectively	O
pulmonary	O
tuberculosis	O
and	O
upper	O
respiratory	O
infection	O
in	O
the	O
two	O
monophasic	O
cases	O
;	O
in	O
the	O
22	O
recurrent	O
ONM	O
patients	O
:	O
pulmonary	O
tuberculosis	O
(	O
3	O
),	O
neurocysticercosis	O
(	O
1	O
),	O
polyarteritis	O
nodosa	O
(	O
1	O
),	O
antinuclear	O
antibody	B-FUNC
and	O
rheumatoid	O
factor	O
(	O
1	O
),	O
antiphospholipid	O
antibody	B-FUNC
primary	O
syndrome	O
(	O
1	O
),	O
diabetes	O
mellitus	O
(	O
1	O
),	O
hypothyroidism	O
(	O
1	O
),	O
and	O
amenorrhea	O
-	O
galactorrhea	O
(	O
4	O
).	O

To	O
directly	O
analyze	O
progenitor	O
differentiation	O
,	O
glial	O
cultures	O
from	O
spinal	O
cords	O
of	O
wild	O
-	O
type	O
mice	O
undergoing	O
remyelination	O
after	O
MHV	O
-	O
A59	O
demyelination	O
were	O
treated	O
for	O
3	O
d	O
with	O
either	O
exogenous	O
FGF2	O
or	O
an	O
FGF2	O
neutralizing	O
antibody	B-FUNC
.	O

TITLE	O
:	O
Neutralizing	O
antibody	B-FUNC
decay	O
and	O
lack	O
of	O
contact	O
transmission	O
after	O
inoculation	O
of	O
3	O
-	O
and	O
4	O
-	O
day	O
-	O
old	O
piglets	O
with	O
porcine	O
respiratory	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Ten	O
female	O
neonatal	O
piglets	O
were	O
infected	O
with	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
to	O
measure	O
the	O
decay	O
of	O
a	O
specific	O
neutralizing	O
antibody	B-FUNC
.	O

However	O
,	O
infectious	O
virus	O
reactivates	O
in	O
antibody	B-FUNC
-	O
deficient	O
mice	O
following	O
viral	O
clearance	O
.	O

We	O
have	O
previously	O
characterized	O
a	O
novel	O
transgenic	O
(	O
Tg	O
)	O
mouse	O
on	O
the	O
IL	O
-	O
2Rbeta	O
-/-	O
genetic	O
background	O
(	O
Tg	O
-/-	O
mice	O
)	O
that	O
lacks	O
autoimmune	O
disease	O
but	O
still	O
contains	O
peripheral	O
T	O
cells	O
that	O
are	O
nonresponsive	O
to	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
.	O

TITLE	O
:	O
The	O
3C	O
-	O
like	O
proteinase	B-FUNC
of	O
an	O
invertebrate	O
nidovirus	O
links	O
coronavirus	O
and	O
potyvirus	O
homologs	O
.	O

The	O
putative	O
3CL	O
(	O
pro	O
)	O
domain	O
including	O
flanking	O
regions	O
(	O
pp1a	O
residues	O
2793	O
to	O
3143	O
)	O
was	O
fused	O
to	O
the	O
Escherichia	O
coli	O
maltose	O
-	O
binding	B-FUNC
protein	O
(	O
MBP	O
)	O
and	O
,	O
when	O
expressed	O
in	O
E	O
.	O
coli	O
,	O
was	O
found	O
to	O
possess	O
N	O
-	O
terminal	O
autoprocessing	O
activity	O
that	O
was	O
not	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
3CL	O
(	O
pro	O
)	O
C	O
-	O
terminal	O
domain	O
.	O

STAT3	O
alpha	O
and	O
STAT3	O
beta	O
splice	O
forms	O
are	O
also	O
differentially	O
activated	O
in	O
response	O
to	O
cytokines	O
including	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
.	O

Furthermore	O
,	O
we	O
suggest	O
that	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
plays	O
a	O
key	O
role	O
in	O
the	O
fibrotic	O
process	O
and	O
that	O
elevated	O
levels	O
of	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
are	O
associated	O
with	O
a	O
continuum	O
from	O
least	O
to	O
more	O
severe	O
fibrosis	O
.	O

To	O
identify	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
the	O
viral	O
spike	O
glycoprotein	O
(	O
S	O
),	O
we	O
expressed	O
soluble	O
truncated	O
histidine	O
-	O
tagged	O
S	O
glycoproteins	O
by	O
using	O
baculovirus	O
expression	O
vectors	O
.	O

Residual	O
sera	B-FUNC
samples	O
from	O
200	O
persons	O
(	O
100	O
men	O
and	O
100	O
women	O
)	O
aged	O
50	O
years	O
or	O
older	O
,	O
randomly	O
selected	O
from	O
a	O
larger	O
population	O
-	O
based	O
survey	O
on	O
cardiovascular	O
diseases	O
,	O
were	O
tested	O
for	O
antibodies	O
against	O
HHV8	O
.	O

Of	O
the	O
proinflammatory	O
cytokines	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
was	O
present	O
in	O
PF	O
but	O
not	O
in	O
plasma	O
,	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
and	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
were	O
found	O
in	O
low	O
concentrations	O
in	O
both	O
PF	O
and	O
plasma	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
(	O
p70	O
)	O
was	O
detectable	O
in	O
plasma	O
but	O
not	O
PF	O
.	O

The	O
vector	O
led	O
to	O
the	O
efficient	O
(>	O
40	O
micro	O
g	O
/	O
10	O
(	O
6	O
)	O
cells	O
)	O
and	O
stable	O
(>	O
20	O
passages	O
)	O
expression	O
of	O
a	O
heterologous	O
gene	O
(	O
green	O
fluorescent	O
protein	O
[	O
GFP	O
]),	O
driven	O
by	O
the	O
transcription	O
-	O
regulating	O
sequences	O
(	O
TRS	B-FUNC
)	O
of	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
3a	O
inserted	O
in	O
the	O
site	O
previously	O
occupied	O
by	O
the	O
nonessential	O
ORFs	O
3a	O
and	O
3b	O
.	O

However	O
,	O
pretreatment	O
of	O
hepatocytes	O
with	O
recombinant	O
mouse	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
inhibited	O
MHV	O
replication	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

TITLE	O
:	O
Synergistic	O
antiviral	O
effect	O
of	O
a	O
combination	O
of	O
mouse	O
interferon	O
-	O
alpha	O
and	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
on	O
mouse	O
hepatitis	O
virus	O
.	O

Fecal	O
samples	O
collected	O
on	O
days	O
0	O
,	O
4	O
,	O
14	O
,	O
and	O
35	O
after	O
arrival	O
were	O
tested	O
for	O
BoTV	O
by	O
use	O
of	O
ELISA	O
and	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
.	O

The	O
ELISA	O
based	O
on	O
recombinant	O
M	O
protein	O
represents	O
an	O
alternative	O
and	O
valid	O
test	O
for	O
detection	O
of	O
antibodies	O
to	O
CCoV	O
in	O
dog	O
sera	B-FUNC
.	O

ABSTRACT	O
:	O
Transfusion	O
-	O
related	O
acute	O
lung	O
injury	O
(	O
TRALI	O
)	O
is	O
a	O
severe	O
reaction	O
between	O
leukocyte	O
antigen	O
and	O
antibody	B-FUNC
during	O
transfusion	O
of	O
plasma	O
-	O
containing	O
components	O
.	O

Increased	O
use	O
of	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
in	O
patients	O
receiving	O
chemotherapy	O
has	O
been	O
paralleled	O
by	O
an	O
increased	O
incidence	O
of	O
bleomycin	O
-	O
induced	O
pulmonary	O
toxicity	O
.	O

0	O
.	O
09	O
mL	O
/	O
kPa	O
;	O
control	O
vs	O
.	O
bleomycin	O
,	O
p	O
<.	O
0001	O
;	O
and	O
bleomycin	O
vs	O
.	O
bleomycin	O
+	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
,	O
p	O
=.	O
0003	O
).	O

In	O
the	O
hemorrhagic	O
shock	O
model	O
,	O
plasma	O
concentrations	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
,	O
interleukin	O
-	O
6	O
,	O
and	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
were	O
significantly	O
lower	O
and	O
interleukin	O
-	O
10	O
was	O
significantly	O
higher	O
in	O
the	O
albumin	O
-	O
treated	O
groups	O
compared	O
with	O
the	O
Ringer	O
'	O
s	O
lactate	O
-	O
treated	O
group	O
.	O

TITLE	O
:	O
Detection	O
of	O
sendai	O
virus	O
and	O
pneumonia	O
virus	O
of	O
mice	O
by	O
use	O
of	O
fluorogenic	O
nuclease	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
analysis	O
.	O

On	O
the	O
basis	O
of	O
comparative	O
genomics	O
,	O
the	O
homology	O
search	O
,	O
phylogenetic	O
analyses	O
,	O
and	O
multi	O
-	O
sequence	O
alignment	O
were	O
used	O
to	O
predict	O
CD13	O
related	O
interacting	O
domains	O
and	O
binding	B-FUNC
sites	O
in	O
the	O
S	O
protein	O
of	O
SARS	O
-	O
CoV	O
.	O
Molecular	O
modeling	O
and	O
docking	O
simulation	O
methods	O
were	O
employed	O
to	O
address	O
the	O
interaction	O
feature	O
between	O
CD13	O
and	O
S	O
protein	O
of	O
SARS	O
-	O
CoV	O
in	O
validating	O
the	O
bioinformatics	O
predictions	O
.	O

ABSTRACT	O
:	O
To	O
constructed	O
a	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
model	O
for	O
the	O
3C	O
like	O
(	O
3CL	O
)	O
proteinase	B-FUNC
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
and	O
to	O
design	O
inhibitors	O
of	O
the	O
3CL	O
proteinase	B-FUNC
based	O
on	O
the	O
3D	O
model	O
.	O

Targeting	O
to	O
the	O
3D	O
model	O
and	O
its	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
the	O
main	O
proteinase	B-FUNC
(	O
Mpro	O
)	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
virtual	O
screening	O
was	O
performed	O
employing	O
molecular	O
docking	O
method	O
to	O
identify	O
possible	O
3CL	O
proteinase	B-FUNC
inhibitors	O
from	O
small	O
molecular	O
databases	O
.	O

In	O
13	O
patients	O
with	O
SARS	O
,	O
the	O
antibody	B-FUNC
responses	O
to	O
N	O
antigen	O
were	O
not	O
detectable	O
in	O
the	O
first	O
week	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

ABSTRACT	O
:	O
This	O
report	O
updates	O
reported	O
cases	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
worldwide	O
and	O
in	O
the	O
United	O
States	O
,	O
describes	O
a	O
change	O
in	O
the	O
recommended	O
timing	O
of	O
collection	O
of	O
a	O
convalescent	O
-	O
phase	O
serum	O
specimen	O
to	O
test	O
for	O
antibody	B-FUNC
to	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
and	O
introduces	O
a	O
new	O
case	O
exclusion	O
criterion	O
based	O
on	O
negative	O
SARS	O
-	O
CoV	O
serology	O
.	O

A	O
super	O
shift	O
band	O
was	O
observed	O
when	O
HNF4	O
antibody	B-FUNC
was	O
pre	O
-	O
incubated	O
with	O
the	O
nuclear	O
extracts	O
indicating	O
the	O
interaction	O
between	O
the	O
HNF4	O
element	O
and	O
mfgl2	O
promoter	O
.	O

Outbreaks	O
of	O
multi	O
-	O
drug	O
resistant	O
(	O
MDR	B-FUNC
)	O
tuberculosis	O
and	O
the	O
atypical	O
mycobacteria	O
simulate	O
SARS	O
on	O
clinical	O
,	O
radiologic	O
,	O
epidemiologic	O
,	O
and	O
diagnostic	O
laboratory	O
grounds	O
and	O
it	O
is	O
only	O
logical	O
then	O
to	O
include	O
them	O
in	O
the	O
differential	O
to	O
find	O
a	O
definitive	O
cause	O
and	O
cure	O
for	O
SARS	O
.	O

The	O
levels	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
T	O
-	O
lymphocyte	O
subset	O
counts	O
were	O
measured	O
in	O
35	O
clinically	O
diagnosed	O
SARS	O
patients	O
by	O
using	O
enzyme	O
linked	O
immunosorbant	O
assay	O
(	O
ELISA	O
).	O

A	O
F	O
-	O
PCR	O
diagnosis	O
kit	B-FUNC
for	O
detecting	O
the	O
coronavirus	O
was	O
developed	O
,	O
and	O
115	O
clinical	O
nasopharyngeal	O
gargling	O
liquid	O
samples	O
were	O
tested	O
.	O

The	O
first	O
step	O
in	O
coronavirus	O
infection	O
is	O
binding	B-FUNC
of	O
the	O
viral	O
spike	O
protein	O
to	O
certain	O
receptor	O
on	O
host	O
cells	O
.	O

ABSTRACT	O
:	O
To	O
primarily	O
investigate	O
the	O
changing	O
mode	O
of	O
anti	O
-	O
SARS	O
coronavirus	O
IgG	O
antibody	B-FUNC
in	O
clinically	O
diagnosed	O
SARS	O
patients	O
and	O
the	O
possibility	O
of	O
subclinical	O
infection	O
in	O
physicians	O
and	O
nurses	O
through	O
close	O
association	O
with	O
SARS	O
patients	O
.	O

The	O
plasma	O
levels	O
of	O
anti	O
-	O
SARS	O
coronavirus	O
IgG	O
antibody	B-FUNC
of	O
57	O
normal	O
subjects	O
,	O
127	O
physicians	O
and	O
nurses	O
worked	O
in	O
SARS	O
wards	O
for	O
one	O
month	O
and	O
73	O
SARS	O
patients	O
with	O
different	O
course	O
of	O
SARS	O
were	O
measured	O
by	O
enzyme	O
linked	O
immunosorbent	O
assay	O
.	O

The	O
specificity	O
and	O
sensitivity	O
of	O
ELISA	O
to	O
detect	O
plasma	O
anti	O
-	O
SARS	O
IgG	O
antibody	B-FUNC
were	O
satisfactory	O
.	O

Analysis	O
of	O
the	O
dimeric	O
interface	O
suggests	O
the	O
3CL	O
proteinase	B-FUNC
may	O
have	O
dimer	O
form	O
in	O
solution	O
.	O

Homopolynucleotides	O
significantly	O
stimulated	O
the	O
ATPase	B-FUNC
activity	I-FUNC
(	O
15	O
-	O
25	O
-	O
fold	O
)	O
with	O
the	O
notable	O
exception	O
of	O
poly	O
(	O
G	O
)	O
and	O
poly	O
(	O
dG	O
),	O
which	O
were	O
non	O
-	O
stimulatory	O
.	O

Klenow	O
-	O
FragELTM	O
DNA	O
Fragmentation	O
Detection	O
Kit	B-FUNC
and	O
immunohistochemical	O
alkaline	O
phosphatase	B-FUNC
detection	O
reagent	O
kit	B-FUNC
were	O
used	O
to	O
detect	O
cell	O
apoptosis	O
and	O
expressions	O
of	O
CD68	O
,	O
CD20	O
,	O
CD4	O
,	O
CD8	O
and	O
CD45RA	O
in	O
the	O
pathological	O
tissues	O
of	O
SARS	O
patients	O
.	O

The	O
positive	O
rates	O
of	O
TnI	O
,	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
and	O
MYO	O
in	O
patients	O
were	O
higher	O
than	O
those	O
in	O
controls	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
objectives	O
of	O
the	O
present	O
study	O
are	O
to	O
describe	O
the	O
clinics	O
view	O
of	O
acute	O
infectious	O
gastroenteritis	O
(	O
GE	O
)	O
at	O
the	O
community	O
,	O
in	O
primary	O
and	O
secondary	O
attention	O
health	O
centers	O
,	O
with	O
special	O
references	O
to	O
viral	O
aetiology	O
(	O
VIGE	O
);	O
to	O
correlate	O
with	O
drinkable	O
water	O
and	O
excrete	O
treatment	O
;	O
to	O
develop	O
for	O
the	O
first	O
time	O
a	O
fast	B-FUNC
diagnostic	O
using	O
electron	O
microscopy	O
in	O
Río	O
Cuarto	O
,	O
Córdoba	O
,	O
Argentina	O
,	O
considering	O
the	O
university	O
and	O
community	O
collaboration	O
in	O
the	O
viral	O
diagnostic	O
.	O

Creatine	O
kinase	O
(	O
CK	O
)	O
and	O
(	O
or	O
)	O
creatine	O
kinase	O
MB	O
(	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
)	O
levels	O
elevated	O
in	O
72	O
.	O
7	O
%	O
patients	O
when	O
they	O
hospitalized	O
.	O

In	O
contrast	O
,	O
the	O
degree	O
of	O
(	O
1	O
)	O
pancreatic	O
inflammation	O
and	O
tissue	O
injury	O
(	O
histological	O
score	O
),	O
(	O
2	O
)	O
up	O
-	O
regulation	O
/	O
expression	O
of	O
P	O
-	O
selectin	B-FUNC
,	O
E	O
-	O
selectin	B-FUNC
and	O
ICAM	O
-	O
1	O
,	O
and	O
(	O
3	O
)	O
neutrophil	O
infiltration	O
was	O
markedly	O
reduced	O
in	O
pancreatic	O
and	O
lung	O
tissue	O
obtained	O
from	O
cerulein	O
-	O
treated	O
5	O
-	O
LO	O
-	O
deficient	O
mice	O
.	O

Nevertheless	O
,	O
higher	O
antibody	B-FUNC
titers	O
were	O
necessary	O
to	O
confer	O
resistance	O
in	O
HIII	O
mice	O
than	O
in	O
LIII	O
ones	O
.	O

A	O
direct	O
correlation	O
between	O
the	O
antibody	B-FUNC
level	O
and	O
resistance	O
to	O
infection	O
was	O
always	O
observed	O
in	O
HIII	O
mice	O
.	O

RESULTS	O
:	O
and	O
measurements	O
:	O
EBC	O
NO	O
(	O
2	O
)(-)	O
correlated	O
well	O
with	O
VT	O
(	O
milliliters	O
per	O
kilogram	O
of	O
BW	O
;	O
r	O
=	O
0	O
.	O
79	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
and	O
expiratory	O
minute	O
volume	O
(	O
r	O
=	O
0	O
.	O
60	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
but	O
not	O
with	O
other	O
ventilatory	O
parameters	O
or	O
parameters	O
of	O
pulmonary	O
(	O
EBC	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
EBC	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
or	O
systemic	O
(	O
serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
procalcitonin	O
)	O
inflammation	O
.	O

Through	O
study	O
on	O
the	O
rest	B-FUNC
of	O
the	O
SARS	O
patients	O
,	O
results	O
showed	O
that	O
16	O
.	O
8	O
%	O
of	O
them	O
were	O
transmitted	O
through	O
family	O
close	O
contact	O
and	O
2	O
.	O
3	O
%	O
due	O
to	O
contact	O
to	O
colleagues	O
.	O

SARS	O
-	O
CoV	O
RNA	O
was	O
identified	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
in	O
7	O
of	O
8	O
cases	O
in	O
fresh	O
autopsy	O
tissue	O
and	O
in	O
8	O
of	O
8	O
cases	O
in	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
lung	O
tissue	O
,	O
including	O
the	O
1	O
negative	O
case	O
in	O
fresh	O
tissue	O
.	O

We	O
found	O
strong	O
evidence	O
for	O
a	O
recombination	O
breakpoint	O
within	O
SARS	O
-	O
CoV	O
RDRP	B-FUNC
,	O
based	O
on	O
different	O
,	O
well	O
supported	O
trees	O
for	O
a	O
5	O
'	O
fragment	O
(	O
supporting	O
SARS	O
-	O
CoV	O
as	O
sister	O
to	O
a	O
clade	O
including	O
all	O
other	O
coronaviruses	O
)	O
and	O
a	O
3	O
'	O
fragment	O
(	O
supporting	O
SARS	O
-	O
CoV	O
as	O
sister	O
to	O
group	O
three	O
avian	O
coronaviruses	O
).	O

The	O
sister	O
relationship	O
between	O
avian	O
coronaviruses	O
and	O
the	O
3	O
'	O
RDRP	B-FUNC
fragment	O
of	O
SARS	O
-	O
CoV	O
suggests	O
an	O
additional	O
host	O
-	O
species	O
shift	O
.	O

In	O
addition	O
,	O
the	O
data	O
from	O
the	O
detection	O
of	O
field	O
samples	O
and	O
IBV	O
strains	O
indicated	O
that	O
using	O
the	O
recombinant	O
protein	O
as	O
coating	O
antigen	O
could	O
achieve	O
an	O
equivalent	O
performance	O
to	O
an	O
ELISA	O
kit	B-FUNC
based	O
on	O
infected	O
material	O
extracts	O
as	O
a	O
source	O
of	O
antigen	O
(	O
s	O
).	O

Reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
analysis	O
of	O
nasopharyngeal	O
specimens	O
seems	O
to	O
be	O
of	O
little	O
utility	O
for	O
the	O
diagnosis	O
of	O
SARS	O
during	O
the	O
early	O
symptomatic	O
phase	O
of	O
this	O
illness	O
in	O
young	O
children	O
.	O

TITLE	O
:	O
Confirmed	O
persistent	O
mouse	O
hepatitis	O
virus	O
infection	O
and	O
transmission	O
by	O
mice	O
with	O
a	O
targeted	O
null	O
mutation	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
to	O
sentinel	O
mice	O
,	O
using	O
short	O
-	O
term	O
exposure	O
.	O

We	O
report	O
confirmed	O
persistent	O
transmission	O
of	O
MHV	O
from	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	B-FUNC
)	O
knockout	O
mice	O
,	O
B6	O
.	O
129S1	O
-	O
Tnftm1Lj	O
(	O
TNF	B-FUNC
-/-),	O
to	O
nude	O
and	O
immunocompetent	O
sentinel	O
mice	O
over	O
a	O
period	O
of	O
five	O
months	O
.	O

Infection	O
with	O
MHV	O
was	O
confirmed	O
in	O
nude	O
sentinel	O
mice	O
by	O
use	O
of	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
detection	O
of	O
viral	O
RNA	O
in	O
ascending	O
colon	O
and	O
feces	O
.	O

The	O
mean	O
concentration	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
in	O
SARS	O
patients	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
control	O
group	O
during	O
all	O
clinical	O
courses	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

RESULTS	O
:	O
The	O
mean	O
concentration	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
in	O
SARS	O
patients	O
did	O
not	O
differ	O
from	O
that	O
in	O
the	O
control	O
group	O
in	O
initial	O
and	O
peak	O
stages	O
,	O
but	O
became	O
significantly	O
higher	O
in	O
remission	O
and	O
recovery	O
stage	O
compared	O
with	O
the	O
control	O
group	O
,	O
initial	O
and	O
peak	O
stages	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Molecular	O
modeling	O
and	O
simulation	O
have	O
confirmed	O
8	O
caveolin	O
-	O
binding	B-FUNC
sites	O
.	O

TITLE	O
:	O
[	O
Detection	O
and	O
analysis	O
of	O
SARS	O
coronavirus	O
-	O
specific	O
antibodies	O
in	O
sera	B-FUNC
from	O
non	O
-	O
SARS	O
children	O
].	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
proteinase	B-FUNC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
has	O
been	O
proposed	O
to	O
be	O
a	O
key	O
target	O
for	O
structural	O
-	O
based	O
drug	O
design	O
against	O
SARS	O
.	O

In	O
order	O
to	O
understand	O
the	O
active	O
form	O
and	O
the	O
substrate	O
specificity	O
of	O
the	O
enzyme	O
,	O
we	O
have	O
cloned	O
,	O
expressed	O
,	O
and	O
purified	O
SARS	O
3C	O
-	O
like	O
proteinase	B-FUNC
.	O

Secondary	O
structure	O
studies	O
for	O
the	O
peptide	O
substrates	O
revealed	O
that	O
substrates	O
with	O
more	O
beta	O
-	O
sheetlike	O
structure	O
tend	O
to	O
react	O
fast	B-FUNC
.	O

TITLE	O
:	O
Prediction	O
of	O
proteinase	B-FUNC
cleavage	O
sites	O
in	O
polyproteins	O
of	O
coronaviruses	O
and	O
its	O
applications	O
in	O
analyzing	O
SARS	O
-	O
CoV	O
genomes	O
.	O

A	O
possible	O
cause	O
of	O
false	O
-	O
positive	O
of	O
SARS	O
-	O
CoV	O
-	O
IgG	O
and	O
IgM	O
antibody	B-FUNC
in	O
SLE	O
patients	O
is	O
coated	O
antigens	O
with	O
SARS	O
-	O
CoV	O
and	O
Vero	O
-	O
E6	O
cells	O
in	O
ELISA	O
methods	O
.	O

The	O
average	O
titers	O
of	O
IgG	O
and	O
IgM	O
antibody	B-FUNC
in	O
positive	O
samples	O
were	O
18	O
.	O
23	O
+/-	O

In	O
this	O
report	O
we	O
present	O
results	O
of	O
comparative	O
sequence	O
analysis	O
of	O
the	O
spike	O
(	O
S	O
),	O
envelope	O
(	O
E	O
),	O
membrane	O
(	O
M	O
),	O
and	O
nucleoprotein	O
(	O
N	O
)	O
structural	O
proteins	O
,	O
and	O
the	O
two	O
most	O
conserved	O
replicase	O
domains	O
,	O
putative	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
and	O
RNA	O
helicase	O
(	O
HEL	O
),	O
aimed	O
at	O
a	O
revision	O
of	O
the	O
Coronaviridae	O
taxonomy	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
-	O
mediated	O
protection	O
against	O
cytotoxic	O
T	O
-	O
cell	O
escape	O
in	O
coronavirus	O
-	O
induced	O
demyelination	O
.	O

BALB	O
/	O
b	O
mice	O
had	O
25	O
-	O
fold	O
more	O
MHV	O
-	O
specific	O
antibody	B-FUNC
-	O
secreting	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
,	O
the	O
site	O
of	O
infection	O
,	O
than	O
B6	O
mice	O
,	O
suggesting	O
that	O
local	O
production	O
of	O
anti	O
-	O
MHV	O
antibody	B-FUNC
contributed	O
to	O
this	O
absence	O
of	O
CTL	O
escape	O
.	O

Additionally	O
,	O
administration	O
of	O
anti	O
-	O
MHV	O
neutralizing	O
antibody	B-FUNC
to	O
infected	O
B6	O
mice	O
suppressed	O
the	O
development	O
of	O
CTL	O
escape	O
mutants	O
.	O

48	O
of	O
55	O
(	O
87	O
%)	O
patients	O
had	O
antibodies	O
to	O
SARS	O
CoV	O
in	O
their	O
convalescent	O
sera	B-FUNC
.	O

In	O
this	O
study	O
,	O
we	O
use	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
and	O
docking	O
techniques	O
to	O
screen	O
29	O
approved	O
and	O
experimental	O
drugs	O
against	O
the	O
theoretical	O
model	O
of	O
the	O
SARS	O
CoV	O
proteinase	B-FUNC
as	O
well	O
as	O
the	O
experimental	O
structure	O
of	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
proteinase	B-FUNC
.	O

Our	O
predictions	O
indicate	O
that	O
existing	O
HIV	O
-	O
1	O
protease	O
inhibitors	O
,	O
L	O
-	O
700	O
,	O
417	O
for	O
instance	O
,	O
have	O
high	O
binding	B-FUNC
affinities	O
and	O
may	O
provide	O
good	O
starting	O
points	O
for	O
designing	O
SARS	O
CoV	O
proteinase	B-FUNC
inhibitors	O
.	O

On	O
multivariate	O
Cox	O
regression	O
,	O
age	O
older	O
than	O
60	O
years	O
(	O
relative	O
risk	O
,	O
5	O
.	O
10	O
[	O
CI	O
,	O
2	O
.	O
30	O
to	O
11	O
.	O
31	O
];	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
lactate	O
dehydrogenase	O
level	O
greater	O
than	O
3	O
.	O
8	O
micro	O
kat	B-FUNC
/	O
L	O
at	O
presentation	O
(	O
relative	O
risk	O
,	O
2	O
.	O
20	O
[	O
CI	O
,	O
1	O
.	O
03	O
to	O
4	O
.	O
71	O
];	O
P	O
=	O
0	O
.	O
04	O
)	O
were	O
independent	O
predictors	O
of	O
mortality	O
.	O

ABSTRACT	O
:	O
The	O
specificities	O
and	O
sensitivities	O
of	O
five	O
recombinant	O
proteins	O
of	O
the	O
surface	O
protective	O
antigen	O
(	O
SpaA	O
)	O
of	O
Erysipelothrix	O
rhusiopathiae	O
were	O
examined	O
by	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
the	O
aim	O
of	O
developing	O
a	O
reliable	O
serological	O
test	O
for	O
the	O
detection	O
of	O
protective	O
antibody	B-FUNC
against	O
E	O
.	O
rhusiopathiae	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
antibody	B-FUNC
titers	O
of	O
nonimmunized	O
control	O
pigs	O
remained	O
very	O
low	O
until	O
they	O
were	O
challenged	O
,	O
and	O
all	O
showed	O
severe	O
symptoms	O
or	O
subsequently	O
died	O
.	O

Because	O
the	O
ELISA	O
titer	O
correlated	O
well	O
with	O
the	O
protection	O
results	O
,	O
the	O
specificity	O
and	O
sensitivity	O
of	O
the	O
ELISA	O
were	O
further	O
evaluated	O
with	O
sera	B-FUNC
collected	O
from	O
pigs	O
reared	O
on	O
1	O
farm	O
on	O
which	O
animals	O
had	O
acute	O
septicemia	O
,	O
2	O
farms	O
on	O
which	O
the	O
animals	O
were	O
infected	O
or	O
free	O
from	O
infection	O
,	O
and	O
10	O
farms	O
on	O
which	O
the	O
animals	O
were	O
vaccinated	O
with	O
live	O
vaccine	O
,	O
among	O
others	O
.	O

In	O
addition	O
,	O
bioinformatic	O
analysis	O
has	O
predicted	O
a	O
number	O
of	O
enzymatic	O
activities	O
associated	O
with	O
proteins	O
of	O
the	O
viral	O
replicase	O
-	O
transcriptase	B-FUNC
complex	O
.	O

The	O
antibody	B-FUNC
titer	O
was	O
expressed	O
as	O
the	O
value	O
of	O
absorbency	O
(	O
A	O
)	O
with	O
common	O
logarithm	O
conversion	O
.	O

RESULTS	O
:	O
The	O
mean	O
concentration	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
in	O
SARS	O
patients	O
did	O
not	O
differ	O
from	O
the	O
control	O
group	O
in	O
3	O
-	O
7	O
day	O
group	O
and	O
8	O
-	O
14	O
day	O
group	O
,	O
but	O
became	O
significantly	O
higher	O
in	O
over	O
14	O
day	O
group	O
as	O
compared	O
to	O
the	O
control	O
group	O
,	O
3	O
-	O
7	O
day	O
group	O
and	O
8	O
-	O
14	O
day	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Although	O
TGF	O
-	O
beta1	O
in	O
sera	B-FUNC
decreased	O
in	O
over	O
14	O
day	O
group	O
,	O
the	O
average	O
was	O
still	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

N385	O
had	O
the	O
highest	O
affinity	O
for	O
forming	O
peptide	O
-	O
antibody	B-FUNC
complexes	O
with	O
SARS	O
serum	O
.	O

ABSTRACT	O
:	O
To	O
discuss	O
the	O
reliability	O
of	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
detection	O
for	O
SARS	O
diagnosis	O
.	O

These	O
data	O
identify	O
an	O
independently	O
folded	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
receptor	O
(	O
MHVR	O
),	O
CEACAM1	O
,	O
has	O
two	O
different	O
functions	O
for	O
MHV	O
entry	O
into	O
cells	O
:	O
binding	B-FUNC
to	O
MHV	O
spike	O
protein	O
(	O
S	O
protein	O
)	O
and	O
activation	O
of	O
the	O
S	O
protein	O
to	O
execute	O
virus	O
-	O
cell	O
membrane	O
fusion	O
,	O
the	O
latter	O
of	O
which	O
is	O
accompanied	O
by	O
conformational	O
changes	O
of	O
the	O
S	O
protein	O
.	O

We	O
assessed	O
the	O
abilities	O
of	O
these	O
three	O
types	O
of	O
soMHVR	O
to	O
bind	B-FUNC
to	O
MHV	O
,	O
activate	O
fusogenicity	O
,	O
and	O
induce	O
conformational	O
changes	O
of	O
the	O
S	O
protein	O
.	O

Further	O
the	O
PEDV	O
binding	B-FUNC
to	O
pAPN	O
was	O
blocked	O
by	O
anti	O
-	O
pAPN	O
and	O
pAPN	O
enhanced	O
PEDV	O
infectivity	O
in	O
Vero	O
cells	O
.	O

The	O
data	O
obtained	O
are	O
compatible	O
with	O
a	O
transcription	O
mechanism	O
including	O
three	O
steps	O
:	O
(	O
i	O
)	O
formation	O
of	O
5	O
'-	O
3	O
'	O
complexes	O
in	O
the	O
genomic	O
RNA	O
,	O
(	O
ii	O
)	O
base	O
-	O
pairing	O
scanning	O
of	O
the	O
nascent	O
negative	O
RNA	O
strand	O
by	O
the	O
TRS	B-FUNC
-	O
L	O
,	O
and	O
(	O
iii	O
)	O
template	O
switching	O
during	O
synthesis	O
of	O
the	O
negative	O
strand	O
to	O
complete	O
the	O
negative	O
sgRNA	O
.	O

Her	O
indolent	O
clinical	O
course	O
of	O
SARS	O
was	O
punctuated	O
by	O
resolution	O
of	O
fever	O
,	O
but	O
there	O
was	O
progressive	O
radiologic	O
deterioration	O
and	O
increasing	O
serum	O
antibody	B-FUNC
titer	O
against	O
SARS	O
coronavirus	O
.	O

The	O
current	O
evidence	O
does	O
not	O
support	O
the	O
use	O
of	O
TNF	O
-	O
alpha	O
monoclonal	O
antibody	B-FUNC
in	O
this	O
group	O
of	O
children	O
.	O

In	O
SNP	O
,	O
infliximab	O
treatment	O
was	O
found	O
to	O
decrease	O
pathologic	O
score	O
(	O
9	O
.	O
4	O
+/-	O
1	O
.	O
2	O
versus	O
3	O
.	O
6	O
+/-	O
0	O
.	O
8	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
serum	O
amylase	B-FUNC
activity	I-FUNC
(	O
20442	O
+/-	O

After	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
the	O
California	O
isolate	O
exhibited	O
an	O
identical	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
pattern	O
to	O
some	O
isolates	O
obtained	O
from	O
California	O
,	O
known	O
as	O
California	O
99	O
isolates	O
.	O

These	O
results	O
suggest	O
a	O
possible	O
binding	B-FUNC
region	O
for	O
the	O
SARS	O
-	O
CoV	O
S	O
-	O
glycoprotein	O
on	O
ACE2	O
and	O
could	O
help	O
in	O
the	O
design	O
of	O
experiments	O
to	O
further	O
elucidate	O
the	O
structure	O
and	O
function	O
of	O
ACE2	O
.	O

ABSTRACT	O
:	O
Fecal	O
secretory	O
immunoglobulin	B-FUNC
A	O
(	O
IgA	O
)	O
antibodies	O
in	O
dogs	O
infected	O
or	O
vaccinated	O
with	O
canine	O
coronavirus	O
(	O
CCV	O
)	O
were	O
evaluated	O
by	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

The	O
six	O
proteins	O
N	O
,	O
E	O
,	O
M	O
,	O
S2	O
,	O
S5	O
,	O
and	O
S6	O
were	O
used	O
for	O
Western	O
blotting	O
(	O
WB	O
)	O
to	O
detect	O
various	O
immunoglobulin	B-FUNC
classes	O
in	O
90	O
serum	O
samples	O
from	O
54	O
probable	O
SARS	O
patients	O
.	O

A	O
few	O
active	O
site	O
residue	O
substitutions	O
in	O
ACE2	O
relative	O
to	O
ACE	O
appear	O
to	O
eliminate	O
the	O
S	O
(	O
2	O
)'	O
substrate	O
-	O
binding	B-FUNC
subsite	O
and	O
account	O
for	O
the	O
observed	O
reactivity	O
change	O
from	O
the	O
peptidyl	O
dipeptidase	B-FUNC
activity	I-FUNC
of	O
ACE	O
to	O
the	O
carboxypeptidase	B-FUNC
activity	I-FUNC
of	O
ACE2	O
.	O

We	O
describe	O
a	O
rapid	O
,	O
sensitive	O
,	O
and	O
highly	O
specific	O
quantitative	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
the	O
detection	O
of	O
HCoV	O
that	O
can	O
easily	O
be	O
implemented	O
in	O
the	O
routine	O
diagnostic	O
setting	O
.	O

According	O
to	O
this	O
structure	O
model	O
,	O
the	O
leader	O
TRS	B-FUNC
is	O
located	O
in	O
the	O
loop	O
of	O
a	O
prominent	O
hairpin	O
(	O
leader	O
TRS	B-FUNC
hairpin	O
;	O
LTH	O
).	O

The	O
recombinant	O
S1	O
protein	O
could	O
react	O
with	O
three	O
antibody	B-FUNC
positive	O
samples	O
from	O
recovered	O
SARS	O
patients	O
,	O
which	O
showed	O
specific	O
bands	O
at	O
64	O
000	O
,	O
but	O
not	O
with	O
the	O
control	O
samples	O
according	O
to	O
results	O
of	O
western	O
blot	O
.	O

CONCLUSIONS	O
:	O
The	O
recombinant	O
N	O
-	O
terminal	O
protein	O
of	O
SARS	O
virus	O
S1	O
subunit	O
displays	O
specific	O
reaction	O
with	O
SARS	O
antibody	B-FUNC
and	O
may	O
provide	O
a	O
good	O
tool	O
for	O
further	O
research	O
of	O
immune	O
response	O
to	O
SARS	O
virus	O
.	O

These	O
data	O
suggest	O
that	O
the	O
80R	O
human	O
monoclonal	O
antibody	B-FUNC
may	O
be	O
a	O
useful	O
viral	O
entry	O
inhibitor	O
for	O
the	O
emergency	O
prophylaxis	O
and	O
treatment	O
of	O
SARS	O
,	O
and	O
that	O
the	O
ACE2	O
-	O
binding	B-FUNC
site	O
of	O
S1	O
could	O
be	O
an	O
attractive	O
target	O
for	O
subunit	O
vaccine	O
and	O
drug	O
development	O
.	O

Staphylococcus	O
aureus	O
Cowan	O
1	O
(	O
SAC	O
)-	O
stimulated	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
secreting	O
cells	O
were	O
increased	O
in	O
early	O
SARS	O
but	O
fell	O
during	O
treatment	O
.	O

ABSTRACT	O
:	O
An	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
a	O
rapid	O
immunochromatographic	O
test	O
for	O
detection	O
of	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
antibodies	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
were	O
developed	O
by	O
utilizing	O
the	O
well	O
-	O
characterized	O
recombinant	O
proteins	O
Gst	O
-	O
N	O
and	O
Gst	O
-	O
U274	O
.	O

Sera	B-FUNC
from	O
some	O
of	O
the	O
patients	O
also	O
showed	O
immunoreactivity	O
to	O
U274	O
(	O
59	O
of	O
81	O
[	O
73	O
%]),	O
a	O
protein	O
that	O
is	O
unique	O
to	O
SARS	O
-	O
CoV	O
.	O
In	O
addition	O
,	O
all	O
of	O
the	O
convalescent	O
-	O
phase	O
sera	B-FUNC
showed	O
immunoreactivity	O
to	O
the	O
spike	O
(	O
S	O
)	O
protein	O
when	O
analyzed	O
by	O
an	O
immunofluorescence	O
method	O
utilizing	O
mammalian	O
cells	O
stably	O
expressing	O
S	O
.	O
However	O
,	O
samples	O
from	O
the	O
acute	O
phase	O
(	O
2	O
to	O
9	O
days	O
after	O
the	O
onset	O
of	O
illness	O
)	O
did	O
not	O
react	O
with	O
S	O
,	O
suggesting	O
that	O
antibodies	O
to	O
N	O
may	O
appear	O
earlier	O
than	O
antibodies	O
to	O
S	O
.	O
Alternatively	O
,	O
this	O
could	O
be	O
due	O
to	O
the	O
difference	O
in	O
the	O
sensitivities	O
of	O
the	O
two	O
methods	O
.	O

The	O
reactivities	O
of	O
the	O
recombinant	O
proteins	O
to	O
a	O
panel	O
of	O
antibodies	O
containing	O
33	O
SARS	O
coronavirus	O
-	O
positive	O
sera	B-FUNC
and	O
66	O
negative	O
sera	B-FUNC
and	O
to	O
antibodies	O
against	O
other	O
animal	O
coronaviruses	O
were	O
screened	O
.	O

We	O
found	O
that	O
the	O
level	O
of	O
neurovirulence	O
of	O
the	O
virus	O
correlates	O
with	O
its	O
differential	O
ability	O
to	O
induce	O
proinflammatory	O
cytokines	O
(	O
interleukin	O
12	O
[	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
]	O
p40	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
,	O
and	O
IL	O
-	O
1beta	O
)	O
in	O
astrocytes	O
and	O
microglia	O
and	O
in	O
mouse	O
brains	O
and	O
spinal	O
cords	O
.	O

Second	O
generation	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
assays	O
are	O
able	O
to	O
detect	O
SARS	O
-	O
CoV	O
in	O
nasopharyngeal	O
aspirates	O
of	O
approximately	O
80	O
%	O
of	O
patients	O
with	O
SARS	O
within	O
the	O
first	O
3	O
days	O
of	O
illness	O
.	O

Bilateral	O
femur	O
fracture	O
produced	O
a	O
significant	O
lung	O
injury	O
,	O
measured	O
by	O
increases	O
in	O
MPO	B-FUNC
(	O
25	O
-	O
43	O
microg	O
/	O
g	O
tissue	O
)	O
and	O
BAL	O
protein	O
(	O
460	O
-	O
605	O
microg	O
/	O
mL	O
).	O

Cytokine	O
profile	O
of	O
SARS	O
patients	O
showed	O
marked	O
elevation	O
of	O
Th1	O
cytokine	O
interferon	O
(	O
IFN	O
)-	O
gamma	O
,	O
inflammatory	O
cytokines	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
for	O
at	O
least	O
2	O
weeks	O
after	O
disease	O
onset	O
,	O
but	O
there	O
was	O
no	O
significant	O
elevation	O
of	O
inflammatory	O
cytokine	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
alpha	O
,	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
Th1	O
cytokine	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
and	O
Th2	O
cytokine	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
.	O

The	O
chemokine	O
profile	O
demonstrated	O
significant	O
elevation	O
of	O
neutrophil	O
chemokine	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
(	O
MCP	B-FUNC
-	O
1	O
),	O
and	O
Th1	O
chemokine	O
IFN	O
-	O
gamma	O
-	O
inducible	O
protein	O
-	O
10	O
(	O
IP	O
-	O
10	O
).	O

Among	O
31	O
case	O
-	O
patients	O
for	O
whom	O
convalescent	O
-	O
phase	O
(>	O
21	O
days	O
)	O
sera	B-FUNC
were	O
available	O
,	O
26	O
%	O
had	O
immunoglobulin	B-FUNC
G	O
to	O
SARS	O
-	O
associated	O
coronavirus	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
four	O
serologic	O
tests	O
(	O
neutralization	O
test	O
,	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
[	O
ELISA	O
],	O
immunofluorescent	O
assay	O
[	O
IFA	O
],	O
and	O
immunochromatographic	O
test	O
[	O
ICT	O
])	O
for	O
detecting	O
antibodies	O
to	O
SARS	O
-	O
CoV	O
in	O
sera	B-FUNC
of	O
537	O
probable	O
SARS	O
case	O
-	O
patients	O
with	O
correlation	O
to	O
the	O
RT	O
-	O
PCR	O
.	O

The	O
tissue	O
concentrations	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
-	O
1	O
(	O
CINC	O
-	O
1	O
)	O
were	O
also	O
measured	O
.	O

During	O
the	O
first	O
half	O
of	O
2003	O
,	O
the	O
spreading	O
of	O
the	O
virus	O
has	O
been	O
very	O
fast	B-FUNC
,	O
with	O
a	O
pandemic	O
mode	O
of	O
evolution	O
.	O

After	O
binding	B-FUNC
to	O
the	O
target	O
cell	O
,	O
the	O
transmembrane	O
spike	O
protein	O
might	O
change	O
conformation	O
by	O
association	O
between	O
the	O
HR1	O
and	O
HR2	O
regions	O
to	O
form	O
an	O
oligomeric	O
structure	O
,	O
leading	O
to	O
fusion	O
between	O
the	O
viral	O
and	O
target	O
-	O
cell	O
membranes	O
.	O

ABSTRACT	O
:	O
The	O
S	O
(	O
spike	O
)	O
protein	O
of	O
the	O
etiologic	O
coronavirus	O
(	O
CoV	O
)	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
plays	O
a	O
central	O
role	O
in	O
mediating	O
viral	O
infection	O
via	O
receptor	B-FUNC
binding	I-FUNC
and	O
membrane	O
fusion	O
between	O
the	O
virion	O
and	O
the	O
host	O
cell	O
.	O

After	O
purification	O
,	O
all	O
of	O
the	O
protein	O
fragments	O
were	O
printed	O
on	O
glass	O
slides	O
to	O
fabricate	O
a	O
protein	O
microarray	O
and	O
then	O
probed	O
with	O
the	O
sera	B-FUNC
from	O
SARS	O
patients	O
to	O
determine	O
the	O
reactivity	O
of	O
these	O
protein	O
fragments	O
.	O

Infection	O
was	O
diagnosed	O
by	O
serology	O
and	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
using	O
primers	O
directed	O
to	O
two	O
separate	O
but	O
highly	O
conserved	O
regions	O
of	O
the	O
MHV	O
genome	O
.	O

Lack	O
of	O
a	O
suitable	O
assay	O
has	O
been	O
a	O
major	O
hindrance	O
for	O
enzyme	O
kinetic	O
studies	O
and	O
a	O
large	O
-	O
scale	O
inhibitor	O
screen	O
for	O
SARS	O
3CL	O
proteinase	B-FUNC
.	O

We	O
have	O
established	O
a	O
continuous	O
colorimetric	O
assay	O
for	O
SARS	O
3CL	O
proteinase	B-FUNC
and	O
applied	O
it	O
to	O
study	O
the	O
enzyme	O
catalytic	O
mechanism	O
.	O

There	O
were	O
no	O
significant	O
differences	O
for	O
the	O
3	O
values	O
among	O
patients	O
with	O
SARS	O
without	O
anti	O
-	O
SARS	O
coronavirus	O
antibody	B-FUNC
,	O
patients	O
with	O
M	O
.	O
pneumoniae	O
infection	O
,	O
and	O
healthy	O
subjects	O
.	O

A	O
significant	O
association	O
between	O
the	O
history	O
of	O
positive	O
exposure	O
to	O
pesticides	O
(	O
i	O
.	O
e	O
.	O
the	O
women	O
themselves	O
or	O
their	O
newborns	O
who	O
showed	O
acetylcholinesterase	B-FUNC
activity	I-FUNC
levels	O
lower	O
than	O
20	O
%)	O
and	O
the	O
presence	O
of	O
IUGR	O
was	O
found	O
.	O

ABSTRACT	O
:	O
Chronic	O
Immune	O
Dysschwannian	O
/	O
Dysneuronal	O
Polyneuropathy	O
is	O
an	O
autoimmune	O
peripheral	O
-	O
nerve	O
and	O
/	O
or	O
nerve	O
-	O
root	O
disorder	O
known	O
to	O
usually	O
respond	O
to	O
intravenous	O
immunoglobulin	B-FUNC
-	O
G	O
treatment	O
.	O

A	O
novel	O
intravenous	O
immunoglobulin	B-FUNC
-	O
G	O
regimen	O
effective	O
for	O
fragile	O
patients	O
is	O
Two	O
Non	O
-	O
Consecutive	O
-	O
Days	O
Every	O
Week	O
,	O
using	O
0	O
.	O
4	O
gm	O
/	O
kg	O
body	O
wt	O
/	O
day	O
.	O

Passive	O
transfer	O
of	O
serum	O
from	O
mice	O
immunized	O
with	O
MVA	O
/	O
S	O
to	O
naïve	O
mice	O
also	O
reduced	O
the	O
replication	O
of	O
SARS	O
-	O
CoV	O
in	O
the	O
respiratory	O
tract	O
after	O
challenge	O
,	O
demonstrating	O
a	O
role	O
for	O
antibody	B-FUNC
to	O
S	O
in	O
protection	O
.	O

In	O
conclusion	O
,	O
IL	O
-	O
1beta	O
-	O
induced	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
TNFalpha	O
production	O
were	O
greater	O
in	O
pediatric	O
than	O
adult	O
PMs	O
.	O

For	O
each	O
HLA	O
supertype	O
,	O
we	O
have	O
selected	O
the	O
15	O
top	O
candidates	O
for	O
test	O
in	O
biochemical	O
binding	B-FUNC
assays	O
.	O

In	O
ACS	B-FUNC
iNO	O
should	O
be	O
considered	O
a	O
beneficial	O
therapeutic	O
option	O
.	O

We	O
have	O
recently	O
identified	O
a	O
29	O
kDa	O
protein	O
that	O
we	O
named	O
feline	O
AGP	O
-	O
related	O
protein	O
(	O
fAGPrP	O
)	O
due	O
to	O
its	O
cross	O
-	O
reactivity	O
with	O
an	O
anti	O
-	O
human	O
AGP	O
monoclonal	O
antibody	B-FUNC
.	O

The	O
concentration	O
of	O
PFIB	O
was	O
0	O
.	O
30	O
-	O
0	O
.	O
32	O
mg	O
/	O
L	O
.	O
Serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
were	O
dynamically	O
measured	O
.	O

The	O
average	O
of	O
LDH	O
,	O
ALT	B-FUNC
,	O
and	O
AST	O
of	O
dead	O
patients	O
were	O
higher	O
than	O
those	O
of	O
the	O
survivors	O
.	O

To	O
assess	O
the	O
extent	O
to	O
which	O
free	O
-	O
ranging	O
cheetahs	O
are	O
exposed	O
to	O
feline	O
and	O
canine	O
viruses	O
,	O
sera	B-FUNC
from	O
81	O
free	O
-	O
ranging	O
cheetahs	O
sampled	O
between	O
1992	O
and	O
1998	O
were	O
evaluated	O
for	O
antibodies	O
against	O
canine	O
distemper	O
virus	O
(	O
CDV	O
),	O
feline	O
coronavirus	O
(	O
feline	O
infectious	O
peritonitis	O
virus	O
;	O
FCoV	O
/	O
FIPV	O
),	O
feline	O
herpesvirus	O
1	O
(	O
FHV1	O
),	O
feline	O
panleukopenia	O
virus	O
(	O
FPV	O
),	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
),	O
and	O
feline	O
calicivirus	O
(	O
FCV	O
)	O
and	O
for	O
feline	O
leukemia	O
virus	O
(	O
FeLV	O
)	O
antigens	O
.	O

Among	O
the	O
peptides	O
used	O
in	O
the	O
study	O
,	O
the	O
affinity	O
of	O
peptides	O
from	O
HCoV	O
-	O
229e	O
(	O
H77	O
and	O
H881	O
)	O
and	O
peptides	O
from	O
SARS	O
-	O
CoV	O
(	O
S978	O
and	O
S1203	O
)	O
for	O
binding	B-FUNC
to	O
HLA	O
-	O
A2	O
was	O
higher	O
than	O
that	O
of	O
other	O
sequences	O
.	O

The	O
amounts	O
of	O
cyclin	B-FUNC
D2	O
and	O
cyclin	B-FUNC
E	O
were	O
not	O
increased	O
significantly	O
after	O
serum	O
stimulation	O
in	O
mock	O
-	O
infected	O
cells	O
,	O
whereas	O
they	O
were	O
decreased	O
in	O
MHV	O
-	O
infected	O
cells	O
,	O
suggesting	O
the	O
possibility	O
that	O
MHV	O
infection	O
may	O
induce	O
cyclin	B-FUNC
D2	O
and	O
cyclin	B-FUNC
E	O
degradation	O
.	O

Anti	O
-	O
SARS	O
antibodies	O
were	O
determined	O
by	O
anti	O
-	O
SARS	O
specific	O
antibody	B-FUNC
detection	O
kit	B-FUNC
and	O
ELISA	O
method	O
.	O

Inhibition	O
of	O
vacuolar	O
acidification	O
impaired	O
infection	O
by	O
SARS	O
-	O
CoV	O
S	O
-	O
bearing	O
pseudotypes	O
,	O
indicating	O
that	O
S	O
-	O
mediated	O
entry	O
requires	O
low	O
pH	O
.	O
Finally	O
,	O
infection	O
by	O
SARS	O
-	O
CoV	O
S	O
pseudotypes	O
but	O
not	O
by	O
vesicular	O
stomatitis	O
virus	O
G	O
pseudotypes	O
was	O
efficiently	O
inhibited	O
by	O
a	O
rabbit	O
serum	O
raised	O
against	O
SARS	O
-	O
CoV	O
particles	O
and	O
by	O
sera	B-FUNC
from	O
SARS	O
patients	O
,	O
demonstrating	O
that	O
SARS	O
-	O
CoV	O
S	O
is	O
a	O
target	O
for	O
neutralizing	O
antibodies	O
and	O
that	O
such	O
antibodies	O
are	O
generated	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
patients	O
.	O

To	O
study	O
the	O
humoral	O
responses	O
against	O
SARS	O
-	O
CoV	O
,	O
we	O
evaluated	O
nucleocapsid	O
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
)	O
proteins	O
-	O
specific	O
antibodies	O
in	O
patients	O
'	O
sera	B-FUNC
by	O
Western	O
blotting	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

The	O
kit	B-FUNC
""""	O
AmpliSens	O
SARS	O
""""	O
for	O
qualitative	O
detection	O
of	O
SARS	O
-	O
related	O
coronavirus	O
RNA	O
by	O
reverse	O
transcription	O
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
in	O
nasopharyngeal	O
wash	O
/	O
aspirates	O
,	O
naso	O
/	O
oropharyngeal	O
swabs	O
,	O
plasma	O
,	O
and	O
extract	O
from	O
feces	O
has	O
been	O
developed	O
in	O
the	O
Central	O
Research	O
Institute	O
for	O
Epidemiology	O
of	O
the	O
RF	O
Ministry	O
of	O
Health	O
.	O

TITLE	O
:	O
Coronavirus	O
3CLpro	O
proteinase	B-FUNC
cleavage	O
sites	O
:	O
possible	O
relevance	O
to	O
SARS	O
virus	O
pathology	O
.	O

We	O
have	O
sequenced	O
four	O
regions	O
of	O
the	O
replicase	O
genes	O
corresponding	O
to	O
the	O
5	O
'-	O
terminal	O
sequence	O
,	O
PL	O
(	O
pro	O
),	O
M	O
(	O
pro	O
),	O
and	O
RdRp	B-FUNC
domains	O
from	O
20	O
heterologous	O
IBV	O
strains	O
,	O
and	O
compared	O
them	O
with	O
previously	O
published	O
coronavirus	O
sequences	O
.	O

Flow	O
cytometric	O
analysis	O
of	O
MAPKs	O
activation	O
by	O
phospho	O
-	O
p38	B-FUNC
and	O
phospho	O
-	O
p44	O
/	O
42	O
(	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
)	O
expression	O
showed	O
that	O
augmented	O
p38	B-FUNC
activation	O
(	O
p	O
=	O
0	O
.	O
044	O
)	O
of	O
CD14	O
monocytes	O
associated	O
with	O
suppressed	O
p38	B-FUNC
activation	O
(	O
p	O
=	O
0	O
.	O
033	O
)	O
of	O
CD8	O
lymphocytes	O
was	O
found	O
in	O
SARS	O
patients	O
.	O

ABSTRACT	O
:	O
To	O
express	O
S2	O
protein	O
of	O
SARS	O
virus	O
fused	O
with	O
Trx	O
and	O
then	O
detect	O
its	O
reactivity	O
to	O
the	O
sera	B-FUNC
from	O
convalescent	O
SARS	O
patients	O
.	O

To	O
analyze	O
the	O
antigenic	O
structure	O
of	O
the	O
SARS	O
-	O
CoV	O
S2	O
domain	O
,	O
the	O
carboxyl	O
-	O
terminal	O
half	O
of	O
the	O
S	O
protein	O
,	O
we	O
first	O
used	O
sera	B-FUNC
from	O
convalescent	O
SARS	O
patients	O
to	O
test	O
the	O
antigenicity	O
of	O
12	O
overlapping	O
fragments	O
spanning	O
the	O
entire	O
S2	O
and	O
identified	O
two	O
antigenic	O
determinants	O
(	O
Leu	O
803	O
to	O
Ala	O
828	O
and	O
Pro	O
1061	O
to	O
Ser	O
1093	O
).	O

The	O
antibody	B-FUNC
response	O
to	O
SCoV	O
S	O
protein	O
involves	O
antibodies	O
to	O
both	O
linear	O
and	O
conformational	O
epitopes	O
,	O
with	O
linear	O
epitopes	O
associated	O
with	O
the	O
carboxyl	O
domain	O
and	O
conformational	O
epitopes	O
associated	O
with	O
the	O
amino	O
terminal	O
domain	O
.	O

In	O
absence	O
of	O
S	O
,	O
expression	O
of	O
M	O
and	O
E	O
or	O
the	O
nucleocapsid	O
protein	O
N	O
did	O
not	O
induce	O
a	O
detectable	O
serum	O
SARS	O
-	O
CoV	O
-	O
neutralizing	O
antibody	B-FUNC
response	O
.	O

We	O
investigated	O
prophylaxis	O
of	O
SARS	O
coronavirus	O
infection	O
with	O
a	O
neutralising	O
human	O
monoclonal	O
antibody	B-FUNC
in	O
ferrets	O
,	O
which	O
can	O
be	O
readily	O
infected	O
with	O
the	O
virus	O
.	O

In	O
30	O
patients	O
with	O
ARDS	O
due	O
to	O
multitrauma	O
,	O
pneumonia	O
or	O
after	O
surgery	O
(	O
p	O
(	O
a	O
)	O
O	O
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)-	O
ratio	O
67	O
+/-	O
23	O
mmHg	O
)	O
pECLA	O
was	O
established	O
by	O
insertion	O
of	O
cannulae	O
to	O
the	O
femoral	O
artery	O
and	O
vein	O
followed	O
by	O
connection	O
with	O
a	O
membrane	O
gas	O
exchanger	B-FUNC
.	O

Pooled	O
sera	B-FUNC
,	O
taken	O
at	O
the	O
first	O
and	O
last	O
sampling	O
,	O
were	O
examined	O
for	O
antibody	B-FUNC
titres	O
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
),	O
and	O
the	O
individual	O
sera	B-FUNC
from	O
all	O
four	O
samplings	O
were	O
examined	O
for	O
the	O
presence	O
and	O
/	O
or	O
titres	O
of	O
antibodies	O
against	O
avian	O
pneumovirus	O
(	O
APV	O
),	O
Mycoplasma	O
gallisepticum	O
,	O
Mycoplasma	O
synoviae	O
and	O
Ornithobacterium	O
rhinotracheale	O
.	O

One	O
week	O
after	O
the	O
second	O
immunization	O
,	O
mice	O
sera	B-FUNC
were	O
collected	O
to	O
detect	O
serum	O
neutralizing	O
antibodies	O
.	O

The	O
non	O
-	O
nitrosylated	O
form	O
of	O
SNAP	B-FUNC
,	O
N	O
-	O
acetylpenicillamine	O
(	O
NAP	O
),	O
was	O
included	O
as	O
a	O
control	O
compound	O
in	O
the	O
assay	O
.	O

RESULTS	O
:	O
Two	O
organic	O
NO	O
donor	O
compounds	O
,	O
S	O
-	O
nitroso	O
-	O
N	O
-	O
acetylpenicillamine	O
(	O
SNAP	B-FUNC
)	O
and	O
sodium	O
nitroprusside	O
(	O
SNP	O
),	O
were	O
tested	O
in	O
a	O
broad	O
range	O
of	O
concentrations	O
.	O

RESULTS	O
:	O
The	O
absorbance	O
(	O
A	O
)	O
value	O
of	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
ranged	O
from	O
0	O
.	O
81	O
to	O
2	O
.	O
06	O
in	O
patients	O
after	O
half	O
an	O
year	O
of	O
SARS	O
onset	O
,	O
and	O
form	O
0	O
.	O
79	O
to	O
2	O
.	O
01	O
in	O
patients	O
before	O
half	O
an	O
year	O
of	O
SARS	O
onset	O
.	O

At	O
day	O
240	O
,	O
36	O
%	O
of	O
the	O
patients	O
were	O
still	O
positive	O
for	O
anti	O
-	O
nucleocapsid	O
protein	O
IgM	O
antibody	B-FUNC
.	O

We	O
used	O
this	O
method	O
to	O
analyze	O
the	O
memory	O
repertoire	O
of	O
a	O
patient	O
who	O
recovered	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
and	O
to	O
isolate	O
monoclonal	O
antibodies	O
specific	O
for	O
different	O
viral	O
proteins	O
,	O
including	O
35	O
antibodies	O
with	O
in	O
vitro	O
neutralizing	O
activity	O
ranging	O
from	O
10	O
(-	O
8	O
)	O
M	O
to	O
10	O
(-	O
11	O
)	O
M	O
.	O
One	O
such	O
antibody	B-FUNC
confers	O
protection	O
in	O
vivo	O
in	O
a	O
mouse	O
model	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

We	O
have	O
developed	O
a	O
system	O
that	O
not	O
only	O
identifies	O
high	O
binding	B-FUNC
T	O
-	O
cell	O
antigenic	O
epitopes	O
,	O
but	O
also	O
class	O
I	O
T	O
-	O
cell	O
antigenic	O
clusters	O
termed	O
immunological	O
hot	O
spots	O
.	O

In	O
addition	O
,	O
other	O
antiviral	O
treatment	O
,	O
RNA	O
interference	O
,	O
monoclonal	O
antibody	B-FUNC
,	O
synthetic	O
peptides	O
,	O
and	O
vaccines	O
are	O
being	O
developed	O
.	O

Neutralizing	O
viral	O
antibodies	O
were	O
demonstrated	O
in	O
the	O
sera	B-FUNC
from	O
all	O
of	O
the	O
patients	O
with	O
SARS	O
symptoms	O
.	O

Bio	O
-	O
panning	O
was	O
carried	O
out	O
against	O
immobilized	O
purified	O
envelope	O
(	O
E	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	O
of	O
SARS	O
-	O
CoV	O
.	O
Their	O
binding	B-FUNC
activity	O
and	O
specificity	O
to	O
E	O
or	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
were	O
characterized	O
by	O
phage	O
-	O
ELISA	O
.	O

The	O
sequence	O
of	O
the	O
epitope	O
or	O
overlapping	O
epitope	O
of	O
scFv	O
antibody	B-FUNC
A17	O
was	O
PTDSTDNNQNGGRNGARPKQRRPQ	O
.	O

Throat	O
or	O
nasopharyngeal	O
swab	O
for	O
SARS	O
-	O
CoV	O
by	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
real	O
-	O
time	O
PCR	O
was	O
positive	O
in	O
40	O
of	O
the	O
47	O
patients	O
(	O
85	O
%)	O
in	O
whom	O
the	O
test	O
was	O
performed	O
.	O

Such	O
differences	O
were	O
detected	O
in	O
individual	O
sera	B-FUNC
from	O
various	O
mouse	O
strains	O
,	O
and	O
were	O
ascribed	O
to	O
the	O
fact	O
that	O
proteins	O
insolubilized	O
on	O
solid	O
supports	O
expose	O
a	O
variety	O
of	O
conformational	O
and	O
cryptic	O
antigenic	O
determinants	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
CC	O
chemokine	O
ligand	B-FUNC
3	O
(	O
CCL3	O
)	O
in	O
activation	O
of	O
dendritic	O
cells	O
(	O
DCs	O
)	O
following	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
was	O
examined	O
.	O

ABSTRACT	O
:	O
CEACAM1a	O
glycoproteins	O
are	O
members	O
of	O
the	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
superfamily	O
and	O
the	O
carcinoembryonic	O
antigen	O
family	O
.	O

TITLE	O
:	O
[	O
Distribution	O
and	O
timing	O
of	O
antibody	B-FUNC
to	O
SARS	O
-	O
CoV	O
in	O
SARS	O
cases	O
of	O
transmission	O
chain	O
or	O
non	O
-	O
transmission	O
chain	O
].	O

More	O
than	O
94	O
%	O
of	O
cases	O
with	O
SARS	O
could	O
produce	O
IgG	O
antibody	B-FUNC
when	O
they	O
were	O
infected	O
by	O
SARS	O
-	O
CoV	O
.	O
Detecting	O
SARS	O
-	O
CoV	O
IgG	O
could	O
provide	O
a	O
diagnostic	O
evidence	O
for	O
case	O
confirmation	O
.	O

Thus	O
,	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	B-FUNC
)/	O
Akt	O
pathway	O
is	O
activated	O
in	O
virus	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

Inflammatory	O
cytokines	O
(	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
protein	O
concentration	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
,	O
lung	O
wet	O
-	O
to	O
-	O
dry	O
weight	O
ratio	O
,	O
histology	O
,	O
immunohistochemistry	O
,	O
and	O
AQP1	O
Western	O
blot	O
were	O
performed	O
.	O

The	O
synthetic	O
peptide	O
S	O
(	O
603	O
-	O
634	O
),	O
which	O
overlaps	O
the	O
site	O
IV	O
sequence	O
reacted	O
with	O
all	O
the	O
convalescent	O
sera	B-FUNC
from	O
42	O
SARS	O
patient	O
,	O
but	O
none	O
of	O
the	O
30	O
serum	O
samples	O
from	O
healthy	O
blood	O
donors	O
,	O
suggesting	O
its	O
potential	O
application	O
as	O
an	O
Ag	O
for	O
developing	O
SARS	O
diagnostics	O
.	O

The	O
infection	O
on	O
Vero	O
E6	O
-	O
a	O
permissive	O
cell	O
line	O
to	O
SARS	O
-	O
CoV	O
-	O
could	O
be	O
neutralized	O
by	O
sera	B-FUNC
from	O
convalescent	O
SARS	O
patients	O
,	O
and	O
the	O
entry	O
was	O
a	O
pH	O
-	O
dependent	O
process	O
.	O

The	O
reliability	O
of	O
the	O
binding	B-FUNC
sites	O
derived	O
by	O
the	O
molecular	O
modeling	O
was	O
confirmed	O
by	O
the	O
fact	O
that	O
the	O
computationally	O
predicted	O
values	O
of	O
the	O
relative	O
free	O
energies	O
of	O
the	O
binding	B-FUNC
for	O
SARS_NP	O
(	O
or	O
hCypA	O
)	O
mutants	O
to	O
the	O
wild	O
-	O
type	O
hCypA	O
(	O
or	O
SARS_NP	O
)	O
are	O
in	O
good	O
agreement	O
with	O
the	O
data	O
determined	O
by	O
SPR	O
.	O

The	O
antibody	B-FUNC
library	O
of	O
Fab	O
fragment	O
from	O
a	O
convalescent	O
patient	O
infected	O
with	O
SARS	O
conronavirus	O
was	O
constructed	O
.	O

The	O
percentages	O
of	O
CD8	O
+	O
DimerX	O
-	O
S1203	O
+	O
cells	O
paralleled	O
the	O
numbers	O
of	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
-	O
positive	O
spots	O
in	O
an	O
ELISPOT	O
assay	O
using	O
the	O
same	O
antigenic	O
peptide	O
.	O

Two	O
-	O
thirds	O
of	O
the	O
speakers	O
were	O
from	O
industry	O
and	O
the	O
rest	B-FUNC
from	O
academia	O
.	O

TITLE	O
:	O
High	O
-	O
throughput	O
screening	O
identifies	O
inhibitors	O
of	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	B-FUNC
.	O

When	O
the	O
cDNA	O
encoding	O
CD209L	O
from	O
clone	O
2	O
.	O
27	O
was	O
cloned	O
and	O
transfected	O
into	O
Chinese	O
hamster	O
ovary	O
cells	O
,	O
the	O
cells	O
expressed	O
human	O
CD209L	O
glycoprotein	O
and	O
became	O
susceptible	O
to	O
infection	O
with	O
SARS	O
-	O
CoV	O
.	O
Immunohistochemistry	O
showed	O
that	O
CD209L	O
is	O
expressed	O
in	O
human	O
lung	O
in	O
type	O
II	O
alveolar	O
cells	O
and	O
endothelial	O
cells	O
,	O
both	O
potential	O
targets	O
for	O
SARS	O
-	O
CoV	O
.	O
Several	O
other	O
enveloped	O
viruses	O
including	O
Ebola	O
and	O
Sindbis	O
also	O
use	O
CD209L	O
as	O
a	O
portal	O
of	O
entry	O
,	O
and	O
HIV	O
and	O
hepatitis	O
C	O
virus	O
can	O
bind	B-FUNC
to	O
CD209L	O
on	O
cell	O
membranes	O
but	O
do	O
not	O
use	O
it	O
to	O
mediate	O
virus	O
entry	O
.	O

A	O
similar	O
endoribonucleolytic	O
activity	O
was	O
detected	O
for	O
the	O
orthologous	O
protein	O
from	O
another	O
coronavirus	O
,	O
demonstrating	O
that	O
the	O
endoribonuclease	B-FUNC
activity	I-FUNC
of	O
Nsp15	O
may	O
be	O
common	O
to	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
The	O
recently	O
emerged	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
contains	O
four	O
structural	O
genes	O
,	O
two	O
replicase	O
-	O
transcriptase	B-FUNC
open	O
reading	O
frames	O
,	O
and	O
more	O
than	O
five	O
potential	O
genes	O
of	O
unknown	O
function	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
E	O
protein	O
forms	O
cation	O
-	O
selective	O
ion	B-FUNC
channels	I-FUNC
.	O

The	O
antisera	O
from	O
the	O
immunized	O
animals	O
efficiently	O
bound	O
to	O
the	O
RBD	O
and	O
blocked	O
binding	B-FUNC
of	O
RBD	O
to	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
,	O
the	O
functional	O
receptor	O
on	O
the	O
susceptible	O
cells	O
for	O
SARS	O
-	O
CoV	O
.	O
With	O
a	O
sensitive	O
and	O
quantitative	O
single	O
-	O
cycle	O
infection	O
assay	O
using	O
pseudovirus	O
bearing	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
,	O
we	O
demonstrated	O
that	O
mouse	O
and	O
rabbit	O
antisera	O
significantly	O
inhibited	O
S	O
protein	O
-	O
mediated	O
virus	O
entry	O
with	O
mean	O
50	O
%	O
inhibitory	O
titers	O
of	O
1	O
:	O
7393	O
and	O
1	O
:	O
2060	O
,	O
respectively	O
.	O

Matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
(	O
MALDI	O
)-	O
mass	O
spectrometry	O
identified	O
it	O
as	O
synaptotagmin	O
-	O
binding	B-FUNC
cytoplasmic	O
RNA	O
-	O
interacting	O
protein	O
(	O
SYNCRIP	O
).	O

The	O
surface	O
form	O
of	O
the	O
cells	O
at	O
advanced	O
infection	O
displayed	O
prolific	O
pseudopodia	O
that	O
,	O
in	O
addition	O
to	O
the	O
rest	B-FUNC
of	O
the	O
plasma	O
membrane	O
,	O
were	O
also	O
active	O
sites	O
of	O
virus	O
release	O
.	O

TITLE	O
:	O
Prognostic	O
value	O
of	O
an	O
early	O
soluble	O
L	O
-	O
selectin	B-FUNC
(	O
sCD62L	O
)	O
assay	O
for	O
risk	O
assessment	O
in	O
blunt	O
multiple	O
trauma	O
:	O
a	O
metaanalysis	O
.	O

Here	O
,	O
we	O
identify	O
SARS	O
coronavirus	O
amino	O
-	O
terminal	O
replicase	O
products	O
nsp1	O
,	O
nsp2	O
,	O
and	O
nsp3	O
and	O
describe	O
trans	O
-	O
cleavage	O
assays	O
that	O
characterize	O
the	O
protease	B-FUNC
activity	I-FUNC
required	O
to	O
generate	O
these	O
products	O
.	O

Long	O
-	O
term	O
surveillance	O
of	O
the	O
change	O
of	O
antibody	B-FUNC
is	O
necessary	O
.	O

The	O
titers	O
of	O
specific	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
were	O
determined	O
by	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
and	O
the	O
neutralizing	O
antibody	B-FUNC
titers	O
were	O
detected	O
with	O
micro	O
-	O
cytopathic	O
effect	O
neutralization	O
test	O
.	O

Titers	O
of	O
both	O
specific	O
IgG	O
antibody	B-FUNC
and	O
neutralizing	O
antibody	B-FUNC
peaked	O
at	O
about	O
six	O
weeks	O
after	O
first	O
vaccination	O
,	O
with	O
the	O
maximum	O
value	O
of	O
1	O
:	O
81	O
920	O
and	O
1	O
:	O
20	O
480	O
,	O
respectively	O
.	O

TITLE	O
:	O
Induction	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
release	O
in	O
lung	O
cells	O
via	O
activator	O
protein	O
-	O
1	O
by	O
recombinant	O
baculovirus	O
displaying	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
spike	O
proteins	O
:	O
identification	O
of	O
two	O
functional	O
regions	O
.	O

IL	B-FUNC
-	I-FUNC
8	I-FUNC
release	O
was	O
effectively	O
induced	O
by	O
vAtEpGS688	O
,	O
a	O
baculovirus	O
exhibiting	O
the	O
aa	O
17	O
-	O
688	O
fragment	O
of	O
S	O
protein	O
,	O
and	O
this	O
induction	O
was	O
attenuated	O
by	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
Ab	O
.	O

The	O
identification	O
of	O
the	O
functional	O
domain	O
for	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
release	O
will	O
provide	O
for	O
the	O
drug	O
design	O
on	O
targeting	O
specific	O
sequence	O
domains	O
of	O
S	O
protein	O
responsible	O
for	O
initiating	O
the	O
inflammatory	O
response	O
.	O

In	O
some	O
patients	O
(	O
10	O
/	O
45	O
),	O
a	O
high	O
level	O
of	O
anti	O
-	O
nucleocapsid	O
antibody	B-FUNC
appeared	O
very	O
early	O
in	O
the	O
course	O
of	O
the	O
illness	O
.	O

These	O
proteins	O
include	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
),	O
RNA	O
helicase	O
,	O
proteases	O
,	O
metal	O
-	O
binding	B-FUNC
proteins	O
,	O
and	O
a	O
number	O
of	O
other	O
proteins	O
of	O
unknown	O
function	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
prove	O
whether	O
the	O
treatment	O
of	O
soluble	O
pAPN	O
could	O
enhance	O
the	O
antibody	B-FUNC
production	O
against	O
PEDV	O
in	O
guinea	O
pigs	O
,	O
rabbits	O
and	O
sows	O
.	O

The	O
results	O
suggested	O
that	O
pAPN	O
could	O
enhance	O
the	O
antibody	B-FUNC
production	O
against	O
PEDV	O
in	O
guinea	O
pigs	O
and	O
rabbits	O
which	O
are	O
free	O
of	O
pAPN	O
,	O
however	O
,	O
the	O
effect	O
of	O
pAPN	O
treatment	O
in	O
sows	O
was	O
not	O
clearly	O
elucidated	O
.	O

Using	O
Western	O
blot	O
and	O
Enzyme	O
-	O
linked	O
Immunosorbent	O
Assay	O
(	O
ELISA	O
),	O
the	O
recombinant	O
N	O
proteins	O
and	O
the	O
synthesized	O
peptides	O
derived	O
from	O
the	O
N	O
protein	O
were	O
screened	O
in	O
sera	B-FUNC
from	O
SARS	O
patients	O
.	O

ABSTRACT	O
:	O
To	O
construct	O
human	O
phage	O
antibody	B-FUNC
library	O
against	O
SARS	O
virus	O
.	O

The	O
present	O
results	O
not	O
only	O
suggest	O
that	O
DNA	O
immunization	O
with	O
pcDNAM	O
,	O
pcDNAN	O
or	O
pcDNASa	O
-	O
pcDNASb	O
could	O
be	O
used	O
as	O
potential	O
DNA	O
vaccination	O
approaches	O
to	O
induce	O
antibody	B-FUNC
in	O
BALB	O
/	O
c	O
mice	O
,	O
but	O
also	O
to	O
illustrate	O
that	O
gene	O
immunization	O
with	O
these	O
SARS	O
DNA	O
vaccines	O
different	O
immune	O
response	O
characters	O
.	O

IgG	O
antibody	B-FUNC
in	O
sera	B-FUNC
continued	O
to	O
be	O
at	O
higher	O
levels	O
among	O
SARS	O
cases	O
22	O
-	O
24	O
weeks	O
after	O
onset	O
.	O

The	O
neutralized	O
antibody	B-FUNC
levels	O
were	O
from	O
1	O
:	O
16	O
to	O
1	O
:	O
203	O
,	O
with	O
medium	O
level	O
of	O
1	O
:	O
43	O
.	O

Autopsy	O
lung	O
tissue	O
sections	O
from	O
SARS	O
patients	O
were	O
stained	O
with	O
ascites	O
of	O
monoclonal	O
antibody	B-FUNC
(	O
M2	O
strain	O
)	O
by	O
immunohistochemical	O
technique	O
.	O

Of	O
the	O
6	O
strains	O
,	O
1	O
was	O
identified	O
as	O
the	O
immunoglobulin	B-FUNC
G3	O
(	O
IgG3	O
)	O
isotype	O
,	O
5	O
were	O
IgG1	O
.	O

Of	O
the	O
196	O
patients	O
,	O
34	O
(	O
17	O
.	O
3	O
%)	O
met	O
the	O
World	O
Health	O
Organization	O
criteria	O
for	O
probable	O
SARS	O
with	O
positive	O
results	O
of	O
serologic	O
testing	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
nasopharyngeal	O
or	O
throat	O
swabs	O
for	O
SARS	O
-	O
CoV	O
,	O
or	O
both	O
.	O

Of	O
those	O
testing	O
positive	O
,	O
the	O
serum	O
levels	O
of	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
decreased	O
significantly	O
during	O
the	O
12	O
months	O
after	O
hospital	O
discharge	O
.	O

RESULTS	O
:	O
Eleven	O
monoclonal	O
cells	O
secreting	O
antibody	B-FUNC
have	O
been	O
developed	O
.	O

TITLE	O
:	O
Generation	O
of	O
predictive	O
pharmacophore	O
model	O
for	O
SARS	O
-	O
coronavirus	O
main	O
proteinase	B-FUNC
.	O

Fragment	O
450	O
-	O
650	O
(	O
S450	O
-	O
650	O
)	O
of	O
the	O
S	O
protein	O
contains	O
receptor	O
-	O
binding	B-FUNC
domain	O
and	O
neutralizing	O
epitopes	O
.	O

The	O
mechanism	O
of	O
enhancement	O
involved	O
the	O
interaction	O
of	O
Abs	O
with	O
conformational	O
epitopes	O
in	O
the	O
hACE	O
-	O
2	O
-	O
binding	B-FUNC
domain	O
.	O

The	O
positive	O
rates	O
of	O
N	O
protein	O
for	O
sera	B-FUNC
collected	O
at	O
1	O
to	O
5	O
,	O
6	O
to	O
10	O
,	O
11	O
to	O
15	O
,	O
and	O
16	O
to	O
20	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
for	O
414	O
samples	O
from	O
298	O
serologically	O
confirmed	O
patients	O
were	O
92	O
.	O
9	O
,	O
69	O
.	O
8	O
,	O
36	O
.	O
4	O
,	O
and	O
21	O
.	O
1	O
%,	O
respectively	O
.	O

ABSTRACT	O
:	O
Human	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
were	O
selected	O
from	O
semisynthetic	O
antibody	B-FUNC
phage	O
display	O
libraries	O
by	O
using	O
whole	O
irradiated	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
virions	O
as	O
target	O
.	O

CONCLUSIONS	O
:	O
The	O
positive	O
rate	O
of	O
SARS	O
coronavirus	O
IgG	O
antibody	B-FUNC
of	O
patients	O
was	O
consistent	O
with	O
the	O
clinical	O
diagnosis	O
.	O

Transgenic	O
mice	O
with	O
human	O
immunoglobulin	B-FUNC
genes	O
were	O
immunized	O
with	O
the	O
recombinant	O
major	O
surface	O
(	O
S	O
)	O
glycoprotein	O
ectodomain	O
of	O
SARS	O
-	O
CoV	O
.	O
Epitopes	O
of	O
2	O
neutralizing	O
MAbs	O
derived	O
from	O
these	O
mice	O
were	O
mapped	O
and	O
evaluated	O
in	O
a	O
murine	O
model	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
a	O
safe	O
and	O
sensitive	O
Spike	O
protein	O
-	O
based	O
immunofluorescence	O
assay	O
for	O
the	O
detection	O
of	O
antibody	B-FUNC
responses	O
to	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Previously	O
,	O
we	O
have	O
identified	O
a	O
truncated	O
antigenic	O
fragment	O
named	O
protein	O
C	O
[	O
441	O
to	O
700	O
amino	O
acids	O
(	O
a	O
.	O
a	O
.)]	O
as	O
the	O
immunodominant	O
fragment	O
of	O
Spike	O
(	O
S	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

In	O
TRS	B-FUNC
mutants	O
with	O
increasing	O
complementarity	O
between	O
TRS	B-FUNC
-	O
L	O
and	O
cTRS	O
-	O
B	O
,	O
a	O
tendency	O
to	O
reach	O
a	O
plateau	O
in	O
DeltaG	O
values	O
was	O
observed	O
,	O
suggesting	O
that	O
a	O
more	O
precise	O
definition	O
of	O
the	O
TRS	B-FUNC
limits	O
might	O
be	O
proposed	O
,	O
specifically	O
that	O
it	O
consists	O
of	O
the	O
central	O
CS	O
and	O
around	O
4	O
nucleotides	O
flanking	O
5	O
'	O
and	O
3	O
'	O
the	O
CS	O
.	O

Further	O
research	O
showed	O
that	O
HAb18G	O
/	O
CD147	O
,	O
a	O
transmembrane	O
molecule	O
,	O
was	O
highly	O
expressed	O
on	O
293	O
cells	O
and	O
that	O
CyPA	O
was	O
integrated	O
with	O
SARS	O
-	O
CoV	O
.	O
HAb18G	O
/	O
CD147	O
-	O
antagonistic	O
peptide	O
(	O
AP	O
)-	O
9	O
,	O
an	O
AP	O
of	O
HAb18G	O
/	O
CD147	O
,	O
had	O
a	O
high	O
rate	O
of	O
binding	B-FUNC
to	O
293	O
cells	O
and	O
an	O
inhibitory	O
effect	O
on	O
SARS	O
-	O
CoV	O
.	O
These	O
results	O
show	O
that	O
HAb18G	O
/	O
CD147	O
,	O
mediated	O
by	O
CyPA	O
bound	O
to	O
SARS	O
-	O
CoV	O
N	O
protein	O
,	O
plays	O
a	O
functional	O
role	O
in	O
facilitating	O
invasion	O
of	O
host	O
cells	O
by	O
SARS	O
-	O
CoV	O
.	O
Our	O
findings	O
provide	O
some	O
evidence	O
for	O
the	O
cytologic	O
mechanism	O
of	O
invasion	O
by	O
SARS	O
-	O
CoV	O
and	O
provide	O
a	O
molecular	O
basis	O
for	O
screening	O
anti	O
-	O
SARS	O
drugs	O
.	O

Serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
levels	O
correlated	O
significantly	O
with	O
FE	O
UA	O
(	O
P	O
<	O
0	O
.	O
001	O
;	O
r	O
=	O
0	O
.	O
785	O
)	O
and	O
inversely	O
with	O
serum	O
UA	O
level	O
(	O
P	O
=	O
0	O
.	O
044	O
;	O
r	O
=	O
-	O
0	O
.	O
509	O
);	O
neither	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
nor	O
TNF	O
-	O
alpha	O
level	O
showed	O
such	O
correlations	O
.	O

However	O
,	O
over	O
all	O
,	O
beta	O
-	O
actin	O
is	O
an	O
unsuitable	O
as	O
reference	O
gene	O
,	O
whereas	O
TATA	O
-	O
Box	O
binding	B-FUNC
protein	O
and	O
peptidyl	O
-	O
prolyl	O
-	O
isomerase	O
A	O
are	O
stable	O
reference	O
genes	O
for	O
expression	O
studies	O
in	O
virus	O
infected	O
cells	O
.	O

Diagnosis	O
is	O
based	O
on	O
antibody	B-FUNC
screening	O
in	O
blood	O
components	O
and	O
on	O
specific	O
-	O
antigen	O
detection	O
in	O
the	O
recipient	O
.	O

TITLE	O
:	O
Recombinant	O
modified	O
vaccinia	O
virus	O
Ankara	O
expressing	O
the	O
spike	O
glycoprotein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
induces	O
protective	O
neutralizing	O
antibodies	O
primarily	O
targeting	O
the	O
receptor	B-FUNC
binding	I-FUNC
region	O
.	O

Our	O
results	O
show	O
that	O
CD14	O
and	O
TLR4	O
are	O
necessary	O
for	O
low	O
-	O
dose	O
(	O
300	O
-	O
microg	O
/	O
ml	O
)	O
LPS	O
-	O
induced	O
microvascular	O
leakage	O
,	O
NF	O
-	O
kappaB	O
activation	O
,	O
neutrophil	O
influx	O
,	O
cytokine	O
and	O
chemokine	O
(	O
KC	O
,	O
macrophage	O
inflammatory	O
protein	O
2	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
,	O
interleukin	O
-	O
6	O
)	O
expression	O
,	O
and	O
subsequent	O
lung	O
damage	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
a	O
quantitative	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
Q	O
-	O
RT	O
-	O
PCR	O
)	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
detection	O
and	O
explore	O
the	O
potential	O
of	O
using	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
mRNA	O
as	O
an	O
internal	O
control	O
to	O
exclude	O
false	O
negative	O
results	O
.	O

TITLE	O
:	O
Identification	O
of	O
single	O
-	O
chain	O
antibody	B-FUNC
fragments	O
specific	O
against	O
SARS	O
-	O
associated	O
coronavirus	O
from	O
phage	O
-	O
displayed	O
antibody	B-FUNC
library	O
.	O

Then	O
,	O
the	O
binding	B-FUNC
ability	O
of	O
SA59B	O
-	O
HRP	O
to	O
SARS	O
-	O
CoV	O
was	O
evaluated	O
by	O
ELISA	O
with	O
S	O
/	O
N	O
of	O
11	O
.	O
6	O
,	O
indicating	O
higher	O
binding	B-FUNC
specificity	O
between	O
them	O
.	O

Anti	O
-	O
JHM	O
antibody	B-FUNC
was	O
detected	O
adjacent	O
to	O
areas	O
of	O
demyelination	O
,	O
consistent	O
with	O
a	O
direct	O
interaction	O
between	O
antibody	B-FUNC
and	O
infected	O
cells	O
.	O

TITLE	O
:	O
Substitutions	O
of	O
conserved	O
amino	O
acids	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
the	O
spike	O
glycoprotein	O
affect	O
utilization	O
of	O
murine	O
CEACAM1a	O
by	O
the	O
murine	O
coronavirus	O
MHV	O
-	O
A59	O
.	O

However	O
,	O
viruses	O
with	O
Y162F	O
substitutions	O
had	O
wild	O
type	O
growth	O
,	O
suggesting	O
that	O
Y162	O
may	O
comprise	O
part	O
of	O
a	O
hydrophobic	O
domain	O
that	O
contacts	O
the	O
MHV	O
-	O
binding	B-FUNC
site	O
of	O
mCEACAM1a	O
.	O

The	O
pseudotype	O
assay	O
was	O
used	O
to	O
profile	O
neutralizing	O
antibody	B-FUNC
responses	O
against	O
SARS	O
-	O
CoV	O
S	O
in	O
sequential	O
serum	O
samples	O
taken	O
from	O
41	O
confirmed	O
SARS	O
patients	O
during	O
the	O
2003	O
outbreak	O
in	O
Hong	O
Kong	O
and	O
shows	O
long	O
-	O
lasting	O
immunity	O
in	O
most	O
recovered	O
patients	O
.	O

Among	O
the	O
clinic	O
diagnosed	O
SARS	O
patients	O
,	O
the	O
positive	O
antibody	B-FUNC
detective	O
rate	O
was	O
90	O
.	O
4	O
%	O
for	O
those	O
which	O
had	O
specific	O
contact	O
history	O
or	O
infectivity	O
,	O
which	O
was	O
higher	O
than	O
that	O
for	O
other	O
population	O
.	O

The	O
antibody	B-FUNC
positive	O
rate	O
was	O
identical	O
between	O
the	O
male	O
and	O
the	O
female	O
.	O

The	O
serum	O
antibody	B-FUNC
profiles	O
were	O
investigated	O
at	O
different	O
times	O
over	O
one	O
and	O
a	O
half	O
years	O
in	O
18	O
of	O
the	O
SARS	O
patients	O
.	O

The	O
ELISA	O
was	O
evaluated	O
in	O
comparison	O
with	O
neutralizing	O
antibody	B-FUNC
assay	O
and	O
the	O
authentic	O
SARS	O
-	O
CoV	O
antigen	O
-	O
based	O
IgG	O
ELISA	O
.	O

The	O
SARS	O
-	O
CoV	O
rNP	O
-	O
based	O
IgG	O
ELISA	O
has	O
92	O
%	O
of	O
sensitivity	O
and	O
specificity	O
compared	O
with	O
the	O
neutralizing	O
antibody	B-FUNC
assay	O
and	O
94	O
%	O
sensitivity	O
and	O
specificity	O
compared	O
with	O
the	O
authentic	O
SARS	O
-	O
CoV	O
antigen	O
-	O
based	O
IgG	O
ELISA	O
.	O

Amino	O
acid	O
residues	O
450	O
-	O
650	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
SARS	O
-	O
CoV	O
(	O
S450	O
-	O
650	O
)	O
contains	O
dominant	O
epitopes	O
for	O
anti	O
-	O
viral	O
antibodies	O
(	O
Abs	O
)	O
in	O
patient	O
sera	B-FUNC
.	O

ECMO	O
was	O
safely	O
and	O
successfully	O
used	O
to	O
provide	O
a	O
period	O
of	O
lung	O
rest	B-FUNC
and	O
time	O
for	O
medical	O
therapy	O
to	O
take	O
effect	O
in	O
a	O
child	O
with	O
an	O
unusual	O
indication	O
for	O
support	O
:	O
a	O
rare	O
disease	O
with	O
an	O
uncertain	O
outcome	O
on	O
the	O
background	O
of	O
prolonged	O
mechanical	O
ventilation	O
.	O

Twenty	O
-	O
two	O
patients	O
received	O
immunoglobulin	B-FUNC
therapy	O
,	O
and	O
32	O
were	O
given	O
corticosteroids	O
.	O

Recently	O
,	O
a	O
small	O
fragment	O
on	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
(	O
residues	O
318	O
-	O
510	O
)	O
was	O
characterized	O
as	O
a	O
minimal	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
),	O
which	O
mediates	O
virus	O
binding	B-FUNC
to	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
,	O
the	O
functional	O
receptor	O
on	O
susceptible	O
cells	O
.	O

The	O
Conf	O
IV	O
and	O
Conf	O
V	O
mAbs	O
significantly	O
blocked	O
RBD	O
-	O
Fc	O
binding	B-FUNC
to	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
,	O
suggesting	O
that	O
their	O
epitopes	O
overlap	O
with	O
the	O
receptor	O
-	O
binding	B-FUNC
sites	O
in	O
the	O
S	O
protein	O
.	O

In	O
a	O
model	O
experiment	O
,	O
when	O
non	O
-	O
ribosomal	O
hexanucleotides	O
were	O
used	O
as	O
primers	O
,	O
in	O
vitro	O
transcribed	O
plasmid	O
RNA	O
was	O
efficiently	O
reverse	O
transcribed	O
when	O
compared	O
with	O
ribosomal	B-FUNC
RNA	I-FUNC
of	O
rat	O
cells	O
.	O

High	O
-	O
titre	O
positive	O
reactions	O
were	O
detected	O
in	O
all	O
SARS	O
positive	O
sera	B-FUNC
.	O

The	O
specificity	O
of	O
the	O
assay	O
appears	O
to	O
be	O
high	O
as	O
no	O
positive	O
reaction	O
was	O
detected	O
in	O
the	O
sera	B-FUNC
of	O
20	O
healthy	O
subjects	O
and	O
73	O
patients	O
with	O
non	O
-	O
SARS	O
,	O
low	O
-	O
tract	O
respiratory	O
infections	O
.	O

Specific	O
hyper	O
-	O
immune	O
sera	B-FUNC
to	O
SARS	O
-	O
CoV	O
and	O
the	O
recombinant	O
proteins	O
,	O
N	O
,	O
N1	O
,	O
N2	O
,	O
N3	O
,	O
and	O
M2	O
were	O
also	O
generated	O
in	O
mice	O
and	O
rabbits	O
.	O

The	O
specificity	O
of	O
these	O
sera	B-FUNC
was	O
confirmed	O
by	O
an	O
immunocytochemical	O
assay	O
on	O
biochips	O
of	O
SARS	O
-	O
CoV	O
infected	O
and	O
uninfected	O
cells	O
.	O

During	O
purification	O
,	O
the	O
full	O
-	O
length	O
GST	O
-	O
RdRp	B-FUNC
was	O
found	O
to	O
cleave	O
into	O
three	O
main	O
fragments	O
:	O
an	O
N	O
-	O
terminal	O
p12	O
fragment	O
,	O
a	O
middle	O
p30	O
fragment	O
,	O
and	O
a	O
C	O
-	O
terminal	O
p64	O
fragment	O
comprising	O
the	O
catalytic	O
domain	O
,	O
presumably	O
due	O
to	O
bacterial	O
proteases	O
.	O

Biochemical	O
assays	O
show	O
that	O
the	O
full	O
-	O
length	O
GST	O
-	O
RdRp	B-FUNC
has	O
RdRp	B-FUNC
activity	O
and	O
the	O
p64	O
and	O
p12	O
fragments	O
form	O
a	O
complex	O
that	O
exhibits	O
comparable	O
RdRp	B-FUNC
activity	O
,	O
whereas	O
the	O
GST	O
-	O
p64	O
protein	O
has	O
no	O
activity	O
,	O
suggesting	O
that	O
the	O
p12	O
domain	O
is	O
required	O
for	O
polymerase	O
activity	O
possibly	O
via	O
involvement	O
in	O
template	O
-	O
primer	O
binding	B-FUNC
.	O

Nonnucleoside	O
HIV	O
-	O
1	O
RT	O
inhibitors	O
are	O
shown	O
to	O
have	O
no	O
evident	O
inhibitory	O
effect	O
on	O
SARS	O
-	O
CoV	O
RdRp	B-FUNC
activity	O
.	O

This	O
work	O
provides	O
a	O
basis	O
for	O
biochemical	O
and	O
structural	O
studies	O
of	O
SARS	O
-	O
CoV	O
RdRp	B-FUNC
and	O
for	O
development	O
of	O
anti	O
-	O
SARS	O
drugs	O
.	O

Similar	O
to	O
other	O
coronavirus	O
N	O
proteins	O
,	O
SARS	O
-	O
CoV	O
N	O
protein	O
is	O
predicted	O
to	O
be	O
phosphorylated	O
and	O
may	O
contain	O
nuclear	O
localization	O
signals	O
,	O
serine	O
/	O
arginine	O
-	O
rich	O
motif	O
,	O
RNA	B-FUNC
binding	I-FUNC
domain	O
and	O
regions	O
responsible	O
for	O
self	O
-	O
association	O
and	O
homo	O
-	O
oligomerization	O
.	O

These	O
results	O
suggest	O
that	O
the	O
N	O
protein	O
oligomerization	O
involves	O
the	O
C	O
-	O
terminal	O
residues	O
285	O
-	O
422	O
,	O
and	O
this	O
region	O
is	O
a	O
good	O
target	O
for	O
mutagenic	O
studies	O
to	O
disrupt	O
N	O
protein	B-FUNC
self	I-FUNC
-	I-FUNC
association	I-FUNC
and	O
virion	O
assembly	O
.	O

ABSTRACT	O
:	O
In	O
this	O
report	O
,	O
the	O
antiviral	O
activity	O
of	O
80R	O
immunoglobulin	B-FUNC
G1	O
(	O
IgG1	O
),	O
a	O
human	O
monoclonal	O
antibody	B-FUNC
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
protein	O
that	O
acts	O
as	O
a	O
viral	O
entry	O
inhibitor	O
in	O
vitro	O
,	O
was	O
investigated	O
in	O
vivo	O
in	O
a	O
mouse	O
model	O
.	O

These	O
monoclonal	O
antibodies	O
would	O
be	O
a	O
useful	O
tool	O
for	O
rapid	O
and	O
specific	O
diagnosis	O
of	O
SARS	O
and	O
also	O
for	O
possible	O
antibody	B-FUNC
-	O
based	O
treatment	O
of	O
the	O
disease	O
.	O

IL	O
-	O
12p70	O
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
and	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
concentrations	O
were	O
consistently	O
highest	O
within	O
5	O
days	O
of	O
peak	O
viral	O
load	O
.	O

TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
RANTES	O
and	O
MCP	B-FUNC
-	O
1	O
levels	O
were	O
increased	O
.	O

As	O
a	O
target	O
for	O
screening	O
,	O
both	O
a	O
homology	O
model	O
and	O
the	O
crystallographic	O
structure	O
of	O
the	O
binding	B-FUNC
pocket	O
of	O
the	O
enzyme	O
were	O
used	O
.	O

Binding	B-FUNC
of	O
both	O
cinanserin	O
and	O
its	O
hydrochloride	O
to	O
bacterially	O
expressed	O
3CLpro	O
of	O
SARS	O
-	O
CoV	O
and	O
the	O
related	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
was	O
demonstrated	O
by	O
surface	O
plasmon	O
resonance	O
technology	O
.	O

TITLE	O
:	O
Characterization	O
of	O
monoclonal	O
antibody	B-FUNC
against	O
SARS	O
coronavirus	O
nucleocapsid	O
antigen	O
and	O
development	O
of	O
an	O
antigen	O
capture	O
ELISA	O
.	O

Baseline	O
total	O
protein	O
C	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
TNF	O
-	O
alpha	O
,	O
and	O
procalcitonin	O
concentrations	O
,	O
and	O
the	O
change	O
in	O
plasma	O
cytokine	O
concentrations	O
from	O
baseline	O
over	O
the	O
initial	O
4	O
days	O
were	O
not	O
useful	O
in	O
predicting	O
outcome	O
.	O

Sukumo	O
extract	O
was	O
found	O
to	O
interact	O
with	O
both	O
the	O
viral	O
envelope	O
glycoprotein	O
and	O
cellular	O
receptors	O
,	O
thus	O
blocking	O
virus	O
-	O
cell	O
binding	B-FUNC
and	O
virus	O
-	O
induced	O
syncytium	O
formation	O
.	O

Epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
airway	O
inflammation	O
as	O
well	O
as	O
a	O
proinflammatory	O
effect	O
in	O
other	O
tissues	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
the	O
inhibitors	O
of	O
JNK	B-FUNC
and	O
PI3K	B-FUNC
/	O
Akt	O
inhibited	O
the	O
establishment	O
of	O
persistence	O
,	O
but	O
those	O
of	O
MAPK	B-FUNC
/	O
ERK	B-FUNC
kinase	O
(	O
MEK	O
;	O
as	O
an	O
inhibitor	O
for	O
ERK1	B-FUNC
/	O
2	O
)	O
and	O
p38	B-FUNC
MAPK	B-FUNC
did	O
not	O
.	O

The	O
gene	O
expression	O
profiles	O
of	O
macrophages	O
infected	O
with	O
SARS	O
-	O
CoV	O
,	O
human	O
coronavirus	O
229E	O
,	O
and	O
influenza	O
A	O
(	O
H1N1	O
)	O
virus	O
were	O
compared	O
by	O
using	O
microarrays	O
and	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcriptase	B-FUNC
PCR	O
.	O

A	O
single	O
step	O
realtime	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
diagnostic	O
kit	B-FUNC
was	O
performed	O
for	O
screening	O
SARS	O
-	O
CoV	O
like	O
virus	O
,	O
the	O
manual	O
nested	O
RT	O
-	O
PCR	O
and	O
DNA	O
sequencing	O
were	O
performed	O
for	O
confirmation	O
.	O

TITLE	O
:	O
A	O
human	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	B-FUNC
against	O
epitope	O
on	O
S2	O
protein	O
.	O

TITLE	O
:	O
[	O
Study	O
on	O
the	O
dynamics	O
of	O
IgG	O
antibody	B-FUNC
in	O
311	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

IgG	O
antibody	B-FUNC
level	O
showed	O
a	O
35	O
.	O
8	O
%	O
decrease	O
within	O
one	O
year	O
.	O

CONCLUSIONS	O
:	O
Data	O
showed	O
that	O
all	O
the	O
SARS	O
convalescent	O
patients	O
had	O
generated	O
high	O
level	O
of	O
specific	O
IgG	O
antibody	B-FUNC
against	O
coronavirus	O
in	O
the	O
early	O
stage	O
of	O
recovery	O
,	O
but	O
the	O
antibody	B-FUNC
level	O
declined	O
along	O
with	O
the	O
progress	O
of	O
convalescence	O
,	O
suggesting	O
that	O
the	O
detection	O
of	O
the	O
IgG	O
antibody	B-FUNC
should	O
go	O
on	O
until	O
it	O
disappeared	O
.	O

One	O
group	O
of	O
piglets	O
served	O
as	O
a	O
control	O
(	O
n	O
=	O
8	O
),	O
a	O
second	O
group	O
(	O
S	O
,	O
n	O
=	O
8	O
)	O
received	O
a	O
porcine	O
surfactant	O
preparation	O
(	O
Curosurf	O
),	O
and	O
a	O
third	O
group	O
received	O
IKK	B-FUNC
-	O
NBD	O
peptide	O
admixed	O
to	O
surfactant	O
(	O
S	O
+	O
IN	O
,	O
n	O
=	O
8	O
).	O

SARS	O
antibody	B-FUNC
could	O
be	O
detected	O
since	O
the	O
sixth	O
day	O
after	O
onset	O
,	O
and	O
the	O
titer	O
increased	O
from	O
1	O
:	O
40	O
to	O
1	O
:	O
600	O
on	O
the	O
ninth	O
day	O
.	O

TITLE	O
:	O
Mouse	O
hepatitis	O
virus	O
3	O
binding	B-FUNC
to	O
macrophages	O
correlates	O
with	O
resistance	O
to	O
experimental	O
infection	O
.	O

We	O
identified	O
the	O
immunodominant	O
antigenic	O
sites	O
responsible	O
for	O
the	O
antibodies	O
in	O
sera	B-FUNC
from	O
SARS	O
patients	O
and	O
antisera	O
from	O
small	O
animals	O
and	O
differentiated	O
the	O
linear	O
from	O
the	O
conformational	O
antibody	B-FUNC
-	O
combining	O
sites	O
comprising	O
the	O
natural	O
epitopes	O
by	O
use	O
of	O
yeast	O
surface	O
display	O
.	O

The	O
antibody	B-FUNC
responses	O
to	O
the	O
N	O
protein	O
fragments	O
in	O
mammalian	O
sera	B-FUNC
revealed	O
that	O
3	O
regions	O
of	O
the	O
N	O
protein	O
are	O
strong	O
antigenic	O
domains	O
.	O

Our	O
model	O
,	O
supported	O
by	O
significant	O
biochemical	O
evidence	O
,	O
suggested	O
receptor	O
-	O
binding	B-FUNC
residues	O
were	O
concentrated	O
in	O
two	O
segments	O
of	O
S1	O
protein	O
.	O

CONCLUSIONS	O
:	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
neutrophil	O
activator	O
production	O
by	O
the	O
isolated	O
perfused	O
liver	O
,	O
in	O
response	O
to	O
a	O
'	O
second	O
hit	O
'	O
of	O
portal	O
LPS	O
,	O
does	O
not	O
appear	O
to	O
be	O
enhanced	O
during	O
AP	O
.	O

High	O
IgG	O
levels	O
were	O
detected	O
in	O
mice	O
immunized	O
with	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.)	O
recombinant	O
spike	O
polypeptide	O
generated	O
by	O
Escherichia	O
coli	O
(	O
S	O
-	O
peptide	O
),	O
mice	O
primed	O
with	O
intramuscular	O
(	O
i	O
.	O
m	O
.)	O
tPA	B-FUNC
-	O
optimize800	O
DNA	O
vaccine	O
(	O
tPA	B-FUNC
-	O
S	O
-	O
DNA	O
)	O
and	O
boosted	O
with	O
i	O
.	O
p	O
.	O

S	O
-	O
peptide	O
showed	O
neutralizing	O
antibody	B-FUNC
titers	O
of	O
<	O
1	O
:	O
20	O
-	O
1	O
:	O
160	O
.	O

The	O
former	O
was	O
less	O
laborious	O
with	O
shorter	O
time	O
for	O
completion	O
and	O
can	O
easily	O
be	O
adapted	O
to	O
an	O
automated	O
system	O
such	O
as	O
the	O
MagNa	O
Pure	B-FUNC
-	O
LC	O
,	O
which	O
can	O
extract	O
nucleic	O
acid	O
from	O
clinical	O
samples	O
and	O
load	O
it	O
into	O
the	O
sample	O
capillaries	O
of	O
the	O
LightCycler	O
.	O

In	O
this	O
article	O
,	O
we	O
describe	O
the	O
problems	O
and	O
solutions	O
of	O
setting	O
up	O
the	O
recombinant	O
SARS	O
-	O
CoV	O
S	O
-	O
based	O
ELISA	O
for	O
antibody	B-FUNC
detection	O
.	O

Results	O
obtained	O
by	O
the	O
recombinant	O
S	O
(	O
rS	O
)-	O
based	O
IgG	O
ELISA	O
using	O
the	O
regenerated	O
S	O
prepared	O
by	O
dialysis	O
with	O
decreasing	O
concentrations	O
of	O
urea	O
or	O
direct	O
addition	O
of	O
different	O
coating	O
buffers	O
,	O
followed	O
by	O
addition	O
of	O
different	O
regeneration	O
buffer	O
,	O
identified	O
4	O
M	O
urea	O
and	O
1	O
M	O
sarcosine	O
for	O
plate	O
coating	O
and	O
no	O
regeneration	O
buffer	O
as	O
the	O
most	O
optimal	O
conditions	O
for	O
antibody	B-FUNC
detection	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
PCR	O
and	O
real	O
-	O
time	O
loop	O
-	O
mediated	O
amplification	O
assays	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
detection	O
.	O

When	O
both	O
the	O
liver	O
and	O
lung	O
were	O
perfused	O
,	O
endotoxin	O
caused	O
marked	O
hypoxemia	O
,	O
large	O
increases	O
in	O
perfusate	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
8	O
-	O
isoprostane	O
concentrations	O
,	O
and	O
severe	O
lung	O
edema	O
.	O

The	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
and	O
the	O
viral	O
RNA	O
were	O
also	O
detected	O
in	O
the	O
sera	B-FUNC
by	O
ELISA	O
and	O
RT	O
-	O
PCR	O
,	O
respectively	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
to	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
spike	O
protein	O
domain	O
2	O
cross	O
-	O
reacts	O
with	O
lung	O
epithelial	O
cells	O
and	O
causes	O
cytotoxicity	O
.	O

The	O
rest	B-FUNC
could	O
be	O
infected	O
with	O
FECV	O
and	O
FIPV	O
but	O
10	O
/	O
22	O
cats	O
had	O
monocytes	O
that	O
only	O
sustained	O
FIPV	O
infection	O
and	O
9	O
/	O
22	O
sustained	O
neither	O
FIPV	O
nor	O
FECV	O
infection	O
.	O

SARS	O
-	O
CoV	O
mediates	O
receptor	B-FUNC
binding	I-FUNC
and	O
entry	O
by	O
its	O
spike	O
(	O
S	O
)	O
glycoprotein	O
,	O
and	O
infection	O
is	O
sensitive	O
to	O
lysosomotropic	O
agents	O
that	O
perturb	O
endosomal	O
pH	O
.	O
We	O
demonstrate	O
here	O
that	O
the	O
lysosomotropic	O
-	O
agent	O
-	O
mediated	O
block	O
to	O
SARS	O
-	O
CoV	O
infection	O
is	O
overcome	O
by	O
protease	O
treatment	O
of	O
target	O
-	O
cell	O
-	O
associated	O
virus	O
.	O

To	O
date	O
,	O
molecular	O
assays	O
for	O
the	O
detection	O
of	O
SARS	O
-	O
CoV	O
has	O
focused	O
mainly	O
on	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
of	O
specimens	O
.	O

ABSTRACT	O
:	O
The	O
association	O
between	O
a	O
robust	O
or	O
depressed	O
antibody	B-FUNC
response	O
and	O
clinical	O
severity	O
of	O
SARS	O
remains	O
unknown	O
.	O

A	O
retrospective	O
analysis	O
of	O
all	O
acute	O
and	O
convalescent	O
-	O
phase	O
sera	B-FUNC
collected	O
from	O
a	O
cohort	O
of	O
laboratory	O
-	O
confirmed	O
SARS	O
cases	O
.	O

TITLE	O
:	O
A	O
serological	O
survey	O
on	O
neutralizing	O
antibody	B-FUNC
titer	O
of	O
SARS	O
convalescent	O
sera	B-FUNC
.	O

ABSTRACT	O
:	O
A	O
seroepidemiologic	O
study	O
was	O
conducted	O
in	O
North	O
China	O
in	O
2003	O
to	O
determine	O
the	O
neutralizing	O
antibody	B-FUNC
titer	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
convalescent	O
sera	B-FUNC
.	O

TITLE	O
:	O
The	O
SARS	O
coronavirus	O
S	O
glycoprotein	O
receptor	B-FUNC
binding	I-FUNC
domain	O
:	O
fine	O
mapping	O
and	O
functional	O
characterization	O
.	O

Glycosylation	O
did	O
not	O
affect	O
binding	B-FUNC
to	O
ACE2	O
.	O

Alanine	O
scanning	O
mutagenesis	O
of	O
the	O
fragment	O
S319	O
-	O
518	O
resulted	O
in	O
the	O
identification	O
of	O
ten	O
residues	O
(	O
K390	O
,	O
R426	O
,	O
D429	O
,	O
T431	O
,	O
I455	O
,	O
N473	O
,	O
F483	O
,	O
Q492	O
,	O
Y494	O
,	O
R495	O
)	O
that	O
significantly	O
reduced	O
binding	B-FUNC
to	O
ACE2	O
,	O
and	O
one	O
residue	O
(	O
D393	O
)	O
that	O
appears	O
to	O
increase	O
binding	B-FUNC
.	O

However	O
,	O
anti	O
-	O
inflammatory	O
agents	O
such	O
as	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
receptor	O
,	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
receptor	O
,	O
IL	B-FUNC
-	I-FUNC
1Ra	I-FUNC
,	O
and	O
TNF	O
-	O
alpha	O
-	O
induced	O
proteins	O
3	O
and	O
6	O
also	O
increased	O
dramatically	O
in	O
the	O
acute	O
severe	O
case	O
.	O

The	O
incidence	O
of	O
IAH	B-FUNC
(	O
defined	O
as	O
intra	O
-	O
abdominal	O
pressure	O
>	O
or	O
=	O
15	O
mmHg	O
)	O
was	O
recorded	O
.	O

APACHE	O
II	O
and	O
Ranson	O
scores	O
on	O
admission	O
were	O
higher	O
in	O
patients	O
who	O
developed	O
IAH	B-FUNC
.	O

The	O
incidence	O
of	O
organ	O
dysfunction	O
was	O
high	O
in	O
patients	O
with	O
IAH	B-FUNC
:	O
respiratory	O
failure	O
95	O
%,	O
cardiovascular	O
failure	O
91	O
%,	O
and	O
renal	O
failure	O
86	O
%.	O

Our	O
work	O
has	O
provided	O
experimental	O
support	O
for	O
testing	O
the	O
protective	O
equine	O
immunoglobulin	B-FUNC
in	O
future	O
large	O
primate	O
or	O
human	O
trials	O
.	O

We	O
assessed	O
whether	O
mannose	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
)	O
gene	O
polymorphisms	O
were	O
associated	O
with	O
susceptibility	O
to	O
SARS	O
-	O
CoV	O
infection	O
or	O
disease	O
severity	O
in	O
an	O
ethnically	O
homogeneous	O
population	O
born	O
in	O
northern	O
China	O
.	O

The	O
results	O
showed	O
that	O
although	O
the	O
incorporated	O
isonucleotides	O
at	O
certain	O
positions	O
of	O
the	O
sequence	O
interfere	O
with	O
the	O
binding	B-FUNC
ability	O
to	O
a	O
different	O
extent	O
,	O
B	O
-	O
form	O
duplexes	O
were	O
maintained	O
and	O
the	O
binding	B-FUNC
abilities	O
of	O
the	O
3	O
'-	O
end	O
-	O
modified	O
duplexes	O
were	O
better	O
than	O
the	O
corresponding	O
mismatched	O
duplexes	O
.	O

Both	O
components	O
of	O
the	O
fusion	O
proteins	O
were	O
detected	O
in	O
Western	O
blot	O
analysis	O
,	O
and	O
binding	B-FUNC
assay	O
confirmed	O
that	O
plant	O
-	O
synthesized	O
pentameric	O
LTB	O
-	O
PEDV	O
fusion	O
bound	O
to	O
the	O
intestinal	O
membrane	O
GM1	O
-	O
ganglioside	O
receptor	O
.	O

TITLE	O
:	O
Cellular	O
composition	O
and	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
expression	O
of	O
the	O
local	O
inflammatory	O
response	O
in	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

Serum	O
antibody	B-FUNC
(	O
IgG	O
)	O
titre	O
was	O
>	O
640	O
.	O

Specific	O
immunoglobulin	B-FUNC
IgM	O
and	O
IgG	O
concentrations	O
were	O
titrated	O
using	O
an	O
antigen	O
microarray	O
developed	O
in	O
-	O
house	O
.	O

Passive	O
transfer	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
from	O
the	O
mother	O
was	O
considered	O
as	O
a	O
possibility	O
.	O

Passive	O
transfer	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
from	O
the	O
mother	O
was	O
considered	O
as	O
a	O
possibility	O
.	O

The	O
antibody	B-FUNC
development	O
in	O
seven	O
cats	O
experimentally	O
infected	O
with	O
FCoV	O
type	O
1	O
revealed	O
that	O
,	O
with	O
progressing	O
duration	O
of	O
infection	O
,	O
antibodies	O
to	O
FCoV	O
type	O
1	O
significantly	O
increased	O
over	O
those	O
to	O
FCoV	O
type	O
2	O
.	O

Using	O
a	O
specific	O
monoclonal	O
antibody	B-FUNC
,	O
we	O
demonstrated	O
that	O
the	O
3a	O
protein	O
displayed	O
a	O
punctate	O
cytoplasmic	O
localization	O
in	O
Drosophila	O
as	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

Three	O
-	O
dimensional	O
reconstruction	O
of	O
negatively	O
stained	O
single	O
particles	O
of	O
Nsp15	O
viewed	O
by	O
transmission	O
electron	O
microscopic	O
analysis	O
suggested	O
that	O
the	O
six	O
subunits	O
were	O
arranged	O
as	O
a	O
dimer	O
of	O
trimers	O
with	O
a	O
number	O
of	O
cavities	O
or	O
channels	O
that	O
may	O
constitute	O
RNA	B-FUNC
binding	I-FUNC
sites	O
.	O

SARS	O
-	O
specific	O
IgG	O
antibody	B-FUNC
is	O
generated	O
in	O
the	O
second	O
week	O
and	O
persists	O
for	O
a	O
long	O
time	O
,	O
whereas	O
IgM	O
is	O
expressed	O
transiently	O
.	O

They	O
could	O
bind	B-FUNC
specifically	O
to	O
protein	O
X4	O
proved	O
by	O
Western	O
blotting	O
.	O

TITLE	O
:	O
Binding	B-FUNC
interaction	O
of	O
SARS	O
coronavirus	O
3CL	O
(	O
pro	O
)	O
protease	O
with	O
vacuolar	O
-	O
H	O
+	O
ATPase	O
G1	O
subunit	O
.	O

STAR	O
demonstrated	O
similar	O
or	O
better	O
sensitivity	O
and	O
precision	O
compared	O
to	O
two	O
commonly	O
used	O
methods	O
,	O
SYBR	O
Green	O
-	O
based	O
and	O
TaqMan	O
probe	O
-	O
based	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
.	O

The	O
MD	O
simulations	O
take	O
into	O
account	O
the	O
different	O
protonation	O
states	O
of	O
two	O
histidine	O
residues	O
in	O
the	O
substrate	O
-	O
binding	B-FUNC
site	O
and	O
explain	O
the	O
pH	O
-	O
activity	O
profile	O
of	O
the	O
enzyme	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
activity	O
of	O
an	O
octapeptide	O
inhibitor	O
designed	O
for	O
SARS	O
coronavirus	O
main	O
proteinase	B-FUNC
.	O

A	O
filter	O
binding	B-FUNC
assay	O
and	O
competition	O
analysis	O
further	O
demonstrated	O
that	O
the	O
N	O
-	O
terminal	O
and	O
C	O
-	O
terminal	O
regions	O
of	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	O
each	O
contain	O
a	O
binding	B-FUNC
activity	O
specific	O
to	O
the	O
viral	O
RNA	O
.	O

Recombinant	O
N	O
protein	O
reacted	O
strongly	O
and	O
specifically	O
with	O
the	O
sera	B-FUNC
from	O
immunized	O
mice	O
and	O
SARS	O
patients	O
.	O

The	O
first	O
qualitative	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
tests	O
for	O
SARS	O
-	O
coronavirus	O
(	O
CoV	O
)	O
were	O
sensitive	O
and	O
capable	O
of	O
detecting	O
1	O
to	O
10	O
genome	O
equivalents	O
.	O

After	O
virus	O
attack	O
,	O
the	O
level	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgG	O
and	O
neutralizing	O
antibody	B-FUNC
were	O
induced	O
by	O
SARS	O
-	O
CoV	O
in	O
the	O
interferon	O
group	O
was	O
weaker	O
than	O
in	O
control	O
group	O
.	O

Sequence	O
analysis	O
indicated	O
that	O
two	O
of	O
the	O
isolated	O
anti	O
-	O
N	O
scFv	O
clones	O
were	O
identical	O
and	O
displayed	O
a	O
high	O
homology	O
with	O
an	O
scFv	O
specific	O
for	O
interleukin	O
11	O
(	O
IL	B-FUNC
-	I-FUNC
11	I-FUNC
),	O
an	O
anti	O
-	O
inflammatory	O
cytokine	O
derived	O
from	O
bone	O
marrow	O
stroma	O
cells	O
.	O

The	O
combination	O
of	O
pulse	O
corticosteroids	O
,	O
pulse	O
cyclophosphamide	O
,	O
and	O
high	O
-	O
dose	O
intravenous	O
immunoglobulin	B-FUNC
seemed	O
effective	O
for	O
the	O
acute	O
phase	O
of	O
severe	O
Churg	O
-	O
Strauss	O
syndrome	O
.	O

ABSTRACT	O
:	O
Spike	O
protein	O
of	O
coronavirus	O
is	O
responsible	O
for	O
virus	O
binding	B-FUNC
,	O
fusion	O
and	O
entry	O
,	O
and	O
is	O
a	O
major	O
inducer	O
of	O
neutralizing	O
antibodies	O
.	O

This	O
paper	O
was	O
to	O
find	O
a	O
soluble	O
and	O
functional	O
recombinant	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
Cov	O
),	O
and	O
to	O
analyze	O
its	O
receptor	B-FUNC
binding	I-FUNC
ability	O
.	O

Three	O
fusion	O
tags	O
(	O
glutathione	O
S	O
-	O
transferase	O
,	O
GST	O
;	O
thioredoxin	O
,	O
Trx	O
;	O
maltose	O
-	O
binding	B-FUNC
protein	O
,	O
MBP	O
),	O
which	O
preferably	O
contributes	O
to	O
increasing	O
solubility	O
and	O
to	O
facilitating	O
the	O
proper	O
folding	O
of	O
heteroprotein	O
,	O
were	O
used	O
to	O
acquire	O
the	O
soluble	O
and	O
functional	O
expression	O
of	O
RBD	O
protein	O
in	O
Escherichia	O
coli	O
(	O
BL21	O
(	O
DE3	O
)	O
and	O
Rosetta	O
-	O
gamiB	O
(	O
DE3	O
)	O
strains	O
).	O

The	O
geometrical	O
mean	O
of	O
GST	O
and	O
GST	O
/	O
RBD	O
binding	B-FUNC
to	O
Vero	O
E6	O
cells	O
were	O
77	O
.	O
08	O
and	O
352	O
.	O
73	O
respectively	O
.	O

Endothelial	O
injury	O
bio	O
-	O
markers	O
tPA	B-FUNC
and	O
sTM	O
were	O
detected	O
by	O
commercial	O
ELISA	O
-	O
methods	O
.	O

The	O
likelihood	O
ratio	O
analysis	O
indicated	O
the	O
excellent	O
discriminating	O
power	O
for	O
SARS	O
at	O
the	O
optimal	O
cut	O
-	O
point	O
of	O
0	O
.	O
49	O
nmol	O
/	O
L	O
for	O
tPA	B-FUNC
and	O
0	O
.	O
20	O
nmol	O
/	O
L	O
for	O
sTM	O
,	O
respectively	O
.	O

This	O
implementation	O
showed	O
high	O
accuracy	O
in	O
the	O
prediction	O
of	O
the	O
promiscuous	O
peptides	O
that	O
bind	B-FUNC
to	O
five	O
HLA	O
-	O
A2	O
allelic	O
variants	O
.	O

MULTIPRED	O
is	O
useful	O
for	O
the	O
identification	O
of	O
peptides	O
that	O
bind	B-FUNC
multiple	O
HLA	O
-	O
A2	O
variants	O
as	O
a	O
group	O
.	O

The	O
ANN	O
MULTIPRED	O
predicts	O
peptide	B-FUNC
binding	I-FUNC
to	O
HLA	O
-	O
A	O
*	O
0205	O
with	O
excellent	O
accuracy	O
(	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
--	O
AROC	O
>	O
0	O
.	O
90	O
),	O
and	O
to	O
HLA	O
-	O
A	O
*	O
0201	O
,	O
HLA	O
-	O
A	O
*	O
0204	O
and	O
HLA	O
-	O
A	O
*	O
0206	O
with	O
high	O
accuracy	O
(	O
AROC	O
>	O
0	O
.	O
85	O
).	O

TITLE	O
:	O
Specific	O
targeting	O
highly	O
conserved	O
residues	O
in	O
the	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
primer	O
grip	O
region	O
.	O

Additionally	O
we	O
have	O
identified	O
a	O
role	O
for	O
the	O
3	O
'-	O
terminal	O
42	O
-	O
nucleotide	O
host	O
protein	B-FUNC
binding	I-FUNC
element	O
in	O
RNA	O
replication	O
and	O
transcription	O
using	O
DI	O
RNA	O
replication	O
assays	O
and	O
targeted	O
recombination	O
and	O
by	O
directly	O
constructing	O
mutants	O
in	O
this	O
protein	B-FUNC
binding	I-FUNC
element	O
using	O
a	O
recently	O
described	O
MHV	O
reverse	O
genetic	O
system	O
.	O

DI	O
RNA	O
replication	O
assays	O
demonstrated	O
that	O
mutations	O
in	O
the	O
3	O
'(+)	O
42	O
host	O
protein	B-FUNC
binding	I-FUNC
element	O
had	O
a	O
deleterious	O
effect	O
on	O
the	O
accumulation	O
of	O
DI	O
RNA	O
.	O

The	O
specific	O
IgG	O
and	O
neutralizing	O
antibody	B-FUNC
titers	O
peaked	O
at	O
approximately	O
week	O
7	O
after	O
the	O
first	O
immunization	O
,	O
with	O
a	O
maximum	O
value	O
of	O
1	O
:	O
14210	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
is	O
a	O
viral	O
RNA	O
-	O
binding	B-FUNC
protein	O
with	O
multiple	O
functions	O
in	O
terms	O
of	O
virus	O
replication	O
and	O
modulating	O
cell	O
signalling	O
pathways	O
.	O

Recovered	O
patients	O
were	O
found	O
to	O
have	O
higher	O
and	O
sustainable	O
levels	O
of	O
both	O
N	O
protein	O
-	O
specific	O
and	O
S	O
glycoprotein	O
-	O
specific	O
Nab	O
responses	O
,	O
suggesting	O
that	O
antibody	B-FUNC
responses	O
likely	O
play	O
an	O
important	O
role	O
in	O
determining	O
the	O
ultimate	O
disease	O
outcome	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
patients	O
.	O

ABSTRACT	O
:	O
Group	O
2	O
coronaviruses	O
encode	O
an	O
accessory	O
envelope	O
glycoprotein	O
species	O
,	O
the	O
hemagglutinin	O
esterase	O
(	O
HE	O
),	O
which	O
possesses	O
sialate	O
-	O
O	O
-	O
acetylesterase	B-FUNC
activity	I-FUNC
and	O
which	O
,	O
presumably	O
,	O
promotes	O
virus	O
spread	O
and	O
entry	O
in	O
vivo	O
by	O
facilitating	O
reversible	O
virion	O
attachment	O
to	O
O	O
-	O
acetylated	O
sialic	O
acids	O
.	O

In	O
this	O
study	O
we	O
assessed	O
the	O
role	O
of	O
the	O
cytoprotective	O
and	O
anti	O
-	O
inflammatory	O
enzyme	O
heme	O
oxygenase	B-FUNC
(	O
HO	O
)-	O
1	O
in	O
a	O
model	O
of	O
nebulized	O
endotoxin	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

Yolk	O
immunoglobulin	B-FUNC
(	O
IgY	O
)	O
was	O
extracted	O
using	O
the	O
water	O
dilution	O
method	O
,	O
followed	O
by	O
further	O
purification	O
on	O
a	O
Sephadex	O
G	O
-	O
75	O
column	O
.	O

Peptide	O
cleavage	O
assay	O
confirms	O
that	O
peptide	O
N8	O
is	O
a	O
dimerization	O
inhibitor	O
with	O
a	O
K	O
(	O
i	O
)	O
of	O
2	O
.	O
20mM	O
.	O
The	O
comparison	O
of	O
the	O
inhibitory	O
activities	O
of	O
N8	O
and	O
its	O
mutants	O
indicates	O
that	O
the	O
hydrophobic	O
interaction	O
of	O
Met	O
-	O
6	O
and	O
the	O
electrostatic	O
interaction	O
of	O
Arg	O
-	O
4	O
contribute	O
most	O
for	O
inhibitor	O
binding	B-FUNC
.	O

Therefore	O
,	O
we	O
assayed	O
the	O
inhibitory	O
effects	O
of	O
small	O
peptides	O
derived	O
from	O
S	O
protein	O
on	O
the	O
binding	B-FUNC
of	O
S	O
protein	O
to	O
ACE2	O
and	O
on	O
the	O
S	O
-	O
protein	O
-	O
pseudotyped	O
retrovirus	O
infectivity	O
.	O

SP	O
-	O
10	O
blocked	O
both	O
binding	B-FUNC
of	O
the	O
S	O
protein	O
and	O
infectivity	O
of	O
S	O
protein	O
-	O
pseudotyped	O
retrovirus	O
to	O
Vero	O
E6	O
cells	O
.	O

TITLE	O
:	O
Longitudinal	O
analysis	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
coronavirus	O
-	O
specific	O
antibody	B-FUNC
in	O
SARS	O
patients	O
.	O

Fifteen	O
out	O
of	O
17	O
tested	O
positive	O
for	O
the	O
IgM	O
antibody	B-FUNC
at	O
1	O
month	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
replicase	O
-	O
transcriptase	B-FUNC
complex	O
is	O
an	O
assembly	O
of	O
viral	O
and	O
cellular	O
proteins	O
that	O
mediate	O
the	O
synthesis	O
of	O
genome	O
and	O
subgenome	O
-	O
sized	O
mRNAs	O
in	O
the	O
virus	O
-	O
infected	O
cell	O
.	O

TITLE	O
:	O
7a	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
inhibits	O
cellular	O
protein	O
synthesis	O
and	O
activates	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
peak	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
TNF	O
-	O
alpha	O
between	O
patients	O
with	O
and	O
without	O
ARDS	O
.	O

Multiple	O
animal	O
groups	O
and	O
postaspiration	O
times	O
of	O
injury	O
were	O
analyzed	O
to	O
gauge	O
the	O
applicability	O
of	O
the	O
predictive	O
approach	O
:	O
rats	O
(	O
6	O
and	O
24	O
h	O
),	O
C57	O
/	O
BL6	O
wild	O
-	O
type	O
mice	O
(	O
5	O
and	O
24	O
h	O
),	O
and	O
transgenic	O
mice	O
on	O
the	O
same	O
background	O
deficient	O
in	O
the	O
gene	O
for	O
monocyte	O
chemoattractant	O
protein	O
1	O
(	O
MCP	B-FUNC
-	O
1	O
[-/-]	O
mice	O
;	O
5	O
and	O
24	O
h	O
).	O

Overall	O
,	O
the	O
four	O
types	O
of	O
aspiration	O
were	O
correctly	O
discriminated	O
in	O
85	O
of	O
96	O
rats	O
(	O
89	O
%),	O
72	O
of	O
78	O
wild	O
-	O
type	O
mice	O
(	O
92	O
%),	O
and	O
59	O
of	O
73	O
MCP	B-FUNC
-	O
1	O
(-/-)	O
mice	O
(	O
81	O
%)	O
by	O
models	O
that	O
used	O
a	O
maximum	O
of	O
only	O
two	O
mediators	O
.	O

(	O
4	O
)	O
Compared	O
with	O
Nc	O
group	O
,	O
the	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
TGF	O
-	O
beta1	O
in	O
both	O
serum	O
and	O
BALF	O
of	O
P1	O
group	O
were	O
significantly	O
increased	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
and	O
the	O
levels	O
of	O
these	O
cytokines	O
in	O
P2	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
P1	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
but	O
significantly	O
lower	O
in	O
P	O
+	O
D	O
group	O
compared	O
with	O
P2	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

We	O
identified	O
three	O
changes	O
in	O
the	O
HCoV	O
-	O
OC43	O
surface	O
glycoprotein	O
that	O
correlated	O
with	O
enhanced	O
neurovirulence	O
in	O
mice	O
;	O
these	O
were	O
located	O
in	O
the	O
domain	O
of	O
the	O
protein	O
responsible	O
for	O
binding	B-FUNC
to	O
host	O
cells	O
.	O

After	O
the	O
sequential	O
probing	O
with	O
sera	B-FUNC
from	O
convalescent	O
SARS	O
-	O
patients	O
and	O
FITC	O
-	O
labeled	O
anti	O
-	O
human	O
IgG	O
,	O
the	O
cells	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

ABSTRACT	O
:	O
The	O
capacity	O
of	O
the	O
surface	O
glycoproteins	O
of	O
enveloped	O
viruses	O
to	O
mediate	O
virus	O
/	O
cell	O
binding	B-FUNC
and	O
membrane	O
fusion	O
requires	O
a	O
proper	O
thiol	O
/	O
disulfide	O
balance	O
.	O

Neutralizing	O
viral	O
antibodies	O
were	O
demonstrated	O
in	O
the	O
convalescence	O
sera	B-FUNC
from	O
SARS	O
patients	O
.	O

Neutralizing	O
viral	O
antibodies	O
were	O
demonstrated	O
in	O
the	O
convalescence	O
sera	B-FUNC
from	O
SARS	O
patients	O
.	O

A	O
polyclonal	O
antibody	B-FUNC
against	O
fgl2	O
was	O
used	O
to	O
detect	O
the	O
expression	O
of	O
both	O
mouse	O
and	O
human	O
fgl2	O
protein	O
in	O
liver	O
samples	O
as	O
well	O
as	O
in	O
PBMC	O
by	O
immunohistochemistry	O
staining	O
in	O
a	O
separate	O
set	O
of	O
studies	O
.	O

This	O
protective	O
ability	O
of	O
the	O
WKV	O
vaccine	O
correlated	O
with	O
the	O
induction	O
of	O
high	O
serum	O
neutralizing	O
-	O
antibody	B-FUNC
titres	O
,	O
but	O
not	O
with	O
cellular	O
immune	O
responses	O
as	O
measured	O
by	O
gamma	O
interferon	O
secretion	O
by	O
mouse	O
splenocytes	O
.	O

Among	O
the	O
vaccine	O
groups	O
,	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgA	O
was	O
found	O
only	O
in	O
the	O
sera	B-FUNC
of	O
mice	O
immunized	O
intranasally	O
with	O
Ad	O
S	O
/	O
N	O
,	O
suggesting	O
that	O
mucosal	O
immunity	O
may	O
play	O
a	O
role	O
in	O
protection	O
for	O
the	O
intranasal	O
Ad	O
S	O
/	O
N	O
delivery	O
system	O
.	O

Previously	O
we	O
identified	O
the	O
extra	O
domain	O
to	O
be	O
involved	O
in	O
enzyme	O
dimerization	O
which	O
has	O
been	O
considered	O
essential	O
for	O
the	O
catalytic	B-FUNC
activity	I-FUNC
.	O

HRC	O
203	O
had	O
greater	O
anti	O
-	O
viral	O
activity	O
on	O
both	O
isolated	O
hepatocytes	O
and	O
macrophages	O
,	O
whereas	O
both	O
ribavirin	O
and	O
HRC	O
203	O
inhibited	O
production	O
of	O
the	O
pro	O
-	O
inflammatory	O
cytokines	O
interferon	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
by	O
macrophages	O
.	O

Results	O
from	O
637	O
Coronase	O
and	O
191	O
7B	O
FIP	O
antibody	B-FUNC
tests	O
were	O
recorded	O
.	O

Specifically	O
,	O
the	O
median	O
Coronase	O
antibody	B-FUNC
titres	O
of	O
Siamese	O
,	O
Persians	O
,	O
Domestic	O
Shorthairs	O
and	O
Bengal	O
cats	O
(	O
100	O
)	O
were	O
significantly	O
lower	O
than	O
that	O
of	O
British	O
Shorthairs	O
,	O
Cornish	O
Rex	B-FUNC
and	O
Burmese	O
cats	O
(	O
400	O
,	O
P	O
<	O
0	O
.	O
0005	O
).	O

CONCLUSIONS	O
:	O
This	O
study	O
reinforces	O
the	O
complexity	O
of	O
interpreting	O
serological	O
tests	O
for	O
FCoV	O
in	O
both	O
healthy	O
cats	O
and	O
patients	O
with	O
signs	O
compatible	O
with	O
FIR	O
Unique	O
to	O
this	O
study	O
is	O
the	O
detection	O
of	O
a	O
significant	O
relationship	O
between	O
breed	O
and	O
median	O
FCoV	O
antibody	B-FUNC
titre	O
.	O

Moreover	O
,	O
SARS	O
-	O
CoV	O
induced	O
THP	O
-	O
1	O
cells	O
to	O
express	O
CCL2	O
/	O
MCP	B-FUNC
-	O
1	O
,	O
CXCL8	O
/	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
CCL3	O
/	O
MIP	O
-	O
1alpha	O
,	O
CXCL10	O
/	O
IP	O
-	O
10	O
,	O
CCL4	O
/	O
MIP	O
-	O
1beta	O
,	O
and	O
CCL5	O
/	O
RANTES	O
,	O
which	O
attracted	O
neutrophils	O
,	O
monocytes	O
,	O
and	O
activated	O
T	O
cells	O
in	O
a	O
chemotaxis	O
assay	O
.	O

METHODS	O
:	O
Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
was	O
employed	O
to	O
detect	O
serum	O
antibody	B-FUNC
against	O
SARS	O
coronavirus	O
in	O
the	O
lysate	O
of	O
whole	O
SARS	O
coronavirus	O
from	O
19	O
SARS	O
patients	O
and	O
200	O
medical	O
staff	O
members	O
without	O
obvious	O
SARS	O
symptoms	O
after	O
possible	O
exposure	O
to	O
the	O
virus	O
during	O
routine	O
medical	O
practice	O
.	O

IL	B-FUNC
-	I-FUNC
15	I-FUNC
and	O
NK	O
cells	O
thus	O
appear	O
dispensable	O
for	O
anti	O
-	O
viral	O
immunity	O
and	O
CNS	O
pathogenesis	O
during	O
acute	O
JHMV	O
infection	O
.	O

TITLE	O
:	O
A	O
human	O
neutralizing	O
antibody	B-FUNC
against	O
a	O
conformational	O
epitope	O
shared	O
by	O
oligomeric	O
SARS	O
S1	O
protein	O
.	O

ABSTRACT	O
:	O
An	O
antibody	B-FUNC
phage	O
-	O
display	O
library	O
was	O
constructed	O
from	O
the	O
B	O
cells	O
of	O
convalescent	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
and	O
screened	O
using	O
inactivated	O
SARS	O
coronavirus	O
(	O
CoV	O
)	O
virions	O
as	O
antigens	O
.	O

The	O
facts	O
that	O
scFv	O
H12	O
bound	O
to	O
the	O
SARS	O
-	O
S1	O
protein	O
under	O
non	O
-	O
reducing	O
conditions	O
and	O
that	O
it	O
did	O
not	O
bind	B-FUNC
to	O
monomeric	O
S1	O
protein	O
under	O
reducing	O
conditions	O
strongly	O
suggest	O
that	O
scFv	O
H12	O
recognizes	O
a	O
conformational	O
epitope	O
shared	O
by	O
oligomeric	O
S1	O
proteins	O
.	O

ABSTRACT	O
:	O
The	O
fusogenic	O
potential	O
of	O
Class	O
I	O
viral	O
envelope	O
glycoproteins	O
is	O
activated	O
by	O
proteloytic	O
cleavage	O
of	O
the	O
precursor	O
glycoprotein	O
to	O
generate	O
the	O
mature	O
receptor	O
-	O
binding	B-FUNC
and	O
transmembrane	O
fusion	O
subunits	O
.	O

Drugs	O
that	O
selectively	O
inhibit	O
this	O
enzyme	O
,	O
when	O
used	O
in	O
combination	O
with	O
inhibitors	O
of	O
reverse	O
transcriptase	B-FUNC
and	O
protease	O
,	O
are	O
believed	O
to	O
be	O
highly	O
effective	O
in	O
suppressing	O
the	O
viral	O
replication	O
.	O

Molecular	O
modeling	O
studies	O
provide	O
a	O
plausible	O
mechanism	O
of	O
action	O
,	O
which	O
is	O
consistent	O
with	O
ligand	B-FUNC
SARs	O
and	O
enzyme	O
photo	O
-	O
cross	O
-	O
linking	O
experiments	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
a	O
specific	O
SARS	O
virus	O
-	O
targeted	O
antibody	B-FUNC
preparation	O
for	O
emergent	O
prophylaxis	O
and	O
treatment	O
of	O
SARS	O
virus	O
infection	O
.	O

By	O
using	O
phage	O
display	O
technology	O
,	O
we	O
constructed	O
a	O
naive	O
antibody	B-FUNC
library	O
from	O
convalescent	O
SARS	O
patient	O
lymphocytes	O
.	O

In	O
addition	O
,	O
the	O
SARS	O
N	O
protein	O
-	O
targeted	O
human	O
Fab	O
antibody	B-FUNC
reacted	O
with	O
the	O
denatured	O
N	O
proteins	O
,	O
whereas	O
none	O
of	O
the	O
S	O
and	O
M	O
protein	O
specific	O
neutralizing	O
antibodies	O
did	O
.	O

TITLE	O
:	O
Nucleocapsid	O
protein	O
of	O
SARS	O
-	O
CoV	O
activates	O
the	O
expression	O
of	O
cyclooxygenase	O
-	O
2	O
by	O
binding	B-FUNC
directly	O
to	O
regulatory	O
elements	O
for	O
nuclear	O
factor	O
-	O
kappa	O
B	O
and	O
CCAAT	O
/	O
enhancer	B-FUNC
binding	I-FUNC
protein	O
.	O

When	O
part	O
of	O
dsRNA	O
or	O
in	O
the	O
presence	O
of	O
nonlabeled	O
dsRNA	O
,	O
the	O
5	O
'-	O
labeled	O
RNA	O
substrates	O
were	O
processed	O
to	O
significantly	O
smaller	O
products	O
,	O
indicating	O
that	O
binding	B-FUNC
to	O
dsRNA	O
in	O
cis	O
or	O
trans	O
modulates	O
the	O
exonucleolytic	O
activity	O
of	O
nsp14	O
.	O

Procedure	O
Serum	O
samples	O
from	O
owned	O
cats	O
presented	O
to	O
three	O
inner	O
city	O
veterinary	O
clinics	O
in	O
Sydney	O
and	O
feral	O
cats	O
from	O
a	O
colony	O
in	O
South	O
Western	O
Sydney	O
over	O
an	O
11	O
-	O
month	O
period	O
were	O
tested	O
for	O
FCoV	O
antibodies	O
using	O
the	O
Immunocomb	O
test	O
kit	B-FUNC
.	O

Plasma	O
samples	O
from	O
improvers	O
with	O
declining	O
cytokine	O
levels	O
over	O
time	O
elicited	O
a	O
progressive	O
increase	O
in	O
all	O
measured	O
aspects	O
of	O
glucocorticoid	O
(	O
GC	O
)-	O
induced	O
GRalpha	O
-	O
mediated	O
activity	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
and	O
a	O
correspondent	O
reduction	O
in	O
NF	O
-	O
kappaB	O
nuclear	O
binding	B-FUNC
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
and	O
transcription	O
of	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1beta	O
(	O
regulated	O
,	O
GRalpha	O
-	O
driven	O
response	O
).	O

However	O
,	O
synthesis	O
of	O
IP	O
-	O
10	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
which	O
are	O
established	O
markers	O
for	O
acute	O
-	O
stage	O
SARS	O
,	O
escapes	O
the	O
virus	O
-	O
induced	O
silencing	O
at	O
least	O
in	O
some	O
cell	O
types	O
.	O

TITLE	O
:	O
Characterization	O
of	O
a	O
torovirus	O
main	O
proteinase	B-FUNC
.	O

For	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
and	O
related	O
viruses	O
,	O
binding	B-FUNC
to	O
cell	O
surface	O
components	O
containing	O
N	O
-	O
acetyl	O
-	O
9	O
-	O
O	O
-	O
acetylneuraminic	O
acid	O
is	O
essential	O
for	O
initiation	O
of	O
an	O
infection	O
.	O

Receptor	B-FUNC
binding	I-FUNC
often	O
involves	O
protein	O
-	O
protein	O
interactions	O
,	O
but	O
carbohydrates	O
may	O
serve	O
as	O
receptor	O
determinants	O
as	O
well	O
.	O

TITLE	O
:	O
Localisation	O
and	O
distribution	O
of	O
O	O
-	O
acetylated	O
N	O
-	O
acetylneuraminic	O
acids	O
,	O
the	O
endogenous	O
substrates	O
of	O
the	O
hemagglutinin	O
-	O
esterases	B-FUNC
of	O
murine	O
coronaviruses	O
,	O
in	O
mouse	O
tissue	O
.	O

To	O
gain	O
insight	O
into	O
the	O
active	O
-	O
site	O
recognition	O
of	O
the	O
C	O
-	O
terminal	O
tail	O
of	O
ubiquitin	B-FUNC
and	O
the	O
related	O
LXGG	O
motif	O
,	O
we	O
propose	O
a	O
model	O
of	O
PLpro	O
in	O
complex	O
with	O
ubiquitin	B-FUNC
-	O
aldehyde	O
that	O
reveals	O
well	O
defined	O
sites	O
within	O
the	O
catalytic	O
cleft	O
that	O
help	O
to	O
account	O
for	O
strict	O
substrate	O
-	O
recognition	O
motifs	O
.	O

The	O
diagnosis	O
of	O
pulmonary	O
hypertension	O
by	O
PAT	B-FUNC
diameter	O
measurements	O
was	O
incorrect	O
in	O
43	O
.	O
7	O
%	O
of	O
patients	O
with	O
ARDS	O
.	O

TITLE	O
:	O
A	O
single	O
amino	O
acid	O
substitution	O
(	O
R441A	O
)	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
SARS	O
coronavirus	O
spike	O
protein	O
disrupts	O
the	O
antigenic	O
structure	O
and	O
binding	B-FUNC
activity	O
.	O

Coincidently	O
,	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
,	O
residues	O
318	O
-	O
510	O
)	O
of	O
SAR	O
-	O
CoV	O
S	O
protein	O
is	O
a	O
major	O
antigenic	O
site	O
to	O
induce	O
neutralizing	O
antibodies	O
.	O

We	O
also	O
demonstrated	O
that	O
the	O
RBD	O
-	O
Fc	O
bearing	O
R441A	O
mutation	O
could	O
not	O
bind	B-FUNC
to	O
soluble	O
and	O
cell	O
-	O
associated	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
functional	O
receptor	O
for	O
SARS	O
-	O
CoV	O
and	O
failed	O
to	O
block	O
S	O
protein	O
-	O
mediated	O
pseudovirus	O
entry	O
,	O
indicating	O
that	O
this	O
point	O
mutation	O
also	O
disrupted	O
the	O
receptor	O
-	O
binding	B-FUNC
motif	O
(	O
RBM	O
)	O
in	O
the	O
RBD	O
.	O

The	O
viral	O
spike	O
(	O
S	O
)	O
glycoprotein	O
is	O
responsible	O
for	O
mediating	O
receptor	B-FUNC
binding	I-FUNC
and	O
membrane	O
fusion	O
.	O

Findings	O
indicate	O
that	O
FCoV	O
-	O
infected	O
cats	O
which	O
do	O
not	O
develop	O
FIP	O
are	O
able	O
to	O
mount	O
an	O
effective	O
FCoV	O
-	O
specific	O
immune	O
response	O
and	O
can	O
avoid	O
excessive	O
macrophage	O
activation	O
and	O
FIP	O
,	O
possibly	O
by	O
upregulation	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
production	O
.	O

It	O
has	O
been	O
reported	O
that	O
after	O
natural	O
infection	O
in	O
humans	O
and	O
immunization	O
in	O
animals	O
with	O
SARS	O
-	O
CoV	O
vaccine	O
,	O
antibody	B-FUNC
is	O
produced	O
and	O
persistent	O
for	O
a	O
long	O
period	O
of	O
time	O
.	O

TITLE	O
:	O
Enzymatic	O
activity	O
of	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	B-FUNC
dimer	O
.	O

We	O
tested	O
the	O
polymorphisms	O
of	O
IFN	O
-	O
gamma	O
,	O
TNF	O
-	O
alpha	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
for	O
their	O
associations	O
with	O
SARS	O
.	O

Detection	O
of	O
rhinovirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
and	O
coronavirus	O
infections	O
in	O
acute	O
otitis	O
media	O
by	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
.	O

Using	O
SARS	O
sera	B-FUNC
as	O
selective	O
molecule	O
,	O
a	O
12	O
mer	O
phage	O
peptide	O
library	O
was	O
biopanned	O
and	O
positive	O
clones	O
containing	O
the	O
mimic	O
epitopes	O
were	O
selected	O
.	O

Fast	B-FUNC
peripheral	O
venous	O
blood	O
samples	O
were	O
collected	O
from	O
61	O
post	O
-	O
SARS	O
patients	O
with	O
osteonecrosis	O
,	O
25	O
males	O
and	O
36	O
females	O
,	O
aged	O
30	O
.	O
4	O
(	O
20	O
-	O
60	O
),	O
and	O
52	O
sex	O
and	O
age	O
-	O
matched	O
healthy	O
persons	O
as	O
controls	O
.	O

In	O
this	O
report	O
,	O
we	O
study	O
the	O
membrane	O
topology	O
of	O
the	O
SARS	O
-	O
CoV	O
E	O
protein	O
by	O
immunofluorescent	O
staining	O
of	O
cells	O
differentially	O
permeabilized	O
with	O
detergents	O
and	O
proteinase	B-FUNC
K	O
protection	O
assay	O
.	O

From	O
this	O
it	O
can	O
be	O
seen	O
how	O
the	O
pseudoknot	O
interacts	O
with	O
the	O
ribosome	O
to	O
block	O
the	O
mRNA	O
entrance	O
channel	O
,	O
compromising	O
the	O
translocation	O
process	O
and	O
leading	O
to	O
a	O
spring	O
-	O
like	O
deformation	O
of	O
the	O
P	O
-	O
site	O
transfer	B-FUNC
RNA	I-FUNC
.	O

Measurements	O
of	O
cytokines	O
(	O
interleukin	O
-	O
6	O
,	O
interleukin	O
-	O
2	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
,	O
and	O
IFN	O
-	O
gamma	O
)	O
suggest	O
a	O
strong	O
T	O
helper	O
cell	O
type	O
1	O
-	O
associated	O
immune	O
response	O
.	O

Group	O
A	O
,	O
B	O
,	O
C	O
mAbs	O
target	O
the	O
epitopes	O
that	O
may	O
overlap	O
with	O
the	O
previously	O
characterized	O
Conf	O
I	O
,	O
III	O
,	O
and	O
VI	O
respectively	O
,	O
but	O
they	O
display	O
different	O
capacity	O
to	O
block	O
the	O
receptor	B-FUNC
binding	I-FUNC
.	O

Strikingly	O
,	O
all	O
of	O
the	O
RBD	O
-	O
specific	O
MAbs	O
had	O
potent	O
neutralizing	O
activity	O
,	O
6	O
of	O
which	O
efficiently	O
blocked	O
the	O
receptor	B-FUNC
binding	I-FUNC
,	O
confirming	O
that	O
the	O
RBD	O
contains	O
the	O
main	O
neutralizing	O
epitopes	O
and	O
that	O
blockage	O
of	O
the	O
receptor	O
association	O
is	O
the	O
major	O
mechanism	O
of	O
SARS	O
-	O
CoV	O
neutralization	O
.	O

The	O
RDRP	B-FUNC
plays	O
an	O
essential	O
role	O
in	O
viral	O
RNA	O
replication	O
where	O
envelope	O
E	O
protein	O
is	O
involved	O
in	O
envelope	O
formation	O
and	O
virus	O
assembly	O
.	O

The	O
expression	O
levels	O
of	O
RDRP	B-FUNC
and	O
envelope	O
E	O
genes	O
were	O
examined	O
by	O
reverse	O
transcription	O
followed	O
by	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
).	O

Blood	O
samples	O
were	O
tested	O
for	O
total	O
antibodies	O
to	O
SARS	O
-	O
CoV	O
by	O
immunofluorescence	O
antibody	B-FUNC
test	O
.	O

The	O
importance	O
of	O
alpha	O
-	O
helical	O
structure	O
in	O
the	O
interaction	O
with	O
native	O
HRC	O
was	O
demonstrated	O
with	O
analog	O
HRC4	O
which	O
binds	B-FUNC
best	O
to	O
HRC	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
we	O
report	O
a	O
serum	O
-	O
free	O
culture	O
system	O
for	O
primary	O
neonatal	O
pulmonary	O
cells	O
that	O
can	O
support	O
the	O
growth	O
of	O
octamer	O
-	O
binding	B-FUNC
transcription	O
factor	O
4	O
+	O
(	O
Oct	O
-	O
4	O
+)	O
epithelial	O
colonies	O
with	O
a	O
surrounding	O
mesenchymal	O
stroma	O
.	O

In	O
addition	O
to	O
Oct	O
-	O
4	O
,	O
these	O
cells	O
also	O
express	O
other	O
stem	O
cell	O
markers	O
such	O
as	O
stage	O
-	O
specific	O
embryonic	O
antigen	O
1	O
(	O
SSEA	O
-	O
1	O
),	O
stem	O
cell	O
antigen	O
1	O
(	O
Sca	O
-	O
1	O
),	O
and	O
Clara	O
cell	O
secretion	O
protein	O
(	O
CCSP	O
)	O
but	O
not	O
c	O
-	O
Kit	B-FUNC
,	O
CD34	O
,	O
and	O
p63	O
,	O
indicating	O
that	O
they	O
represent	O
a	O
subpopulation	O
of	O
Clara	O
cells	O
that	O
have	O
been	O
implicated	O
as	O
lung	O
stem	O
/	O
progenitor	O
cells	O
in	O
lung	O
injury	O
models	O
.	O

These	O
cytokines	O
,	O
especially	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
,	O
TNF	O
-	O
alpha	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
have	O
important	O
roles	O
in	O
the	O
lung	O
dysfunction	O
.	O

When	O
surviving	O
cells	O
were	O
treated	O
with	O
the	O
JNK	B-FUNC
-	O
specific	O
inhibitor	O
,	O
SP600125	O
,	O
at	O
50h	O
.	O
p	O
.	O
i	O
.,	O
all	O
cells	O
died	O
,	O
suggesting	O
that	O
the	O
JNK	B-FUNC
signaling	O
pathway	O
is	O
necessary	O
for	O
maintenance	O
of	O
persistently	O
infected	O
cells	O
.	O

TITLE	O
:	O
Hexamethylene	O
amiloride	O
blocks	O
E	O
protein	O
ion	B-FUNC
channels	I-FUNC
and	O
inhibits	O
coronavirus	O
replication	O
.	O

No	O
positive	O
results	O
for	O
antibody	B-FUNC
to	O
SARS	O
-	O
CoV	O
were	O
detected	O
in	O
the	O
25	O
healthy	O
persons	O
.	O

Moreover	O
,	O
progress	O
in	O
the	O
drug	O
development	O
based	O
on	O
different	O
molecular	O
targets	O
is	O
also	O
summarized	O
,	O
including	O
1	O
)	O
Compounds	O
that	O
block	O
the	O
S	O
protein	O
-	O
ACE2	O
-	O
mediated	O
viral	O
entry	O
;	O
2	O
)	O
Compounds	O
targeting	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
);	O
3	O
)	O
Compounds	O
targeting	O
papain	O
-	O
like	O
protease	O
2	O
(	O
PLP2	O
);	O
4	O
)	O
Compounds	O
targeting	O
SARS	O
-	O
CoV	O
RdRp	B-FUNC
;	O
5	O
)	O
Compounds	O
targeting	O
SARS	O
-	O
CoV	O
helicase	O
;	O
6	O
)	O
Active	O
compounds	O
with	O
unspecified	O
targets	O
;	O
and	O
7	O
)	O
Research	O
on	O
siRNA	O
.	O

Binding	B-FUNC
of	O
viral	O
peptides	O
was	O
affected	O
by	O
the	O
naturally	O
occurring	O
polymorphisms	O
at	O
residues	O
190	O
and	O
192	O
,	O
which	O
are	O
located	O
at	O
second	O
extracellular	O
loop	O
-	O
transmembrane	O
helix	O
5	O
interface	O
.	O

TITLE	O
:	O
Domain	O
-	O
swapped	O
structure	O
of	O
the	O
potent	O
antiviral	O
protein	O
griffithsin	O
and	O
its	O
mode	O
of	O
carbohydrate	B-FUNC
binding	I-FUNC
.	O

The	O
protein	O
has	O
a	O
novel	O
fold	O
,	O
a	O
dimeric	O
tent	O
-	O
like	O
beta	O
structure	O
with	O
an	O
amphipathic	O
surface	O
,	O
and	O
a	O
central	O
hydrophobic	O
cavity	O
that	O
binds	B-FUNC
lipid	O
molecules	O
.	O

We	O
investigated	O
human	O
pulmonary	O
fibroblast	O
(	O
HPF	O
)	O
cells	O
,	O
were	O
transfected	O
with	O
plasmids	O
containing	O
the	O
M	O
or	O
N	O
gene	O
,	O
by	O
TdT	B-FUNC
-	O
mediated	O
dUTP	O
nick	O
end	O
labeling	O
(	O
TUNEL	O
),	O
Hoechst	O
33342	O
staining	O
for	O
nuclei	O
,	O
and	O
observation	O
of	O
morphology	O
.	O

TITLE	O
:	O
An	O
episulfide	O
cation	O
(	O
thiiranium	O
ring	O
)	O
trapped	O
in	O
the	O
active	O
site	O
of	O
HAV	O
3C	O
proteinase	B-FUNC
inactivated	O
by	O
peptide	O
-	O
based	O
ketone	O
inhibitors	O
.	O

TITLE	O
:	O
Interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
and	O
interleukin	O
-	O
4	O
downregulate	O
expression	O
of	O
the	O
SARS	O
coronavirus	O
receptor	O
ACE2	O
in	O
Vero	O
E6	O
cells	O
.	O

Gel	O
filtration	O
and	O
enzyme	B-FUNC
activity	I-FUNC
assays	O
confirmed	O
that	O
the	O
hexamer	O
is	O
the	O
active	O
form	O
for	O
nsp15	O
and	O
demonstrate	O
the	O
specificity	O
of	O
nsp15	O
for	O
uridylate	O
.	O

A	O
novel	O
HLA	O
-	O
A	O
*	O
0201	O
-	O
restricted	O
decameric	O
epitope	O
P15	O
(	O
S411	O
-	O
420	O
,	O
KLPDDFMGCV	O
)	O
derived	O
from	O
the	O
S	O
protein	O
was	O
identified	O
and	O
found	O
to	O
localize	O
within	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
receptor	O
-	O
binding	B-FUNC
region	O
of	O
the	O
S1	O
domain	O
.	O

TITLE	O
:	O
Structural	O
and	O
functional	O
basis	O
for	O
ADP	O
-	O
ribose	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
binding	B-FUNC
by	O
viral	O
macro	O
domains	O
.	O

The	O
data	O
revealed	O
that	O
viral	O
macro	O
domains	O
have	O
relatively	O
poor	O
ADP	O
-	O
ribose	O
1	O
"""-"	O
phosphohydrolase	O
activities	O
(	O
which	O
were	O
previously	O
proposed	O
to	O
be	O
their	O
biologically	O
relevant	O
function	O
)	O
but	O
bind	B-FUNC
efficiently	O
free	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
1	O
-	O
bound	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
in	O
vitro	O
.	O

They	O
bind	B-FUNC
to	O
the	O
protein	O
in	O
a	O
distinct	O
manner	O
compared	O
to	O
all	O
published	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
)	O
complex	O
structures	O
.	O

ABSTRACT	O
:	O
Protein	O
ubiquitination	O
has	O
been	O
identified	O
as	O
a	O
regulatory	O
mechanism	O
in	O
key	O
cellular	O
activities	O
,	O
and	O
deubiquitination	O
is	O
recognized	O
as	O
an	O
important	O
step	O
in	O
processes	O
governed	O
by	O
ubiquitin	B-FUNC
and	O
ubiquitin	B-FUNC
-	O
like	O
modifiers	O
.	O

TITLE	O
:	O
Immunogenicity	O
of	O
a	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
SARS	O
coronavirus	O
spike	O
protein	O
in	O
mice	O
:	O
implications	O
for	O
a	O
subunit	O
vaccine	O
.	O

Mice	O
vaccinated	O
with	O
S318	O
-	O
510	O
deglycosylated	O
by	O
PNGase	B-FUNC
F	I-FUNC
(	O
dgS318	O
-	O
510	O
)	O
showed	O
a	O
lower	O
neutralizing	O
antibody	B-FUNC
response	O
but	O
had	O
similar	O
numbers	O
of	O
INF	O
-	O
gamma	O
-	O
producing	O
cells	O
in	O
the	O
spleen	O
.	O

Antibody	B-FUNC
binding	B-FUNC
to	O
discontinuous	O
peptides	O
provides	O
evidence	O
that	O
amino	O
acids	O
274	O
-	O
283	O
and	O
373	O
-	O
382	O
assemble	O
to	O
a	O
structural	O
unit	O
particularly	O
rich	O
in	O
basic	O
amino	O
acids	O
.	O

The	O
SCoV	O
5	O
'	O
UTR	O
was	O
predicted	O
to	O
contain	O
a	O
fourth	O
stem	O
-	O
loop	O
,	O
named	O
SL3	O
,	O
in	O
which	O
the	O
leader	O
transcriptional	O
regulatory	O
sequence	O
(	O
TRS	B-FUNC
)	O
is	O
folded	O
into	O
a	O
hairpin	O
loop	O
.	O

A	O
chimera	O
containing	O
the	O
SCoV	O
5	O
'	O
UTR	O
in	O
which	O
the	O
SCoV	O
TRS	B-FUNC
was	O
replaced	O
with	O
the	O
MHV	O
TRS	B-FUNC
was	O
also	O
not	O
viable	O
.	O

A	O
total	O
of	O
680	O
samples	O
collected	O
from	O
IBV	O
antibody	B-FUNC
negative	O
birds	O
were	O
negative	O
for	O
IBV	O
by	O
the	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
.	O

Herein	O
,	O
we	O
screened	O
12	O
,	O
000	O
people	O
in	O
a	O
community	O
stricken	O
by	O
SARS	O
10	O
months	O
previously	O
and	O
found	O
53	O
individuals	O
(	O
0	O
.	O
44	O
%)	O
who	O
had	O
immunoglobulin	B-FUNC
G	O
antibodies	O
to	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
(	O
N	O
)	O
produced	O
in	O
bacteria	O
.	O

ABSTRACT	O
:	O
Three	O
commercially	O
available	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
PCR	O
assays	O
(	O
the	O
Artus	O
RealArt	O
HPA	O
coronavirus	O
LightCycler	O
,	O
the	O
Artus	O
RealArt	O
HPA	O
coronavirus	O
Rotor	O
-	O
Gene	O
,	O
and	O
the	O
EraGen	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
POL	O
assay	O
)	O
and	O
three	O
RNA	O
extraction	O
methodologies	O
were	O
evaluated	O
for	O
the	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
RNA	O
from	O
91	O
stool	O
specimens	O
.	O

Recombinant	O
M13	O
phages	O
displaying	O
the	O
peptides	O
SHRLP	O
(	O
Y	O
/	O
Q	O
)(	O
P	O
/	O
V	O
)	O
or	O
GPRPVTH	O
on	O
the	O
g3p	O
minor	O
coat	O
protein	O
showed	O
strong	O
binding	B-FUNC
affinity	O
with	O
2C10	O
(	O
70	O
%	O
and	O
30	O
%	O
of	O
recovered	O
phages	O
,	O
respectively	O
)	O
after	O
multiple	O
panning	O
.	O

We	O
further	O
show	O
that	O
the	O
RBD	O
of	O
S1	O
forms	O
dimers	O
via	O
an	O
extensive	O
interface	O
that	O
is	O
disrupted	O
in	O
receptor	O
-	O
and	O
antibody	B-FUNC
-	O
bound	O
crystal	O
structures	O
,	O
and	O
we	O
propose	O
a	O
role	O
for	O
the	O
dimer	O
in	O
virus	O
stability	O
and	O
infectivity	O
.	O

In	O
contrast	O
,	O
mutation	O
of	O
amino	O
acid	O
Gln	O
-	O
74	O
to	O
an	O
alanine	O
,	O
which	O
does	O
not	O
affect	O
the	O
binding	B-FUNC
activity	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
,	O
showed	O
minimal	O
,	O
if	O
any	O
,	O
detrimental	O
effect	O
on	O
the	O
infectivity	O
of	O
IBV	O
.	O

TITLE	O
:	O
Coronavirus	O
nucleocapsid	O
protein	O
is	O
an	O
RNA	B-FUNC
chaperone	I-FUNC
.	O

Coronavirus	O
nucleoproteins	O
(	O
N	O
)	O
are	O
nonspecific	O
RNA	O
-	O
binding	B-FUNC
proteins	O
with	O
long	O
disordered	O
regions	O
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
N	O
protein	O
was	O
an	O
RNA	B-FUNC
chaperone	I-FUNC
.	O

All	O
patients	O
with	O
respiratory	O
disease	O
for	O
whom	O
bronchoalveolar	O
lavage	O
was	O
performed	O
were	O
screened	O
by	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
for	O
the	O
presence	O
of	O
all	O
4	O
HCoVs	O
.	O

Protection	O
based	O
criteria	O
were	O
:	O
virus	O
re	O
-	O
isolation	O
attempts	O
from	O
trachea	O
,	O
tracheal	O
and	O
renal	O
histopathology	O
as	O
well	O
as	O
IBV	O
antigens	O
detection	O
by	O
immunofluorescent	O
antibody	B-FUNC
technique	O
in	O
kidney	O
sections	O
.	O

Moreover	O
,	O
both	O
anti	O
-	O
S1	O
and	O
anti	O
-	O
S2	O
IgGs	O
were	O
able	O
to	O
abolish	O
the	O
binding	B-FUNC
between	O
S	O
protein	O
and	O
its	O
cellular	O
receptor	O
(	O
s	O
),	O
although	O
anti	O
-	O
S1	O
IgG	O
showed	O
a	O
significantly	O
higher	O
blocking	O
efficiency	O
.	O

The	O
unexpected	O
blocking	O
ability	O
of	O
anti	O
-	O
S2	O
IgG	O
towards	O
the	O
receptor	B-FUNC
binding	I-FUNC
implied	O
a	O
possible	O
role	O
of	O
the	O
S2	O
subunit	O
in	O
virus	O
docking	O
process	O
and	O
argues	O
against	O
the	O
current	O
hypothesis	O
of	O
viral	O
entry	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
functional	O
roles	O
of	O
the	O
previously	O
reported	O
neutralizing	O
epitopes	O
within	O
S2	O
subunit	O
were	O
investigated	O
using	O
an	O
antigen	O
specific	O
antibody	B-FUNC
depletion	O
assay	O
.	O

ELISA	O
and	O
Western	O
blot	O
demonstrated	O
that	O
the	O
S1	O
could	O
react	O
with	O
the	O
convalescent	O
sera	B-FUNC
of	O
people	O
infected	O
by	O
SARS	O
-	O
CoV	O
.	O
Furthermore	O
,	O
ligand	B-FUNC
blot	O
assay	O
showed	O
that	O
the	O
recombinant	O
S1	O
could	O
react	O
with	O
ACE2	O
,	O
the	O
receptor	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
molecular	O
mass	O
of	O
expressed	O
S1	O
was	O
about	O
70	O
kDa	O
,	O
which	O
was	O
higher	O
than	O
that	O
of	O
the	O
30	O
kDa	O
expected	O
.	O

The	O
alphaSIP	O
molecule	O
consisted	O
of	O
a	O
single	O
chain	O
antibody	B-FUNC
(	O
scFv	O
)	O
specific	O
for	O
the	O
porcine	O
coronavirus	O
,	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
linked	O
to	O
the	O
alpha	O
-	O
CH3	O
domain	O
from	O
human	O
IgA	O
.	O
To	O
express	O
the	O
full	O
-	O
length	O
IgA	O
,	O
the	O
individual	O
light	O
and	O
heavy	O
chains	O
from	O
the	O
TGEV	O
-	O
specific	O
mAb	O
6A	O
.	O
C3	O
were	O
inserted	O
into	O
separate	O
PVX	O
constructs	O
and	O
plants	O
were	O
co	O
-	O
infected	O
with	O
both	O
constructs	O
.	O

This	O
defect	O
was	O
associated	O
with	O
altered	O
surface	O
expression	O
of	O
L	O
-	O
selectin	B-FUNC
;	O
sialyl	O
Lewis	O
(	O
x	O
),	O
an	O
L	O
-	O
selectin	B-FUNC
counterreceptor	O
,	O
previously	O
was	O
proved	O
to	O
be	O
critical	O
in	O
aseptic	O
ALI	O
.	O

TITLE	O
:	O
[	O
Identification	O
of	O
mimotope	O
peptides	O
which	O
bind	B-FUNC
to	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
specific	O
monoclonal	O
antibody	B-FUNC
2C5	O
with	O
phage	O
-	O
displayed	O
peptides	O
library	O
].	O

Furthermore	O
,	O
phages	O
displaying	O
peptide	O
TPEQQFT	O
could	O
specifically	O
inhibit	O
the	O
binding	B-FUNC
of	O
MAb	O
2C5	O
with	O
SARS	O
-	O
CoV	O
spike	O
protein	O
.	O

The	O
poly	O
(	O
dimethylsiloxane	O
)	O
microfluidic	O
channels	O
were	O
created	O
on	O
the	O
gold	O
surface	O
and	O
were	O
used	O
for	O
antigen	O
-	O
antibody	B-FUNC
and	O
DNA	O
-	O
DNA	O
interaction	O
studies	O
.	O

For	O
this	O
project	O
,	O
we	O
used	O
recombinant	O
baculoviruses	O
expressing	O
different	O
lengths	O
of	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
in	O
a	O
capture	O
assay	O
to	O
deduce	O
the	O
minimal	O
DC	O
-	O
SIGN	O
binding	B-FUNC
region	O
.	O

TITLE	O
:	O
Binding	B-FUNC
interaction	O
of	O
quercetin	O
-	O
3	O
-	O
beta	O
-	O
galactoside	O
and	O
its	O
synthetic	O
derivatives	O
with	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
):	O
structure	O
-	O
activity	O
relationship	O
studies	O
reveal	O
salient	O
pharmacophore	O
features	O
.	O

Sera	B-FUNC
from	O
12	O
healthy	O
subjects	O
were	O
used	O
as	O
normal	O
controls	O
.	O

The	O
elevation	O
of	O
IP	O
-	O
10	O
and	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
antedated	O
the	O
development	O
of	O
chest	O
involvement	O
and	O
reached	O
peak	O
levels	O
earlier	O
than	O
the	O
radiographic	O
scores	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
responsible	O
for	O
viral	O
binding	B-FUNC
with	O
ACE2	O
molecules	O
.	O

However	O
,	O
the	O
ability	O
of	O
S450	O
-	O
510	O
,	O
either	O
alone	O
or	O
in	O
fusion	O
with	O
GFP	O
,	O
to	O
bind	B-FUNC
with	O
ACE2	O
was	O
significantly	O
poorer	O
compared	O
with	O
S450	O
-	O
650	O
.	O

In	O
the	O
T	O
group	O
,	O
although	O
the	O
MPO	B-FUNC
activity	O
was	O
also	O
higher	O
than	O
in	O
the	O
C	O
group	O
,	O
it	O
much	O
less	O
increased	O
than	O
in	O
the	O
P	O
group	O
.	O

Six	O
deaths	O
of	O
refractory	O
shock	O
included	O
4	O
who	O
had	O
ARDS	O
and	O
DIC	O
and	O
2	O
who	O
had	O
shock	O
with	O
DIC	O
3	O
patients	O
had	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
)	O
has	O
not	O
been	O
previously	O
described	O
in	O
children	O
with	O
DSS	O
and	O
may	O
lead	O
to	O
fluid	O
refractory	O
shock	O
if	O
not	O
corrected	O
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	B-FUNC
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
induces	O
long	O
-	O
term	O
protective	O
immunity	O
in	O
an	O
animal	O
model	O
.	O

In	O
hAPN	O
an	O
R741T	O
substitution	O
caused	O
a	O
gain	O
of	O
receptor	B-FUNC
activity	I-FUNC
for	O
TGEV	O
but	O
not	O
for	O
FCoV	O
or	O
CCoV	O
.	O
Therefore	O
,	O
entry	O
and	O
host	O
range	O
of	O
these	O
group	O
1	O
coronaviruses	O
depend	O
on	O
the	O
ability	O
of	O
the	O
viral	O
spike	O
glycoproteins	O
to	O
recognize	O
small	O
,	O
species	O
-	O
specific	O
amino	O
acid	O
differences	O
in	O
the	O
APN	O
proteins	O
of	O
different	O
species	O
.	O

Tissue	O
leukocyte	O
sequestration	O
was	O
assessed	O
by	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
activity	O
.	O

The	O
role	O
of	O
circulating	O
trypsin	O
,	O
phospholipase	O
A2	O
,	O
platelet	O
activating	O
factor	O
,	O
release	O
of	O
free	O
fatty	O
acids	O
,	O
chemoattractants	O
such	O
as	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)-	O
alpha	O
,	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
fMet	O
-	O
leu	O
-	O
phe	O
(	O
a	O
bacterial	O
wall	O
product	O
),	O
nitric	O
oxide	O
,	O
substance	O
P	O
,	O
and	O
macrophage	O
inhibitor	O
factor	O
is	O
currently	O
studied	O
.	O

Since	O
the	O
enzyme	O
is	O
a	O
homodimer	O
and	O
the	O
individual	O
monomers	O
are	O
inactive	O
,	O
two	O
approaches	O
are	O
being	O
used	O
to	O
develop	O
inhibitors	O
:	O
enzyme	B-FUNC
activity	I-FUNC
inhibitors	O
that	O
target	O
the	O
active	O
site	O
and	O
dimerization	O
inhibitors	O
.	O

It	O
also	O
inhibited	O
the	O
release	O
of	O
cytochrome	B-FUNC
c	I-FUNC
from	O
mitochondria	O
and	O
the	O
activation	O
of	O
caspase	O
-	O
9	O
.	O

Due	O
to	O
the	O
lack	O
of	O
potential	O
drugs	O
for	O
the	O
treatment	O
of	O
SARS	O
,	O
the	O
discovery	O
of	O
inhibitors	O
against	O
SARS	O
3C	O
-	O
like	O
proteinase	B-FUNC
,	O
which	O
can	O
potentially	O
be	O
optimized	O
as	O
drugs	O
appears	O
to	O
be	O
highly	O
desirable	O
.	O

Our	O
results	O
show	O
that	O
additional	O
residues	O
at	O
the	O
N	O
terminus	O
,	O
but	O
not	O
at	O
the	O
C	O
terminus	O
,	O
of	O
M	O
(	O
pro	O
)	O
are	O
detrimental	O
to	O
enzyme	B-FUNC
activity	I-FUNC
.	O

Second	O
,	O
ATA	O
inhibits	O
the	O
phosphatase	B-FUNC
activity	I-FUNC
of	O
the	O
viral	O
enzyme	O
H1L	O
,	O
which	O
is	O
required	O
to	O
initiate	O
viral	O
transcription	O
.	O

TITLE	O
:	O
Use	O
of	O
anti	O
-	O
coronavirus	O
antibody	B-FUNC
testing	O
of	O
cerebrospinal	O
fluid	O
for	O
diagnosis	O
of	O
feline	O
infectious	O
peritonitis	O
involving	O
the	O
central	O
nervous	O
system	O
in	O
cats	O
.	O

ABSTRACT	O
:	O
Recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
nucleocapsid	O
and	O
spike	O
protein	O
-	O
based	O
immunoglobulin	B-FUNC
G	O
immunoassays	O
were	O
developed	O
and	O
evaluated	O
.	O

Our	O
assays	O
demonstrated	O
high	O
sensitivity	O
and	O
specificity	O
to	O
the	O
SARS	O
coronavirus	O
in	O
sera	B-FUNC
collected	O
from	O
patients	O
as	O
late	O
as	O
2	O
years	O
postonset	O
of	O
symptoms	O
.	O

These	O
assays	O
will	O
be	O
useful	O
not	O
only	O
for	O
routine	O
SARS	O
coronavirus	O
diagnostics	O
but	O
also	O
for	O
epidemiological	O
and	O
antibody	B-FUNC
kinetic	O
studies	O
.	O

We	O
found	O
that	O
an	O
upstream	O
calcium	O
-	O
dependent	O
PKC	B-FUNC
isozyme	O
PKC	B-FUNC
alpha	O
that	O
modulates	O
the	O
downstream	O
ERK	B-FUNC
/	O
NF	O
-	O
kappaB	O
pathway	O
through	O
an	O
influx	O
of	O
extracellular	O
Ca2	O
+	O
is	O
induced	O
by	O
the	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
ERK	B-FUNC
/	O
NF	O
-	O
kappaB	O
was	O
identified	O
to	O
be	O
involved	O
in	O
the	O
activation	O
of	O
COX	O
-	O
2	O
promoter	O
and	O
production	O
of	O
COX	O
-	O
2	O
protein	O
in	O
HEK293T	O
cells	O
.	O

This	O
pathway	O
can	O
be	O
blocked	O
by	O
PKC	B-FUNC
epsilon	O
-	O
specific	O
,	O
small	O
interfering	O
RNA	O
,	O
PI3K	B-FUNC
/	O
JNK	B-FUNC
kinase	O
-	O
specific	O
inhibitors	O
as	O
well	O
as	O
dominant	O
negative	O
JNK	B-FUNC
.	O

TITLE	O
:	O
Inhibition	O
of	O
infection	O
caused	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
by	O
equine	O
neutralizing	O
antibody	B-FUNC
in	O
aged	O
mice	O
.	O

Thus	O
,	O
this	O
antibody	B-FUNC
should	O
be	O
a	O
potential	O
candidate	O
for	O
treatment	O
of	O
elderly	O
patients	O
suffering	O
from	O
SARS	O
.	O

Caspase	O
-	O
1	O
activation	O
,	O
and	O
overproduction	O
of	O
IL	O
-	O
1beta	O
and	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
play	O
an	O
important	O
role	O
in	O
the	O
course	O
of	O
ALI	O
,	O
and	O
Caspase	O
-	O
1	O
inhibition	O
is	O
effective	O
for	O
the	O
treatment	O
of	O
ALI	O
in	O
experimental	O
SAP	O
.	O

CONCLUSIONS	O
:	O
Caspase	O
-	O
1	O
activation	O
,	O
and	O
overproduction	O
of	O
IL	O
-	O
1beta	O
and	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
play	O
an	O
important	O
role	O
in	O
the	O
course	O
of	O
ALI	O
,	O
and	O
Caspase	O
-	O
1	O
inhibition	O
is	O
effective	O
for	O
the	O
treatment	O
of	O
ALI	O
in	O
experimental	O
SAP	O
.	O

Preliminary	O
data	O
suggest	O
that	O
such	O
differential	O
signalling	O
involves	O
p38	B-FUNC
MAP	O
kinase	O
rather	O
than	O
NF	O
-	O
kappaB	O
.	O
SARS	O
coronavirus	O
infection	O
of	O
primary	O
human	O
macrophages	O
is	O
associated	O
with	O
a	O
strong	O
induction	O
of	O
chemokines	O
without	O
an	O
associated	O
type	O
1	O
interferon	O
response	O
.	O

Patients	O
in	O
the	O
control	O
group	O
did	O
not	O
show	O
an	O
elevation	O
of	O
sE	O
-	O
Selectin	B-FUNC
and	O
sICAM	O
-	O
1	O
levels	O
longitudinally	O
.	O

Increased	O
levels	O
of	O
measured	O
molecules	O
(	O
TGF	O
-	O
beta1	O
,	O
p	O
<	O
0	O
.	O
02	O
,	O
sE	O
-	O
Selectin	B-FUNC
,	O
p	O
<	O
0	O
.	O
02	O
,	O
sL	O
-	O
Selectin	B-FUNC
,	O
p	O
=	O
0	O
.	O
06	O
,	O
sICAM	O
-	O
1	O
,	O
p	O
<	O
0	O
.	O
03	O
)	O
were	O
demonstrated	O
among	O
survivors	O
in	O
the	O
sepsis	O
and	O
ARDS	O
groups	O
of	O
patients	O
and	O
were	O
positively	O
correlated	O
with	O
length	O
of	O
stay	O
(	O
p	O
<	O
0	O
.	O
04	O
)	O
and	O
mechanical	O
ventilation	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Immunized	O
sera	B-FUNC
elicited	O
against	O
most	O
civet	O
S	O
glycoproteins	O
displayed	O
potent	O
neutralizing	O
activities	O
against	O
autologous	O
viruses	O
but	O
were	O
much	O
less	O
efficient	O
(	O
50	O
%	O
inhibitory	O
concentration	O
,	O
20	O
-	O
to	O
40	O
-	O
fold	O
)	O
at	O
neutralizing	O
SARS	O
-	O
CoV	O
and	O
vice	O
versa	O
.	O

ABSTRACT	O
:	O
Carbohydrate	O
-	O
binding	B-FUNC
agents	O
(	O
CBAs	O
)	O
inhibit	O
HIV	O
-	O
1	O
and	O
it	O
is	O
proposed	O
that	O
therapy	O
with	O
such	O
agents	O
may	O
have	O
important	O
implications	O
for	O
the	O
future	O
of	O
anti	O
-	O
HIV	O
therapy	O
.	O

ABSTRACT	O
:	O
The	O
positive	O
strand	O
RNA	O
coronavirus	O
,	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
induces	O
a	O
G2	O
/	O
M	O
phase	O
arrest	O
and	O
reduction	O
in	O
the	O
G1	O
and	O
G1	O
/	O
S	O
phase	O
transition	O
regulator	O
cyclin	B-FUNC
D1	O
.	O

After	O
purification	O
,	O
the	O
purity	O
of	O
these	O
recombinant	O
spike	O
proteins	O
was	O
examined	O
on	O
SDS	O
-	O
PAGE	O
and	O
their	O
identity	O
verified	O
with	O
Western	O
blot	O
analysis	O
using	O
anti	O
-	O
his	O
antibodies	O
and	O
sera	B-FUNC
from	O
convalescent	O
stage	O
SARS	O
-	O
CoV	O
-	O
infected	O
patients	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
used	O
the	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
to	O
detect	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
in	O
sick	O
poults	O
30	O
to	O
120	O
days	O
of	O
age	O
from	O
a	O
particular	O
producer	O
region	O
in	O
Brazil	O
.	O

TITLE	O
:	O
Positive	O
rate	O
of	O
serum	O
SARS	O
-	O
CoV	O
immunoglobulin	B-FUNC
G	O
antibody	B-FUNC
among	O
healthcare	O
workers	O
.	O

ABSTRACT	O
:	O
As	O
a	O
critical	O
adaptive	O
mechanism	O
,	O
amino	O
acid	O
replacements	O
on	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	O
could	O
alter	O
the	O
receptor	O
-	O
binding	B-FUNC
specificity	O
of	O
this	O
envelope	O
glycoprotein	O
and	O
in	O
turn	O
lead	O
to	O
the	O
emergence	O
or	O
reemergence	O
of	O
this	O
viral	O
zoonosis	O
.	O

RNA	O
has	O
been	O
shown	O
to	O
bind	B-FUNC
to	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
),	O
although	O
recently	O
the	O
C	O
-	O
terminal	O
half	O
of	O
the	O
protein	O
has	O
also	O
been	O
implicated	O
in	O
RNA	B-FUNC
binding	I-FUNC
.	O

SARS	O
-	O
CoV	O
detection	O
rates	O
in	O
sera	B-FUNC
were	O
highest	O
in	O
the	O
first	O
9	O
days	O
of	O
illness	O
,	O
whereas	O
detection	O
was	O
highest	O
in	O
throat	O
washes	O
5	O
-	O
14	O
days	O
after	O
onset	O
of	O
symptoms	O
.	O

Positive	O
SARS	O
-	O
CoV	O
specific	O
IgG	O
antibody	B-FUNC
was	O
found	O
25	O
.	O
61	O
%	O
(	O
n	O
=	O
328	O
),	O
13	O
.	O
03	O
%	O
(	O
n	O
=	O
238	O
),	O
12	O
.	O
59	O
%	O
(	O
n	O
=	O
135	O
),	O
5	O
.	O
04	O
%	O
(	O
n	O
=	O
139	O
)	O
and	O
9	O
.	O
43	O
%	O
(	O
n	O
=	O
53	O
)	O
among	O
volunteers	O
,	O
which	O
were	O
sampled	O
in	O
May	O
2003	O
,	O
Dec	O
.	O
2003	O
,	O
Jan	O
.	O
2004	O
,	O
July	O
2004	O
and	O
June	O
2005	O
respectively	O
.	O

No	O
specific	O
IgM	O
antibody	B-FUNC
was	O
found	O
in	O
all	O
of	O
those	O
samples	O
.	O

Functional	O
classification	O
of	O
identified	O
up	O
-	O
regulated	O
proteins	O
indicated	O
that	O
protein	O
metabolism	O
and	O
modification	O
,	O
particularly	O
in	O
the	O
ubiquitin	B-FUNC
proteasome	O
pathway	O
,	O
was	O
the	O
main	O
biological	O
process	O
occurring	O
in	O
SARS	O
CoV	O
3CLpro	O
-	O
expressing	O
cells	O
.	O

The	O
binding	B-FUNC
required	O
Ca	O
(	O
2	O
+)	O
and	O
was	O
inhibited	O
by	O
maltose	O
.	O

The	O
serum	O
collectin	O
,	O
mannan	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
),	O
exhibited	O
no	O
detectable	O
binding	B-FUNC
to	O
the	O
purified	O
S	O
-	O
protein	O
.	O

S	O
-	O
protein	O
binds	B-FUNC
and	O
activates	O
macrophages	O
but	O
not	O
dendritic	O
cells	O
(	O
DCs	O
).	O

These	O
results	O
indicate	O
that	O
SARS	O
-	O
CoV	O
3a	O
protein	O
,	O
through	O
limiting	O
the	O
expression	O
of	O
cyclin	B-FUNC
D3	O
,	O
may	O
inhibit	O
Rb	O
phosphorylation	O
,	O
which	O
in	O
turn	O
leads	O
to	O
a	O
block	O
in	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
and	O
an	O
inhibition	O
of	O
cell	O
proliferation	O
.	O

Two	O
calculation	O
examples	O
,	O
the	O
peptide	O
substrate	O
specificity	O
of	O
the	O
SARS	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-FUNC
and	O
the	O
affinity	O
prediction	O
for	O
epitope	O
-	O
peptides	O
with	O
Class	O
I	O
MHC	O
molecules	O
are	O
studied	O
by	O
using	O
the	O
peptide	O
reagent	O
design	O
strategy	O
.	O

The	O
Beaudette	O
strain	O
was	O
found	O
to	O
contain	O
a	O
putative	O
heparan	O
sulfate	O
(	O
HS	O
)-	O
binding	B-FUNC
site	O
,	O
indicating	O
that	O
the	O
Beaudette	O
virus	O
may	O
use	O
HS	O
as	O
a	O
selective	O
receptor	O
.	O

The	O
set	O
of	O
best	O
performing	O
compounds	O
was	O
then	O
used	O
for	O
similarity	O
search	O
over	O
the	O
1	O
million	O
entries	O
in	O
the	O
Ligand	B-FUNC
.	O

It	O
is	O
important	O
to	O
consider	O
that	O
in	O
patients	O
with	O
anti	O
-	O
GBM	O
disease	O
antibody	B-FUNC
-	O
negative	O
relapses	O
are	O
possible	O
.	O

The	O
preliminary	O
purified	O
recombinant	O
protein	O
was	O
evaluated	O
for	O
its	O
antigenicity	O
and	O
reactivity	O
through	O
Western	O
blotting	O
and	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
monoclonal	O
antibody	B-FUNC
against	O
M	O
protein	O
of	O
PEDV	O
and	O
porcine	O
polyclonal	O
anti	O
-	O
PEDV	O
antiserum	O
as	O
the	O
primary	O
antibody	B-FUNC
.	O

This	O
RNA	B-FUNC
binding	I-FUNC
motif	O
of	O
3a	O
does	O
not	O
share	O
homology	O
with	O
any	O
other	O
known	O
RNA	B-FUNC
binding	I-FUNC
protein	O
and	O
may	O
have	O
an	O
important	O
role	O
in	O
viral	O
capsid	O
assembly	O
and	O
pathogenesis	O
.	O

To	O
analyze	O
the	O
immunogenicity	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
),	O
SARS	O
-	O
CoV	O
,	O
spike	O
DNA	O
vaccine	O
and	O
the	O
immunoregulatory	O
activity	O
of	O
interleukin	O
-	O
2	O
(	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
),	O
DNA	O
vaccine	O
plasmids	O
pcDNA	O
-	O
S	O
and	O
pcDNA	O
-	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
were	O
constructed	O
and	O
inoculated	O
into	O
BALB	O
/	O
c	O
mice	O
with	O
or	O
without	O
pcDNA	O
-	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
by	O
using	O
three	O
different	O
immunization	O
routes	O
(	O
the	O
intramuscular	O
route	O
,	O
electroporation	O
,	O
or	O
the	O
oral	O
route	O
with	O
live	O
attenuated	O
Salmonella	O
enterica	O
serovar	O
Typhimurium	O
).	O

The	O
antibody	B-FUNC
titer	O
in	O
BALB	O
/	O
c	O
mice	O
following	O
immunization	O
with	O
recombinant	O
S	O
protein	O
was	O
detectable	O
after	O
the	O
first	O
immunization	O
.	O

ABSTRACT	O
:	O
All	O
plus	O
-	O
strand	O
RNA	O
viruses	O
encode	O
an	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
that	O
functions	O
as	O
the	O
catalytic	O
subunit	O
of	O
the	O
viral	O
replication	O
/	O
transcription	O
complex	O
,	O
directing	O
viral	O
RNA	O
synthesis	O
in	O
concert	O
with	O
other	O
viral	O
proteins	O
and	O
,	O
sometimes	O
,	O
host	O
proteins	O
.	O

We	O
report	O
here	O
the	O
first	O
successful	O
expression	O
and	O
purification	O
of	O
an	O
arterivirus	O
RdRp	B-FUNC
that	O
is	O
catalytically	O
active	O
in	O
the	O
absence	O
of	O
other	O
viral	O
or	O
cellular	O
proteins	O
.	O

TITLE	O
:	O
Proteinase	B-FUNC
dysbalance	O
in	O
pathology	O
:	O
the	O
neprilysin	O
(	O
NEP	O
)	O
and	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
families	O
.	O

The	O
majority	O
of	O
cases	O
of	O
pulmonary	O
-	O
renal	O
syndrome	O
are	O
associated	O
with	O
ANCAs	O
,	O
either	O
c	O
-	O
ANCA	O
or	O
p	O
-	O
ANCA	O
,	O
due	O
to	O
autoantibodies	O
against	O
the	O
target	O
antigens	O
proteinase	B-FUNC
-	O
3	O
and	O
myeloperoxidase	O
respectively	O
.	O

Serum	O
interleukin	O
(	O
IL	O
)-	O
8	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
concentrations	O
were	O
measured	O
in	O
20	O
of	O
these	O
patients	O
.	O

Intra	O
-	O
abdominal	O
hypertension	O
induced	O
acute	O
lung	O
injury	O
and	O
MODS	O
with	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
elevation	O
,	O
even	O
though	O
AD	O
improved	O
hemodynamic	O
parameters	O
in	O
extensively	O
burned	O
patients	O
.	O

CONCLUSIONS	O
:	O
Intra	O
-	O
abdominal	O
hypertension	O
induced	O
acute	O
lung	O
injury	O
and	O
MODS	O
with	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
elevation	O
,	O
even	O
though	O
AD	O
improved	O
hemodynamic	O
parameters	O
in	O
extensively	O
burned	O
patients	O
.	O

EGF	B-FUNC
stimulates	O
proliferation	O
of	O
intestinal	O
crypt	O
epithelial	O
cells	O
and	O
promotes	O
recovery	O
from	O
atrophic	O
enteritis	O
in	O
PEDV	O
-	O
infected	O
piglets	O
.	O

CONCLUSIONS	O
:	O
This	O
large	O
-	O
scale	O
analysis	O
identified	O
important	O
discriminatory	O
parameters	O
related	O
to	O
the	O
patients	O
'	O
demographic	O
profile	O
(	O
age	O
and	O
gender	O
),	O
severity	O
of	O
illness	O
(	O
pulse	O
rate	O
and	O
neutrophil	O
count	O
),	O
and	O
multisystem	O
derangement	O
(	O
platelet	O
count	O
,	O
CPK	O
,	O
ALT	B-FUNC
and	O
LDH	O
),	O
all	O
of	O
which	O
prognosticated	O
adverse	O
outcomes	O
during	O
the	O
SARS	O
episode	O
.	O

RESULTS	O
:	O
Cerulein	O
injection	O
caused	O
severe	O
AP	O
,	O
confirmed	O
by	O
an	O
increase	O
in	O
serum	O
amylase	O
and	O
lipase	O
levels	O
,	O
histopathological	O
findings	O
of	O
severe	O
AP	O
,	O
and	O
pancreatic	O
MPO	B-FUNC
activity	O
,	O
compared	O
to	O
the	O
values	O
obtained	O
in	O
the	O
sham	O
group	O
.	O

The	O
objectives	O
of	O
the	O
present	O
study	O
were	O
to	O
analyze	O
antibody	B-FUNC
reactivity	O
to	O
ORF8a	O
in	O
patients	O
with	O
SARS	O
and	O
to	O
elucidate	O
the	O
function	O
of	O
ORF8a	O
.	O

Since	O
it	O
has	O
been	O
suggested	O
that	O
the	O
receptor	O
-	O
binding	B-FUNC
motif	O
(	O
RBM	O
)	O
of	O
SARS	O
-	O
CoV	O
may	O
have	O
been	O
acquired	O
from	O
a	O
group	O
1	O
coronavirus	O
,	O
we	O
conducted	O
a	O
surveillance	O
study	O
and	O
identified	O
bat	O
-	O
SARS	O
-	O
CoV	O
and	O
bat	O
-	O
CoV	O
HKU2	O
in	O
8	O
.	O
7	O
%	O
and	O
7	O
.	O
5	O
%	O
respectively	O
of	O
R	O
.	O
sinicus	O
in	O
Hong	O
Kong	O
and	O
Guangdong	O
.	O

High	O
titer	O
antibody	B-FUNC
was	O
detected	O
in	O
the	O
serum	O
of	O
immunized	O
Balb	O
/	O
c	O
mice	O
,	O
and	O
mice	O
immunized	O
with	O
S1	O
protein	O
produced	O
high	O
titer	O
IgG1	O
,	O
IgG2a	O
,	O
IgG2b	O
and	O
IgG3	O
,	O
while	O
those	O
immunized	O
with	O
S2	O
protein	O
produced	O
high	O
titer	O
IgG1	O
,	O
IgG2a	O
,	O
but	O
lower	O
titer	O
IgG2b	O
and	O
IgG3	O
.	O

Acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
III	O
(	O
APACHE	O
III	O
),	O
multiple	O
organ	O
dysfunction	O
syndrome	O
score	O
(	O
MODS	O
score	O
),	O
and	O
lung	O
injury	O
score	O
(	O
LIS	B-FUNC
)	O
were	O
determined	O
on	O
the	O
onset	O
day	O
of	O
ARDS	O
for	O
all	O
the	O
patients	O
.	O

The	O
graphs	O
of	O
characteristic	O
distributions	O
of	O
dinucleotide	O
GC	O
for	O
the	O
coding	O
sequences	O
of	O
the	O
first	O
exon	O
of	O
beta	O
-	O
globin	B-FUNC
gene	O
of	O
eleven	O
different	O
species	O
and	O
the	O
construction	O
of	O
phylogenetic	O
tree	O
of	O
twenty	O
four	O
coronavirus	O
genomes	O
illustrate	O
the	O
utility	O
of	O
the	O
approach	O
.	O

Our	O
results	O
demonstrate	O
that	O
SARS	O
-	O
CoV	O
PLpro	O
can	O
differentiate	O
between	O
ubiquitin	B-FUNC
-	O
like	O
modifiers	O
sharing	O
a	O
common	O
C	O
-	O
terminal	O
sequence	O
,	O
and	O
that	O
the	O
debranching	O
activity	O
of	O
the	O
PLpro	O
is	O
linkage	O
type	O
selective	O
.	O

These	O
glycoproteins	O
are	O
key	O
to	O
the	O
infection	O
process	O
as	O
they	O
are	O
mediators	O
of	O
the	O
receptor	B-FUNC
binding	I-FUNC
and	O
membrane	O
fusion	O
of	O
the	O
virion	O
with	O
the	O
host	O
cell	O
.	O

Inflammatory	O
stimuli	O
can	O
activate	O
IkappaB	O
kinase	O
(	O
IKK	B-FUNC
)	O
signalsome	O
and	O
subsequently	O
the	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
),	O
which	O
influences	O
gene	O
expression	O
of	O
cyclooxygenase	O
-	O
2	O
(	O
Cox	O
-	O
2	O
)	O
along	O
with	O
other	O
transcription	O
factors	O
.	O

In	O
general	O
,	O
there	O
was	O
no	O
relationship	O
between	O
severity	O
of	O
SCD	O
and	O
the	O
incidence	O
of	O
ACS	B-FUNC
,	O
but	O
in	O
71	O
%	O
of	O
cases	O
a	O
vaso	O
-	O
occlusive	O
crisis	O
(	O
VOC	O
)	O
preceded	O
the	O
episodes	O
.	O

nsp3a	O
exhibits	O
a	O
ubiquitin	B-FUNC
-	O
like	O
globular	O
fold	O
of	O
residues	O
1	O
to	O
112	O
and	O
a	O
flexibly	O
extended	O
glutamic	O
acid	O
-	O
rich	O
domain	O
of	O
residues	O
113	O
to	O
183	O
.	O

Fluorescently	O
tagged	O
MSCs	B-FUNC
were	O
detected	O
in	O
the	O
lung	O
tissues	O
by	O
confocal	O
microscopy	O
and	O
flow	O
cytometry	O
in	O
both	O
naïve	O
and	O
LPS	O
-	O
injured	O
animals	O
up	O
to	O
3	O
d	O
.	O
Treatment	O
with	O
MSCs	B-FUNC
alone	O
significantly	O
reduced	O
LPS	O
-	O
induced	O
acute	O
pulmonary	O
inflammation	O
in	O
mice	O
,	O
while	O
administration	O
of	O
pANGPT1	O
-	O
transfected	O
MSCs	B-FUNC
resulted	O
in	O
a	O
further	O
improvement	O
in	O
both	O
alveolar	O
inflammation	O
and	O
permeability	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
variation	O
of	O
specific	O
antibody	B-FUNC
among	O
convalescent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
through	O
a	O
three	O
-	O
year	O
program	O
.	O

Sera	B-FUNC
samples	O
were	O
collected	O
from	O
SARS	O
cases	O
in	O
the	O
5th	O
,	O
20th	O
and	O
35th	O
month	O
after	O
onset	O
of	O
the	O
illness	O
.	O

Results	O
showed	O
that	O
despite	O
the	O
fact	O
that	O
the	O
positive	O
rates	O
of	O
ELISA	O
antibody	B-FUNC
were	O
100	O
%,	O
82	O
.	O
4	O
%	O
and	O
84	O
.	O
6	O
%	O
respectively	O
,	O
the	O
neutralizing	O
antibody	B-FUNC
was	O
still	O
positive	O
for	O
all	O
the	O
samples	O
.	O

Although	O
airway	O
cells	O
secrete	O
TNF	O
-	O
alpha	O
in	O
response	O
to	O
ricin	B-FUNC
,	O
blocking	O
TNF	O
-	O
alpha	O
did	O
not	O
prevent	O
ricin	B-FUNC
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O
Decreased	O
levels	O
of	O
IkappaB	O
-	O
alpha	O
in	O
airway	O
cells	O
exposed	O
to	O
ricin	B-FUNC
suggest	O
that	O
translational	O
suppression	O
may	O
be	O
responsible	O
for	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O
Inhibition	O
of	O
p38	B-FUNC
MAPK	B-FUNC
by	O
a	O
chemical	O
inhibitor	O
or	O
NF	O
-	O
kappaB	O
by	O
short	O
interfering	O
RNA	O
resulted	O
in	O
a	O
marked	O
reduction	O
in	O
the	O
expression	O
of	O
proinflammatory	O
genes	O
,	O
demonstrating	O
the	O
importance	O
of	O
these	O
two	O
pathways	O
in	O
ricin	B-FUNC
intoxication	O
.	O

In	O
contrast	O
,	O
there	O
were	O
significantly	O
weaker	O
cellular	O
immune	O
responses	O
,	O
as	O
well	O
as	O
less	O
antibody	B-FUNC
production	O
than	O
in	O
the	O
control	O
groups	O
.	O

The	O
dead	O
cow	O
had	O
no	O
serum	O
antibody	B-FUNC
against	O
BCV	O
although	O
the	O
co	O
-	O
habitants	O
did	O
.	O

Previous	O
vaccine	O
reports	O
have	O
noted	O
robust	O
neutralizing	O
antibody	B-FUNC
and	O
inflammatory	O
responses	O
in	O
ferrets	O
,	O
resulting	O
in	O
enhanced	O
hepatitis	O
.	O

Isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
analysis	O
indicated	O
a	O
two	O
-	O
metal	B-FUNC
binding	I-FUNC
mode	O
for	O
divalent	O
cations	O
by	O
nsp14	O
.	O

Furthermore	O
,	O
increased	O
pathogenesis	O
was	O
associated	O
with	O
significantly	O
enhanced	O
accumulation	O
of	O
neutrophils	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
,	O
interleukin	O
-	O
6	O
,	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-FUNC
2	O
,	O
and	O
IFN	O
-	O
gamma	O
within	O
the	O
CNS	O
.	O

Cells	O
exposed	O
to	O
hypoxia	O
generate	O
reactive	O
oxygen	O
species	O
which	O
activate	O
PKC	B-FUNC
zeta	O
which	O
in	O
turn	O
phosphorylates	O
the	O
Na	O
,	O
K	O
-	O
ATPase	O
at	O
the	O
Ser18	O
residue	O
in	O
the	O
N	O
-	O
terminus	O
of	O
the	O
alpha1	O
-	O
subunit	O
leading	O
the	O
ubiquitination	O
of	O
any	O
of	O
the	O
four	O
lysines	O
(	O
K16	O
,	O
K17	O
,	O
K19	O
,	O
K20	O
)	O
adjacent	O
to	O
the	O
Ser18	O
residue	O
.	O

TITLE	O
:	O
The	O
""""	O
SARS	O
-	O
unique	O
domain	O
""""	O
(	O
SUD	O
)	O
of	O
SARS	O
coronavirus	O
is	O
an	O
oligo	O
(	O
G	O
)-	O
binding	B-FUNC
protein	O
.	O

The	O
geometric	O
mean	O
titre	O
of	O
neutralizing	O
antibody	B-FUNC
peaked	O
2	O
weeks	O
after	O
the	O
second	O
vaccination	O
,	O
but	O
decreased	O
4	O
weeks	O
later	O
.	O

The	O
geometric	O
mean	O
titre	O
of	O
neutralizing	O
antibody	B-FUNC
peaked	O
2	O
weeks	O
after	O
the	O
second	O
vaccination	O
,	O
but	O
decreased	O
4	O
weeks	O
later	O
.	O

These	O
observations	O
are	O
confirmed	O
by	O
direct	O
in	O
vitro	O
binding	B-FUNC
of	O
recombinant	O
protein	O
7a	O
to	O
the	O
wild	O
type	O
and	O
mutant	O
K287C	O
/	O
K294C	O
I	O
domain	O
showing	O
that	O
the	O
I	O
domain	O
is	O
the	O
7a	O
binding	B-FUNC
site	O
in	O
the	O
alpha	O
(	O
L	O
)	O
chain	O
of	O
LFA	O
-	O
1	O
.	O

Coinfected	O
pigs	O
showed	O
a	O
greater	O
and	O
more	O
sustained	O
transcription	O
of	O
proinflammatory	O
cytokines	O
,	O
especially	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
MCP	B-FUNC
-	O
1	O
,	O
than	O
pigs	O
infected	O
with	O
either	O
PRCV	O
or	O
B	O
.	O
bronchiseptica	O
alone	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
human	O
coronavirus	O
229E	O
infection	O
in	O
human	O
epithelial	O
lung	O
cells	O
(	O
L132	O
)	O
by	O
chloroquine	O
:	O
involvement	O
of	O
p38	B-FUNC
MAPK	B-FUNC
and	O
ERK	B-FUNC
.	O

The	O
pseudo	O
-	O
typed	O
lentiviral	O
particles	O
were	O
used	O
to	O
develop	O
an	O
in	O
vitro	O
microneutralization	O
assay	O
that	O
was	O
both	O
sensitive	O
and	O
specific	O
for	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	B-FUNC
.	O

In	O
this	O
study	O
,	O
the	O
crystal	O
structures	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
M	O
(	O
pro	O
)	O
and	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
(	O
SARS	O
-	O
CoV	O
)	O
M	O
(	O
pro	O
)	O
mutant	O
(	O
H41A	O
),	O
in	O
complex	O
with	O
an	O
N	O
-	O
terminal	O
autocleavage	O
substrate	O
,	O
were	O
individually	O
determined	O
to	O
elucidate	O
the	O
structural	O
flexibility	O
and	O
substrate	O
binding	B-FUNC
of	O
M	O
(	O
pro	O
).	O

These	O
data	O
indicate	O
that	O
(	O
i	O
)	O
CXCL10	O
enhances	O
innate	O
immune	O
responses	O
,	O
resulting	O
in	O
protection	O
from	O
MHV	O
-	O
induced	O
neurological	O
and	O
liver	O
disease	O
;	O
(	O
ii	O
)	O
elevated	O
NK	O
cell	O
IFN	O
-	O
gamma	O
expression	O
in	O
the	O
brain	O
of	O
MHV	O
-	O
CXCL10	O
-	O
infected	O
mice	O
occurs	O
independently	O
of	O
NKG2D	O
;	O
and	O
(	O
iii	O
)	O
NKG2D	O
signaling	O
promotes	O
antiviral	O
activity	O
within	O
the	O
livers	O
of	O
MHV	O
-	O
infected	O
mice	O
that	O
is	O
not	O
dependent	O
on	O
IFN	O
-	O
gamma	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
secretion	O
.	O

Further	O
,	O
these	O
viruses	O
were	O
neutralized	O
by	O
a	O
human	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
),	O
S230	O
.	O
15	O
,	O
but	O
the	O
parent	O
icSZ16	O
-	O
S	O
K479N	O
strain	O
was	O
eight	O
times	O
more	O
resistant	O
than	O
the	O
mutants	O
.	O

31	O
mL	O
/	O
min	O
,	O
lung	O
(	O
s	O
)	O
rest	B-FUNC
(	O
tidal	O
volume	O
,	O
2	O
.	O
7	O
+/-	O

vaccination	O
,	O
as	O
evidenced	O
by	O
higher	O
prevalence	O
of	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
and	O
/	O
or	O
IFN	O
-	O
gamma	O
-	O
producing	O
CD3	O
+/	O
CD8	O
+	O
T	O
cells	O
in	O
both	O
lungs	O
and	O
spleen	O
;	O
3	O
)	O
the	O
i	O
.	O
n	O
.	O

Using	O
a	O
membrane	O
-	O
strip	O
based	O
Western	O
blot	O
approach	O
,	O
the	O
reactivity	O
of	O
each	O
antigen	O
fragment	O
against	O
a	O
panel	O
of	O
animal	O
sera	B-FUNC
was	O
determined	O
.	O

Possibly	O
,	O
cross	O
-	O
reactive	O
antibody	B-FUNC
responses	O
were	O
observed	O
using	O
229E	O
and	O
OC43	O
serum	O
pairs	O
.	O

The	O
membrane	O
(	O
M	O
)	O
protein	O
genes	O
of	O
six	O
PEDV	O
isolates	O
were	O
amplified	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
then	O
cloned	O
,	O
sequenced	O
,	O
and	O
compared	O
with	O
each	O
other	O
as	O
well	O
as	O
those	O
ten	O
PEDV	O
reference	O
strains	O
.	O

in	O
various	O
tissues	O
and	O
excreta	O
,	O
while	O
neutralizing	O
antibody	B-FUNC
titers	O
rose	O
at	O
7	O
d	O
.	O
p	O
.	O
i	O
.	O
and	O
peaked	O
at	O
14	O
d	O
.	O
p	O
.	O
i	O
.	O

Broad	O
spectrum	O
agents	O
that	O
can	O
serve	O
as	O
disrafters	O
or	O
neutralize	O
the	O
viral	O
infectivity	O
by	O
binding	B-FUNC
to	O
the	O
envelope	O
lipid	O
or	O
sugar	O
moieties	O
will	O
not	O
be	O
affected	O
by	O
the	O
vagaries	O
of	O
hypermutation	O
of	O
surface	O
antigens	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
the	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
-	O
1082	O
genotype	O
may	O
be	O
a	O
risk	O
marker	O
for	O
development	O
of	O
acute	O
respiratory	O
failure	O
after	O
trauma	O
.	O

The	O
levels	O
of	O
PCT	O
correlate	O
with	O
levels	O
of	O
TNF	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
.	O

Combination	O
vaccinations	O
using	O
B1	O
and	O
VG	O
/	O
GA	O
did	O
not	O
interfere	O
with	O
IBV	O
immunity	O
based	O
on	O
challenge	O
or	O
serum	O
antibody	B-FUNC
production	O
.	O

We	O
detected	O
antibody	B-FUNC
reactive	O
with	O
SARS	O
-	O
CoV	O
antigen	O
in	O
47	O
(	O
6	O
.	O
7	O
%)	O
of	O
705	O
bat	O
serum	O
specimens	O
comprising	O
26	O
species	O
collected	O
in	O
Africa	O
;	O
thus	O
,	O
African	O
bats	O
may	O
harbor	O
agents	O
related	O
to	O
putative	O
group	O
4	O
CoV	O
.	O

They	O
are	O
nucleic	O
acid	O
-	O
binding	B-FUNC
proteins	O
whose	O
main	O
recognized	O
function	O
is	O
to	O
package	O
viral	O
genomes	O
into	O
protective	O
structures	O
called	O
nucleocapsids	O
.	O

Autoantibodies	O
to	O
several	O
cytokines	O
,	O
including	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
have	O
been	O
found	O
in	O
human	O
plasma	O
and	O
other	O
tissues	O
.	O

Furthermore	O
,	O
immune	O
complexes	O
consisting	O
of	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
autoantibodies	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
are	O
very	O
stable	O
due	O
to	O
the	O
high	O
affinity	O
of	O
autoantibodies	O
against	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
.	O

Furthermore	O
,	O
an	O
ectodomain	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
(	O
S1188HA	O
)	O
could	O
associate	O
with	O
lipid	O
rafts	O
after	O
binding	B-FUNC
to	O
its	O
receptor	O
,	O
and	O
colocalize	O
with	O
raft	O
-	O
resident	O
marker	O
ganglioside	O
GM1	O
.	O

This	O
suggests	O
that	O
recombinant	O
protein	O
/	O
peptide	O
-	O
based	O
subunit	O
vaccines	O
containing	O
the	O
spike	O
protein	O
,	O
especially	O
the	O
receptor	O
-	O
bind	B-FUNC
domain	O
of	O
SARS	O
-	O
CoV	O
,	O
could	O
be	O
developed	O
as	O
safe	O
and	O
effective	O
SARS	O
vaccines	O
.	O

To	O
investigate	O
endotoxemia	O
,	O
plasma	O
TNFalpha	O
,	O
IL	O
-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
the	O
liberation	O
capacity	O
of	O
those	O
cytokines	O
from	O
mononuclear	O
cells	O
after	O
LPS	O
challenge	O
(	O
Delta	O
values	O
),	O
and	O
plasma	O
antibodies	O
to	O
endotoxins	O
and	O
alpha	O
-	O
hemolysin	O
of	O
Staphylococcus	O
aureus	O
in	O
ALI	O
/	O
ARDS	O
.	O

However	O
,	O
compared	O
to	O
conventional	O
vaccines	O
,	O
DNA	O
vaccines	O
usually	O
induce	O
poor	O
antibody	B-FUNC
responses	O
.	O

ABSTRACT	O
:	O
During	O
acute	O
viral	O
hepatitis	O
,	O
the	O
intrahepatic	O
tolerance	O
sustained	O
by	O
immunosuppressive	O
cytokines	O
such	O
as	O
interleukin	O
(	O
IL	O
)-	O
4	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)-	O
beta	O
and	O
prostaglandin	O
E2	O
(	O
PGE2	O
),	O
produced	O
by	O
Kupffer	O
cells	O
(	O
KC	O
),	O
liver	O
sinusoidal	O
endothelial	O
cells	O
(	O
LSEC	O
),	O
natural	O
killer	O
(	O
NK	O
)	O
T	O
cells	O
and	O
natural	O
regulatory	O
T	O
cells	O
may	O
be	O
disturbed	O
.	O

Results	O
showed	O
that	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
TGF	O
-	O
beta	O
and	O
PGE2	O
production	O
in	O
the	O
liver	O
decreased	O
in	O
L2	O
-	O
MHV3	O
-	O
infected	O
mice	O
and	O
increased	O
in	O
51	O
.	O
6	O
-	O
MHV3	O
-	O
and	O
CL12	O
-	O
MHV3	O
-	O
infected	O
mice	O
.	O

To	O
help	O
elucidate	O
these	O
roles	O
,	O
we	O
have	O
characterized	O
the	O
first	O
virally	O
encoded	O
cyclophilin	B-FUNC
(	O
mimicyp	O
)	O
derived	O
from	O
the	O
largest	O
virus	O
discovered	O
to	O
date	O
(	O
the	O
Mimivirus	O
)	O
that	O
is	O
also	O
a	O
causative	O
agent	O
of	O
pneumonia	O
in	O
humans	O
.	O

TITLE	O
:	O
Analysis	O
of	O
the	O
mechanism	O
of	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
infection	O
:	O
aminopeptidase	O
N	O
is	O
not	O
important	O
and	O
a	O
process	O
of	O
acidification	O
of	O
the	O
endosome	O
is	O
necessary	O
.	O

Tracheobronchial	O
suction	O
fluid	O
was	O
collected	O
every	O
2	O
hours	O
and	O
assayed	O
for	O
interleukins	O
(	O
IL	O
-	O
1beta	O
,	O
-	O
8	O
,	O
and	O
-	O
10	O
),	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
,	O
transforming	O
growth	O
factor	O
-	O
beta1	O
,	O
soluble	O
Fas	O
ligand	B-FUNC
(	O
sFasL	O
),	O
and	O
complement	O
factor	O
5a	O
.	O

IL	B-FUNC
-	I-FUNC
8	I-FUNC
increased	O
sharply	O
in	O
the	O
first	O
6	O
.	O
5	O
hours	O
postexposure	O
(	O
P	O
<	O
.	O
001	O
),	O
and	O
IL	O
-	O
1beta	O
in	O
the	O
first	O
6	O
.	O
1	O
hours	O
(	O
P	O
<	O
.	O
001	O
).	O

We	O
attempted	O
to	O
investigate	O
the	O
effects	O
of	O
different	O
immunization	O
protocols	O
and	O
adjuvant	O
on	O
the	O
antibody	B-FUNC
responses	O
to	O
inactivated	O
SARS	O
-	O
CoV	O
vaccine	O
.	O

All	O
bronchoalveolar	O
lavage	O
specimens	O
were	O
screened	O
using	O
a	O
set	O
of	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
assays	O
targeting	O
17	O
different	O
respiratory	O
viruses	O
.	O

Plasma	O
biomarkers	O
of	O
inflammation	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
intercellular	O
adhesion	O
molecule	O
1	O
),	O
of	O
coagulation	O
(	O
thrombomodulin	O
,	O
protein	O
C	O
)	O
and	O
of	O
fibrinolysis	O
(	O
plasminogen	O
activator	O
inhibitor	O
1	O
)	O
were	O
measured	O
by	O
ELISA	O
.	O

All	O
markers	O
except	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
were	O
significantly	O
different	O
between	O
survivors	O
and	O
nonsurvivors	O
.	O

One	O
of	O
these	O
domains	O
is	O
located	O
within	O
the	O
previously	O
described	O
SARS	O
-	O
unique	O
domain	O
,	O
and	O
there	O
is	O
a	O
nucleic	O
acid	O
chaperone	O
-	O
like	O
domain	O
located	O
immediately	O
downstream	O
of	O
the	O
papain	O
-	O
like	O
proteinase	B-FUNC
domain	O
.	O

Here	O
we	O
investigate	O
the	O
free	O
energy	O
landscape	O
for	O
a	O
minimal	O
-	O
1	O
programmed	O
ribosomal	O
frameshifting	O
machinery	O
,	O
including	O
the	O
codon	O
-	O
anticodon	O
base	B-FUNC
pairs	I-FUNC
at	O
the	O
slippery	O
site	O
,	O
the	O
downstream	O
messenger	O
RNA	O
structure	O
and	O
the	O
spacer	O
between	O
the	O
slippery	O
site	O
and	O
the	O
downstream	O
structure	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
and	O
screening	O
of	O
antisense	O
peptide	O
based	O
combinatorial	O
peptide	O
libraries	O
towards	O
an	O
aromatic	O
region	O
of	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
A	O
combination	O
of	O
high	O
-	O
performance	O
affinity	O
chromatography	O
and	O
antisense	O
peptide	O
based	O
combinatorial	O
peptide	O
libraries	O
was	O
used	O
to	O
screen	O
a	O
potential	O
inhibitor	O
for	O
SARS	O
-	O
CoV	O
.	O
An	O
aromatic	O
-	O
amino	O
acid	O
-	O
rich	O
region	O
within	O
the	O
transmembrane	O
domain	O
at	O
the	O
C	O
terminal	O
of	O
spike	O
(	O
S	O
)	O
protein	O
identified	O
as	O
a	O
membrane	O
-	O
active	O
region	O
was	O
chosen	O
as	O
the	O
target	O
sense	O
peptide	O
(	O
SP	O
)	O
and	O
immobilized	O
as	O
affinity	O
ligand	B-FUNC
.	O

TITLE	O
:	O
A	O
novel	O
mutation	O
in	O
murine	O
hepatitis	O
virus	O
nsp5	O
,	O
the	O
viral	O
3C	O
-	O
like	O
proteinase	B-FUNC
,	O
causes	O
temperature	O
-	O
sensitive	O
defects	O
in	O
viral	O
growth	O
and	O
protein	O
processing	O
.	O

In	O
this	O
study	O
,	O
reverse	O
transcriptase	B-FUNC
PCR	O
sequencing	O
of	O
the	O
RNA	O
genome	O
of	O
an	O
isolate	O
of	O
the	O
MHV	O
ts	O
virus	O
Alb	O
ts6	O
,	O
referred	O
to	O
as	O
Alb	O
/	O
ts	O
/	O
nsp5	O
/	O
V148A	O
,	O
identified	O
a	O
putative	O
ts	O
mutation	O
in	O
nsp5	O
(	O
T10651C	O
,	O
Val148Ala	O
),	O
the	O
viral	O
3C	O
-	O
like	O
proteinase	B-FUNC
(	O
3CLpro	O
).	O

Interestingly	O
,	O
this	O
feature	O
can	O
be	O
lost	O
during	O
cell	O
culture	O
adaptation	O
by	O
a	O
single	O
mutation	O
in	O
the	O
cleavage	O
motif	O
;	O
this	O
,	O
however	O
,	O
preserves	O
a	O
heparan	B-FUNC
sulfate	I-FUNC
binding	I-FUNC
motif	O
and	O
renders	O
infection	O
by	O
the	O
virus	O
heparan	O
sulfate	O
dependent	O
.	O

The	O
unusually	O
complex	O
coronavirus	O
replicase	O
/	O
transcriptase	B-FUNC
is	O
comprised	O
of	O
15	O
or	O
16	O
virus	O
-	O
specific	O
subunits	O
that	O
are	O
autoproteolytically	O
derived	O
from	O
two	O
large	O
polyproteins	O
.	O

The	O
most	O
promising	O
compounds	O
include	O
carbohydrate	O
-	O
binding	B-FUNC
agents	O
,	O
neutralizing	O
antibodies	O
and	O
drugs	O
targeting	O
a	O
coronaviral	O
envelope	O
protein	O
.	O

ABSTRACT	O
:	O
Waste	O
ashes	O
from	O
three	O
types	O
of	O
hospital	O
waste	O
(	O
HW	O
)	O
incinerators	O
,	O
built	O
in	O
SARS	O
(	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
)	O
period	O
and	O
currently	O
running	O
in	O
China	O
,	O
were	O
collected	O
and	O
polycyclic	O
aromatic	O
hydrocarbons	O
(	O
PAH	B-FUNC
)	O
properties	O
in	O
the	O
ashes	O
were	O
investigated	O
.	O

The	O
identification	O
of	O
antigenic	O
N	O
protein	O
fragments	O
has	O
implications	O
to	O
provide	O
basic	O
information	O
for	O
the	O
design	O
of	O
DNA	O
vaccine	O
against	O
SARS	O
-	O
CoV	O
.	O
The	O
present	O
results	O
not	O
only	O
suggest	O
that	O
DNA	O
immunization	O
with	O
pVax	O
-	O
N3	O
could	O
be	O
used	O
as	O
potential	O
DNA	O
vaccination	O
approaches	O
to	O
induce	O
antibody	B-FUNC
in	O
BALB	O
/	O
c	O
mice	O
,	O
but	O
also	O
illustrates	O
that	O
gene	O
immunization	O
with	O
these	O
SARS	O
DNA	O
vaccines	O
can	O
generate	O
different	O
immune	O
responses	O
.	O

Molecular	O
modeling	O
analysis	O
suggested	O
that	O
ADS	O
-	O
J1	O
may	O
bind	B-FUNC
to	O
the	O
deep	O
pocket	O
of	O
the	O
hydrophobic	O
groove	O
on	O
the	O
surface	O
of	O
the	O
central	O
coiled	O
-	O
coil	O
of	O
SARS	O
-	O
CoV	O
S	O
HR	O
protein	O
and	O
prevent	O
the	O
entrance	O
of	O
the	O
SARS	O
-	O
CoV	O
into	O
the	O
host	O
cells	O
.	O

The	O
RTC	O
appeared	O
to	O
be	O
protected	O
by	O
membranes	O
,	O
as	O
newly	O
synthesized	O
viral	O
RNA	O
and	O
several	O
replicase	O
/	O
transcriptase	B-FUNC
subunits	O
were	O
protease	O
-	O
and	O
nuclease	O
-	O
resistant	O
and	O
became	O
susceptible	O
to	O
degradation	O
only	O
upon	O
addition	O
of	O
a	O
non	O
-	O
ionic	O
detergent	O
.	O

At	O
the	O
present	O
time	O
,	O
diagnostics	O
have	O
progressed	O
to	O
the	O
point	O
that	O
RT	O
-	O
PCR	O
has	O
a	O
sensitivity	O
approaching	O
80	O
%	O
within	O
the	O
first	O
few	O
days	O
of	O
onset	O
of	O
illness	O
,	O
while	O
serology	O
has	O
a	O
sensitivity	O
close	O
to	O
100	O
%	O
on	O
convalescent	O
sera	B-FUNC
taken	O
>	O
21	O
days	O
after	O
illness	O
onset	O
.	O

Clinical	O
and	O
general	O
laboratory	O
manifestations	O
included	O
fever	O
,	O
chills	O
,	O
rigor	O
,	O
myalgia	O
,	O
malaise	O
,	O
diarrhoea	O
,	O
cough	O
,	O
dyspnoea	O
,	O
pneumonia	O
,	O
lymphopenia	O
,	O
neutrophilia	O
,	O
thrombocytopenia	O
,	O
and	O
elevated	O
serum	O
lactate	O
dehydrogenase	O
(	O
LD	O
),	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
and	O
creatine	O
kinase	O
(	O
CK	O
)	O
activities	O
.	O

Therefore	O
,	O
it	O
will	O
be	O
useful	O
in	O
screening	O
binding	B-FUNC
candidates	O
for	O
a	O
given	O
RNA	O
target	O
motif	O
with	O
one	O
chip	O
.	O

RESULTS	O
:	O
A	O
type	O
of	O
medium	O
or	O
low	O
titer	O
anti	O
-	O
lung	O
tissue	O
antibodies	O
were	O
found	O
in	O
the	O
sera	B-FUNC
of	O
SARS	O
patients	O
at	O
the	O
early	O
stage	O
of	O
the	O
disease	O
.	O

Intravenous	O
injection	O
with	O
anti	O
-	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
antibody	B-FUNC
3	O
hours	O
after	O
infection	O
had	O
no	O
effect	O
on	O
SARS	O
-	O
CoV	O
infection	O
.	O

A	O
gene	O
for	O
hemagglutinin	O
-	O
esterase	O
was	O
absent	O
in	O
TCoV	O
.	O
The	O
region	O
between	O
the	O
membrane	O
(	O
M	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
genes	O
contained	O
three	O
potential	O
small	O
ORFs	O
:	O
ORF	O
-	O
X	O
,	O
a	O
previously	O
uncharacterized	O
ORF	O
with	O
an	O
associated	O
putative	O
TRS	B-FUNC
within	O
the	O
M	O
gene	O
(	O
apparently	O
shared	O
among	O
all	O
group	O
III	O
coronaviruses	O
),	O
and	O
previously	O
described	O
ORFs	O
5a	O
and	O
5b	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
report	O
a	O
study	O
of	O
the	O
binding	B-FUNC
and	O
interaction	O
with	O
model	O
membranes	O
of	O
a	O
peptide	O
pertaining	O
to	O
the	O
putative	O
fusion	O
domain	O
of	O
SARS	O
-	O
CoV	O
,	O
SARS	O
FP	O
,	O
as	O
well	O
as	O
the	O
structural	O
changes	O
that	O
take	O
place	O
in	O
both	O
the	O
phospholipid	O
and	O
the	O
peptide	O
molecules	O
upon	O
this	O
interaction	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
an	O
simple	O
and	O
sensitive	O
method	O
for	O
detecting	O
anti	O
-	O
coronavirus	O
IgG	O
antibodies	O
in	O
bat	O
sera	B-FUNC
based	O
on	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

A	O
commercial	O
ELISA	O
kit	B-FUNC
for	O
detecting	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
was	O
modified	O
for	O
detecting	O
coronavirus	O
antibodies	O
in	O
bat	O
serum	O
samples	O
.	O

This	O
SPA	O
-	O
ELISA	O
method	O
is	O
applicable	O
for	O
detecting	O
coronavirus	O
antibody	B-FUNC
in	O
bat	O
sera	B-FUNC
.	O

RESULTS	O
:	O
The	O
test	O
results	O
of	O
the	O
positive	O
and	O
negative	O
controls	O
in	O
the	O
kit	B-FUNC
and	O
the	O
serum	O
samples	O
from	O
convalescent	O
;	O
patient	O
were	O
consistent	O
with	O
expectation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
leflunomide	O
,	O
an	O
immunomodulatory	O
agent	O
,	O
on	O
oxidant	O
/	O
antioxidant	O
status	O
with	O
nitric	O
oxide	O
(	O
NO	O
)	O
level	O
and	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
activity	O
in	O
rats	O
with	O
sepsis	O
-	O
induced	O
ALI	O
.	O

TITLE	O
:	O
A	O
chimeric	O
multi	O
-	O
epitope	O
DNA	O
vaccine	O
elicited	O
specific	O
antibody	B-FUNC
response	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
which	O
attenuated	O
the	O
virulence	O
of	O
SARS	O
-	O
CoV	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Epitope	O
-	O
based	O
vaccines	O
designed	O
to	O
induce	O
antibody	B-FUNC
responses	O
specific	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
are	O
being	O
developed	O
as	O
a	O
means	O
for	O
increasing	O
vaccine	O
potency	O
.	O

Moreover	O
,	O
cleavage	O
was	O
mapped	O
to	O
the	O
same	O
region	O
where	O
,	O
in	O
coronaviruses	O
carrying	O
furin	O
-	O
activated	O
spikes	O
,	O
the	O
receptor	B-FUNC
binding	I-FUNC
subunit	O
of	O
the	O
protein	O
is	O
separated	O
from	O
the	O
membrane	O
-	O
anchored	O
fusion	O
subunit	O
.	O

Multiple	O
logistic	O
regression	O
analysis	O
revealed	O
that	O
patients	O
with	O
increased	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
as	O
well	O
as	O
decreased	O
IL	B-FUNC
-	I-FUNC
7	I-FUNC
serum	O
levels	O
had	O
a	O
significantly	O
greater	O
risk	O
for	O
mortality	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
SARS	O
peptide	O
antibody	B-FUNC
system	O
described	O
presents	O
an	O
alternative	O
tagging	O
opportunity	O
in	O
the	O
growing	O
field	O
of	O
protein	O
science	O
.	O

Therefore	O
,	O
therapeutic	O
targeting	O
of	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
/	O
or	O
IL	B-FUNC
-	I-FUNC
23	I-FUNC
for	O
the	O
treatment	O
of	O
autoimmune	O
diseases	O
may	O
offer	O
unique	O
advantages	O
by	O
reducing	O
disease	O
severity	O
without	O
muting	O
protective	O
responses	O
following	O
viral	O
infection	O
.	O

The	O
assay	O
is	O
based	O
on	O
TaqMan	O
technology	O
,	O
consisting	O
of	O
two	O
primers	O
and	O
one	O
probe	O
labeled	O
with	O
the	O
reporter	O
dye	O
6	O
-	O
carboxyfluorescein	O
that	O
binds	B-FUNC
selectively	O
to	O
the	O
transmembrane	O
-	O
protein	O
gene	O
of	O
BCoV	O
.	O
The	O
BCoV	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
was	O
able	O
to	O
detect	O
the	O
tested	O
BCoV	O
and	O
BCoV	O
-	O
like	O
viruses	O
(	O
canine	O
respiratory	O
coronavirus	O
and	O
bubaline	O
coronavirus	O
),	O
whereas	O
other	O
common	O
viral	O
pathogens	O
of	O
cattle	O
were	O
not	O
recognised	O
by	O
the	O
established	O
oligonucleotide	O
set	O
,	O
thus	O
showing	O
that	O
the	O
test	O
was	O
specific	O
for	O
bovine	O
-	O
like	O
CoVs	O
.	O

ABSTRACT	O
:	O
Experimental	O
and	O
clinical	O
studies	O
support	O
the	O
key	O
role	O
of	O
interleukin	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
a	O
potent	O
proinflammatory	O
cytokine	O
,	O
in	O
the	O
development	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

To	O
gain	O
insight	O
into	O
the	O
C	O
-	O
terminal	O
recognition	O
region	O
of	O
ubiquitin	B-FUNC
by	O
DUBs	O
,	O
we	O
synthesized	O
positional	O
scanning	O
libraries	O
of	O
fluorigenic	O
tetrapeptides	O
and	O
tested	O
them	O
on	O
three	O
examples	O
of	O
human	O
DUBs	O
[	O
OTU	O
-	O
1	O
(	O
ovarian	O
tumour	O
1	O
),	O
Iso	O
-	O
T	O
(	O
isopeptidase	O
T	O
)	O
and	O
UCH	O
-	O
L3	O
(	O
ubiquitin	B-FUNC
C	O
-	O
terminal	O
hydrolase	O
L3	O
)]	O
and	O
one	O
viral	O
ubiquitin	B-FUNC
-	O
specific	O
protease	O
,	O
namely	O
PLpro	O
(	O
papain	O
-	O
like	O
protease	O
)	O
from	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)	O
virus	O
.	O

In	O
most	O
cases	O
the	O
results	O
show	O
flexibility	O
in	O
the	O
P4	O
position	O
,	O
very	O
high	O
specificity	O
for	O
arginine	O
in	O
the	O
P3	O
position	O
and	O
glycine	O
in	O
the	O
P2	O
position	O
,	O
in	O
accord	O
with	O
the	O
sequence	O
of	O
the	O
natural	O
substrate	O
,	O
ubiquitin	B-FUNC
.	O

Surprisingly	O
,	O
screening	O
of	O
the	O
P2	O
position	O
revealed	O
that	O
UCH	O
-	O
L3	O
,	O
in	O
contrast	O
with	O
all	O
the	O
other	O
tested	O
DUBs	O
,	O
demonstrates	O
substantial	O
tolerance	O
of	O
alanine	O
and	O
valine	O
at	O
P2	O
,	O
and	O
a	O
parallel	O
analysis	O
using	O
the	O
appropriate	O
mutation	O
of	O
the	O
full	O
-	O
length	O
ubiquitin	B-FUNC
confirms	O
this	O
.	O

Immune	O
responses	O
were	O
compared	O
in	O
immature	O
DCs	O
inoculated	O
with	O
BVLPs	O
or	O
with	O
VLPs	O
formed	O
by	O
S	O
,	O
E	O
and	O
M	O
proteins	O
of	O
human	O
SARS	O
-	O
CoV	O
.	O
BVLPs	O
showed	O
a	O
stronger	O
ability	O
to	O
stimulate	O
DCs	O
in	O
terms	O
of	O
cytokine	O
induction	O
as	O
evidenced	O
by	O
2	O
to	O
6	O
fold	O
higher	O
production	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
TNF	O
-	O
alpha	O
.	O

We	O
further	O
found	O
that	O
RS	O
motif	O
phosphorylation	O
did	O
not	O
significantly	O
affect	O
RNA	B-FUNC
binding	I-FUNC
of	O
the	O
nucleocapsid	O
protein	O
but	O
impaired	O
its	O
multimerization	O
ability	O
.	O

For	O
p38	B-FUNC
activation	O
and	O
apoptosis	O
induction	O
,	O
the	O
3a	O
cytoplasmic	O
domain	O
was	O
sufficient	O
.	O

Finally	O
,	O
strategies	O
to	O
reduce	O
PBEF	O
availability	O
(	O
neutralizing	O
antibody	B-FUNC
)	O
resulted	O
in	O
significant	O
protection	O
from	O
VILI	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
in	O
vitro	O
anti	O
-	O
HIV	O
evaluation	O
of	O
a	O
new	O
series	O
of	O
6	O
-	O
arylmethyl	O
-	O
substituted	O
S	O
-	O
DABOs	O
as	O
potential	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
.	O

We	O
have	O
shown	O
that	O
these	O
compounds	O
can	O
inhibit	O
SARS	O
-	O
CoV	O
helicase	B-FUNC
activity	I-FUNC
and	O
viral	O
growth	O
in	O
cell	O
culture	O
systems	O
.	O

The	O
resultant	O
recombinant	O
protein	O
was	O
produced	O
and	O
used	O
in	O
antibody	B-FUNC
detection	O
assays	O
via	O
western	O
blot	O
analysis	O
of	O
serum	O
samples	O
.	O

One	O
of	O
them	O
,	O
nsp3	O
,	O
contains	O
an	O
ADRP	O
(	O
adenosine	O
diphosphate	O
-	O
ribose	O
-	O
1	O
'-	O
phosphatase	B-FUNC
)	O
domain	O
which	O
was	O
revealed	O
in	O
recent	O
studies	O
to	O
have	O
ADP	O
-	O
ribose	O
-	O
1	O
'-	O
monophosphatase	O
(	O
Appr	O
-	O
1	O
'-	O
pase	O
)	O
activity	O
.	O

Both	O
antibody	B-FUNC
-	O
displaying	O
human	O
cells	O
and	O
virus	O
particles	O
bound	O
antigen	O
specifically	O
.	O

Up	O
to	O
10	O
(	O
6	O
)-	O
fold	O
enrichment	O
of	O
antibody	B-FUNC
expressing	O
cells	O
was	O
achieved	O
with	O
one	O
round	O
of	O
antigen	O
coupled	O
magnetic	O
bead	O
pre	O
-	O
selection	O
followed	O
by	O
FACS	O
sorting	O
.	O

Inhibitor	O
10	O
with	O
a	O
5	O
-	O
chloropyridinyl	O
ester	O
at	O
position	O
4	O
of	O
the	O
indole	O
ring	O
is	O
the	O
most	O
potent	O
inhibitor	O
with	O
a	O
SARS	O
-	O
CoV	O
3CLpro	O
IC	O
(	O
50	O
)	O
value	O
of	O
30	O
nM	O
and	O
an	O
antiviral	O
EC	O
(	O
50	O
)	O
value	O
of	O
6	O
.	O
9	O
microM	O
.	O
Molecular	O
docking	O
studies	O
have	O
provided	O
possible	O
binding	B-FUNC
modes	O
of	O
these	O
inhibitors	O
.	O

To	O
understand	O
the	O
involvement	O
of	O
cholesterol	O
in	O
the	O
initial	O
steps	O
of	O
the	O
viral	O
life	O
cycle	O
,	O
we	O
applied	O
a	O
cell	O
-	O
based	O
binding	B-FUNC
assay	O
with	O
cells	O
expressing	O
the	O
S	O
protein	O
and	O
cells	O
containing	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

TITLE	O
:	O
A	O
SARS	O
DNA	O
vaccine	O
induces	O
neutralizing	O
antibody	B-FUNC
and	O
cellular	O
immune	O
responses	O
in	O
healthy	O
adults	O
in	O
a	O
Phase	O
I	O
clinical	O
trial	O
.	O

The	O
VRC	O
SARS	O
DNA	O
vaccine	O
was	O
well	O
tolerated	O
and	O
produced	O
cellular	O
immune	O
responses	O
and	O
neutralizing	O
antibody	B-FUNC
in	O
healthy	O
adults	O
.	O

Efficiency	O
of	O
bovine	O
antibody	B-FUNC
production	O
could	O
be	O
enhanced	O
using	O
cholera	O
toxin	O
subunit	O
b	O
,	O
and	O
milk	O
production	O
could	O
be	O
rapidly	O
accelerated	O
using	O
recombinant	O
bovine	O
somatotropin	O
hormone	O
.	O

The	O
antibody	B-FUNC
prevalence	O
was	O
high	O
at	O
both	O
sampling	O
times	O
with	O
approximately	O
85	O
%	O
and	O
80	O
%	O
of	O
animals	O
positive	O
for	O
antibodies	O
to	O
BCV	O
and	O
to	O
BRSV	O
,	O
respectively	O
.	O

Using	O
a	O
commercial	O
ELISA	O
kit	B-FUNC
,	O
it	O
was	O
found	O
that	O
the	O
antibodies	O
detected	O
in	O
pigs	O
of	O
all	O
the	O
raising	O
stages	O
and	O
sows	O
were	O
raised	O
against	O
PRCV	O
but	O
not	O
TGEV	O
.	O

TITLE	O
:	O
Topology	O
and	O
membrane	O
anchoring	B-FUNC
of	O
the	O
coronavirus	O
replication	O
complex	O
:	O
not	O
all	O
hydrophobic	O
domains	O
of	O
nsp3	O
and	O
nsp6	O
are	O
membrane	O
spanning	O
.	O

Moreover	O
,	O
the	O
protection	O
seems	O
to	O
be	O
associated	O
with	O
a	O
restricted	O
phospholipase	B-FUNC
A2	I-FUNC
activity	I-FUNC
.	O

TITLE	O
:	O
DIHYDROPYRIMIDINE	O
DEHYDROGENASE	O
DEFICIENCY	O
(	O
DPD	B-FUNC
)	O
IN	O
GI	O
MALIGNANCIES	O
:	O
EXPERIENCE	O
OF	O
4	O
-	O
YEARS	O
.	O

METHODOLOGY	O
:	O
Twenty	O
-	O
three	O
patients	O
were	O
tested	O
for	O
DPD	B-FUNC
deficiency	O
after	O
excessive	O
toxicities	O
from	O
5	O
-	O
FU	O
and	O
/	O
or	O
capecitabine	O
.	O

Cleavage	O
of	O
S	O
and	O
release	O
of	O
HCoV	O
-	O
HKU1	O
S	O
pseudotyped	O
virus	O
were	O
inhibited	O
by	O
furin	O
or	O
furin	O
-	O
like	O
enzyme	B-FUNC
inhibitors	I-FUNC
.	O

TITLE	O
:	O
A	O
noncovalent	O
class	O
of	O
papain	O
-	O
like	O
protease	O
/	O
deubiquitinase	B-FUNC
inhibitors	O
blocks	O
SARS	O
virus	O
replication	O
.	O

The	O
association	O
of	O
China	O
with	O
the	O
rest	B-FUNC
of	O
the	O
world	O
through	O
travel	O
and	O
trade	O
means	O
that	O
events	O
in	O
the	O
country	O
can	O
affect	O
distant	O
populations	O
.	O

These	O
proteins	O
are	O
quickly	O
internalized	O
upon	O
binding	B-FUNC
of	O
antibodies	O
.	O

Significant	O
associations	O
of	O
coronavirus	O
seropositivity	O
and	O
antibody	B-FUNC
levels	O
with	O
age	O
,	O
gender	O
,	O
race	O
,	O
socioeconomic	O
status	O
,	O
smoking	O
status	O
,	O
and	O
season	O
of	O
the	O
blood	O
draw	O
were	O
tested	O
with	O
chi	O
-	O
square	O
and	O
regression	O
analyses	O
.	O

We	O
used	O
the	O
consensus	O
peptide	O
-	O
binding	B-FUNC
motif	O
for	O
the	O
Major	O
Histocompatibility	O
Complex	O
molecule	O
H	O
-	O
2K	O
(	O
b	O
)	O
to	O
design	O
a	O
heteroclitic	O
version	O
of	O
the	O
mouse	O
hepatitis	O
virus	O
-	O
specific	O
subdominant	O
S598	O
determinant	O
.	O

Furthermore	O
,	O
229E	O
infection	O
was	O
inhibited	O
in	O
CPL	B-FUNC
knockdown	O
cells	O
by	O
small	O
interfering	O
RNA	O
,	O
compared	O
with	O
what	O
was	O
seen	O
for	O
a	O
normal	O
counterpart	O
producing	O
CPL	B-FUNC
.	O

Because	O
sera	B-FUNC
endotoxins	O
were	O
elevated	O
,	O
she	O
was	O
treated	O
by	O
endotoxin	O
adsorption	O
therapy	O
on	O
hospital	O
day	O
3	O
.	O

The	O
functions	O
of	O
the	O
macro	O
domain	O
are	O
poorly	O
understood	O
,	O
but	O
it	O
has	O
been	O
suggested	O
to	O
be	O
an	O
ADP	O
-	O
ribose	O
-	O
binding	B-FUNC
module	O
.	O

343	O
-	O
367	O
,	O
373	O
-	O
390	O
and	O
411	O
-	O
428	O
)	O
and	O
is	O
spatially	O
located	O
neighboring	O
the	O
receptor	O
-	O
binding	B-FUNC
motif	O
(	O
RPM	O
)	O
region	O
of	O
the	O
RBD	O
.	O

Transduced	O
cells	O
that	O
bind	B-FUNC
soluble	O
HCoV	O
-	O
HKU1	O
S	O
(	O
1	O
-	O
600	O
)	O
glycoprotein	O
with	O
C	O
-	O
terminal	O
FLAG	O
were	O
sorted	O
.	O

TITLE	O
:	O
Broadening	O
of	O
neutralization	O
activity	O
to	O
directly	O
block	O
a	O
dominant	O
antibody	B-FUNC
-	O
driven	O
SARS	O
-	O
coronavirus	O
evolution	O
pathway	O
.	O

For	O
vaccine	O
-	O
induced	O
enhanced	O
susceptibility	O
to	O
infection	O
with	O
certain	O
viruses	O
like	O
feline	O
coronavirus	O
,	O
Dengue	O
virus	O
,	O
and	O
feline	O
immunodeficiency	O
virus	O
,	O
it	O
has	O
been	O
shown	O
that	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
plays	O
an	O
important	O
role	O
.	O

Mutation	O
of	O
a	O
semi	O
-	O
conserved	O
Ile	O
(	O
I95	O
)	O
residue	O
in	O
the	O
same	O
region	O
showed	O
moderately	O
destabilizing	O
effect	O
on	O
the	O
IBV	O
nsp9	O
homodimer	O
but	O
minimal	O
effect	O
on	O
its	O
RNA	O
-	O
binding	B-FUNC
activity	O
.	O

CD8	O
(+)	O
T	O
cells	O
in	O
the	O
persistently	O
infected	O
CNS	O
are	O
thus	O
characterized	O
by	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
independent	O
,	O
low	O
level	O
proliferation	O
and	O
an	O
activated	O
/	O
memory	O
phenotype	O
.	O

GSK	B-FUNC
-	O
3	O
-	O
specific	O
inhibitor	O
treatment	O
dephosphorylated	O
the	O
N	O
protein	O
,	O
and	O
this	O
could	O
be	O
recovered	O
by	O
the	O
constitutively	O
active	O
GSK	B-FUNC
-	O
3	O
kinase	O
.	O

The	O
effect	O
of	O
GSK	B-FUNC
-	O
3	O
inhibitor	O
was	O
reproduced	O
in	O
another	O
coronavirus	O
,	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
.	O

Our	O
results	O
indicate	O
that	O
GSK	B-FUNC
-	O
3	O
is	O
critical	O
for	O
CoV	O
N	O
protein	O
phosphorylation	O
and	O
suggest	O
that	O
it	O
plays	O
a	O
role	O
in	O
regulating	O
the	O
viral	O
life	O
cycle	O
.	O

An	O
investigation	O
of	O
the	O
binding	B-FUNC
properties	O
of	O
the	O
elicited	O
antibodies	O
showed	O
that	O
they	O
were	O
highly	O
conformation	O
specific	O
for	O
the	O
coiled	O
-	O
coil	O
epitope	O
because	O
they	O
specifically	O
recognized	O
the	O
native	O
trimeric	O
conformation	O
of	O
C	O
-	O
terminal	O
heptad	O
repeat	O
region	O
.	O

In	O
summary	O
,	O
we	O
have	O
demonstrated	O
that	O
calmodulin	O
is	O
able	O
to	O
bind	B-FUNC
ACE2	O
and	O
suggest	O
that	O
the	O
ACE2	O
ectodomain	O
shedding	O
and	O
/	O
or	O
sheddase	O
(	O
s	O
)	O
activation	O
regulated	O
by	O
calmodulin	O
is	O
independent	O
from	O
the	O
phorbol	O
ester	O
-	O
induced	O
shedding	O
.	O

For	O
comparison	O
,	O
we	O
also	O
describe	O
the	O
crystal	O
structure	O
of	O
the	O
homologous	O
X	O
-	O
domain	O
from	O
Human	O
Coronavirus	O
229E	O
,	O
a	O
Group	O
-	O
1	O
coronavirus	O
,	O
which	O
does	O
bind	B-FUNC
ADP	O
-	O
ribose	O
.	O

All	O
of	O
these	O
were	O
classified	O
as	O
pure	B-FUNC
culture	O
or	O
many	O
pathogenic	O
bacteria	O
in	O
mixed	O
culture	O
.	O

The	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
is	O
composed	O
of	O
two	O
subunits	O
;	O
the	O
S1	O
subunit	O
contains	O
a	O
receptor	O
-	O
binding	B-FUNC
domain	O
that	O
engages	O
with	O
the	O
host	O
cell	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
and	O
the	O
S2	O
subunit	O
mediates	O
fusion	O
between	O
the	O
viral	O
and	O
host	O
cell	O
membranes	O
.	O

The	O
S	O
protein	O
plays	O
key	O
parts	O
in	O
the	O
induction	O
of	O
neutralizing	O
-	O
antibody	B-FUNC
and	O
T	O
-	O
cell	O
responses	O
,	O
as	O
well	O
as	O
protective	O
immunity	O
,	O
during	O
infection	O
with	O
SARS	O
-	O
CoV	O
.	O
In	O
this	O
Review	O
,	O
we	O
highlight	O
recent	O
advances	O
in	O
the	O
development	O
of	O
vaccines	O
and	O
therapeutics	O
based	O
on	O
the	O
S	O
protein	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
fragment	O
expression	O
and	O
purification	O
.	O

When	O
ectopically	O
expressed	O
in	O
mammalian	O
cells	O
,	O
8ab	O
induced	O
the	O
proteolysis	O
of	O
ATF6	O
and	O
the	O
translocation	O
of	O
its	O
cleaved	O
DNA	O
-	O
binding	B-FUNC
and	O
transcription	O
-	O
activation	O
domains	O
from	O
the	O
ER	O
to	O
the	O
nucleus	O
.	O

Although	O
the	O
recombinant	O
protein	O
obtained	O
has	O
not	O
shown	O
the	O
expected	O
fusion	O
effect	O
with	O
Hela	O
cell	O
membrane	O
,	O
this	O
work	O
may	O
enrich	O
the	O
understanding	O
of	O
the	O
process	O
of	O
membrane	O
fusion	O
mediated	O
by	O
S2	O
protein	O
and	O
lay	O
the	O
foundation	O
for	O
future	O
study	O
of	O
targeting	O
cell	O
transport	O
system	O
based	O
on	O
cell	O
-	O
specific	O
binding	B-FUNC
peptide	O
.	O

Within	O
S	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
mediates	O
the	O
interaction	O
with	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
SARS	O
-	O
CoV	O
host	O
cell	O
receptor	O
.	O

Reported	O
here	O
is	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
the	O
RBD	O
in	O
complex	O
with	O
the	O
Fab	O
of	O
a	O
neutralizing	O
mouse	O
monoclonal	O
antibody	B-FUNC
,	O
F26G19	O
,	O
elicited	O
by	O
immunization	O
with	O
chemically	O
inactivated	O
SARS	O
-	O
CoV	O
.	O
The	O
RBD	O
-	O
F26G19	O
Fab	O
complex	O
represents	O
the	O
first	O
example	O
of	O
the	O
structural	O
characterization	O
of	O
an	O
antibody	B-FUNC
elicited	O
by	O
an	O
immune	O
response	O
to	O
SARS	O
-	O
CoV	O
or	O
any	O
fragment	O
of	O
it	O
.	O

These	O
data	O
suggest	O
that	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
does	O
not	O
contribute	O
to	O
antiviral	O
function	O
within	O
the	O
CNS	O
but	O
enhances	O
morbidity	O
associated	O
with	O
viral	O
encephalitis	O
by	O
increasing	O
the	O
ratio	O
of	O
IFN	O
-	O
gamma	O
to	O
protective	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
.	O

Most	O
neonates	O
receiving	O
ECMO	O
suffer	O
from	O
meconium	O
aspiration	O
syndrome	O
(	O
MAS	O
),	O
congenital	O
diaphragmatic	O
hernia	O
(	O
CDH	O
),	O
sepsis	O
or	O
persistent	O
pulmonary	O
hypertension	O
(	O
PPH	B-FUNC
).	O

An	O
ELISA	O
-	O
based	O
IgG	O
antibody	B-FUNC
detection	O
assay	O
using	O
recombinant	O
HCoV	O
-	O
HKU1	O
nucleocapsid	O
and	O
spike	O
(	O
S	O
)	O
proteins	O
(	O
genotype	O
A	O
)	O
were	O
developed	O
for	O
the	O
diagnosis	O
of	O
CoV	O
-	O
HKU1	O
infections	O
,	O
Additionally	O
,	O
a	O
neutralization	O
antibody	B-FUNC
assay	O
using	O
the	O
HCoV	O
-	O
HKU1	O
pseudotyped	O
virus	O
was	O
developed	O
to	O
detect	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
in	O
serum	O
with	O
antibody	B-FUNC
positivity	O
in	O
an	O
S	O
protein	O
-	O
based	O
ELISA	O
.	O

ABSTRACT	O
:	O
The	O
incidence	O
of	O
intra	O
-	O
abdominal	O
hypertension	O
(	O
IAH	B-FUNC
)	O
in	O
patients	O
with	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
)	O
is	O
approximately	O
60	O
-	O
80	O
%.	O

Despite	O
several	O
intervention	O
options	O
,	O
the	O
mortality	O
in	O
patients	O
developing	O
ACS	B-FUNC
remains	O
high	O
:	O
50	O
-	O
75	O
%.	O

Preliminary	O
results	O
from	O
recent	O
studies	O
suggest	O
these	O
drugs	O
up	O
-	O
regulate	O
the	O
production	O
of	O
interferons	O
(-	O
alpha	O
,	O
-	O
beta	O
,	O
and	O
-	O
gamma	O
),	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
-	O
alpha	O
)	O
but	O
downregulate	O
some	O
proinflammatory	O
cytokines	O
including	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
.	O

The	O
concentration	O
of	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
alone	O
was	O
considerably	O
increased	O
in	O
the	O
patients	O
who	O
later	O
developed	O
respiratory	O
failure	O
.	O

Notably	O
,	O
nsp1	O
specifically	O
binds	B-FUNC
SLIII	O
and	O
its	O
flanking	O
sequences	O
in	O
the	O
5	O
'	O
UTR	O
with	O
approximately	O
2	O
.	O
5	O
muM	O
affinity	O
.	O

These	O
results	O
together	O
indicate	O
that	O
nsp1	O
is	O
an	O
RNA	O
-	O
binding	B-FUNC
protein	O
that	O
may	O
function	O
to	O
regulate	O
viral	O
genome	O
translation	O
or	O
replication	O
but	O
not	O
by	O
binding	B-FUNC
SLV	O
-	O
VI	O
within	O
its	O
own	O
coding	O
region	O
.	O

CEACAM1	O
(	O
a	O
)-	O
4C1	O
was	O
capable	O
of	O
binding	B-FUNC
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
was	O
detected	O
at	O
approximately	O
120kDa	O
in	O
the	O
small	O
intestinal	O
secretions	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
M	O
protein	O
inhibits	O
type	O
I	O
interferon	O
production	O
by	O
impeding	O
the	O
formation	O
of	O
TRAF3	O
.	O
TANK	O
.	O
TBK1	B-FUNC
/	O
IKKepsilon	O
complex	O
.	O

M	O
protein	O
physically	O
associates	O
with	O
RIG	O
-	O
I	O
,	O
TBK1	B-FUNC
,	O
IKKepsilon	O
,	O
and	O
TRAF3	O
and	O
likely	O
sequesters	O
some	O
of	O
them	O
in	O
membrane	O
-	O
associated	O
cytoplasmic	O
compartments	O
.	O

At	O
30	O
days	O
post	O
-	O
vaccination	O
,	O
all	O
vaccinated	O
calves	O
displayed	O
high	O
antibody	B-FUNC
titres	O
against	O
BCoV	O
.	O
Sequence	O
analysis	O
of	O
the	O
S	O
gene	O
of	O
wild	O
-	O
type	O
and	O
cell	O
-	O
adapted	O
438	O
/	O
06	O
-	O
TN	O
strain	O
detected	O
10	O
nucleotide	O
changes	O
,	O
9	O
of	O
which	O
were	O
non	O
-	O
synonymous	O
.	O

As	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
has	O
been	O
reported	O
to	O
regulate	O
apoptosis	O
in	O
different	O
pathologic	O
conditions	O
,	O
finding	O
ways	O
to	O
modulate	O
the	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
may	O
offer	O
a	O
new	O
direction	O
toward	O
the	O
inhibition	O
of	O
apoptosis	O
triggered	O
by	O
SARS	O
-	O
CoV	O
.	O

Among	O
these	O
nsps	O
,	O
nsp9	O
has	O
been	O
shown	O
to	O
possess	O
single	O
-	O
stranded	O
DNA	O
/	O
RNA	O
-	O
binding	B-FUNC
properties	O
.	O

TITLE	O
:	O
Label	O
-	O
free	O
,	O
electrical	O
detection	O
of	O
the	O
SARS	O
virus	O
N	O
-	O
protein	O
with	O
nanowire	O
biosensors	O
utilizing	O
antibody	B-FUNC
mimics	O
as	O
capture	O
probes	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
2003	O
,	O
the	O
three	O
-	O
dimensional	O
structures	O
of	O
several	O
of	O
the	O
replicase	O
/	O
transcriptase	B-FUNC
components	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
the	O
non	O
-	O
structural	O
proteins	O
(	O
Nsps	O
),	O
have	O
been	O
determined	O
.	O

Owing	O
to	O
their	O
affinity	O
towards	O
intestinal	O
cells	O
and	O
immunoglobulin	B-FUNC
G	O
,	O
the	O
Slayer	O
fusion	O
proteins	O
enabled	O
the	O
adhesion	O
of	O
antibodies	O
to	O
human	O
epithelial	O
cells	O
.	O

A	O
double	O
antibody	B-FUNC
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
DAS	O
-	O
ELISA	O
)	O
based	O
on	O
the	O
use	O
of	O
monoclonal	O
antibodies	O
was	O
developed	O
for	O
the	O
detection	O
of	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
).	O

Rats	O
with	O
LC	O
+	O
CASP	O
also	O
had	O
distinct	O
aspects	O
of	O
inflammation	O
compared	O
with	O
CASP	O
alone	O
,	O
i	O
.	O
e	O
.,	O
significantly	O
higher	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
(	O
5	O
and	O
24	O
h	O
),	O
IL	O
-	O
1beta	O
(	O
24	O
h	O
),	O
CINC	O
-	O
1	O
(	O
24	O
h	O
),	O
and	O
MCP	B-FUNC
-	O
1	O
(	O
24	O
h	O
),	O
and	O
significantly	O
lower	O
levels	O
of	O
MPO	B-FUNC
(	O
5	O
h	O
),	O
MIP	O
-	O
2	O
(	O
5	O
h	O
),	O
and	O
CINC	O
-	O
1	O
(	O
5	O
h	O
).	O

Lipopolysaccharide	O
administration	O
results	O
in	O
significant	O
lung	O
injury	O
with	O
impaired	O
AFC	O
,	O
while	O
dobutamine	O
improves	O
alveolar	O
fluid	O
reabsorption	O
with	O
elevation	O
of	O
aquaporin	B-FUNC
-	O
1	O
and	O
aquaporin	B-FUNC
-	O
5	O
.	O

The	O
recombinant	O
nspl4	O
proteins	O
with	O
either	O
GST	O
fusion	O
or	O
6	O
-	O
histidine	O
tag	O
were	O
shown	O
to	O
possess	O
ribonuclease	B-FUNC
activity	I-FUNC
but	O
nspl4	O
with	O
a	O
short	O
MGHHHHHHGS	O
tag	O
sequence	O
at	O
the	O
N	O
-	O
terminus	O
increased	O
the	O
solubility	O
of	O
nspl4	O
protein	O
and	O
facilitated	O
the	O
protein	O
purification	O
.	O

The	O
GBP	O
domain	O
of	O
the	O
fusion	O
protein	O
serves	O
as	O
an	O
anchoring	B-FUNC
component	O
onto	O
the	O
gold	O
surface	O
,	O
exploiting	O
the	O
gold	O
binding	B-FUNC
affinity	O
of	O
the	O
domain	O
,	O
whereas	O
the	O
SCVme	O
domain	O
is	O
a	O
recognition	O
element	O
for	O
anti	O
-	O
SCVme	O
antibody	B-FUNC
,	O
the	O
target	O
analyte	O
in	O
this	O
study	O
.	O

AFM	O
and	O
SPR	O
imaging	O
analyses	O
demonstrated	O
that	O
anti	O
-	O
SCVme	O
specifically	O
bound	O
to	O
the	O
fusion	O
protein	O
immobilized	O
onto	O
the	O
gold	O
-	O
micropatterned	O
chip	O
,	O
implying	O
that	O
appropriate	O
orientation	O
of	O
bound	O
fusion	O
protein	O
by	O
GBP	O
resulted	O
in	O
optimal	O
exposure	O
of	O
the	O
SCVme	O
domain	O
to	O
the	O
assay	O
solution	O
,	O
resulting	O
in	O
efficient	O
capture	O
of	O
anti	O
-	O
SCVme	O
antibody	B-FUNC
.	O

The	O
VN	O
yielded	O
79	O
negative	O
and	O
21	O
positive	O
sera	B-FUNC
but	O
the	O
ELISA	O
confirmed	O
only	O
74	O
as	O
negative	O
.	O

Blood	O
DNA	O
samples	O
were	O
evaluated	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
for	O
feline	O
leukemia	O
virus	O
(	O
FeLV	O
)	O
proviral	O
DNA	O
,	O
whereas	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
was	O
run	O
on	O
fecal	O
samples	O
for	O
detection	O
of	O
coronavirus	O
RNA	O
.	O

The	O
nucleocapsid	O
DNA	O
vaccine	O
had	O
good	O
immunogenicity	O
and	O
can	O
induce	O
specific	O
humoral	O
and	O
cellular	O
immunity	O
in	O
BALB	O
/	O
c	O
mice	O
,	O
while	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
plays	O
an	O
immunoadjuvant	O
role	O
and	O
enhances	O
specific	O
immune	O
responses	O
.	O

Furthermore	O
,	O
in	O
the	O
ARDS	O
population	O
,	O
we	O
found	O
that	O
the	O
endotoxin	O
levels	O
in	O
the	O
BAL	O
fluid	O
were	O
higher	O
in	O
the	O
survival	O
than	O
in	O
the	O
nonsurvival	O
group	O
and	O
BAL	O
fluid	O
concentrations	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
IL	O
-	O
1beta	O
and	O
sera	B-FUNC
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
were	O
lower	O
in	O
the	O
survival	O
than	O
in	O
the	O
nonsurvival	O
group	O
,	O
and	O
they	O
were	O
associated	O
with	O
a	O
high	O
negative	O
predictive	O
value	O
.	O

Full	O
length	O
SARS	O
-	O
CoV	O
E	O
displayed	O
channel	B-FUNC
activity	I-FUNC
when	O
transiently	O
expressed	O
in	O
human	O
embryonic	O
kidney	O
293	O
(	O
HEK	O
-	O
293	O
)	O
cells	O
in	O
a	O
whole	O
-	O
cell	O
patch	O
clamp	O
set	O
-	O
up	O
.	O

Our	O
data	O
showed	O
enhanced	O
expression	O
of	O
IFN	O
-	O
gamma	O
;	O
interleukin	O
(	O
IL	O
)-	O
1	O
beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
;	O
and	O
oligoadenyl	O
synthetase	O
A	O
mRNA	O
after	O
CpG	O
ODN	O
administration	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
the	O
HCoV	O
-	O
OC43	O
N	O
protein	O
contains	O
three	O
RNA	O
-	O
binding	B-FUNC
regions	O
in	O
its	O
N	O
-	O
terminal	O
region	O
(	O
residues	O
1	O
-	O
173	O
)	O
and	O
central	O
-	O
linker	O
region	O
(	O
residues	O
174	O
-	O
232	O
and	O
233	O
-	O
300	O
).	O

TITLE	O
:	O
Serum	O
lipopolysaccharide	B-FUNC
binding	I-FUNC
protein	O
levels	O
predict	O
severity	O
of	O
lung	O
injury	O
and	O
mortality	O
in	O
patients	O
with	O
severe	O
sepsis	O
.	O

We	O
performed	O
a	O
prospective	O
,	O
multicenter	O
,	O
observational	O
study	O
to	O
investigate	O
the	O
time	O
-	O
course	O
of	O
lipopolysaccharide	B-FUNC
binding	I-FUNC
protein	O
(	O
LBP	O
)	O
serum	O
levels	O
in	O
patients	O
with	O
severe	O
sepsis	O
and	O
examined	O
whether	O
serial	O
serum	O
levels	O
of	O
LBP	O
could	O
be	O
used	O
as	O
a	O
marker	O
of	O
outcome	O
.	O

Furthermore	O
,	O
CCoV	O
-	O
II	O
infection	O
resulted	O
in	O
truncated	O
bid	O
(	O
tbid	O
)	O
translocation	O
from	O
the	O
cytosolic	O
to	O
the	O
mitochondrial	O
fraction	O
,	O
the	O
cytochrome	B-FUNC
c	I-FUNC
release	O
from	O
mitochondria	O
,	O
and	O
alterations	O
in	O
the	O
pro	O
-	O
and	O
anti	O
-	O
apoptotic	O
proteins	O
of	O
bcl	O
-	O
2	O
family	O
.	O

It	O
was	O
also	O
related	O
to	O
a	O
relatively	O
higher	O
binding	B-FUNC
capacity	O
to	O
cellular	O
receptors	O
.	O

The	O
recombinant	O
IBV	O
was	O
in	O
effect	O
a	O
chimaeric	O
virus	O
with	O
the	O
replicase	O
gene	O
derived	O
from	O
Beaudette	O
and	O
the	O
rest	B-FUNC
of	O
the	O
genome	O
from	O
M41	O
.	O

Scanning	O
electron	O
microscopy	O
of	O
oxygenator	O
fibers	O
showed	O
significantly	O
increased	O
binding	B-FUNC
and	O
shape	O
change	O
of	O
platelets	O
after	O
interventional	O
lung	O
assist	O
.	O

For	O
the	O
rest	B-FUNC
of	O
the	O
outcomes	O
,	O
we	O
either	O
summarized	O
previous	O
systematic	O
reviews	O
or	O
conducted	O
new	O
systematic	O
reviews	O
;	O
randomized	O
and	O
non	O
-	O
randomized	O
comparative	O
trials	O
,	O
prospective	O
cohorts	O
,	O
and	O
case	O
-	O
control	O
studies	O
were	O
included	O
.	O

This	O
binding	B-FUNC
site	O
is	O
similar	O
to	O
the	O
ssRNA	O
-	O
binding	B-FUNC
site	O
of	O
the	O
sterile	O
alpha	O
motif	O
domain	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
Vts1p	O
protein	O
,	O
although	O
the	O
two	O
proteins	O
do	O
not	O
share	O
a	O
common	O
globular	O
fold	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
show	O
that	O
animal	O
age	O
,	O
perhaps	O
due	O
to	O
increased	O
innate	O
immune	O
resistance	O
,	O
strongly	O
influences	O
the	O
outcome	O
of	O
acute	O
PRRSV	O
infection	O
,	O
whereas	O
an	O
antibody	B-FUNC
response	O
is	O
triggered	O
at	O
a	O
low	O
threshold	O
of	O
infection	O
that	O
is	O
independent	O
of	O
age	O
.	O

Furthermore	O
,	O
preliminary	O
results	O
of	O
fast	B-FUNC
classification	O
of	O
the	O
whole	O
CATH	O
v2	O
.	O
5	O
.	O
1	O
database	O
based	O
on	O
the	O
new	O
macrostructure	O
similarity	O
are	O
given	O
as	O
a	O
pilot	O
study	O
.	O

The	O
purified	O
recombinant	O
polypeptide	O
was	O
employed	O
to	O
develop	O
an	O
ELISA	O
test	O
for	O
the	O
detection	O
of	O
TGEV	O
-	O
like	O
CCoV	O
-	O
specific	O
antibodies	O
in	O
dog	O
sera	B-FUNC
.	O

DNA	O
sequencing	O
showed	O
a	O
novel	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
STAT3	O
)	O
gene	O
mutation	O
within	O
intron	O
12	O
,	O
specifically	O
adenine	O
to	O
cytosine	O
,	O
two	O
base	B-FUNC
pairs	I-FUNC
upstream	O
of	O
exon	O
13	O
.	O

ABSTRACT	O
:	O
We	O
analyzed	O
antibody	B-FUNC
responses	O
in	O
sera	B-FUNC
from	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
)-	O
infected	O
and	O
uninfected	O
cats	O
.	O

At	O
this	O
time	O
,	O
a	O
second	O
wave	O
of	O
enhanced	O
production	O
of	O
cytokines	O
(	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
gamma	O
interferon	O
[	O
IFN	O
-	O
gamma	O
],	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
5	I-FUNC
),	O
chemokines	O
(	O
CXCL9	O
,	O
CXCL10	O
,	O
CCL2	O
,	O
CCL3	O
,	O
and	O
CCL5	O
),	O
and	O
receptors	O
(	O
CXCR3	O
,	O
CCR2	O
,	O
and	O
CCR5	O
),	O
was	O
detected	O
in	O
the	O
lungs	O
,	O
associated	O
with	O
an	O
influx	O
of	O
T	O
lymphocytes	O
.	O

Eighty	O
-	O
four	O
intestine	O
segments	O
assayed	O
by	O
the	O
developed	O
RRT	O
-	O
PCR	O
and	O
immunofluorescence	O
antibody	B-FUNC
assay	O
(	O
IFA	O
)	O
revealed	O
that	O
there	O
were	O
6	O
segments	O
negative	O
for	O
TCoV	O
by	O
both	O
assays	O
,	O
45	O
positive	O
for	O
TCoV	O
by	O
IFA	O
,	O
and	O
77	O
positive	O
for	O
TCoV	O
by	O
RRT	O
-	O
PCR	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
cytokine	O
and	O
maturation	O
responses	O
of	O
pure	B-FUNC
populations	O
of	O
porcine	O
plasmacytoid	O
dendritic	O
cells	O
to	O
porcine	O
viruses	O
and	O
toll	O
-	O
like	O
receptor	O
agonists	O
.	O

TITLE	O
:	O
[	O
24	O
-	O
year	O
old	O
male	O
with	O
fever	O
,	O
multi	O
-	O
organ	O
dysfunction	O
and	O
fast	B-FUNC
progressing	O
ARDS	O
].	O

Ventilatory	O
parameters	O
were	O
reduced	O
to	O
a	O
highly	O
protective	O
mode	O
,	O
allowing	O
a	O
fast	B-FUNC
reduction	O
of	O
tidal	O
volume	O
from	O
495	O
(	O
401	O
to	O
570	O
)	O
mL	O
to	O
336	O
(	O
292	O
to	O
404	O
)	O
mL	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
of	O
peak	O
inspiratory	O
pressure	O
from	O
36	O
(	O
32	O
to	O
40	O
)	O
cmH2O	O
to	O
31	O
(	O
28	O
to	O
35	O
)	O
cmH2O	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

We	O
also	O
show	O
that	O
GRFT	O
specifically	O
binds	B-FUNC
to	O
the	O
SARS	O
-	O
CoV	O
spike	O
glycoprotein	O
and	O
inhibits	O
viral	O
entry	O
.	O

IFN	O
-	O
gamma	O
levels	O
and	O
the	O
inflammatory	O
response	O
were	O
not	O
altered	O
,	O
although	O
the	O
level	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)	O
mRNA	O
was	O
increased	O
.	O

Importantly	O
,	O
the	O
initial	O
specimen	O
evaluated	O
by	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
was	O
negative	O
for	O
novel	O
2009	O
H1N1	O
influenza	O
virus	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
we	O
attempted	O
to	O
establish	O
a	O
simple	O
detection	O
method	O
for	O
classification	O
of	O
IBV	O
S1	O
genotypes	O
by	O
direct	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

We	O
also	O
show	O
that	O
rSARS	O
-	O
CoV	O
-	O
DeltaE	O
and	O
rSARS	O
-	O
CoV	O
-	O
Delta	O
[	O
E	O
,	O
6	O
-	O
9b	O
]	O
induced	O
anti	O
-	O
virus	O
T	O
cell	O
and	O
antibody	B-FUNC
responses	O
.	O

We	O
have	O
tested	O
the	O
performance	O
of	O
the	O
EpiSearch	O
algorithm	O
for	O
six	O
experimental	O
data	O
sets	O
of	O
phage	O
display	O
experiments	O
,	O
the	O
human	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
-	O
2	O
(	O
HER	O
-	O
2	O
/	O
neu	O
),	O
the	O
antibody	B-FUNC
mAb	O
Bo2C11	O
targeting	O
the	O
C	O
(	O
2	O
)	O
domain	O
of	O
FVIII	O
,	O
antibodies	O
mAb	O
17b	O
and	O
mAb	O
b12	O
of	O
the	O
HIV	O
envelope	O
protein	O
gp120	O
,	O
mAb	O
13b5	O
targeting	O
HIV	O
-	O
1	O
capsid	O
protein	O
and	O
80R	O
of	O
the	O
SARS	O
coronavirus	O
spike	O
protein	O
.	O

Fusion	O
proteins	O
containing	O
M	O
amino	O
-	O
terminal	O
50	O
residues	O
encompassing	O
the	O
first	O
transmembrane	O
domain	O
were	O
found	O
to	O
be	O
sufficient	O
for	O
membrane	O
binding	B-FUNC
,	O
multimerization	O
,	O
and	O
Golgi	O
retention	O
.	O

The	O
majority	O
of	O
patients	O
had	O
a	O
pure	B-FUNC
motor	O
variant	O
of	O
GBS	O
(	O
92	O
%)	O
with	O
relatively	O
infrequent	O
cranial	O
nerve	O
involvement	O
(	O
30	O
%).	O

TITLE	O
:	O
Induced	O
,	O
selective	O
proteolysis	O
of	O
MLK3	O
negatively	O
regulates	O
MLK3	O
/	O
JNK	B-FUNC
signalling	O
.	O

ABSTRACT	O
:	O
Neutralizing	O
antibody	B-FUNC
responses	O
to	O
the	O
surface	O
glycoproteins	O
of	O
enveloped	O
viruses	O
play	O
an	O
important	O
role	O
in	O
immunity	O
.	O

Our	O
data	O
show	O
that	O
the	O
neutralizing	O
mAbs	O
bind	B-FUNC
to	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
SARS	O
S	O
protein	O
.	O

Quantum	O
dots	O
(	O
QDs	O
)	O
posses	O
unique	O
fluorescence	O
properties	O
that	O
have	O
also	O
been	O
explored	O
for	O
their	O
application	O
to	O
virus	O
detection	O
when	O
combined	O
with	O
direct	O
antibody	B-FUNC
conjugation	O
or	O
streptavidin	O
-	O
biotin	B-FUNC
binding	I-FUNC
systems	O
.	O

TITLE	O
:	O
[	O
Effect	O
of	O
qingyi	O
decoction	O
in	O
treating	O
severe	O
acute	O
pancreatitis	O
and	O
its	O
impacts	O
on	O
blood	O
level	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
,	O
interleukin	O
-	O
6	O
and	O
inteleukin	O
-	O
8	O
].	O

In	O
addition	O
,	O
the	O
efficacy	O
in	O
the	O
treated	O
group	O
was	O
also	O
superior	O
to	O
that	O
in	O
the	O
control	O
group	O
in	O
terms	O
of	O
reducing	O
mortality	O
,	O
operation	O
transferring	O
rate	O
,	O
and	O
blood	O
levels	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
on	O
the	O
7th	O
and	O
9th	O
day	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Seven	O
of	O
the	O
eight	O
TGEV	O
antibody	B-FUNC
-	O
positive	O
farms	O
were	O
also	O
positive	O
for	O
PRCV	O
antibody	B-FUNC
.	O

TITLE	O
:	O
Indirect	O
ELISA	O
and	O
indirect	O
immunofluorescent	O
antibody	B-FUNC
assay	O
for	O
detecting	O
the	O
antibody	B-FUNC
against	O
murine	O
norovirus	O
S7	O
in	O
mice	O
.	O

In	O
this	O
ELISA	O
system	O
,	O
mouse	O
sera	B-FUNC
obtained	O
2	O
weeks	O
after	O
infection	O
or	O
later	O
showed	O
significantly	O
high	O
OD	O
values	O
and	O
were	O
judged	O
positive	O
.	O

TITLE	O
:	O
Induction	O
of	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
-	O
inducible	O
protein	O
10	O
by	O
SARS	O
-	O
CoV	O
infection	O
,	O
interferon	O
alfacon	O
1	O
and	O
interferon	O
inducer	O
in	O
human	O
bronchial	O
epithelial	O
Calu	O
-	O
3	O
cells	O
and	O
BALB	O
/	O
c	O
mice	O
.	O

This	O
phenomenon	O
,	O
seen	O
in	O
antibody	B-FUNC
-	O
antigen	O
and	O
virus	O
-	O
cell	O
membrane	O
interactions	O
,	O
is	O
useful	O
in	O
designing	O
bioinspired	O
materials	O
for	O
targeted	O
delivery	O
of	O
drugs	O
or	O
imaging	O
agents	O
.	O

The	O
data	O
presented	O
herein	O
show	O
that	O
(	O
1	O
)	O
ligand	B-FUNC
presentation	O
does	O
not	O
disrupt	O
ELP	O
(	O
BC	O
)	O
self	O
-	O
assembly	O
;	O
(	O
2	O
)	O
both	O
multivalent	O
ligand	B-FUNC
presentation	O
and	O
upregulated	O
receptor	O
expression	O
are	O
needed	O
for	O
receptor	O
-	O
mediated	O
interaction	O
;	O
(	O
3	O
)	O
increased	O
size	O
of	O
the	O
hydrophobic	O
segment	O
of	O
the	O
block	O
copolymer	O
promotes	O
multivalent	O
interaction	O
with	O
membrane	O
receptors	O
,	O
potentially	O
due	O
to	O
changes	O
in	O
the	O
nanoscale	O
architecture	O
of	O
the	O
micelle	O
;	O
and	O
(	O
4	O
)	O
nanoscale	O
presentation	O
of	O
the	O
ligand	B-FUNC
is	O
important	O
,	O
as	O
presentation	O
of	O
the	O
ligand	B-FUNC
by	O
micrometer	O
-	O
sized	O
aggregates	O
of	O
an	O
ELP	O
showed	O
a	O
low	O
level	O
of	O
binding	B-FUNC
/	O
uptake	O
by	O
receptor	O
-	O
positive	O
cells	O
compared	O
to	O
its	O
presentation	O
on	O
the	O
corona	O
of	O
a	O
micelle	O
.	O

Samples	O
collected	O
from	O
the	O
asymptomatic	O
contactors	O
were	O
all	O
negative	O
for	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
.	O

TITLE	O
:	O
Secretory	O
phospholipase	B-FUNC
A₂	O
pathway	O
during	O
pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
preliminary	O
study	O
.	O

RESULTS	O
:	O
Cytochrome	B-FUNC
p450	I-FUNC
levels	O
in	O
phenobarbital	O
pre	O
-	O
treated	O
animals	O
were	O
significantly	O
higher	O
than	O
non	O
pre	O
-	O
treated	O
animals	O
(	O
300	O
vs	O
100	O
pmol	O
/	O
mg	O
protein	O
).	O

A	O
monoclonal	O
antibody	B-FUNC
designated	O
2D2	O
was	O
prepared	O
against	O
the	O
IBV	O
N	O
protein	O
,	O
and	O
a	O
series	O
of	O
23	O
partially	O
overlapping	O
,	O
tagged	O
fragments	O
of	O
the	O
IBV	O
N	O
gene	O
were	O
expressed	O
.	O

The	O
results	O
showed	O
that	O
groups	O
with	O
at	O
least	O
50	O
%	O
positive	O
sera	B-FUNC
in	O
the	O
IgM	O
ELISA	O
at	O
10	O
days	O
post	O
vaccination	O
had	O
a	O
high	O
level	O
of	O
protection	O
against	O
challenge	O
.	O

The	O
three	O
amino	O
acid	O
differences	O
between	O
the	O
high	O
and	O
low	O
virulent	O
variants	O
,	O
of	O
which	O
two	O
localized	O
to	O
the	O
putative	O
receptor	O
-	O
binding	B-FUNC
domain	O
and	O
one	O
in	O
the	O
esterase	O
domain	O
,	O
had	O
no	O
impact	O
on	O
receptor	O
-	O
binding	B-FUNC
or	O
-	O
release	O
activities	O
.	O

When	O
expressed	O
on	O
cultured	O
BHK	O
cells	O
,	O
the	O
mCEACAM1b	O
and	O
mCEACAM1ba	O
proteins	O
had	O
similar	O
levels	O
of	O
MHV	O
-	O
A59	O
receptor	B-FUNC
activity	I-FUNC
.	O

The	O
results	O
showed	O
that	O
sodium	O
new	O
houttuyfonate	O
significantly	O
raised	O
IB	O
antibody	B-FUNC
titer	O
in	O
the	O
chickens	O
and	O
also	O
markedly	O
promoted	O
lymphocyte	O
proliferation	O
.	O

The	O
serum	O
levels	O
of	O
IFN	O
-	O
γ	O
and	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
in	O
groups	O
1	O
-	O
4	O
were	O
higher	O
than	O
those	O
in	O
groups	O
5	O
and	O
6	O
.	O

Antibody	B-FUNC
assays	O
remain	O
nonspecific	O
and	O
insensitive	O
,	O
and	O
the	O
confirmatory	O
diagnostic	O
test	O
is	O
still	O
growth	O
of	O
the	O
organism	O
in	O
culture	O
.	O

Half	O
of	O
the	O
animals	O
from	O
each	O
group	O
were	O
euthanized	O
at	O
4	O
and	O
the	O
rest	B-FUNC
at	O
8h	O
after	O
LPS	O
inoculation	O
.	O

p42	O
is	O
a	O
subunit	O
of	O
the	O
26S	O
proteasome	O
;	O
this	O
large	O
,	O
multi	O
-	O
protein	O
complex	O
is	O
a	O
component	O
of	O
the	O
ubiquitin	B-FUNC
-	O
proteasome	O
pathway	O
,	O
which	O
is	O
involved	O
in	O
a	O
variety	O
of	O
basic	O
cellular	O
processes	O
and	O
inflammatory	O
responses	O
.	O

RESULTS	O
:	O
Seventy	O
-	O
one	O
consecutive	O
ACS	B-FUNC
episodes	O
in	O
67	O
patients	O
were	O
randomly	O
allocated	O
to	O
oxygen	O
(	O
n	O
=	O
36	O
)	O
or	O
NIV	O
(	O
n	O
=	O
35	O
)	O
for	O
3	O
days	O
in	O
a	O
medical	O
step	O
-	O
down	O
unit	O
.	O

These	O
results	O
indicate	O
that	O
SARS	O
-	O
CoV	O
spike	O
protein	O
triggers	O
ACE2	O
signaling	O
and	O
activates	O
fibrosis	O
-	O
associated	O
CCL2	O
expression	O
through	O
the	O
Ras	O
-	O
ERK	B-FUNC
-	O
AP	O
-	O
1	O
pathway	O
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
these	O
infections	O
on	O
general	O
health	O
and	O
reproduction	O
parameters	O
measurable	O
on	O
herd	O
level	O
and	O
to	O
explore	O
the	O
association	O
between	O
antibody	B-FUNC
status	O
and	O
some	O
herd	O
characteristics	O
.	O

Ten	O
herds	O
were	O
antibody	B-FUNC
negative	O
to	O
both	O
viruses	O
and	O
were	O
compared	O
with	O
69	O
herds	O
positive	O
to	O
BCV	O
or	O
BRSV	O
or	O
both	O
.	O

A	O
protein	O
-	O
ligand	B-FUNC
X	O
-	O
ray	O
structure	O
of	O
15	O
g	O
-	O
bound	O
SARS	O
-	O
CoV	O
PLpro	O
and	O
a	O
corresponding	O
model	O
of	O
15	O
h	O
docked	O
to	O
PLpro	O
provide	O
intriguing	O
molecular	O
insight	O
into	O
the	O
ligand	B-FUNC
-	O
binding	B-FUNC
site	O
interactions	O
.	O

Purportedly	O
,	O
these	O
viruses	O
bind	B-FUNC
to	O
O	O
-	O
acetylated	O
sialic	O
acids	O
(	O
O	O
-	O
Ac	O
-	O
Sias	O
)	O
primarily	O
through	O
S	O
,	O
with	O
HE	O
serving	O
merely	O
as	O
receptor	O
-	O
destroying	O
enzyme	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
an	O
exonic	O
splicing	O
enhancer	O
(	O
ESE	O
)	O
located	O
in	O
exon	O
2	O
,	O
which	O
is	O
a	O
putative	O
binding	B-FUNC
site	O
for	O
a	O
splicing	O
regulatory	O
protein	O
SF2	O
/	O
ASF	O
.	O

TITLE	O
:	O
A	O
single	O
asparagine	O
-	O
linked	O
glycosylation	O
site	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
glycoprotein	O
facilitates	O
inhibition	O
by	O
mannose	O
-	O
binding	B-FUNC
lectin	O
through	O
multiple	O
mechanisms	O
.	O

ABSTRACT	O
:	O
Mannose	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
)	O
is	O
a	O
serum	O
protein	O
that	O
plays	O
an	O
important	O
role	O
in	O
host	O
defenses	O
as	O
an	O
opsonin	O
and	O
through	O
activation	O
of	O
the	O
complement	O
system	O
.	O

Moreover	O
,	O
the	O
interaction	O
between	O
MBL	O
and	O
SARS	O
-	O
S	O
blocked	O
viral	O
binding	B-FUNC
to	O
the	O
C	O
-	O
type	O
lectin	O
,	O
DC	O
-	O
SIGN	O
.	O

27	O
pg	O
/	O
mL	O
.	O
The	O
values	O
of	O
C	O
-	O
reactive	O
Protein	O
(	O
CRP	O
)	O
measured	O
after	O
48h	O
,	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
(	O
APACHE	O
II	O
)	O
score	O
on	O
admission	O
and	O
Ranson	O
score	O
showed	O
the	O
similar	O
correlation	O
,	O
but	O
serum	O
amylase	O
level	O
did	O
not	O
correlate	O
significantly	O
with	O
Ranson	O
score	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
concentration	O
and	O
APACHE	O
II	O
score	O
.	O

The	O
combination	O
of	O
SIRS	O
score	O
on	O
admission	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
serum	O
concentration	O
can	O
be	O
early	O
,	O
predictor	O
of	O
illness	O
severity	O
and	O
outcome	O
in	O
SAP	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
SIRS	O
score	O
on	O
admission	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
serum	O
concentration	O
can	O
be	O
early	O
,	O
predictor	O
of	O
illness	O
severity	O
and	O
outcome	O
in	O
SAP	O
.	O

These	O
data	O
demonstrate	O
that	O
HB	O
-	O
EGF	B-FUNC
may	O
be	O
a	O
potential	O
novel	O
systemic	O
anti	O
-	O
inflammatory	O
agent	O
for	O
the	O
prevention	O
of	O
the	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
after	O
intestinal	O
injury	O
.	O

ABSTRACT	O
:	O
The	O
N	O
-	O
terminal	O
domain	O
of	O
nucleocapsid	O
protein	O
from	O
human	O
coronavirus	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
N	O
-	O
NTD	O
)	O
mostly	O
contains	O
positively	O
charged	O
residues	O
and	O
has	O
been	O
identified	O
as	O
being	O
responsible	O
for	O
RNA	B-FUNC
binding	I-FUNC
during	O
ribonucleocapsid	O
formation	O
in	O
the	O
coronavirus	O
.	O

Synergistic	O
interactions	O
also	O
occur	O
between	O
trefoil	O
factor	O
family	O
(	O
TFF	O
)	O
peptides	O
and	O
growth	O
factors	O
such	O
as	O
EGF	B-FUNC
.	O

Results	O
indicate	O
that	O
pulmonary	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
TNF	O
-	O
α	O
were	O
higher	O
in	O
Sftpd	O
(-/-)	O
mice	O
when	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
.	O

Our	O
data	O
indicate	O
that	O
three	O
truncated	O
pAPNs	O
positively	O
reacted	O
with	O
the	O
specific	O
antiserum	O
and	O
the	O
major	O
binding	B-FUNC
regions	O
of	O
pAPN	O
were	O
limited	O
in	O
regions	O
36aa	O
-	O
223aa	O
,	O
349aa	O
-	O
591aa	O
and	O
592	O
-	O
963aa	O
.	O

In	O
vitro	O
,	O
ectopic	O
expression	O
of	O
transcription	O
factors	O
,	O
in	O
particular	O
CCAAT	O
/	O
enhancer	O
-	O
binding	B-FUNC
protein	O
alpha	O
(	O
C	O
/	O
EBPα	O
)	O
and	O
C	O
/	O
EBPβ	O
,	O
can	O
convert	O
B	O
cells	O
into	O
functional	O
macrophages	O
.	O

ABSTRACT	O
:	O
A	O
cross	O
-	O
sectional	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
association	O
between	O
herd	O
-	O
level	O
characteristics	O
,	O
management	O
routines	O
and	O
farm	O
-	O
level	O
antibody	B-FUNC
status	O
of	O
bovine	O
coronavirus	O
(	O
BCV	O
)	O
and	O
bovine	O
respiratory	O
syncytial	O
virus	O
(	O
BRSV	O
)	O
in	O
257	O
Swedish	O
dairy	O
herds	O
.	O

Two	O
of	O
6	O
cats	O
with	O
FIP	O
had	O
increased	O
macro	O
-	O
CK1	O
and	O
increased	O
CK	B-FUNC
-	I-FUNC
BB	I-FUNC
activity	O
.	O

RESULTS	O
:	O
CK	B-FUNC
-	I-FUNC
MM	I-FUNC
was	O
the	O
predominant	O
isoenzyme	O
in	O
the	O
serum	O
of	O
healthy	O
dogs	O
and	O
cats	O
,	O
followed	O
by	O
macro	O
-	O
CK2	O
and	O
CK	B-FUNC
-	I-FUNC
BB	I-FUNC
in	O
dogs	O
and	O
by	O
both	O
macroenzymes	O
in	O
cats	O
.	O

Growth	B-FUNC
hormone	I-FUNC
releasing	O
peptide	O
-	O
2	O
(	O
GHRP	O
-	O
2	O
),	O
a	O
ghrelin	O
agonist	O
,	O
has	O
been	O
shown	O
to	O
exert	O
beneficial	O
effects	O
on	O
various	O
inflammatory	O
diseases	O
.	O

S	O
(	O
TR2	O
)	O
(	O
an	O
88	O
kDa	O
truncated	O
SARS	O
-	O
CoV	O
TW1	O
S	O
protein	O
carrying	O
the	O
S	O
fragments	O
S	O
-	O
74	O
-	O
253	O
,	O
S	O
-	O
294	O
-	O
739	O
,	O
and	O
S	O
-	O
1129	O
-	O
1255	O
)	O
is	O
capable	O
of	O
expressing	O
a	O
major	O
form	O
of	O
glycoprotein	O
as	O
endo	O
H	O
-	O
sensitive	O
(∼	O
115	O
kDa	O
)	O
in	O
CHO	B-FUNC
cells	O
.	O

To	O
explore	O
the	O
link	O
between	O
coronavirus	O
infection	O
and	O
the	O
ubiquitin	B-FUNC
system	O
,	O
we	O
asked	O
whether	O
protein	O
degradation	O
by	O
the	O
26S	O
proteasome	O
plays	O
a	O
role	O
in	O
severe	O
coronavirus	O
infections	O
using	O
a	O
murine	O
model	O
of	O
SARS	O
-	O
like	O
pneumonitis	O
induced	O
by	O
murine	O
hepatitis	O
virus	O
strain	O
1	O
(	O
MHV	O
-	O
1	O
).	O

Based	O
on	O
spatial	O
and	O
energetic	O
criteria	O
,	O
1	O
,	O
8	O
-	O
cineole	O
interfered	O
with	O
the	O
binding	B-FUNC
between	O
RNA	O
and	O
IBV	O
N	O
-	O
protein	O
.	O

We	O
utilized	O
a	O
highly	O
sensitive	O
antibody	B-FUNC
profiling	O
technology	O
to	O
study	O
autoantibodies	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
severe	O
sepsis	O
,	O
conditions	O
characterized	O
by	O
intensive	O
immune	O
activation	O
leading	O
to	O
multiple	O
organ	O
dysfunction	O
.	O

Cholesterol	O
depletion	O
from	O
viral	O
membrane	O
may	O
not	O
affect	O
the	O
adsorption	O
process	O
as	O
neither	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
nor	O
the	O
binding	B-FUNC
to	O
aminopeptidase	O
N	O
was	O
reduced	O
post	O
-	O
MβCD	O
treatment	O
.	O

Recombinant	O
plasmid	O
pSY	O
-	O
S1	O
/	O
IL18	O
was	O
constructed	O
by	O
cloning	O
chicken	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
into	O
fowlpox	O
virus	O
transfer	O
plasmid	O
containing	O
S1	O
gene	O
and	O
transfected	O
into	O
the	O
chicken	O
embryo	O
fibroblasts	O
cell	O
pre	O
-	O
infected	O
with	O
S	O
-	O
FPV	O
-	O
017	O
to	O
generate	O
rFPV	O
-	O
S1	O
/	O
IL18	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
ELISA	O
antibody	B-FUNC
levels	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
elicited	O
by	O
either	O
rFPV	O
-	O
S1	O
or	O
rFPV	O
-	O
S1	O
/	O
IL18	O
.	O

Moreover	O
,	O
a	O
strong	O
cellular	O
immune	O
response	O
demonstrated	O
by	O
elevated	O
IFN	O
-	O
γ	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
was	O
also	O
observed	O
in	O
these	O
mice	O
.	O

Exogenous	O
IFN	O
enhanced	O
IFN	O
-	O
dependent	O
gene	O
expression	O
in	O
BMM	O
at	O
early	O
times	O
after	O
infection	O
and	O
in	O
BMDC	O
at	O
all	O
times	O
after	O
infection	O
but	O
did	O
not	O
stimulate	O
expression	O
of	O
molecules	O
that	O
signal	O
through	O
myeloid	O
differentiation	O
factor	O
88	O
(	O
MyD88	O
),	O
such	O
as	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
).	O

High	O
gestational	O
age	O
,	O
high	O
SNAP	B-FUNC
-	O
II	O
score	O
and	O
oxygenation	O
index	O
(	O
OI	O
),	O
and	O
Apgar	O
score	O
at	O
5	O
minutes	O
<	O
5	O
were	O
independent	O
risks	O
for	O
death	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
8b	O
reduces	O
viral	O
replication	O
by	O
down	O
-	O
regulating	O
E	O
via	O
an	O
ubiquitin	B-FUNC
-	O
independent	O
proteasome	O
pathway	O
.	O

Here	O
,	O
we	O
showed	O
that	O
the	O
down	O
-	O
regulation	O
of	O
E	O
is	O
not	O
dependent	O
on	O
the	O
lysine	O
residues	O
on	O
8b	O
and	O
the	O
reduction	O
of	O
polyubiquitination	O
of	O
E	O
mutants	O
is	O
not	O
correlated	O
with	O
their	O
down	O
-	O
regulation	O
by	O
8b	O
,	O
suggesting	O
an	O
ubiquitin	B-FUNC
-	O
independent	O
proteasome	O
pathway	O
is	O
involved	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
8b	O
negatively	O
modulates	O
virus	O
replication	O
by	O
down	O
-	O
regulating	O
E	O
via	O
an	O
ubiquitin	B-FUNC
-	O
independent	O
proteasome	O
pathway	O
.	O

The	O
antiviral	O
effects	O
of	O
ISG20	O
were	O
all	O
dependent	O
on	O
its	O
exonuclease	B-FUNC
activity	I-FUNC
.	O

We	O
previously	O
identified	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
S	O
protein	O
as	O
a	O
major	O
target	O
of	O
neutralizing	O
antibodies	O
in	O
animal	O
models	O
and	O
thus	O
proposed	O
a	O
RBD	O
-	O
based	O
vaccine	O
.	O

When	O
comparing	O
mild	O
with	O
severe	O
nvA	O
(	O
H1N1	O
)	O
groups	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
and	O
TNFα	O
were	O
significantly	O
higher	O
in	O
the	O
severe	O
group	O
.	O

More	O
specifically	O
,	O
Zn	O
(	O
2	O
+)	O
was	O
found	O
to	O
block	O
the	O
initiation	O
step	O
of	O
EAV	O
RNA	O
synthesis	O
,	O
whereas	O
in	O
the	O
case	O
of	O
the	O
SARS	O
-	O
CoV	O
RdRp	B-FUNC
elongation	O
was	O
inhibited	O
and	O
template	O
binding	B-FUNC
reduced	O
.	O

ELISA	O
indicated	O
that	O
the	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
S1	O
protein	O
had	O
no	O
cross	O
reaction	O
with	O
S1	O
proteins	O
of	O
transmissible	O
gastroenteritis	O
virus	O
,	O
a	O
porcine	O
coronavirus	O
,	O
and	O
infectious	O
bronchitis	O
virus	O
,	O
an	O
avian	O
coronavirus	O
.	O

This	O
provides	O
direct	O
insights	O
into	O
the	O
correlation	O
between	O
quaternary	O
structure	O
and	O
catalytic	B-FUNC
activity	I-FUNC
of	O
the	O
enzyme	O
.	O

Since	O
dermatomyositis	O
(	O
DM	O
)-	O
specific	O
skin	O
alterations	O
were	O
not	O
found	O
,	O
none	O
of	O
the	O
patients	O
in	O
this	O
study	O
fulfilled	O
Bohan	O
and	O
Peter	O
'	O
s	O
criteria	O
for	O
DM	O
;	O
however	O
,	O
anti	O
-	O
PL	O
-	O
7	O
antibody	B-FUNC
was	O
detected	O
in	O
case	O
number	O
1	O
.	O

Neonates	O
who	O
received	O
opioid	O
infusion	O
had	O
higher	O
risk	O
for	O
mortality	O
(	O
adjusted	O
odds	O
ratio	O
[	O
AOR	B-FUNC
]	O
1	O
.	O
57	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1	O
.	O
13	O
,	O
2	O
.	O
18	O
),	O
severe	O
neurological	O
injury	O
(	O
AOR	B-FUNC
1	O
.	O
63	O
,	O
95	O
%	O
CI	O
1	O
.	O
30	O
,	O
2	O
.	O
04	O
),	O
severe	O
retinopathy	O
of	O
prematurity	O
(	O
AOR	B-FUNC
1	O
.	O
39	O
,	O
95	O
%	O
CI	O
1	O
.	O
08	O
,	O
1	O
.	O
79	O
),	O
and	O
bronchopulmonary	O
dysplasia	O
(	O
AOR	B-FUNC
1	O
.	O
36	O
,	O
95	O
%	O
CI	O
1	O
.	O
03	O
,	O
1	O
.	O
79	O
).	O

The	O
other	O
two	O
cases	O
showed	O
negative	O
on	O
both	O
serum	O
N	O
protein	O
antibody	B-FUNC
and	O
immunohistochemical	O
expression	O
.	O

Here	O
,	O
the	O
peptides	O
capable	O
of	O
binding	B-FUNC
the	O
pAPN	O
were	O
,	O
for	O
the	O
first	O
time	O
,	O
identified	O
by	O
biopanning	O
using	O
a	O
random	O
12	O
-	O
mer	O
peptide	O
library	O
to	O
the	O
immobilized	O
protein	O
.	O

Likewise	O
,	O
PRRSV	O
did	O
not	O
impact	O
a	O
specific	O
TGEV	O
-	O
associated	O
enhancement	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
expression	O
.	O

ABSTRACT	O
:	O
Central	O
nervous	O
system	O
(	O
CNS	O
)	O
infections	O
and	O
autoimmune	O
inflammatory	O
disorders	O
are	O
often	O
associated	O
with	O
retention	O
of	O
antibody	B-FUNC
-	O
secreting	O
cells	O
(	O
ASC	O
).	O

In	O
IFN	O
-	O
γR	O
(-/-)	O
mice	O
,	O
Th17	O
response	O
is	O
enhanced	O
and	O
the	O
elevated	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
production	O
contributes	O
to	O
severe	O
liver	O
damage	O
as	O
well	O
as	O
detrimental	O
inflammation	O
because	O
neutralization	O
of	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
effectively	O
suppresses	O
inflammation	O
and	O
protects	O
mice	O
from	O
liver	O
injury	O
.	O

TITLE	O
:	O
Structures	O
of	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
domains	O
of	O
MHV	O
-	O
A59	O
nucleocapsid	O
protein	O
corroborate	O
a	O
conserved	O
RNA	O
-	O
protein	B-FUNC
binding	I-FUNC
mechanism	O
in	O
coronavirus	O
.	O

In	O
the	O
S2	O
domain	O
of	O
type	O
I	O
FIPV	O
,	O
3	O
and	O
7	O
peptides	O
containing	O
linear	O
immunodominant	O
antibody	B-FUNC
-	O
binding	B-FUNC
epitopes	O
were	O
identified	O
in	O
the	O
IH	O
and	O
HR2	O
regions	O
,	O
respectively	O
.	O

LTB4	O
produced	O
statistically	O
significant	O
increases	O
in	O
MPO	B-FUNC
and	O
α	O
-	O
defensins	O
,	O
whereas	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
ECP	O
,	O
and	O
α	O
(	O
2	O
)-	O
macroglobulin	O
were	O
unaffected	O
.	O

Importantly	O
,	O
PD098059	O
(	O
an	O
ERK1	B-FUNC
/	O
2	O
inhibitor	O
)	O
treatment	O
significantly	O
reduced	O
IFN	O
-	O
α	O
-	O
induced	O
ERK1	B-FUNC
and	O
STAT1	O
phosphorylation	O
,	O
inhibiting	O
IFN	O
-	O
α	O
-	O
induced	O
expression	O
of	O
2	O
'-	O
5	O
'-	O
OAS	O
in	O
vector	O
control	O
cells	O
and	O
PLpro	O
-	O
expressing	O
cells	O
.	O

Co	O
-	O
detection	O
S	O
and	O
N	O
antibody	B-FUNC
was	O
achieved	O
74	O
%	O
positive	O
rate	O
.	O

It	O
has	O
enabled	O
us	O
to	O
determine	O
the	O
structures	O
of	O
two	O
coronavirus	O
receptor	O
-	O
binding	B-FUNC
domains	O
each	O
complexed	O
with	O
their	O
receptor	O
at	O
moderate	O
resolutions	O
.	O

Both	O
purified	O
Lb	O
(	O
pro	O
)	O
protein	O
and	O
in	O
vivo	O
ectopically	O
expressed	O
Lb	O
(	O
pro	O
)	O
removed	O
ubiquitin	B-FUNC
(	O
Ub	O
)	O
moieties	O
from	O
cellular	O
substrates	O
,	O
acting	O
on	O
both	O
lysine	O
-	O
48	O
-	O
and	O
lysine	O
-	O
63	O
-	O
linked	O
polyubiquitin	O
chains	O
.	O

The	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
FIPV	O
infection	O
has	O
been	O
recognised	O
in	O
experimentally	O
infected	O
cats	O
,	O
and	O
cellular	O
immunity	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
preventing	O
the	O
onset	O
of	O
FIP	O
.	O

This	O
article	O
will	O
focus	O
on	O
the	O
role	O
of	O
CC	O
chemokine	O
receptor	O
2	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
the	O
pathogenesis	O
and	O
resolution	O
in	O
ALI	O
/	O
ARDS	O
.	O

TITLE	O
:	O
Alizarine	O
derivatives	O
as	O
new	O
dual	O
inhibitors	O
of	O
the	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
-	O
associated	O
DNA	O
polymerase	O
and	O
RNase	O
H	O
activities	O
effective	O
also	O
on	O
the	O
RNase	B-FUNC
H	I-FUNC
activity	I-FUNC
of	O
non	O
-	O
nucleoside	O
resistant	O
reverse	O
transcriptases	O
.	O

Here	O
we	O
demonstrate	O
that	O
emodin	O
can	O
inhibit	O
the	O
3a	O
ion	O
channel	O
of	O
coronavirus	O
SARS	O
-	O
CoV	O
and	O
HCoV	O
-	O
OC43	O
as	O
well	O
as	O
virus	O
release	O
from	O
HCoV	O
-	O
OC43	O
with	O
a	O
K1	O
/	O
2	O
value	O
of	O
about	O
20	O
μM	O
.	O
We	O
suggest	O
that	O
viral	O
ion	B-FUNC
channels	I-FUNC
,	O
in	O
general	O
,	O
may	O
be	O
a	O
good	O
target	O
for	O
the	O
development	O
of	O
antiviral	O
agents	O
.	O

In	O
this	O
study	O
we	O
sequentially	O
followed	O
up	O
19	O
recovered	O
SARS	O
patients	O
over	O
a	O
3	O
-	O
y	O
period	O
in	O
order	O
to	O
characterize	O
the	O
dynamic	O
changes	O
in	O
antibody	B-FUNC
responses	O
against	O
viral	O
components	O
in	O
detail	O
.	O

The	O
viral	O
genome	O
was	O
amplified	O
by	O
real	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
a	O
nasopharyngeal	O
swab	O
specimen	O
.	O

TITLE	O
:	O
[	O
Simultaneous	O
multiple	O
assay	O
(	O
Luminex	O
xTAG	O
respiratory	O
viral	O
panel	O
FAST	B-FUNC
assay	O
)	O
efficacy	O
in	O
human	O
respiratory	O
virus	O
detection	O
].	O

Similarly	O
,	O
the	O
S2	O
and	O
N	O
antigen	O
-	O
based	O
MFI	O
was	O
98	O
%	O
sensitive	O
and	O
100	O
%	O
specific	O
in	O
detecting	O
anticoronavirus	O
antibodies	O
in	O
rat	O
sera	B-FUNC
.	O

Real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
was	O
used	O
for	O
detection	O
of	O
H1N1	O
virus	O
in	O
the	O
respiratory	O
specimens	O
.	O

Both	O
post	O
-	O
SARS	O
and	O
FMS	B-FUNC
groups	O
had	O
sleep	O
instability	O
as	O
indicated	O
by	O
the	O
high	O
sleep	O
EEG	O
cyclical	O
alternating	O
pattern	O
rate	O
.	O

The	O
clinical	O
and	O
sleep	O
features	O
of	O
chronic	O
post	O
-	O
SARS	O
form	O
a	O
syndrome	O
of	O
chronic	O
fatigue	O
,	O
pain	O
,	O
weakness	O
,	O
depression	O
and	O
sleep	O
disturbance	O
,	O
which	O
overlaps	O
with	O
the	O
clinical	O
and	O
sleep	O
features	O
of	O
FMS	B-FUNC
and	O
chronic	O
fatigue	O
syndrome	O
.	O

Molecular	O
detection	O
for	O
15	O
viral	O
species	O
and	O
subtypes	O
was	O
performed	O
on	O
three	O
types	O
of	O
respiratory	O
specimens	O
(	O
nose	O
,	O
throat	O
swabs	O
and	O
nasopharyngeal	O
aspirates	O
)	O
using	O
a	O
multiplex	O
RT	O
-	O
PCR	O
kit	B-FUNC
(	O
Seeplex	O
™	O
RV	O
detection	O
,	O
Seegene	O
)	O
and	O
additional	O
monoplex	O
real	O
-	O
time	O
RT	O
-	O
PCRs	O
.	O

The	O
contents	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
α	O
(	O
TNF	O
-	O
α	O
)	O
and	O
interleukin	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
in	O
plasma	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
also	O
increased	O
distinctly	O
compared	O
with	O
the	O
control	O
group	O
[	O
TNF	O
-	O
α	O
(	O
ng	O
/	O
L	O
)	O
in	O
plasma	O
:	O
328	O
.	O
89	O
±	O
6	O
.	O
26	O
vs	O
.	O
62	O
.	O
12	O
±	O
2	O
.	O
98	O
,	O
TNF	O
-	O
α	O
(	O
ng	O
/	O
L	O
)	O
in	O
BALF	O
:	O
164	O
.	O
87	O
±	O
4	O
.	O
59	O
vs	O
.	O
29	O
.	O
51	O
±	O
1	O
.	O
12	O
;	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
(	O
ng	O
/	O
L	O
)	O
in	O
plasma	O
:	O
128	O
.	O
51	O
±	O
4	O
.	O
13	O
vs	O
.	O
19	O
.	O
32	O
±	O
1	O
.	O
53	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
(	O
ng	O
/	O
L	O
)	O
in	O
BALF	O
:	O
94	O
.	O
97	O
±	O
1	O
.	O
14	O
vs	O
.	O
22	O
.	O
72	O
±	O
0	O
.	O
19	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
].	O

In	O
addition	O
,	O
measurement	O
of	O
plasma	O
membrane	O
voltage	B-FUNC
gated	I-FUNC
ion	I-FUNC
channel	I-FUNC
activity	I-FUNC
by	O
whole	O
-	O
cell	O
patch	O
clamp	O
suggested	O
that	O
E	O
protein	O
was	O
not	O
present	O
in	O
the	O
plasma	O
membrane	O
.	O

In	O
addition	O
,	O
a	O
plaque	O
reduction	O
assay	O
was	O
performed	O
using	O
sera	B-FUNC
from	O
groups	O
pg611	O
,	O
pg612	O
-	O
6D	O
,	O
pg11	O
-	O
6D	O
,	O
and	O
phosphate	O
-	O
buffered	O
saline	O
(	O
blank	O
control	O
)	O
to	O
analyze	O
TGEV	O
-	O
neutralizing	O
antibody	B-FUNC
activity	I-FUNC
in	O
vitro	O
.	O

The	O
immunoreactivity	O
of	O
the	O
protein	O
to	O
the	O
antibody	B-FUNC
was	O
confirmed	O
by	O
Western	O
blot	O
analysis	O
.	O

We	O
introduced	O
venovenous	O
(	O
V	O
-	O
V	O
)	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
to	O
rest	B-FUNC
the	O
lung	O
,	O
and	O
V	O
-	O
V	O
ECMO	O
was	O
changed	O
to	O
right	O
and	O
left	O
atrial	O
ECMO	O
because	O
of	O
unsatisfactory	O
oxygen	O
support	O
on	O
POD	O
23	O
.	O

The	O
RBD	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
plays	O
important	O
roles	O
in	O
receptor	B-FUNC
binding	I-FUNC
and	O
induction	O
of	O
specific	O
neutralizing	O
antibodies	O
against	O
virus	O
infection	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
the	O
pathogenic	O
processes	O
that	O
result	O
in	O
demyelination	O
are	O
initiated	O
early	O
during	O
infection	O
and	O
that	O
they	O
can	O
be	O
diminished	O
by	O
exogenous	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
delivered	O
soon	O
after	O
disease	O
onset	O
.	O

The	O
expression	O
and	O
antigenicity	O
of	O
S	O
fragments	O
was	O
confirmed	O
by	O
immunofluorescence	O
antibody	B-FUNC
(	O
IFA	O
)	O
assay	O
using	O
an	O
anti	O
-	O
histidine	O
monoclonal	O
antibody	B-FUNC
or	O
anti	O
-	O
TCoV	O
serum	O
.	O

The	O
aim	O
of	O
this	O
research	O
was	O
to	O
investigate	O
whether	O
soluble	O
endothelial	O
selectin	B-FUNC
(	O
sES	O
)	O
could	O
be	O
a	O
biomarker	O
for	O
ALI	O
.	O

A	O
prophylaxis	O
with	O
a	O
single	O
shot	O
of	O
hepatitis	O
B	O
immunoglobulin	B-FUNC
may	O
be	O
effective	O
in	O
reducing	O
the	O
risk	O
of	O
HBV	O
seroconversion	O
or	O
reactivation	O
and	O
may	O
be	O
suggested	O
in	O
all	O
naïve	O
or	O
HBcAb	O
-	O
positive	O
transplant	O
recipients	O
.	O

ABSTRACT	O
:	O
Delayed	O
acute	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
)	O
due	O
to	O
retroperitoneal	O
bleeding	O
is	O
rare	O
.	O

In	O
our	O
multivariate	O
regression	O
model	O
,	O
time	O
to	O
ACS	B-FUNC
diagnosis	O
and	O
total	O
number	O
of	O
days	O
of	O
oxygen	O
supplementation	O
were	O
independent	O
predictors	O
of	O
length	O
of	O
hospitalization	O
in	O
both	O
hemoglobin	O
SC	O
and	O
SS	O
episodes	O
of	O
ACS	B-FUNC
.	O

Furthermore	O
,	O
the	O
truncated	O
rS	O
-	O
AD	O
peptide	O
was	O
able	O
to	O
bind	B-FUNC
to	O
the	O
surface	O
of	O
cells	O
from	O
swine	O
testes	O
in	O
a	O
competitive	O
manner	O
and	O
completely	O
inhibit	O
viral	O
infection	O
.	O

According	O
to	O
the	O
proposed	O
working	O
model	O
for	O
N	O
gene	O
transcriptional	O
activation	O
,	O
the	O
long	O
-	O
distance	O
RNA	O
-	O
RNA	O
interaction	O
relocates	O
the	O
distant	O
active	O
domain	O
in	O
close	O
proximity	O
with	O
the	O
N	O
gene	O
TRS	B-FUNC
,	O
which	O
probably	O
increases	O
the	O
frequency	O
of	O
template	O
switching	O
during	O
the	O
synthesis	O
of	O
negative	O
RNA	O
.	O

These	O
results	O
suggest	O
that	O
the	O
proposed	O
SL4	O
in	O
the	O
MHV	O
5	O
'	O
UTR	O
functions	O
in	O
part	O
as	O
a	O
spacer	O
element	O
that	O
orients	O
SL1	O
,	O
SL2	O
,	O
and	O
the	O
transcriptional	O
regulatory	O
sequence	O
(	O
TRS	B-FUNC
),	O
and	O
this	O
spacer	O
function	O
may	O
play	O
an	O
important	O
role	O
in	O
directing	O
subgenomic	O
RNA	O
synthesis	O
.	O

Here	O
,	O
we	O
present	O
an	O
overview	O
of	O
recently	O
identified	O
P2Y	B-FUNC
receptor	I-FUNC
agonists	O
that	O
enhance	O
the	O
pulmonary	O
endothelial	O
barrier	O
and	O
inhibit	O
and	O
/	O
or	O
reverse	O
endothelial	O
barrier	O
disruption	O
.	O

ABSTRACT	O
:	O
Antibody	B-FUNC
-	O
enhanced	O
replication	O
(	O
AER	O
)	O
of	O
dengue	O
type	O
-	O
2	O
virus	O
(	O
DENV	O
-	O
2	O
)	O
strains	O
and	O
production	O
of	O
antibody	B-FUNC
-	O
enhanced	O
disease	O
(	O
AED	O
)	O
was	O
tested	O
in	O
out	O
-	O
bred	O
mice	O
.	O

Similarly	O
,	O
nuclear	O
trafficking	O
of	O
the	O
RSV	O
Gag	O
protein	O
is	O
required	O
for	O
efficient	O
encapsidation	O
of	O
the	O
viral	O
genomic	O
RNA	O
(	O
gRNA	O
)	O
into	O
assembling	O
virus	O
particles	O
.	O
19	O
Recently	O
,	O
we	O
reported	O
that	O
the	O
viral	O
RNA	O
itself	O
appears	O
to	O
be	O
a	O
key	O
factor	O
in	O
controlling	O
the	O
nucleus	O
/	O
cytosol	O
distribution	O
of	O
RSV	O
Gag	O
.	O
22	O
Our	O
data	O
demonstrate	O
that	O
binding	B-FUNC
of	O
RSV	O
RNA	O
to	O
the	O
Gag	O
protein	O
promotes	O
Gag	O
-	O
CRM1	O
-	O
RanGTP	O
binding	B-FUNC
,	O
resulting	O
in	O
export	O
of	O
the	O
retroviral	O
RNP	O
from	O
the	O
nucleus	O
.	O

Furthermore	O
,	O
these	O
T	O
reg	O
cells	O
express	O
both	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
IFN	O
-	O
γ	O
after	O
peptide	O
stimulation	O
.	O

Identification	O
of	O
T	O
reg	O
cell	O
target	O
epitopes	O
by	O
cytokine	O
production	O
is	O
also	O
applicable	O
in	O
autoimmune	O
disease	O
because	O
myelin	O
oligodendrocyte	O
glycoprotein	O
-	O
specific	O
Foxp3	O
(+)	O
T	O
reg	O
cells	O
express	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
at	O
the	O
peak	O
of	O
disease	O
in	O
mice	O
with	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

Different	O
SARS	O
vaccine	O
candidates	O
elicit	O
sera	B-FUNC
that	O
differ	O
in	O
their	O
capacity	O
to	O
induce	O
ADE	O
in	O
immune	O
cells	O
despite	O
their	O
comparable	O
potency	O
to	O
neutralize	O
infection	O
in	O
ACE2	O
-	O
bearing	O
cells	O
.	O

IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
in	O
serum	O
were	O
(	O
94	O
,	O
pg	O
/	O
ml	O
,	O
77	O
pg	O
/	O
ml	O
and	O
84	O
pg	O
/	O
ml	O
)	O
respectively	O
in	O
the	O
three	O
patients	O
,	O
while	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
levels	O
were	O
(	O
30	O
,	O
2	O
pg	O
/	O
ml	O
,	O
128	O
pg	O
/	O
ml	O
and	O
40	O
,	O
5	O
pg	O
/	O
ml	O
).	O

Pairing	O
this	O
instrument	O
technology	O
with	O
modified	O
polymerases	O
should	O
result	O
in	O
a	O
new	O
paradigm	O
for	O
high	O
-	O
throughput	O
,	O
ultra	O
-	O
fast	B-FUNC
PCR	O
and	O
will	O
hopefully	O
improve	O
our	O
ability	O
to	O
quickly	O
respond	O
to	O
the	O
next	O
viral	O
pandemic	O
.	O

Aldehyde	O
inhibitors	O
can	O
bind	B-FUNC
reversibly	O
to	O
the	O
active	O
-	O
site	O
sulfhydryl	O
of	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
).	O

The	O
complex	B-FUNC
II	I-FUNC
and	O
complex	O
IV	O
,	O
on	O
the	O
other	O
hand	O
,	O
revealed	O
unaltered	O
activity	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
SARS	O
pseudovirus	O
cell	O
entry	O
by	O
lactoferrin	O
binding	B-FUNC
to	O
heparan	O
sulfate	O
proteoglycans	O
.	O

ABSTRACT	O
:	O
In	O
May	O
2011	O
,	O
an	O
outbreak	O
of	O
Shiga	O
toxin	O
-	O
producing	O
enterohaemorrhagic	O
E	O
coli	O
O104	O
:	O
H4	O
in	O
northern	O
Germany	O
led	O
to	O
a	O
high	O
proportion	O
of	O
patients	O
developing	O
post	O
-	O
enteritis	O
haemolytic	O
uraemic	O
syndrome	O
and	O
thrombotic	O
microangiopathy	O
that	O
were	O
unresponsive	O
to	O
therapeutic	O
plasma	O
exchange	O
or	O
complement	O
-	O
blocking	O
antibody	B-FUNC
(	O
eculizumab	O
).	O

ABSTRACT	O
:	O
MTU1	O
(	O
TRMU	O
)	O
is	O
a	O
mitochondrial	O
enzyme	O
responsible	O
for	O
the	O
2	O
-	O
thiolation	O
of	O
the	O
wobble	O
U	O
in	O
tRNA	B-FUNC
(	O
Lys	O
),	O
tRNA	B-FUNC
(	O
Glu	O
)	O
and	O
tRNA	B-FUNC
(	O
Gln	O
),	O
a	O
post	O
-	O
transcriptional	O
modification	O
believed	O
to	O
be	O
important	O
for	O
accurate	O
and	O
efficient	O
synthesis	O
of	O
the	O
13	O
respiratory	O
chain	O
subunits	O
encoded	O
by	O
mtDNA	O
.	O

Cytochrome	B-FUNC
P450	I-FUNC
Family	O
3A	O
(	O
CYP4F3A	O
)	O
is	O
an	O
ω	O
-	O
oxidase	O
that	O
inactivates	O
Leukotriene	O
B4	O
(	O
LTB4	O
)	O
in	O
human	O
neutrophils	O
and	O
the	O
liver	O
.	O

After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
only	O
rs2248690	O
(	O
AOR	B-FUNC
,	O
1	O
.	O
63	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
30	O
-	O
2	O
.	O
04	O
)	O
was	O
found	O
to	O
be	O
associated	O
with	O
SARS	O
susceptibility	O
.	O

Irrespective	O
of	O
the	O
techniques	O
used	O
,	O
the	O
majority	O
of	O
hmAbs	O
specifically	O
reacted	O
with	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
and	O
likely	O
prevented	O
receptor	B-FUNC
binding	I-FUNC
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
has	O
a	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
that	O
is	O
believed	O
to	O
be	O
important	O
for	O
enteropathogenicity	O
,	O
but	O
that	O
has	O
so	O
far	O
appeared	O
to	O
be	O
dispensable	O
for	O
infection	O
of	O
cultured	O
cells	O
.	O

Indeed	O
,	O
the	O
use	O
intravenous	O
immunoglobulin	B-FUNC
has	O
utterly	O
changed	O
prognosis	O
.	O

The	O
prevalence	O
of	O
FCoV	O
antigen	O
and	O
antibody	B-FUNC
in	O
Korean	O
cats	O
are	O
expected	O
to	O
gradually	O
increase	O
due	O
to	O
the	O
rising	O
numbers	O
of	O
stray	O
and	O
companion	O
cats	O
.	O

Interleukin	O
6	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
levels	O
were	O
significantly	O
higher	O
in	O
patients	O
who	O
developed	O
renal	O
,	O
respiratory	O
,	O
and	O
circulatory	O
failure	O
,	O
as	O
was	O
the	O
case	O
for	O
patients	O
with	O
multiorgan	O
failure	O
.	O

Knockdown	O
of	O
expression	O
of	O
known	O
mediators	O
of	O
the	O
antiviral	O
signaling	O
pathway	O
revealed	O
that	O
the	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
-	O
poly	O
(	O
I	O
:	O
C	O
)	O
synergy	O
depends	O
on	O
the	O
presence	O
of	O
the	O
transcriptional	O
factors	O
RelA	O
and	O
IFN	O
regulatory	O
factor	O
3	O
and	O
IκB	O
kinases	O
.	O

Moreover	O
,	O
this	O
synergy	O
was	O
blocked	O
by	O
an	O
IκB	O
kinase	B-FUNC
inhibitor	I-FUNC
,	O
BAY	O
11	O
-	O
7082	O
.	O

In	O
support	O
of	O
this	O
model	O
,	O
we	O
reported	O
that	O
the	O
S	O
protein	O
of	O
mouse	O
hepatitis	O
virus	O
type	O
2	O
(	O
MHV	O
-	O
2	O
),	O
which	O
is	O
highly	O
similar	O
to	O
the	O
S	O
protein	O
of	O
SARS	O
-	O
CoV	O
,	O
requires	O
two	O
-	O
step	O
conformational	O
changes	O
mediated	O
by	O
sequential	O
receptor	B-FUNC
binding	I-FUNC
and	O
proteolysis	O
to	O
be	O
activated	O
for	O
membrane	O
fusion	O
.	O

For	O
antibody	B-FUNC
detection	O
,	O
Escherichia	O
coli	O
BL21	O
and	O
baculovirus	O
-	O
expressed	O
recombinant	O
nucleocapsid	O
of	O
HCoV	O
-	O
HKU1	O
have	O
been	O
used	O
for	O
IgG	O
and	O
IgM	O
detection	O
in	O
sera	B-FUNC
of	O
patients	O
and	O
normal	O
individuals	O
,	O
using	O
Western	O
blot	O
and	O
enzyme	O
-	O
linked	O
immunoassay	O
.	O

The	O
high	O
binding	B-FUNC
site	O
plasticity	O
is	O
a	O
major	O
challenge	O
in	O
computational	O
drug	O
discovery	O
/	O
design	O
efforts	O
.	O

TITLE	O
:	O
Crosstalk	O
between	O
innate	O
and	O
adaptive	O
immune	O
responses	O
to	O
infectious	O
bronchitis	O
virus	O
after	O
vaccination	O
and	O
challenge	O
of	O
chickens	O
varying	O
in	O
serum	O
mannose	O
-	O
binding	B-FUNC
lectin	O
concentrations	O
.	O

TITLE	O
:	O
Virus	O
-	O
binding	B-FUNC
activity	O
of	O
the	O
truncated	O
C	O
subunit	O
of	O
porcine	O
aminopeptidase	O
N	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
overlapping	O
region	O
(	O
aa	O
673	O
-	O
722	O
)	O
between	O
rpAPN	O
-	O
C2	O
and	O
rpAPN	O
-	O
C3	O
is	O
indicated	O
to	O
play	O
a	O
key	O
role	O
in	O
viral	O
binding	B-FUNC
.	O

To	O
examine	O
whether	O
germline	O
rearranged	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
variable	O
region	O
genes	O
could	O
be	O
used	O
as	O
source	O
of	O
antibody	B-FUNC
repertoire	O
,	O
an	O
immunized	O
phage	O
-	O
displayed	O
scFv	O
library	O
was	O
prepared	O
using	O
splenocytic	O
genomic	O
DNA	O
as	O
template	O
.	O

Both	O
libraries	O
yielded	O
specific	O
anti	O
-	O
N	O
scFvs	O
that	O
exhibited	O
similar	O
binding	B-FUNC
characteristics	O
towards	O
recombinant	O
N	O
protein	O
,	O
except	O
the	O
immunized	O
library	O
gave	O
a	O
larger	O
number	O
of	O
specific	O
anti	O
-	O
N	O
scFv	O
,	O
and	O
clones	O
with	O
identical	O
nucleotide	O
sequences	O
were	O
found	O
.	O

ABSTRACT	O
:	O
SARS	O
coronavirus	O
(	O
SCoV	O
)	O
nonstructural	O
protein	O
(	O
nsp	O
)	O
1	O
,	O
a	O
potent	O
inhibitor	O
of	O
host	O
gene	O
expression	O
,	O
possesses	O
a	O
unique	O
mode	O
of	O
action	O
:	O
it	O
binds	B-FUNC
to	O
40S	O
ribosomes	O
to	O
inactivate	O
their	O
translation	O
functions	O
and	O
induces	O
host	O
mRNA	O
degradation	O
.	O

Sprague	O
-	O
Dawley	O
rats	O
(	O
3	O
-	O
10	O
/	O
group	O
)	O
were	O
given	O
15	O
mg	O
/	O
kg	O
or	O
150	O
mg	O
/	O
kg	O
l	O
-	O
ergothioneine	O
intravenously	O
1h	O
before	O
or	O
18	O
h	O
after	O
cytokine	O
(	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
and	O
IFNγ	O
)	O
insufflation	O
.	O

ABSTRACT	O
:	O
Among	O
different	O
coronavirus	O
genera	O
,	O
the	O
receptor	O
-	O
binding	B-FUNC
S1	O
subunits	O
of	O
their	O
spike	O
proteins	O
differ	O
in	O
primary	O
,	O
secondary	O
,	O
and	O
tertiary	O
structures	O
.	O

In	O
addition	O
to	O
interferon	O
(	O
IFN	O
)-	O
α	O
,	O
plenty	O
of	O
keratinocyte	O
-	O
derived	O
chemokines	O
(	O
KC	O
),	O
macrophage	O
inflammatory	O
protein	O
2	O
(	O
MIP	O
-	O
2	O
),	O
regulated	O
on	O
activation	O
normal	O
T	O
-	O
cell	O
expressed	O
and	O
secreted	O
(	O
RANTES	O
),	O
and	O
monocyte	O
chemotactic	O
protein	O
1	O
(	O
MCP	B-FUNC
-	O
1	O
)	O
were	O
significantly	O
released	O
into	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
of	O
the	O
model	O
.	O

The	O
initial	O
laboratory	O
profile	O
showed	O
only	O
an	O
increase	O
in	O
alanine	O
aminotransferase	O
enzyme	B-FUNC
activity	I-FUNC
.	O

We	O
have	O
hypothesized	O
that	O
because	O
the	O
germline	O
antibodies	O
are	O
so	O
different	O
from	O
the	O
mature	O
HIV	O
-	O
1	O
-	O
specific	O
bnAbs	O
they	O
may	O
not	O
bind	B-FUNC
the	O
epitopes	O
of	O
the	O
mature	O
antibodies	O
and	O
provided	O
the	O
first	O
evidence	O
to	O
support	O
this	O
hypothesis	O
by	O
using	O
individual	O
putative	O
germline	O
-	O
like	O
predecessor	O
antibodies	O
.	O

TITLE	O
:	O
Functional	O
transcriptional	O
regulatory	O
sequence	O
(	O
TRS	B-FUNC
)	O
RNA	B-FUNC
binding	I-FUNC
and	O
helix	O
destabilizing	O
determinants	O
of	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
.	O

NMR	O
studies	O
of	O
the	O
MHV	O
NTD	B-FUNC
·	I-FUNC
TRS	I-FUNC
complex	O
revealed	O
that	O
this	O
region	O
defines	O
a	O
major	O
RNA	B-FUNC
binding	I-FUNC
interface	O
in	O
MHV	O
with	O
site	O
-	O
directed	O
spin	O
labeling	O
studies	O
consistent	O
with	O
a	O
model	O
in	O
which	O
the	O
adenosine	O
-	O
rich	O
3	O
'-	O
region	O
of	O
TRS	B-FUNC
is	O
anchored	O
by	O
Arg	O
-	O
125	O
,	O
Tyr	O
-	O
127	O
,	O
and	O
Tyr	O
-	O
190	O
in	O
a	O
way	O
that	O
is	O
critical	O
for	O
efficient	O
subgenomic	O
RNA	O
synthesis	O
in	O
MHV	O
.	O

No	O
differences	O
were	O
detected	O
in	O
antibody	B-FUNC
prevalence	O
estimates	O
between	O
tigers	O
captured	O
as	O
part	O
of	O
a	O
research	O
program	O
and	O
those	O
captured	O
to	O
mitigate	O
human	O
-	O
tiger	O
conflicts	O
.	O

Chromatin	O
immunoprecipitaion	O
(	O
ChIP	O
)	O
and	O
reporter	O
gene	O
assays	O
in	O
3b	O
expressing	O
jurkat	O
cells	O
showed	O
recruitment	O
of	O
3b	O
on	O
the	O
RUNX1	O
binding	B-FUNC
element	O
that	O
led	O
to	O
an	O
increase	O
in	O
RUNX1b	O
transactivation	O
potential	O
on	O
the	O
IL2	O
promoter	O
.	O

In	O
primary	O
rat	O
alveolar	O
type	O
II	O
cells	O
alcohol	O
and	O
adenosine	O
decreased	O
the	O
abundance	O
of	O
the	O
Na	O
,	O
K	O
-	O
ATPase	O
at	O
the	O
basolateral	O
membrane	O
via	O
a	O
mechanism	O
that	O
required	O
activation	O
of	O
the	O
AMPK	B-FUNC
.	O

Tuberculin	O
skin	O
test	O
and	O
sputum	O
smear	O
for	O
acid	O
-	O
fast	B-FUNC
bacilli	O
were	O
negative	O
.	O

Dogs	O
from	O
Fort	O
Resolution	O
,	O
NWT	O
were	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
less	O
likely	O
to	O
have	O
moderate	O
or	O
high	O
antibody	B-FUNC
titers	O
to	O
the	O
3	O
agents	O
than	O
dogs	O
in	O
the	O
shelter	O
.	O

The	O
endoribonuclease	B-FUNC
activity	I-FUNC
of	O
the	O
SARS	O
-	O
CoV	O
Nsp15	O
(	O
sNsp15	O
)	O
was	O
stimulated	O
by	O
retinoblastoma	O
protein	O
(	O
pRb	O
)	O
in	O
vitro	O
,	O
and	O
the	O
two	O
proteins	O
can	O
be	O
coimmunoprecipitated	O
from	O
cellular	O
extracts	O
.	O

The	O
endoribonuclease	B-FUNC
activity	I-FUNC
of	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
A59	O
Nsp15	O
was	O
also	O
increased	O
by	O
pRb	O
in	O
vitro	O
,	O
and	O
an	O
MHV	O
with	O
mutations	O
in	O
the	O
LXCXE	O
/	O
D	O
-	O
motif	O
,	O
named	O
vLC	O
,	O
exhibited	O
a	O
smaller	O
plaque	O
diameter	O
and	O
reduced	O
the	O
virus	O
titer	O
by	O
∼	O
1	O
log	O
.	O

TITLE	O
:	O
Nonstructural	O
proteins	O
7	O
and	O
8	O
of	O
feline	O
coronavirus	O
form	O
a	O
2	O
:	O
1	O
heterotrimer	O
that	O
exhibits	O
primer	O
-	O
independent	O
RNA	B-FUNC
polymerase	I-FUNC
activity	I-FUNC
.	O

This	O
study	O
describes	O
ultrasensitive	O
ELISA	O
using	O
19B6	O
monoclonal	O
antibody	B-FUNC
as	O
the	O
capture	O
antibody	B-FUNC
and	O
IgY	O
as	O
the	O
detecting	O
antibody	B-FUNC
against	O
the	O
most	O
abundant	O
SARS	O
-	O
CoV	O
NP	O
antigens	O
.	O

Lung	O
proinflammatory	O
cytokines	O
were	O
induced	O
at	O
1	O
to	O
14	O
dpi	O
,	O
but	O
most	O
returned	O
to	O
baseline	O
by	O
28	O
dpi	O
except	O
interleukin	O
12	O
(	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
)	O
and	O
gamma	O
interferon	O
.	O

ABSTRACT	O
:	O
In	O
childhood	O
Guillain	O
-	O
Barré	O
syndrome	O
(	O
GBS	O
),	O
the	O
clinical	O
profiles	O
using	O
intravenous	O
immunoglobulin	B-FUNC
(	O
IVIg	O
)	O
in	O
addition	O
to	O
supportive	O
care	O
were	O
studied	O
.	O

Further	O
observations	O
suggest	O
that	O
the	O
zinc	O
-	O
binding	B-FUNC
domain	O
may	O
start	O
to	O
unfold	O
during	O
the	O
first	O
transition	O
.	O

Antibody	B-FUNC
against	O
RbCoV	O
was	O
detected	O
in	O
20	O
(	O
67	O
%)	O
of	O
30	O
rabbit	O
sera	B-FUNC
tested	O
by	O
an	O
N	O
-	O
protein	O
-	O
based	O
Western	O
blot	O
assay	O
,	O
whereas	O
neutralizing	O
antibody	B-FUNC
was	O
detected	O
in	O
1	O
of	O
these	O
20	O
rabbits	O
.	O

The	O
detection	O
limit	O
of	O
the	O
one	O
-	O
step	O
multiplex	O
RT	O
-	O
PCR	O
for	O
GAR	B-FUNC
,	O
GCR	O
,	O
BCV	O
,	O
and	O
BToV	O
was	O
10	O
(	O
2	O
),	O
10	O
(	O
0	O
),	O
10	O
(	O
1	O
),	O
and	O
10	O
(	O
2	O
)	O
TCID	O
(	O
50	O
)/	O
ml	O
,	O
respectively	O
,	O
and	O
that	O
for	O
GBR	O
was	O
10	O
(	O
6	O
)	O
copies	O
/	O
ml	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
the	O
one	O
-	O
step	O
multiplex	O
RT	O
-	O
PCR	O
developed	O
here	O
for	O
the	O
detection	O
of	O
GAR	B-FUNC
,	O
GBR	O
,	O
GCR	O
,	O
BCV	O
,	O
and	O
BToV	O
can	O
be	O
expected	O
to	O
be	O
a	O
useful	O
tool	O
for	O
the	O
rapid	O
and	O
cost	O
-	O
effective	O
diagnosis	O
and	O
surveillance	O
of	O
viral	O
diarrhea	O
in	O
adult	O
cattle	O
.	O

Four	O
biflavonoids	O
(	O
1	O
-	O
4	O
),	O
three	O
sterols	O
(	O
5	O
-	O
7	O
),	O
and	O
two	O
stilbene	O
derivatives	O
(	O
8	O
-	O
9	O
)	O
were	O
identified	O
and	O
evaluated	O
for	O
their	O
antiviral	O
potential	O
on	O
the	O
DV	O
-	O
NS5	O
RdRp	B-FUNC
.	O

To	O
investigate	O
single	O
-	O
chain	O
fragment	O
variable	O
(	O
scFv	O
)	O
repertoire	O
against	O
pAPN	O
,	O
the	O
genes	O
encoding	O
the	O
immunoglobulin	B-FUNC
light	O
chain	O
variable	O
region	O
(	O
VL	O
)	O
and	O
heavy	O
chain	O
variable	O
region	O
(	O
VH	O
)	O
were	O
amplified	O
by	O
reverse	O
transcript	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
using	O
a	O
series	O
of	O
degenerate	O
primers	O
from	O
the	O
spleen	O
of	O
BABL	O
/	O
c	O
mice	O
immunized	O
with	O
native	O
pAPN	O
.	O

on	O
day	O
0	O
and	O
28	O
and	O
sacrificed	O
for	O
serum	O
antibody	B-FUNC
measurements	O
or	O
challenged	O
with	O
live	O
virus	O
on	O
day	O
56	O
.	O

The	O
κ	O
value	O
for	O
the	O
in	O
-	O
house	O
ELISA	O
using	O
the	O
S	O
-	O
E	O
fragment	O
compared	O
to	O
a	O
commercial	O
kit	B-FUNC
was	O
0	O
.	O
9172	O
,	O
indicating	O
a	O
high	O
agreement	O
between	O
these	O
two	O
methods	O
.	O

ABSTRACT	O
:	O
The	O
interplay	O
between	O
IFN	O
-	O
γ	O
,	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
and	O
neutrophils	O
during	O
CNS	O
inflammatory	O
disease	O
is	O
complex	O
due	O
to	O
cross	O
-	O
regulatory	O
factors	O
affecting	O
both	O
positive	O
and	O
negative	O
feedback	O
loops	O
.	O

CNS	O
inflammatory	O
conditions	O
were	O
selectively	O
manipulated	O
by	O
adoptive	O
transfer	O
of	O
virus	O
-	O
primed	O
wild	O
-	O
type	O
(	O
WT	O
)	O
or	O
IFN	O
-	O
γ	O
deficient	O
(	O
GKO	O
)	O
memory	O
CD4	O
+	O
T	O
cells	O
into	O
infected	O
SCID	O
mice	O
,	O
coupled	O
with	O
antibody	B-FUNC
-	O
mediated	O
neutrophil	O
depletion	O
and	O
cytokine	O
blockade	O
.	O

Furthermore	O
,	O
co	O
-	O
transfer	O
of	O
WT	O
and	O
GKO	O
CD4	O
+	O
T	O
cells	O
prolonged	O
survival	O
in	O
an	O
IFN	O
-	O
γ	O
dependent	O
manner	O
,	O
although	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
transcription	O
was	O
not	O
reduced	O
.	O

Animals	O
were	O
examined	O
for	O
T	O
lymphocyte	O
proliferation	O
,	O
anti	O
-	O
PEDV	O
antibodies	O
,	O
IFN	O
-	O
γ	O
and	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
protein	O
levels	O
,	O
and	O
cytotoxic	O
T	O
cell	O
function	O
in	O
mouse	O
peripheral	O
blood	O
and	O
spleen	O
.	O

This	O
different	O
antigenic	O
phenotype	O
was	O
also	O
confirmed	O
by	O
a	O
neutralizing	O
test	O
with	O
clinically	O
isolated	O
human	O
sera	B-FUNC
.	O

Here	O
,	O
random	O
mutagenesis	O
and	O
DNA	O
shuffling	O
of	O
the	O
single	O
-	O
chain	O
variable	O
fragment	O
of	O
the	O
neutralizing	O
antibody	B-FUNC
80R	O
followed	O
by	O
bacterial	O
display	O
screening	O
using	O
anchored	O
periplasmic	O
expression	O
(	O
APEx	O
)	O
were	O
used	O
to	O
generate	O
a	O
number	O
of	O
higher	O
-	O
affinity	O
variants	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)-	O
neutralizing	O
antibody	B-FUNC
80R	O
with	O
equilibrium	O
dissociation	O
constants	O
(	O
K	O
(	O
D	O
))	O
as	O
low	O
as	O
37	O
pM	O
,	O
a	O
>	O
270	O
-	O
fold	O
improvement	O
relative	O
to	O
that	O
of	O
the	O
parental	O
80R	O
single	O
-	O
chain	O
variable	O
fragment	O
(	O
scFv	O
).	O

A	O
rat	O
model	O
of	O
bleomycin	O
(	O
BLM	O
)-	O
induced	O
lung	O
fibrosis	O
and	O
a	O
fibrotic	O
cell	O
model	O
with	O
transforming	B-FUNC
growth	I-FUNC
factor	I-FUNC
beta	I-FUNC
-	O
1	O
induction	O
were	O
employed	O
in	O
the	O
studies	O
.	O

In	O
a	O
fibrotic	O
cell	O
model	O
with	O
transforming	B-FUNC
growth	I-FUNC
factor	I-FUNC
beta	I-FUNC
-	O
1	O
induction	O
,	O
the	O
human	O
lung	O
epithelial	O
A549	O
acquired	O
a	O
mesenchymal	O
phenotype	O
and	O
an	O
increase	O
of	O
vimentin	O
expression	O
with	O
a	O
concomitant	O
decrease	O
of	O
E	O
-	O
cadherin	O
.	O

All	O
the	O
patients	O
on	O
admission	O
were	O
tested	O
for	O
H1N1	O
,	O
by	O
real	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Flow	O
cytometry	O
(	O
using	O
an	O
anti	O
-	O
feline	O
AGP	O
antibody	B-FUNC
),	O
serum	O
protein	O
electrophoresis	O
,	O
routine	O
haematology	O
and	O
measurement	O
of	O
the	O
serum	O
AGP	O
concentration	O
were	O
performed	O
using	O
blood	O
samples	O
from	O
32	O
healthy	O
cats	O
(	O
19	O
FCoV	O
-	O
seropositive	O
),	O
13	O
cats	O
with	O
FIP	O
and	O
12	O
with	O
other	O
diseases	O
(	O
6	O
FCoV	O
-	O
seropositive	O
).	O

TITLE	O
:	O
Coronavirus	O
E	O
protein	O
forms	O
ion	B-FUNC
channels	I-FUNC
with	O
functionally	O
and	O
structurally	O
-	O
involved	O
membrane	O
lipids	O
.	O

Coronaviruses	O
have	O
the	O
largest	O
RNA	O
genomes	O
,	O
and	O
encode	O
an	O
exoribonuclease	B-FUNC
activity	I-FUNC
that	O
is	O
required	O
for	O
high	O
-	O
fidelity	O
replication	O
.	O

An	O
indirect	O
ELISA	O
using	O
recombinant	O
N	O
protein	O
as	O
antigen	O
was	O
established	O
to	O
screen	O
antibody	B-FUNC
-	O
producing	O
hybridoma	O
cell	O
lines	O
.	O

Plasma	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
and	O
mini	O
-	O
BAL	O
protein	O
were	O
both	O
significantly	O
associated	O
with	O
increased	O
oxygenation	O
index	O
(	O
P	O
=	O
0	O
.	O
02	O
and	O
0	O
.	O
01	O
,	O
respectively	O
),	O
whereas	O
there	O
was	O
a	O
trend	O
toward	O
an	O
association	O
between	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
oxygenation	O
index	O
(	O
P	O
=	O
0	O
.	O
057	O
).	O

Here	O
we	O
describe	O
the	O
crystal	O
structures	O
of	O
the	O
receptor	O
-	O
binding	B-FUNC
domains	O
(	O
RBDs	O
)	O
of	O
two	O
closely	O
related	O
CoV	O
strains	O
,	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
and	O
porcine	O
respiratory	O
CoV	O
(	O
PRCV	O
),	O
in	O
complex	O
with	O
their	O
receptor	O
,	O
porcine	O
APN	O
(	O
pAPN	O
),	O
or	O
with	O
a	O
neutralizing	O
antibody	B-FUNC
.	O

However	O
,	O
rosmariquinone	O
(	O
7	O
)	O
showed	O
a	O
different	O
kinetic	O
mechanism	O
through	O
mixed	O
-	O
type	O
simple	O
reversible	O
slow	O
-	O
binding	B-FUNC
inhibition	O
.	O

The	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
expression	O
levels	O
on	O
CD4	O
(+)	O
T	O
and	O
CD8	O
(+)	O
T	O
cells	O
were	O
determined	O
by	O
using	O
flow	O
cytometry	O
.	O

The	O
correlation	O
between	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
level	O
and	O
liver	O
injury	O
was	O
studied	O
.	O

Our	O
results	O
showed	O
that	O
the	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
expression	O
was	O
significantly	O
elevated	O
in	O
the	O
liver	O
and	O
serum	O
of	O
BALB	O
/	O
cJ	O
mice	O
infected	O
with	O
MHV	O
-	O
3	O
.	O

Treatment	O
with	O
peptide	O
-	O
N	O
-	O
glycosidase	O
F	O
(	O
PNGase	B-FUNC
F	I-FUNC
),	O
which	O
removes	O
all	O
types	O
of	O
N	O
-	O
glycan	O
side	O
chains	O
from	O
glycoproteins	O
,	O
eliminated	O
the	O
infectivity	O
of	O
S	O
-	O
pseudovirus	O
.	O

The	O
ratios	O
of	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
to	O
CK	O
in	O
both	O
moderate	O
and	O
severe	O
groups	O
were	O
significantly	O
lower	O
than	O
in	O
healthy	O
controls	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

all	O
sera	B-FUNC
samples	O
from	O
patients	O
with	O
SARS	O
positive	O
were	O
the	O
ELISA	O
positive	O
(	O
100	O
%	O
sensitivity	O
).	O

TITLE	O
:	O
Quantitative	O
and	O
sensitive	O
detection	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
using	O
bispecific	O
monoclonal	O
antibody	B-FUNC
-	O
based	O
enzyme	O
-	O
linked	O
immunoassay	O
.	O

ABSTRACT	O
:	O
The	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)	O
is	O
one	O
of	O
the	O
most	O
attracting	O
targets	O
for	O
the	O
development	O
of	O
early	O
phase	O
infection	O
inhibitors	O
.	O

Moreover	O
it	O
should	O
be	O
reported	O
that	O
many	O
of	O
the	O
known	O
RT	O
inhibitors	O
,	O
targeting	O
the	O
polymerase	O
function	O
,	O
enhance	O
the	O
RNase	B-FUNC
H	I-FUNC
activity	I-FUNC
,	O
indicating	O
that	O
,	O
although	O
spatially	O
distinct	O
,	O
a	O
close	O
relation	O
occurs	O
between	O
the	O
two	O
functions	O
.	O

ABSTRACT	O
:	O
Epstein	O
-	O
Barr	O
virus	O
-	O
induced	O
gene	O
3	O
(	O
EBI3	O
)	O
associates	O
with	O
p28	O
and	O
p35	O
to	O
form	O
the	O
immunomodulatory	O
cytokines	O
IL	B-FUNC
-	I-FUNC
27	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
35	I-FUNC
,	O
respectively	O
.	O

ABSTRACT	O
:	O
The	O
degradative	O
activity	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
),	O
termed	O
ribonuclease	O
H	O
(	O
RNase	O
H	O
),	O
which	O
hydrolyzes	O
the	O
RNA	O
component	O
of	O
the	O
heteroduplex	O
RNA	O
:	O
DNA	O
replication	O
intermediate	O
,	O
is	O
an	O
excellent	O
target	O
for	O
drug	O
discovery	O
.	O

Six	O
series	O
of	O
new	O
AQ	O
derivatives	O
with	O
various	O
substituents	O
at	O
positions	O
1	O
,	O
2	O
,	O
3	O
and	O
4	O
of	O
the	O
AQ	O
ring	O
were	O
tested	O
,	O
and	O
new	O
analogs	O
able	O
to	O
inhibit	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
RNase	B-FUNC
H	I-FUNC
activity	I-FUNC
in	O
the	O
low	O
micromolar	O
range	O
were	O
found	O
.	O

Three	O
hundred	O
and	O
twenty	O
clinical	O
specimens	O
were	O
tested	O
with	O
the	O
AdvanSure	O
RV	O
real	O
-	O
time	O
PCR	O
Kit	B-FUNC
and	O
conventional	O
multiplex	O
reverse	O
transcription	O
(	O
RT	O
)-	O
PCR	O
assay	O
.	O

RESULTS	O
:	O
The	O
limit	O
of	O
detection	O
(	O
LOD	B-FUNC
)	O
was	O
1	O
.	O
31	O
plaque	O
-	O
forming	O
units	O
(	O
PFU	O
)/	O
mL	O
for	O
human	O
rhinoviruses	O
(	O
hRVs	O
),	O
4	O
.	O
93	O
PFU	O
/	O
mL	O
for	O
human	O
coronavirus	O
HCoV	O
-	O
229E	O
/	O
NL63	O
,	O
2	O
.	O
67	O
PFU	O
/	O
mL	O
for	O
human	O
coronavirus	O
HCoV	O
-	O
OC43	O
,	O
18	O
.	O
20	O
PFU	O
/	O
mL	O
for	O
parainfluenza	O
virus	O
1	O
(	O
PIV	O
)-	O
1	O
,	O
24	O
.	O
57	O
PFU	O
/	O
mL	O
for	O
PIV	O
-	O
2	O
,	O
1	O
.	O
73	O
PFU	O
/	O
mL	O
for	O
PIV	O
-	O
3	O
,	O
1	O
.	O
79	O
PFU	O
/	O
mL	O
for	O
influenza	O
virus	O
group	O
(	O
Flu	O
)	O
A	O
,	O
59	O
.	O
51	O
PFU	O
/	O
mL	O
for	O
FluB	O
,	O
5	O
.	O
46	O
PFU	O
/	O
mL	O
for	O
human	O
respiratory	O
syncytial	O
virus	O
(	O
hRSV	O
)-	O
A	O
,	O
17	O
.	O
23	O
PFU	O
/	O
mL	O
for	O
hRSV	O
-	O
B	O
,	O
9	O
.	O
99	O
PFU	O
/	O
mL	O
for	O
human	O
adenovirus	O
(	O
ADVs	O
).	O

After	O
3	O
days	O
of	O
hospitalization	O
,	O
the	O
APACHEII	O
,	O
score	O
SAA	O
levels	O
,	O
serum	O
CRP	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
in	O
the	O
treatment	O
group	O
was	O
lower	O
than	O
those	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Evolution	O
of	O
infectious	O
bronchitis	O
virus	O
in	O
Taiwan	O
:	O
positively	O
selected	O
sites	O
in	O
the	O
nucleocapsid	O
protein	O
and	O
their	O
effects	O
on	O
RNA	O
-	O
binding	B-FUNC
activity	O
.	O

The	O
major	O
clinical	O
symptoms	O
associated	O
with	O
HCoV	O
-	O
HKU1	O
infection	O
were	O
examined	O
statistically	O
and	O
sequence	O
variations	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
),	O
spike	O
,	O
and	O
nucleocapsid	O
genes	O
were	O
also	O
analyzed	O
.	O

Previously	O
,	O
using	O
Xenomouse	O
(	O
Amgen	O
British	O
Columbia	O
Inc	O
),	O
we	O
produced	O
a	O
panel	O
of	O
neutralizing	O
Human	O
monoclonal	O
antibodies	O
(	O
HmAbs	O
)	O
that	O
could	O
specifically	O
bind	B-FUNC
to	O
the	O
ectodomain	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
glycoprotein	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
non	O
-	O
S1	O
binding	B-FUNC
neutralizing	O
HmAbs	O
that	O
can	O
specifically	O
bind	B-FUNC
to	O
the	O
conserved	O
S2	O
domain	O
of	O
the	O
S	O
protein	O
.	O

However	O
,	O
occasional	O
samples	O
show	O
a	O
falsely	O
low	O
or	O
negative	O
FCoV	O
antibody	B-FUNC
test	O
.	O

Increasing	O
amounts	O
of	O
virus	O
correlated	O
with	O
lower	O
signals	O
in	O
indirect	O
immunoflourescent	O
,	O
enzyme	O
-	O
linked	O
immunosorbent	O
asssay	O
and	O
rapid	O
immunomigration	O
antibody	B-FUNC
tests	O
.	O

We	O
have	O
studied	O
the	O
transcription	O
of	O
a	O
novel	O
sgmRNA	O
associated	O
with	O
this	O
potential	O
ORF	O
and	O
found	O
it	O
to	O
be	O
transcribed	O
via	O
a	O
previously	O
unidentified	O
noncanonical	O
TRS	B-FUNC
-	O
B	O
.	O
Using	O
an	O
IBV	O
reverse	O
genetics	O
system	O
,	O
we	O
demonstrated	O
that	O
the	O
template	O
-	O
switching	O
event	O
during	O
intergenic	O
region	O
(	O
IR	O
)	O
sgmRNA	O
synthesis	O
occurs	O
at	O
the	O
5	O
'	O
end	O
of	O
the	O
noncanonical	O
TRS	B-FUNC
-	O
B	O
and	O
recombines	O
between	O
nucleotides	O
5	O
and	O
6	O
of	O
the	O
8	O
-	O
nucleotide	O
consensus	O
TRS	B-FUNC
-	O
L	O
.	O
Introduction	O
of	O
a	O
complete	O
TRS	B-FUNC
-	O
B	O
showed	O
that	O
higher	O
transcription	O
levels	O
are	O
achieved	O
by	O
increasing	O
the	O
number	O
of	O
nucleotide	O
matches	O
between	O
TRS	B-FUNC
-	O
L	O
and	O
TRS	B-FUNC
-	O
B	O
.	O
Translation	O
of	O
a	O
protein	O
from	O
the	O
sgmRNA	O
was	O
demonstrated	O
using	O
enhanced	O
green	O
fluorescent	O
protein	O
,	O
suggesting	O
the	O
translation	O
of	O
a	O
fifth	O
,	O
novel	O
,	O
group	O
-	O
specific	O
protein	O
for	O
IBV	O
.	O

Glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
and	O
Ubiquitin	B-FUNC
were	O
chosen	O
for	O
normalization	O
in	O
this	O
experimental	O
set	O
.	O

Monkey	O
and	O
human	O
kidney	O
cells	O
(	O
LLC	O
-	O
MK2	O
,	O
Vero	O
,	O
and	O
769	O
-	O
P	O
)	O
and	O
swine	O
kidney	O
cells	O
were	O
permissive	O
for	O
both	O
viruses	O
,	O
but	O
only	O
SARS	O
-	O
CoV	O
infection	O
could	O
be	O
blocked	O
by	O
anti	O
-	O
hACE2	O
antibody	B-FUNC
and	O
could	O
be	O
neutralized	O
by	O
preincubation	O
of	O
virus	O
with	O
soluble	O
ACE2	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
mice	O
in	O
high	O
-	O
fat	O
diet	O
group	O
and	O
the	O
two	O
virus	O
infection	O
groups	O
had	O
significantly	O
increased	O
AST	O
and	O
ALT	B-FUNC
levels	O
with	O
also	O
elevated	O
TC	O
and	O
LDL	O
-	O
C	O
levels	O
.	O

A	O
monoclonal	O
antibody	B-FUNC
,	O
4H4	O
,	O
against	O
the	O
Kakegawa	O
strain	O
belonging	O
to	O
group	O
1	O
lacked	O
significant	O
neutralizing	O
activity	O
for	O
viruses	O
of	O
groups	O
2	O
,	O
3	O
,	O
and	O
4	O
.	O

TITLE	O
:	O
Structural	O
and	O
biochemical	O
basis	O
for	O
the	O
difference	O
in	O
the	O
helicase	B-FUNC
activity	I-FUNC
of	O
two	O
different	O
constructs	O
of	O
SARS	O
-	O
CoV	O
helicase	O
.	O

ABSTRACT	O
:	O
Most	O
betacoronaviruses	O
possess	O
an	O
hemagglutinin	O
-	O
esterase	O
(	O
HE	O
)	O
protein	O
,	O
which	O
appears	O
to	O
play	O
a	O
role	O
in	O
binding	B-FUNC
to	O
or	O
release	O
from	O
the	O
target	O
cell	O
.	O

NMR	O
chemical	O
shift	O
perturbation	O
analysis	O
reveals	O
that	O
the	O
N	O
-	O
terminal	O
region	O
of	O
an	O
MHV	O
N	O
SR	O
-	O
rich	O
linker	O
peptide	O
(	O
residues	O
198	O
to	O
230	O
)	O
binds	B-FUNC
to	O
the	O
acidic	O
face	O
of	O
MHV	O
nsp3a	O
containing	O
the	O
acidic	O
α2	O
helix	O
with	O
an	O
affinity	O
(	O
expressed	O
as	O
K	O
(	O
a	O
))	O
of	O
8	O
.	O
1	O
×	O
10	O
(	O
3	O
)	O
M	O
(-	O
1	O
).	O

TITLE	O
:	O
Heparin	O
-	O
binding	B-FUNC
protein	O
(	O
HBP	O
):	O
an	O
early	O
marker	O
of	O
respiratory	O
failure	O
after	O
trauma	O
?	O

The	O
subcellular	O
localization	O
and	O
function	O
of	O
PEDV	O
E	O
protein	O
were	O
investigated	O
by	O
examining	O
its	O
effects	O
on	O
cell	O
growth	O
,	O
cell	O
cycle	O
progression	O
,	O
interleukin	O
-	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
expression	O
and	O
cell	O
survival	O
.	O

Hantavirus	O
serology	O
(	O
immunofluorescence	O
antibody	B-FUNC
assay	O
):	O
1	O
:	O
2048	O
;	O
serotype	O
Puumala	O
.	O

The	O
serum	O
antibody	B-FUNC
titers	O
in	O
the	O
prime	O
-	O
boost	O
birds	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
multivalent	O
DNA	O
vaccine	O
group	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
but	O
not	O
significantly	O
different	O
compared	O
to	O
the	O
inactivated	O
vaccine	O
group	O
at	O
49	O
days	O
of	O
age	O
.	O

The	O
discovery	O
of	O
viruses	O
encoding	O
deubiquitinating	O
enzymes	O
(	O
DUBs	O
)	O
suggests	O
they	O
remove	O
ubiquitin	B-FUNC
to	O
evade	O
ubiquitin	B-FUNC
-	O
dependent	O
antiviral	O
responses	O
;	O
however	O
,	O
this	O
has	O
never	O
been	O
conclusively	O
demonstrated	O
in	O
virus	O
-	O
infected	O
cells	O
.	O

To	O
dissect	O
this	O
dual	O
specificity	O
,	O
which	O
relies	O
on	O
a	O
single	O
catalytic	O
site	O
,	O
we	O
determined	O
the	O
crystal	O
structure	O
of	O
equine	O
arteritis	O
virus	O
PLP2	O
in	O
complex	O
with	O
ubiquitin	B-FUNC
(	O
1	O
.	O
45	O
Å	O
).	O

TITLE	O
:	O
Heparin	O
-	O
binding	B-FUNC
protein	O
(	O
HBP	O
)	O
in	O
critically	O
ill	O
patients	O
with	O
influenza	O
A	O
(	O
H1N1	O
)	O
infection	O
.	O

The	O
incidence	O
of	O
IAH	B-FUNC
in	O
patients	O
with	O
SAP	O
is	O
approximately	O
60	O
-	O
80	O
%.	O

After	O
infectious	O
challenge	O
by	O
TCoV	O
,	O
clinical	O
signs	O
and	O
TCoV	O
detected	O
by	O
immunofluorescence	O
antibody	B-FUNC
(	O
IFA	O
)	O
assay	O
were	O
observed	O
in	O
less	O
number	O
of	O
turkeys	O
in	O
vaccination	O
groups	O
than	O
that	O
in	O
challenge	O
control	O
groups	O
.	O

DPP4	O
specifically	O
co	O
-	O
purified	O
with	O
the	O
receptor	O
-	O
binding	B-FUNC
S1	O
domain	O
of	O
the	O
hCoV	O
-	O
EMC	O
spike	O
protein	O
from	O
lysates	O
of	O
susceptible	O
Huh	O
-	O
7	O
cells	O
.	O

Tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
α	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
on	O
the	O
fourth	O
and	O
seventh	O
days	O
,	O
and	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
on	O
the	O
seventh	O
day	O
after	O
treatment	O
showed	O
significant	O
decrease	O
in	O
the	O
somatostatin	O
,	O
somatostatin	O
+	O
ulinastatin	O
,	O
somatostatin	O
+	O
S	O
miltiorrhiza	O
and	O
somatostatin	O
+	O
ulinastatin	O
+	O
S	O
miltiorrhiza	O
subgroups	O
compared	O
with	O
the	O
basic	O
treatment	O
subgroup	O
.	O

Further	O
studies	O
show	O
that	O
PEDV	O
N	O
protein	O
induces	O
ER	O
stress	O
and	O
activates	O
NF	O
-	O
κB	O
,	O
which	O
is	O
responsible	O
for	O
the	O
up	O
-	O
regulation	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
Bcl	O
-	O
2	O
expression	O
.	O

An	O
outbreak	O
of	O
heartworm	O
exposure	O
occurred	O
from	O
1995	O
to	O
2003	O
and	O
higher	O
than	O
expected	O
levels	O
of	O
FCoV	O
-	O
antibody	B-FUNC
-	O
positive	O
mountain	O
lions	O
were	O
observed	O
from	O
2005	O
to	O
2008	O
,	O
with	O
foci	O
in	O
southern	O
Mendocino	O
and	O
eastern	O
Lake	O
counties	O
.	O

Importantly	O
soluble	O
fibrinogen	O
in	O
acute	O
-	O
phase	O
concentrations	O
(	O
4	O
-	O
10	O
mg	O
mL	O
(-	O
1	O
)	O
)	O
dose	O
-	O
dependently	O
reduced	O
neutrophil	O
firm	O
adhesion	O
to	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
α	O
-	O
activated	O
endothelium	O
to	O
40	O
%	O
under	O
flow	O
conditions	O
.	O

No	O
blood	O
donor	O
had	O
antibody	B-FUNC
against	O
either	O
virus	O
.	O

Convalescent	O
SARS	O
sera	B-FUNC
may	O
contain	O
cross	O
-	O
reactive	O
antibodies	O
against	O
other	O
betacoronaviruses	O
and	O
confound	O
seroprevalence	O
study	O
for	O
HCoV	O
-	O
EMC	O
.	O

Based	O
on	O
the	O
208	O
base	B-FUNC
pair	I-FUNC
(	O
bp	O
)	O
sequence	O
of	O
novel	O
HCoV	O
reported	O
by	O
HPA	O
of	O
UK	O
,	O
we	O
designed	O
and	O
obtained	O
several	O
pairs	O
of	O
primer	O
(	O
F	O
-	O
1	O
,	O
R	O
-	O
1	O
;	O
F	O
-	O
2	O
,	O
R	O
-	O
2	O
)	O
and	O
Taqman	O
probes	O
(	O
TZ1	O
,	O
TZ2	O
)	O
for	O
detection	O
of	O
novel	O
HCoV	O
.	O
Two	O
of	O
probes	O
were	O
modified	O
with	O
LNA	O
(	O
LNA	O
-	O
TZ1	O
,	O
LNA	O
-	O
TZ2	O
).	O

The	O
addition	O
of	O
the	O
SILAC	O
label	O
allowed	O
discrimination	O
of	O
proteins	O
that	O
were	O
likely	O
to	O
specifically	O
bind	B-FUNC
to	O
the	O
N	O
protein	O
over	O
background	O
binding	B-FUNC
.	O

Overall	O
,	O
142	O
cellular	O
proteins	O
were	O
selected	O
as	O
potentially	O
binding	B-FUNC
to	O
the	O
N	O
protein	O
,	O
many	O
as	O
part	O
of	O
larger	O
possible	O
complexes	O
.	O

Recent	O
studies	O
involving	O
the	O
administration	O
of	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	B-FUNC
)	O
for	O
the	O
treatment	O
of	O
experimental	O
ALI	O
/	O
ARDS	O
have	O
shown	O
promising	O
results	O
.	O

Blocking	O
of	O
p53	O
activation	O
significantly	O
inhibited	O
the	O
occurrence	O
of	O
apoptosis	O
through	O
suppressing	O
the	O
TGEV	O
-	O
induced	O
FasL	O
expression	O
,	O
Bcl	O
-	O
2	O
reduction	O
,	O
Bax	O
and	O
cytochrome	B-FUNC
c	I-FUNC
redistribution	O
,	O
while	O
inhibition	O
of	O
p38	B-FUNC
activity	O
moderately	O
blocked	O
apoptosis	O
induction	O
and	O
partly	O
attenuated	O
the	O
accumulation	O
and	O
activation	O
of	O
p53	O
.	O

Genomes	O
carrying	O
the	O
original	O
mutations	O
in	O
S3	O
or	O
S4	O
plus	O
compensatory	O
mutations	O
restoring	O
base	B-FUNC
pairing	I-FUNC
were	O
viable	O
and	O
had	O
robust	O
growth	O
phenotypes	O
.	O

The	O
main	O
protective	O
mechanisms	O
of	O
L	O
-	O
4F	O
are	O
due	O
to	O
direct	O
inhibition	O
of	O
endotoxin	B-FUNC
activity	I-FUNC
and	O
preservation	O
of	O
HDL	O
anti	O
-	O
oxidant	O
activity	O
.	O

Common	O
respiratory	O
viruses	O
were	O
identified	O
by	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
.	O

Docking	O
studies	O
were	O
performed	O
to	O
model	O
the	O
binding	B-FUNC
interaction	O
of	O
the	O
compound	O
26m	O
with	O
the	O
SARS	O
-	O
CoV	O
3CL	O
protease	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
recently	O
emerged	O
human	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
mediates	O
infection	O
by	O
binding	B-FUNC
to	O
the	O
cellular	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
).	O

We	O
have	O
utilized	O
solution	O
-	O
state	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
to	O
investigate	O
DC	O
-	O
SIGNR	O
binding	B-FUNC
and	O
herein	O
report	O
the	O
first	O
backbone	O
assignment	O
of	O
its	O
active	O
,	O
calcium	O
-	O
bound	O
carbohydrate	O
recognition	O
domain	O
.	O

ABSTRACT	O
:	O
Among	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
associated	O
functions	O
,	O
DNA	O
polymerase	O
and	O
Ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
are	O
both	O
essential	O
for	O
HIV	O
replication	O
and	O
excellent	O
targets	O
for	O
drug	O
development	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
receptor	O
-	O
binding	B-FUNC
domain	O
in	O
the	O
S	O
protein	O
of	O
the	O
novel	O
human	O
coronavirus	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
as	O
an	O
essential	O
target	O
for	O
vaccine	O
development	O
.	O

Adalimumab	O
is	O
a	O
recombinant	O
human	O
monoclonal	O
antibody	B-FUNC
that	O
blocks	O
the	O
effects	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
.	O

To	O
deliver	O
viral	O
antigens	O
to	O
the	O
mucosal	O
immune	O
system	O
of	O
chickens	O
safely	O
and	O
effectively	O
,	O
we	O
constructed	O
a	O
Lactococcus	O
lactis	O
strain	O
carrying	O
IBV	O
multi	O
-	O
epitope	O
gene	O
EpiC	O
fused	O
with	O
the	O
gene	O
of	O
the	O
cell	O
-	O
wall	O
anchoring	B-FUNC
domain	O
of	O
Staphylococcus	O
aureus	O
protein	O
A	O
.	O
SDS	O
-	O
PAGE	O
and	O
Western	O
blot	O
results	O
indicated	O
that	O
the	O
fused	O
peptide	O
was	O
located	O
partially	O
on	O
the	O
cell	O
surface	O
.	O

Up	O
to	O
60	O
%	O
of	O
the	O
population	O
has	O
been	O
positive	O
for	O
specific	O
serum	O
antibody	B-FUNC
in	O
community	O
-	O
based	O
surveys	O
,	O
but	O
mortality	O
is	O
very	O
uncommon	O
.	O

ABSTRACT	O
:	O
A	O
25	O
-	O
kDa	O
protein	O
,	O
with	O
an	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
homologous	O
to	O
that	O
of	O
xylanase	B-FUNC
inhibitor	O
and	O
designated	O
as	O
xylanase	B-FUNC
inbibitor	O
-	O
like	O
protein	O
(	O
XILP	O
)	O
was	O
purified	O
from	O
sorghum	O
seeds	O
.	O

Attachment	O
to	O
sialic	O
acid	O
is	O
mediated	O
by	O
receptor	B-FUNC
binding	I-FUNC
proteins	O
that	O
are	O
constituents	O
of	O
viral	O
envelopes	O
or	O
exposed	O
at	O
the	O
surface	O
of	O
non	O
-	O
enveloped	O
viruses	O
.	O

Thus	O
,	O
VP3	O
-	O
CTD	O
is	O
a	O
2	O
',	O
5	O
'-	O
PDE	B-FUNC
able	O
to	O
functionally	O
substitute	O
for	O
ns2	O
in	O
MHV	O
infection	O
.	O

Here	O
we	O
describe	O
a	O
general	O
method	O
to	O
integrate	O
proteinaceous	O
receptors	O
and	O
cellular	O
components	O
into	O
supported	O
bilayers	O
for	O
SPT	B-FUNC
fusion	O
studies	O
.	O

The	O
importance	O
of	O
this	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
ability	O
during	O
infection	O
is	O
,	O
however	O
,	O
quite	O
different	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
this	O
locus	O
,	O
which	O
contains	O
the	O
gene	O
for	O
accessory	O
protein	O
3a	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
encodes	O
a	O
protein	O
that	O
forms	O
ion	B-FUNC
channels	I-FUNC
and	O
regulates	O
virus	O
release	O
.	O

Sera	B-FUNC
from	O
European	O
sheep	O
,	O
goats	O
,	O
cattle	O
,	O
and	O
other	O
camelids	O
had	O
no	O
such	O
antibodies	O
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	B-FUNC
domain	O
as	O
a	O
target	O
for	O
developing	O
SARS	O
vaccines	O
.	O

Based	O
on	O
our	O
previous	O
studies	O
,	O
we	O
believe	O
that	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
in	O
the	O
S1	O
subunit	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
is	O
the	O
most	O
important	O
target	O
for	O
developing	O
a	O
SARS	O
vaccine	O
.	O

By	O
comparing	O
our	O
results	O
with	O
published	O
expression	O
profiling	O
studies	O
in	O
animal	O
models	O
of	O
sepsis	O
and	O
lung	O
injury	O
,	O
we	O
found	O
aquaporin	B-FUNC
-	O
1	O
to	O
be	O
differentially	O
expressed	O
across	O
all	O
studies	O
.	O

The	O
present	O
study	O
describes	O
a	O
dynamic	O
mechanism	O
in	O
which	O
LIM	O
kinase	O
1	O
(	O
LIMK1	O
),	O
a	O
cofilin	O
kinase	O
,	O
and	O
slingshot	O
-	O
1Long	O
(	O
SSH	O
-	O
1L	O
),	O
a	O
cofilin	O
phosphatase	B-FUNC
,	O
are	O
engaged	O
by	O
procoagulant	O
and	O
proinflammatory	O
mediator	O
thrombin	O
to	O
regulate	O
these	O
responses	O
.	O

In	O
contrast	O
,	O
Beaudette	O
spike	O
ectodomain	O
had	O
relatively	O
weak	O
ability	O
to	O
bind	B-FUNC
to	O
chicken	O
trachea	O
,	O
but	O
displayed	O
marked	O
extended	O
host	O
range	O
to	O
mammalian	O
cells	O
.	O

TITLE	O
:	O
Pathogenic	O
mouse	O
hepatitis	O
virus	O
or	O
poly	O
(	O
I	O
:	O
C	O
)	O
induce	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
in	O
hepatocytes	O
in	O
murine	O
models	O
of	O
hepatitis	O
.	O

These	O
results	O
suggest	O
that	O
hepatocyte	O
-	O
specific	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
expression	O
in	O
poly	O
(	O
I	O
:	O
C	O
)	O
induced	O
liver	O
injury	O
was	O
partially	O
dependent	O
of	O
NK	O
cells	O
and	O
with	O
limited	O
role	O
of	O
NKT	O
cells	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
effects	O
of	O
low	O
dietary	O
vitamin	O
A	O
content	O
on	O
antibody	B-FUNC
responses	O
in	O
feedlot	O
calves	O
inoculated	O
with	O
an	O
inactivated	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
vaccine	O
.	O

Sera	B-FUNC
from	O
dromedary	O
camels	O
had	O
a	O
high	O
prevalence	O
of	O
antibody	B-FUNC
reactive	O
to	O
MERS	O
-	O
CoV	O
by	O
MERS	O
NT	O
(	O
93	O
.	O
6	O
%)	O
and	O
MERS	O
ppNT	O
(	O
98	O
.	O
2	O
%)	O
assay	O
.	O

The	O
antibody	B-FUNC
titres	O
ranged	O
up	O
to	O
1	O
,	O
280	O
and	O
higher	O
in	O
MN	O
assays	O
and	O
10	O
,	O
240	O
and	O
higher	O
in	O
ppNT	O
assays	O
.	O

No	O
other	O
investigated	O
species	O
had	O
any	O
antibody	B-FUNC
reactivity	O
to	O
MERS	O
-	O
CoV	O
.	O
While	O
seropositivity	O
does	O
not	O
exclude	O
the	O
possibility	O
of	O
infection	O
with	O
a	O
closely	O
related	O
virus	O
,	O
our	O
data	O
highlight	O
the	O
need	O
to	O
attempt	O
detection	O
of	O
MERSCoV	O
or	O
related	O
coronaviruses	O
in	O
dromedary	O
camels	O
.	O

Mice	O
that	O
were	O
infected	O
with	O
800	O
plaque	O
forming	O
unit	O
(	O
PFU	O
)	O
of	O
CA	O
/	O
07	O
virus	O
rapidly	O
lost	O
weight	O
,	O
which	O
was	O
concurrent	O
with	O
detection	O
of	O
high	O
pulmonary	O
concentrations	O
of	O
MCP	B-FUNC
-	O
1	O
,	O
MIG	O
,	O
IP	O
-	O
10	O
and	O
TIMP	O
-	O
1	O
.	O

ABSTRACT	O
:	O
Following	O
the	O
recognition	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
as	O
the	O
""""	O
endothelium	O
-	O
derived	O
relaxing	O
factor	O
","""	O
an	O
explosion	O
of	O
laboratory	O
and	O
clinical	O
research	O
led	O
to	O
the	O
development	O
of	O
inhaled	O
NO	O
as	O
a	O
potential	O
therapy	O
for	O
patients	O
with	O
pulmonary	O
arterial	O
hypertension	O
(	O
PAH	B-FUNC
).	O

Surprisingly	O
,	O
a	O
polyclonal	O
antibody	B-FUNC
to	O
the	O
S	O
protein	O
of	O
MHV	O
,	O
a	O
group	O
a	O
murine	O
betacoronavirus	O
,	O
cross	O
-	O
reacted	O
in	O
immunoblots	O
with	O
the	O
S2	O
domain	O
of	O
group	O
c	O
MERS	O
-	O
CoV	O
spike	O
protein	O
.	O

Logistic	O
regression	O
showed	O
no	O
association	O
between	O
ACS	B-FUNC
and	O
detection	O
of	O
HRV	O
,	O
hCoV	O
,	O
hBoV	O
,	O
hMPV	O
,	O
and	O
other	O
respiratory	O
pathogens	O
.	O

E2	O
treatment	O
during	O
intestinal	O
ischemia	O
was	O
effective	O
to	O
reduce	O
the	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
IL	O
-	O
1β	O
in	O
explant	O
supernatant	O
,	O
but	O
only	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
levels	O
were	O
reduced	O
by	O
E2	O
at	O
reperfusion	O
phase	O
.	O

The	O
lung	O
wet	O
/	O
dry	O
ratio	O
was	O
measured	O
at	O
4	O
h	O
.	O
The	O
mRNA	O
expression	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)-	O
α	O
,	O
interleukin	O
(	O
IL	O
)-	O
1β	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
in	O
the	O
lung	O
and	O
kidney	O
were	O
measured	O
by	O
TaqMan	O
real	O
-	O
time	O
PCR	O
.	O

Based	O
on	O
the	O
IgG	O
antibody	B-FUNC
positivity	O
of	O
the	O
serum	O
samples	O
,	O
the	O
patient	O
was	O
diagnosed	O
as	O
having	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
in	O
the	O
past	O
.	O

Here	O
we	O
show	O
the	O
resistance	O
of	O
ferrets	O
to	O
MERS	O
-	O
CoV	O
infection	O
and	O
inability	O
of	O
ferret	O
DDP4	O
to	O
bind	B-FUNC
MERS	O
-	O
CoV	O
.	O
Site	O
-	O
directed	O
mutagenesis	O
of	O
amino	O
acids	O
variable	O
in	O
ferret	O
DPP4	O
thus	O
revealed	O
the	O
functional	O
human	O
DPP4	O
virus	O
binding	B-FUNC
site	O
.	O

Adenosine	O
deaminase	O
(	O
ADA	B-FUNC
),	O
a	O
DPP4	O
binding	B-FUNC
protein	O
,	O
competed	O
for	O
virus	O
binding	B-FUNC
,	O
acting	O
as	O
a	O
natural	O
antagonist	O
for	O
MERS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
α	O
(	O
TNF	O
-	O
α	O
)	O
receptor	O
-	O
I	O
is	O
required	O
for	O
TNF	O
-	O
α	O
-	O
mediated	O
fulminant	O
virus	O
hepatitis	O
caused	O
by	O
murine	O
hepatitis	O
virus	O
strain	O
-	O
3	O
infection	O
.	O

TITLE	O
:	O
Adjuvant	O
effects	O
of	O
mannose	O
-	O
binding	B-FUNC
lectin	O
ligands	O
on	O
the	O
immune	O
response	O
to	O
infectious	O
bronchitis	O
vaccine	O
in	O
chickens	O
with	O
high	O
or	O
low	O
serum	O
mannose	O
-	O
binding	B-FUNC
lectin	O
concentrations	O
.	O

ABSTRACT	O
:	O
Mannose	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
)	O
plays	O
a	O
major	O
role	O
in	O
the	O
immune	O
response	O
as	O
a	O
soluble	O
pattern	O
-	O
recognition	O
receptor	O
.	O

The	O
addition	O
of	O
MBL	O
ligands	O
to	O
the	O
IBV	O
vaccine	O
,	O
especially	O
FOS	O
,	O
enhanced	O
the	O
production	O
of	O
IBV	O
-	O
specific	O
IgG	O
antibody	B-FUNC
production	O
in	O
L10H	O
chickens	O
,	O
but	O
not	O
L10L	O
chickens	O
after	O
the	O
second	O
vaccination	O
.	O

In	O
this	O
study	O
we	O
identified	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
of	O
the	O
prototype	O
IBV	O
strain	O
M41	O
.	O

TITLE	O
:	O
Vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
in	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
Cytokine	O
levels	O
(	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
TGFβ	O
)	O
as	O
potential	O
biomarkers	O
of	O
systemic	O
inflammatory	O
response	O
in	O
trauma	O
patients	O
.	O

Levels	O
of	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
were	O
significantly	O
lower	O
in	O
the	O
injured	O
groups	O
as	O
compared	O
to	O
the	O
controls	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
evaluate	O
the	O
salivary	O
interleukin	O
(	O
IL	O
)-	O
1β	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
21	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
,	O
and	O
pentraxin	O
-	O
3	O
(	O
PTX3	O
)	O
concentrations	O
in	O
patients	O
with	O
and	O
without	O
OSAS	O
.	O

IL	O
-	O
1β	O
,	O
IL	B-FUNC
-	I-FUNC
21	I-FUNC
,	O
and	O
PTX3	O
concentrations	O
were	O
similar	O
in	O
the	O
study	O
groups	O
.	O

Scavenging	O
of	O
superoxide	O
by	O
pretreating	O
the	O
DKO	O
mice	O
with	O
MnTMPYP	O
(	O
a	O
superoxide	O
dismutase	O
mimetic	O
)	O
restored	O
the	O
inflammatory	O
responses	O
to	O
LPS	O
challenge	O
including	O
reduced	O
lung	O
myeloperoxidase	B-FUNC
activity	I-FUNC
and	O
vascular	O
permeability	O
.	O

TITLE	O
:	O
Lipid	O
charge	O
regulation	O
of	O
non	O
-	O
specific	O
biological	O
ion	B-FUNC
channels	I-FUNC
.	O

ABSTRACT	O
:	O
Ion	B-FUNC
channels	I-FUNC
are	O
specialized	O
proteins	O
that	O
enable	O
the	O
movement	O
of	O
charges	O
through	O
otherwise	O
impermeable	O
lipidic	O
membranes	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
antibody	B-FUNC
reactors	O
among	O
camels	O
in	O
Dubai	O
,	O
United	O
Arab	O
Emirates	O
,	O
in	O
2005	O
.	O

MSCs	B-FUNC
may	O
be	O
able	O
to	O
""""	O
reprogramme	O
""""	O
the	O
immune	O
response	O
to	O
reduce	O
destructive	O
inflammatory	O
elements	O
while	O
preserving	O
the	O
host	O
response	O
to	O
pathogens	O
.	O

To	O
probe	O
the	O
functions	O
of	O
these	O
domains	O
in	O
the	O
N	O
protein	O
of	O
the	O
model	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
we	O
constructed	O
mutants	O
in	O
which	O
each	O
RNA	O
-	O
binding	B-FUNC
domain	O
was	O
replaced	O
by	O
its	O
counterpart	O
from	O
the	O
N	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
Coronaviruses	O
encode	O
papain	O
-	O
like	O
proteases	O
(	O
PLpro	O
)	O
that	O
are	O
often	O
multifunctional	O
enzymes	O
with	O
protease	B-FUNC
activity	I-FUNC
to	O
process	O
the	O
viral	O
replicase	O
polyprotein	O
and	O
deubiquitinating	O
(	O
DUB	O
)/	O
deISGylating	O
activity	O
,	O
which	O
is	O
hypothesized	O
to	O
modify	O
the	O
innate	O
immune	O
response	O
to	O
infection	O
.	O

During	O
evolution	O
coronaviruses	O
have	O
developed	O
a	O
large	O
diversity	O
of	O
binding	B-FUNC
specificities	O
demonstrating	O
the	O
high	O
flexibility	O
of	O
the	O
coronaviral	O
spike	O
protein	O
,	O
which	O
is	O
responsible	O
for	O
binding	B-FUNC
to	O
target	O
cells	O
.	O

MERS	O
-	O
CoV	O
4a	O
protein	O
contains	O
a	O
double	O
-	O
stranded	O
RNA	O
-	O
binding	B-FUNC
domain	O
capable	O
of	O
interacting	O
with	O
poly	O
(	O
I	O
·	O
C	O
).	O

TITLE	O
:	O
Screening	O
and	O
identification	O
of	O
T	O
helper	O
1	O
and	O
linear	O
immunodominant	O
antibody	B-FUNC
-	O
binding	B-FUNC
epitopes	O
in	O
spike	O
1	O
domain	O
and	O
membrane	O
protein	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
.	O

The	O
development	O
of	O
an	O
FIP	O
-	O
preventive	O
vaccine	O
requires	O
an	O
antigen	O
that	O
does	O
not	O
induce	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
,	O
and	O
T	O
helper	O
(	O
Th	O
)	O
1	O
activity	O
plays	O
an	O
important	O
role	O
in	O
protect	O
against	O
FIPV	O
infection	O
.	O

This	O
response	O
is	O
mediated	O
by	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
IFNγ	O
that	O
decreases	O
viral	O
clearance	O
;	O
levels	O
of	O
both	O
of	O
these	O
mediators	O
were	O
decreased	O
in	O
patient	O
1	O
.	O

A	O
M	O
.	O
suis	O
-	O
expression	O
library	O
was	O
screened	O
for	O
immunogens	O
using	O
sera	B-FUNC
from	O
infected	O
pigs	O
.	O

Assay	O
specificity	O
was	O
tested	O
using	O
sera	B-FUNC
from	O
pigs	O
seropositive	O
for	O
other	O
pathogens	O
(	O
2	O
different	O
pigs	O
seropositive	O
for	O
each	O
pathogen	O
).	O

Treatment	O
consists	O
of	O
rest	B-FUNC
,	O
analgesics	O
,	O
rigorous	O
glycemic	O
control	O
and	O
low	O
-	O
dose	O
aspirin	O
.	O

The	O
resultant	O
cDNAs	O
were	O
amplified	O
by	O
primer	O
-	O
specific	O
PCR	O
,	O
pooled	O
,	O
size	O
fractionated	O
and	O
sequenced	O
on	O
the	O
Ion	O
Torrent	O
PGM	B-FUNC
platform	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
provide	O
evidence	O
that	O
mouse	O
susceptibility	O
to	O
MHV	O
-	O
3	O
-	O
induced	O
FH	O
may	O
rely	O
on	O
C5a	O
/	O
C5aR	O
interactions	O
,	O
for	O
which	O
ERK1	B-FUNC
/	O
2	O
and	O
p38	B-FUNC
pathways	O
participate	O
in	O
up	O
-	O
regulating	O
Fgl2	O
expression	O
.	O

Our	O
findings	O
showed	O
that	O
both	O
mucosal	O
compartments	O
harbor	O
similar	O
percentages	O
of	O
memory	O
CD4	O
(+)	O
T	O
cells	O
and	O
displayed	O
comparable	O
cytokine	O
(	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
IFN	O
-	O
γ	O
,	O
and	O
TNF	O
-	O
α	O
)	O
responses	O
to	O
mitogenic	O
stimulations	O
prior	O
to	O
infection	O
.	O

Nasopharyngeal	O
samples	O
were	O
collected	O
from	O
5235	O
adult	O
pilgrims	O
from	O
22	O
countries	O
and	O
screened	O
for	O
MERS	O
-	O
CoV	O
using	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
.	O

Macrophages	O
in	O
chronic	O
lesions	O
of	O
antibody	B-FUNC
-	O
mediated	O
demyelinating	O
encephalomyelitis	O
showed	O
lysosomal	O
activity	O
but	O
very	O
little	O
p22phox	O
or	O
iNOS	O
expressions	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
Fast	B-FUNC
Technology	O
Analysis	O
(	O
FTA	O
)	O
Cards	O
as	O
an	O
improved	O
method	O
for	O
specimen	O
collection	O
and	O
shipment	O
targeting	O
viruses	O
associated	O
with	O
Bovine	O
Respiratory	O
Disease	O
Complex	O
.	O

We	O
highlight	O
challenges	O
and	O
potential	O
pitfalls	O
that	O
occur	O
when	O
dealing	O
with	O
a	O
novel	O
emerging	O
coronavirus	O
like	O
MERS	O
-	O
CoV	O
.	O
In	O
addition	O
we	O
describe	O
problems	O
that	O
might	O
occur	O
when	O
animal	O
sera	B-FUNC
are	O
tested	O
in	O
serological	O
assays	O
for	O
the	O
identification	O
of	O
putative	O
reservoirs	O
.	O

Finally	O
,	O
in	O
the	O
Znhigh	O
group	O
,	O
we	O
documented	O
an	O
earlier	O
and	O
higher	O
systemic	O
TGEV	O
-	O
specific	O
serum	O
antibody	B-FUNC
response	O
.	O

Network	O
analyses	O
demonstrated	O
strongly	O
polarized	O
clusters	O
of	O
immune	O
regulatory	O
(	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
,	O
TGF	O
-	O
β	O
,	O
FOXP3	O
,	O
GATA3	O
,	O
RORC2	O
,	O
Tbet	O
)	O
and	O
antiviral	O
(	O
IFN	O
-	O
α	O
,	O
IFN	O
-	O
β	O
,	O
IL	B-FUNC
-	I-FUNC
28	I-FUNC
,	O
IL	O
-	O
29	O
)	O
genes	O
.	O

We	O
report	O
a	O
case	O
of	O
multiple	O
drug	O
poisoning	O
:	O
ACE	O
inhibitor	O
(	O
ACE	O
-	O
I	O
),	O
beta	O
-	O
blockers	O
and	O
calcium	B-FUNC
channel	I-FUNC
blockers	O
.	O

The	O
rapid	O
test	O
was	O
used	O
for	O
detection	O
of	O
influenza	O
virus	O
(	O
Kit	B-FUNC
Biotrin	O
,	O
Inc	O
.	O
Ireland	O
),	O
and	O
real	O
-	O
time	O
multiplex	O
polymerase	O
chain	O
reaction	O
(	O
FTD	O
,	O
Respiratory	O
pathogens	O
,	O
multiplex	O
Fast	B-FUNC
Trade	O
Kit	B-FUNC
,	O
Malta	O
)	O
for	O
detection	O
of	O
influenza	O
virus	O
(	O
H1N1	O
,	O
B	O
),	O
rhinovirus	O
,	O
parainfluenza	O
virus	O
,	O
adenovirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
parechovirus	O
,	O
bocavirus	O
,	O
metapneumovirus	O
,	O
and	O
human	O
coronavirus	O
.	O

Furthermore	O
,	O
alanine	O
scanning	O
of	O
the	O
RBD	O
has	O
identified	O
several	O
residues	O
at	O
the	O
DPP4	O
-	O
binding	B-FUNC
surface	O
that	O
serve	O
as	O
neutralizing	O
epitopes	O
for	O
Mersmab1	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
improve	O
the	O
availability	O
of	O
existing	O
nucleic	O
acid	O
amplification	O
-	O
based	O
diagnostic	O
methods	O
for	O
MERS	O
-	O
CoV	O
infections	O
by	O
providing	O
a	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
kit	B-FUNC
,	O
including	O
an	O
internal	O
control	O
and	O
two	O
target	O
regions	O
recommended	O
by	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
).	O

Lung	O
and	O
blood	O
bacterial	O
burden	O
was	O
not	O
affected	O
by	O
MV	O
pneumonia	O
and	O
MV	O
increased	O
lung	O
AM	O
expression	O
,	O
whereas	O
receptor	B-FUNC
activity	I-FUNC
modifying	O
protein	O
(	O
RAMP	O
)	O
1	O
-	O
3	O
expression	O
was	O
increased	O
in	O
pneumonia	O
and	O
reduced	O
by	O
MV	O
.	O

The	O
spike	O
glycoprotein	O
is	O
the	O
major	O
immunodominant	O
antigen	O
of	O
coronaviruses	O
and	O
has	O
proven	O
to	O
be	O
an	O
excellent	O
target	O
for	O
vaccine	O
designs	O
that	O
seek	O
to	O
block	O
coronavirus	O
entry	O
and	O
promote	O
antibody	B-FUNC
targeting	O
of	O
infected	O
cells	O
.	O

We	O
compared	O
dynamics	O
of	O
vaccine	O
viral	O
subpopulations	O
,	O
viral	O
loads	O
,	O
persistence	O
in	O
trachea	O
and	O
cloaca	O
,	O
and	O
the	O
magnitude	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
1BV	O
)-	O
specific	O
antibody	B-FUNC
induction	O
after	O
vaccination	O
with	O
two	O
commercial	O
ArkDPI	O
-	O
derived	O
Arkansas	O
(	O
Ark	O
)	O
serotype	O
vaccines	O
.	O

Thus	O
we	O
found	O
differences	O
in	O
mucosal	O
antibody	B-FUNC
induction	O
and	O
selection	O
and	O
persistence	O
of	O
vaccine	O
viruses	O
between	O
two	O
ArkDPI	O
-	O
derived	O
vaccines	O
from	O
different	O
manufacturers	O
.	O

Tissue	O
and	O
faecal	O
samples	O
collected	O
post	O
mortem	O
from	O
cats	O
diagnosed	O
with	O
or	O
without	O
FIP	O
were	O
subjected	O
to	O
RNA	O
extraction	O
and	O
quantitative	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
to	O
detect	O
FCoV	O
RNA	O
.	O

However	O
,	O
their	O
fatal	O
outcomes	O
and	O
critically	O
severe	O
illness	O
were	O
significantly	O
associated	O
with	O
high	O
serum	O
levels	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)-	O
α	O
.	O

However	O
,	O
neutralizing	O
antibody	B-FUNC
titers	O
and	O
the	O
memory	O
B	O
cell	O
response	O
are	O
short	O
lived	O
in	O
SARS	O
-	O
recovered	O
patients	O
and	O
the	O
antibody	B-FUNC
will	O
target	O
primary	O
homologous	O
strain	O
.	O

TITLE	O
:	O
Friday	O
night	O
ventilation	O
:	O
a	O
safety	O
starting	O
tool	O
kit	B-FUNC
for	O
mechanically	O
ventilated	O
patients	O
.	O

Here	O
,	O
we	O
identify	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
as	O
a	O
novel	O
PEDV	O
-	O
encoded	O
interferon	O
(	O
IFN	O
)	O
antagonist	O
and	O
demonstrate	O
that	O
N	O
protein	O
antagonizes	O
IFN	O
production	O
by	O
sequestering	O
the	O
interaction	O
between	O
IRF3	O
and	O
TBK1	B-FUNC
,	O
a	O
critical	O
step	O
in	O
type	O
I	O
IFN	O
signaling	O
.	O

ABSTRACT	O
:	O
Activin	B-FUNC
A	O
and	O
its	O
binding	B-FUNC
protein	O
follistatin	O
(	O
FS	O
)	O
are	O
increased	O
in	O
inflammatory	O
disorders	O
and	O
sepsis	O
.	O

Peak	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
were	O
significantly	O
elevated	O
in	O
ALI	O
/	O
ARDS	O
patients	O
.	O

Antibody	B-FUNC
-	O
mediated	O
infection	O
was	O
dependent	O
on	O
signaling	O
-	O
competent	O
members	O
of	O
the	O
human	O
FcγRII	O
family	O
,	O
which	O
were	O
shown	O
to	O
confer	O
susceptibility	O
to	O
otherwise	O
naïve	O
ST486	O
cells	O
,	O
as	O
binding	B-FUNC
of	O
immune	O
complexes	O
to	O
cell	O
surface	O
FcγRII	O
was	O
necessary	O
but	O
not	O
sufficient	O
to	O
trigger	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
infection	O
.	O

Human	O
MSCs	B-FUNC
were	O
well	O
tolerated	O
and	O
improved	O
oxygenation	O
and	O
decreased	O
pulmonary	O
oedema	O
in	O
a	O
sheep	O
model	O
of	O
severe	O
ARDS	O
.	O

Clinical	O
data	O
and	O
laboratory	O
findings	O
including	O
autoantibodies	O
,	O
immunoglobulin	B-FUNC
levels	O
as	O
well	O
as	O
number	O
of	O
T	O
,	O
B	O
and	O
NK	O
cells	O
were	O
evaluated	O
.	O

Pro	O
-	O
inflammatory	O
cytokines	O
,	O
interleukin	O
(	O
IL	O
)-	O
1β	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)-	O
α	O
,	O
were	O
also	O
increased	O
significantly	O
at	O
72	O
h	O
post	O
-	O
infection	O
.	O

Oseltamivir	O
,	O
anti	O
-	O
infective	O
drugs	O
,	O
methylprednisolone	O
,	O
albumin	O
,	O
and	O
intravenous	O
immunoglobulin	B-FUNC
were	O
administered	O
.	O

For	O
FCoV	O
screening	O
,	O
speed	O
and	O
sensitivity	O
are	O
important	O
,	O
and	O
for	O
FCoV	O
elimination	O
antibody	B-FUNC
titre	O
is	O
essential	O
.	O

The	O
majority	O
of	O
these	O
centers	O
(	O
77	O
%)	O
reported	O
""""	O
lung	O
rest	B-FUNC
""""	O
to	O
be	O
the	O
primary	O
goal	O
of	O
mechanical	O
ventilation	O
,	O
whereas	O
9	O
%	O
reported	O
""""	O
lung	O
recruitment	O
""""	O
to	O
be	O
their	O
ventilation	O
strategy	O
.	O

The	O
molecule	O
consists	O
of	O
a	O
ubiquitin	B-FUNC
-	O
like	O
domain	O
and	O
a	O
catalytic	O
core	O
domain	O
.	O

The	O
catalytic	O
domain	O
displays	O
an	O
extended	O
right	O
-	O
hand	O
fold	O
with	O
a	O
zinc	O
ribbon	O
and	O
embraces	O
a	O
solvent	O
-	O
exposed	O
substrate	O
-	O
binding	B-FUNC
region	O
.	O

Diagnosis	O
was	O
confirmed	O
by	O
a	O
microscopic	O
agglutination	O
test	O
(	O
MAT	B-FUNC
)	O
covering	O
15	O
leptospira	O
serovars	O
and	O
real	O
-	O
time	O
polymerase	O
-	O
chain	O
reaction	O
(	O
PCR	O
).	O

RESULTS	O
:	O
Our	O
results	O
showed	O
that	O
the	O
specificity	O
(	O
100	O
%)	O
and	O
the	O
positive	O
predictive	O
value	O
(	O
100	O
%)	O
of	O
the	O
CLART	O
Pneumovir	O
kit	B-FUNC
were	O
high	O
,	O
but	O
its	O
sensitivity	O
(	O
53	O
%),	O
its	O
negative	O
predictive	O
value	O
(	O
64	O
%),	O
and	O
its	O
kappa	O
value	O
(	O
50	O
%)	O
were	O
low	O
.	O

S	O
protein	O
containing	O
the	O
substitution	O
of	O
D1128	O
with	O
alanine	O
(	O
D1128A	O
)	O
exhibited	O
a	O
significant	O
decrease	O
in	O
binding	B-FUNC
capability	O
to	O
mAb	O
1A9	O
compared	O
to	O
wild	O
-	O
type	O
S	O
protein	O
.	O

TITLE	O
:	O
Immunoglobulin	B-FUNC
A	O
as	O
an	O
early	O
humoral	O
responder	O
after	O
mucosal	O
avian	O
coronavirus	O
vaccination	O
.	O

Upon	O
challenge	O
with	O
a	O
lethal	O
dose	O
of	O
SARS	O
-	O
CoV	O
,	O
virus	O
-	O
specific	O
memory	O
CD8	O
T	O
cells	O
efficiently	O
produced	O
multiple	O
effector	O
cytokines	O
(	O
gamma	O
interferon	O
[	O
IFN	O
-	O
γ	O
],	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
[	O
TNF	O
-	O
α	O
],	O
and	O
interleukin	O
2	O
[	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
])	O
and	O
cytolytic	O
molecules	O
(	O
granzyme	O
B	O
)	O
and	O
reduced	O
lung	O
viral	O
loads	O
.	O

The	O
JIA	O
patients	O
showed	O
significantly	O
lower	O
HPV16	O
neutralising	O
antibody	B-FUNC
titres	O
than	O
controls	O
1	O
month	O
after	O
the	O
administration	O
of	O
the	O
third	O
dose	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
whereas	O
no	O
significant	O
difference	O
was	O
observed	O
in	O
HPV18	O
neutralising	O
antibody	B-FUNC
titres	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
-	O
dependent	O
SARS	O
coronavirus	O
infection	O
is	O
mediated	O
by	O
antibodies	O
against	O
spike	O
proteins	O
.	O

Quantitative	O
-	O
PCR	O
and	O
immunofluorescence	O
staining	O
results	O
indicate	O
that	O
SARS	O
-	O
CoV	O
is	O
capable	O
of	O
replication	O
in	O
HL	O
-	O
CZ	O
cells	O
,	O
and	O
of	O
displaying	O
virus	O
-	O
induced	O
cytopathic	O
effects	O
and	O
increased	O
levels	O
of	O
TNF	O
-	O
α	O
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
two	O
days	O
post	O
-	O
infection	O
.	O

Therefore	O
,	O
the	O
E	O
protein	O
PBM	O
is	O
a	O
virulence	O
domain	O
that	O
activates	O
immunopathology	O
most	O
likely	O
by	O
using	O
syntenin	O
as	O
a	O
mediator	O
of	O
p38	B-FUNC
MAPK	B-FUNC
induced	O
inflammation	O
.	O

ABSTRACT	O
:	O
Reduced	O
levels	O
of	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
Rett	O
syndrome	O
(	O
RTT	O
),	O
a	O
severe	O
neurodevelopmental	O
disorder	O
caused	O
by	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
gene	O
encoding	O
methyl	O
-	O
CpG	O
-	O
binding	B-FUNC
protein	O
2	O
(	O
MeCP2	O
).	O

Finally	O
,	O
the	O
PEDV	O
and	O
TGEV	O
infection	O
affected	O
the	O
MAPK	B-FUNC
pathway	O
,	O
and	O
inhibition	O
of	O
MAPK	B-FUNC
pathway	O
regulated	O
the	O
changes	O
of	O
tight	O
junctions	O
and	O
microfilaments	O
of	O
cells	O
.	O

The	O
epitope	O
was	O
further	O
tested	O
for	O
binding	B-FUNC
against	O
the	O
HLA	O
molecules	O
,	O
using	O
in	O
silico	O
docking	O
techniques	O
,	O
to	O
verify	O
the	O
binding	B-FUNC
cleft	O
epitope	O
interaction	O
.	O

A	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
in	O
the	O
MERS	O
-	O
CoV	O
envelope	O
-	O
embedded	O
spike	O
protein	O
specifically	O
engages	O
human	O
CD26	O
(	O
hCD26	O
)	O
to	O
initiate	O
viral	O
entry	O
.	O

Interleukin	O
-	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
),	O
as	O
a	O
proinflammatory	O
mediator	O
causing	O
recruitment	O
of	O
inflammatory	O
cells	O
,	O
induces	O
an	O
increase	O
in	O
oxidant	O
stress	O
mediators	O
and	O
makes	O
it	O
as	O
a	O
key	O
parameter	O
for	O
localized	O
inflammation	O
.	O

The	O
concentrations	O
of	O
plasma	O
vWF	O
and	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
were	O
significantly	O
increased	O
in	O
all	O
severe	O
pulmonary	O
contusion	O
patients	O
at	O
all	O
time	O
points	O
in	O
comparison	O
with	O
the	O
control	O
group	O
.	O

Interestingly	O
,	O
both	O
plasma	O
vWF	O
and	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
levels	O
steadily	O
increased	O
in	O
the	O
non	O
-	O
survivor	O
group	O
.	O

CONCLUSIONS	O
:	O
The	O
elevated	O
levels	O
of	O
plasma	O
vWF	O
and	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
severe	O
pulmonary	O
contusion	O
patients	O
reflect	O
the	O
severity	O
of	O
pulmonary	O
injury	O
and	O
patients	O
outcomes	O
,	O
suggesting	O
that	O
the	O
plasma	O
vWF	O
and	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
are	O
sensitive	O
markers	O
for	O
clinical	O
evaluation	O
of	O
the	O
severity	O
of	O
pulmonary	O
injury	O
and	O
predication	O
of	O
patient	O
prognosis	O
.	O

TITLE	O
:	O
The	O
Antibody	B-FUNC
Germline	O
/	O
Maturation	O
Hypothesis	O
,	O
Elicitation	O
of	O
Broadly	O
Neutralizing	O
Antibodies	O
Against	O
HIV	O
-	O
1	O
and	O
Cord	O
Blood	O
IgM	O
Repertoires	O
.	O

We	O
provided	O
the	O
initial	O
evidence	O
supporting	O
this	O
antibody	B-FUNC
germline	O
/	O
maturation	O
hypothesis	O
,	O
which	O
prompted	O
a	O
number	O
of	O
studies	O
to	O
design	O
vaccine	O
immunogens	O
that	O
could	O
bind	B-FUNC
putative	O
germline	O
predecessors	O
of	O
known	O
bnAbs	O
and	O
to	O
explore	O
complex	O
B	O
cell	O
lineages	O
.	O

Significant	O
improvement	O
was	O
observed	O
in	O
HR	O
,	O
MAP	O
,	O
PaO2	O
/	O
FiO2	O
,	O
total	O
bilirubin	O
(	O
TBIL	O
)	O
and	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
levels	O
after	O
treatment	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

RESULTS	O
:	O
Significant	O
improvement	O
was	O
observed	O
in	O
HR	O
,	O
MAP	O
,	O
PaO2	O
/	O
FiO2	O
,	O
total	O
bilirubin	O
(	O
TBIL	O
)	O
and	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
levels	O
after	O
treatment	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Our	O
results	O
suggest	O
that	O
targeting	O
conserved	O
regions	O
with	O
less	O
plasticity	O
and	O
more	O
structural	O
constraint	O
rather	O
than	O
the	O
SARS	O
-	O
CoV	O
RBD	O
-	O
like	O
region	O
(	O
s	O
)	O
should	O
have	O
broader	O
utility	O
for	O
antibody	B-FUNC
-	O
based	O
immunotherapy	O
.	O

Structural	O
analysis	O
suggests	O
that	O
S377	O
-	O
588	O
-	O
Fc	O
contains	O
the	O
stably	O
folded	O
RBD	O
structure	O
,	O
the	O
full	O
receptor	O
-	O
binding	B-FUNC
site	O
,	O
and	O
major	O
neutralizing	O
epitopes	O
,	O
such	O
that	O
additional	O
structures	O
to	O
this	O
fragment	O
introduce	O
non	O
-	O
neutralizing	O
epitopes	O
and	O
may	O
also	O
alter	O
the	O
tertiary	O
structure	O
of	O
the	O
RBD	O
.	O

Leucocyte	O
and	O
lymphocyte	O
subsets	O
,	O
antibody	B-FUNC
titers	O
,	O
α1	O
-	O
acid	O
glycoprotein	O
(	O
AGP	O
),	O
globulin	O
fractions	O
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
IFN	O
-	O
γ	O
in	O
blood	O
and	O
fecal	O
FCoV	O
excretion	O
were	O
determined	O
in	O
HB	O
(	O
n	O
=	O
75	O
)	O
and	O
in	O
cats	O
from	O
other	O
breeds	O
(	O
n	O
=	O
94	O
).	O

This	O
interaction	O
disrupted	O
the	O
association	O
between	O
PDK1	B-FUNC
and	O
PKB	O
/	O
Akt	O
,	O
and	O
led	O
to	O
down	O
-	O
regulation	O
of	O
PKB	O
/	O
Akt	O
activity	O
.	O

Several	O
subgenomic	O
mRNAs	O
(	O
sgmRNAs	O
)	O
encoding	O
structural	O
proteins	O
are	O
generated	O
by	O
template	O
switching	O
from	O
the	O
body	O
transcription	O
regulatory	O
sequence	O
(	O
TRS	B-FUNC
)	O
to	O
the	O
leader	O
TRS	B-FUNC
.	O

Maximum	O
enrolled	O
children	O
were	O
of	O
viral	O
encephalitis	O
(	O
46	O
.	O
59	O
%)	O
and	O
rest	B-FUNC
,	O
were	O
of	O
pyogenic	O
meningitis	O
,	O
tuberculosis	O
meningitis	O
and	O
cerebral	O
malaria	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
indirect	O
immunofluorescence	O
antibody	B-FUNC
test	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
the	O
diagnosis	O
of	O
infection	O
by	O
Leishmania	O
infantum	O
in	O
clinically	O
normal	O
and	O
sick	O
cats	O
.	O

CONCLUSIONS	O
:	O
Serious	O
community	O
-	O
based	O
infectious	O
diseases	O
are	O
a	O
personal	O
concern	O
for	O
GPs	O
and	O
FPs	B-FUNC
,	O
and	O
have	O
considerable	O
effects	O
on	O
their	O
clinical	O
practice	O
.	O

Three	O
young	O
consecutive	O
patients	O
with	O
homozygous	O
sickle	O
cell	O
disease	O
were	O
admitted	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
due	O
to	O
ACS	B-FUNC
.	O

The	O
yellowish	O
coloration	O
of	O
tracheal	O
secretions	O
and	O
BALF	O
observed	O
during	O
ACS	B-FUNC
appears	O
to	O
be	O
related	O
to	O
an	O
intense	O
exudative	O
process	O
rather	O
than	O
to	O
the	O
presence	O
of	O
bilirubin	O
.	O

Changes	O
in	O
the	O
expression	O
levels	O
of	O
transforming	B-FUNC
growth	I-FUNC
factor	I-FUNC
beta	I-FUNC
1	O
(	O
TGF	O
-	O
β1	O
),	O
caspase	O
-	O
8	O
,	O
and	O
heat	O
shock	O
protein	O
90	O
alpha	O
(	O
HSP90α	O
)	O
were	O
also	O
verified	O
by	O
western	O
blot	O
analysis	O
.	O

ABSTRACT	O
:	O
Chickens	O
from	O
two	O
inbred	O
lines	O
selected	O
for	O
high	O
(	O
L10H	O
)	O
or	O
low	O
(	O
L10L	O
)	O
mannose	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
)	O
serum	O
concentrations	O
were	O
infected	O
with	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
and	O
innate	O
as	O
well	O
as	O
adaptive	O
immunological	O
parameters	O
were	O
measured	O
throughout	O
the	O
experimental	O
period	O
.	O

Indeed	O
,	O
we	O
demonstrate	O
here	O
that	O
iminosugar	O
treatment	O
altered	O
the	O
N	O
-	O
linked	O
glycan	O
structure	O
of	O
angiotensin	O
I	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
which	O
did	O
not	O
affect	O
its	O
expression	O
on	O
the	O
cell	O
surface	O
or	O
its	O
binding	B-FUNC
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
glycoprotein	O
.	O

Quantifying	O
the	O
similarities	O
between	O
bacterial	O
populations	O
by	O
using	O
Fast	B-FUNC
UniFrac	O
analysis	O
indicated	O
that	O
bacterial	O
profiles	O
were	O
apparently	O
divisible	O
into	O
6	O
oropharyngeal	O
types	O
in	O
the	O
tested	O
subjects	O
.	O

Evaluation	O
of	O
the	O
antibody	B-FUNC
response	O
of	O
two	O
types	O
of	O
PEDV	O
vaccines	O
is	O
to	O
be	O
carried	O
out	O
.	O

1	O
.	O
22	O
(	O
0	O
.	O
61	O
,	O
1	O
.	O
52	O
),	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
(	O
ng	O
/	O
L	O
):	O
56	O
.	O
50	O
(	O
27	O
.	O
15	O
,	O
139	O
.	O
90	O
)	O
vs	O
.	O

Factors	O
,	O
APACHEII	O
score	O
,	O
LIS	B-FUNC
score	O
,	O
PaO2	O
/	O
FiO2	O
,	O
Ang	O
-	O
2	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
founded	O
statistical	O
significance	O
in	O
univariate	O
analysis	O
were	O
analyzed	O
using	O
multivariable	O
logistic	O
regression	O
.	O

Plasma	O
levels	O
of	O
Ang	O
-	O
2	O
was	O
better	O
in	O
predicting	O
ARDS	O
than	O
APACHEII	O
score	O
,	O
SOFA	O
score	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
.	O

The	O
antibody	B-FUNC
profiling	O
data	O
presented	O
the	O
correlation	O
of	O
neutralizing	O
activity	O
with	O
the	O
level	O
of	O
spike	O
protein	O
antibody	B-FUNC
.	O

A	O
.	O
fumigatus	O
was	O
later	O
cultured	O
and	O
detected	O
on	O
antibody	B-FUNC
testing	O
.	O

This	O
review	O
will	O
give	O
an	O
overview	O
of	O
the	O
literature	O
on	O
avian	O
coronavirus	O
spike	O
proteins	O
with	O
particular	O
focus	O
on	O
our	O
recent	O
studies	O
on	O
binding	B-FUNC
of	O
recombinant	O
soluble	O
spike	O
protein	O
to	O
chicken	O
tissues	O
.	O

Receptor	O
-	O
binding	B-FUNC
domains	O
(	O
RBD	O
)	O
have	O
been	O
identified	O
in	O
the	O
S	O
of	O
diverse	O
CoV	O
;	O
they	O
usually	O
contain	O
antigenic	O
determinants	O
targeted	O
by	O
antibodies	O
that	O
neutralize	O
CoV	O
infections	O
.	O

TITLE	O
:	O
Identification	O
of	O
residues	O
on	O
human	O
receptor	O
DPP4	O
critical	O
for	O
MERS	O
-	O
CoV	O
binding	B-FUNC
and	O
entry	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infects	O
host	O
cells	O
through	O
binding	B-FUNC
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
on	O
its	O
spike	O
glycoprotein	O
to	O
human	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
hDPP4	O
).	O

FP	O
assumes	O
α	O
-	O
helical	O
conformation	O
with	O
significant	O
distortion	O
at	O
the	O
central	O
Gly	O
residues	O
;	O
enabling	O
a	O
close	O
packing	O
among	O
sidechains	O
of	O
aromatic	O
residues	O
including	O
W	O
,	O
Y	O
and	O
F	O
.	O
The	O
3	O
-	O
D	O
structure	O
of	O
PMT	B-FUNC
is	O
characterized	O
by	O
a	O
helix	O
-	O
loop	O
-	O
helix	O
with	O
extensive	O
aromatic	O
interactions	O
within	O
the	O
helices	O
.	O

Paramagnetic	O
spin	O
labeled	O
NMR	O
has	O
demonstrated	O
surface	O
localization	O
of	O
PMT	B-FUNC
whereas	O
FP	O
and	O
IFP	O
inserted	O
into	O
the	O
micelles	O
.	O

bioinformatics	O
analysis	O
of	O
our	O
kinome	O
data	O
,	O
including	O
pathway	O
overrepresentation	O
analysis	O
(	O
ORA	O
)	O
and	O
functional	O
network	O
analysis	O
,	O
suggested	O
that	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	B-FUNC
)/	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
)	O
and	O
phosphoinositol	O
3	O
-	O
kinase	O
(	O
PI3K	B-FUNC
)/	O
serine	O
-	O
threonine	O
kinase	O
(	O
AKT	O
)/	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
signaling	O
responses	O
were	O
specifically	O
modulated	O
in	O
response	O
to	O
MERS	O
-	O
CoV	O
infection	O
in	O
vitro	O
throughout	O
the	O
course	O
of	O
infection	O
.	O

Further	O
,	O
we	O
have	O
demonstrated	O
that	O
a	O
subset	O
of	O
licensed	O
kinase	B-FUNC
inhibitors	I-FUNC
targeting	O
the	O
ERK	B-FUNC
/	O
MAPK	B-FUNC
and	O
PI3K	B-FUNC
/	O
AKT	O
/	O
mTOR	O
pathways	O
significantly	O
inhibited	O
MERS	O
-	O
CoV	O
replication	O
in	O
vitro	O
whether	O
they	O
were	O
added	O
before	O
or	O
after	O
viral	O
infection	O
.	O

While	O
all	O
vaccines	O
protected	O
against	O
lethal	O
infection	O
,	O
addition	O
of	O
adjuvant	O
significantly	O
increased	O
serum	O
neutralizing	O
-	O
antibody	B-FUNC
titers	O
and	O
reduced	O
lung	O
virus	O
titers	O
on	O
day	O
3	O
postchallenge	O
.	O

The	O
porcine	O
APN	O
transgene	O
was	O
constructed	O
by	O
fusing	O
with	O
mouse	O
proximal	O
APN	O
promoter	O
at	O
5	O
'	O
terminus	O
and	O
bovine	O
growth	B-FUNC
hormone	I-FUNC
polyadenylation	O
site	O
at	O
its	O
3	O
'	O
terminus	O
.	O

Although	O
the	O
primary	O
function	O
of	O
PLpro	O
and	O
3CLpro	O
are	O
to	O
process	O
the	O
viral	O
polyprotein	O
in	O
a	O
coordinated	O
manner	O
,	O
PLpro	O
has	O
the	O
additional	O
function	O
of	O
stripping	O
ubiquitin	B-FUNC
and	O
ISG15	O
from	O
host	O
-	O
cell	O
proteins	O
to	O
aid	O
coronaviruses	O
in	O
their	O
evasion	O
of	O
the	O
host	O
innate	O
immune	O
responses	O
.	O

This	O
article	O
describes	O
the	O
study	O
design	O
and	O
challenges	O
encountered	O
during	O
the	O
implementation	O
and	O
phase	O
1	O
component	O
of	O
the	O
START	O
(	O
STem	O
cells	O
for	O
ARDS	O
Treatment	O
)	O
trial	O
,	O
a	O
phase	O
1	O
/	O
2	O
trial	O
of	O
bone	O
marrow	O
-	O
derived	O
human	O
MSCs	B-FUNC
for	O
moderate	O
-	O
severe	O
ARDS	O
.	O

However	O
,	O
receptor	B-FUNC
binding	I-FUNC
,	O
endosomal	O
uptake	O
,	O
and	O
probably	O
signaling	O
via	O
Toll	O
-	O
like	O
receptor	O
7	O
(	O
TLR7	O
)	O
were	O
critical	O
for	O
sensing	O
of	O
MERS	O
-	O
CoV	O
by	O
pDCs	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
validation	O
of	O
a	O
new	O
probe	O
-	O
based	O
insulated	O
isothermal	O
reverse	O
transcriptase	B-FUNC
PCR	O
(	O
iiRT	O
-	O
PCR	O
)	O
assay	O
for	O
rapid	O
detection	O
of	O
classical	O
swine	O
fever	O
virus	O
(	O
CSFV	O
)	O
on	O
a	O
compact	O
,	O
user	O
-	O
friendly	O
device	O
(	O
POCKIT	O
(™)	O
Nucleic	O
Acid	O
Analyzer	O
)	O
that	O
does	O
not	O
need	O
data	O
interpretation	O
by	O
the	O
user	O
.	O

Lack	O
of	O
ATP1A1	O
did	O
not	O
affect	O
virus	O
binding	B-FUNC
to	O
host	O
cells	O
but	O
resulted	O
in	O
inhibited	O
entry	O
of	O
MHV	O
and	O
VSV	O
.	O

The	O
rapid	O
diagnostic	O
test	O
was	O
performed	O
in	O
23	O
of	O
the	O
faecal	O
samples	O
directly	O
,	O
while	O
the	O
rest	B-FUNC
were	O
placed	O
into	O
a	O
sterile	O
cotton	O
tipped	O
swab	O
suitable	O
for	O
collection	O
and	O
transportation	O
of	O
viruses	O
(	O
Sigma	O
Σ	O
-	O
VCM	O
(®))	O
and	O
stored	O
at	O
-	O
20	O
°	O
C	O
.	O

Calves	O
with	O
initial	O
antibody	B-FUNC
titers	O
against	O
BRSV	O
<	O
1	O
:	O
64	O
that	O
were	O
treated	O
for	O
BRD	O
had	O
a	O
slower	O
rate	O
of	O
anti	O
-	O
BRSV	O
antibody	B-FUNC
decay	O
than	O
did	O
similar	O
calves	O
that	O
were	O
not	O
treated	O
for	O
BRD	O
.	O

The	O
specific	O
detection	O
of	O
anti	O
-	O
FCoV	O
antibodies	O
was	O
possible	O
in	O
all	O
heparin	O
-	O
anticoagulated	O
plasma	O
,	O
serum	O
,	O
whole	O
blood	O
,	O
and	O
ascitic	O
fluid	O
samples	O
from	O
anti	O
-	O
FCoV	O
antibody	B-FUNC
positive	O
cats	O
,	O
and	O
nonspecific	O
reaction	O
was	O
not	O
noted	O
in	O
samples	O
from	O
anti	O
-	O
FCoV	O
antibody	B-FUNC
negative	O
cats	O
.	O

Applying	O
recombinantly	O
expressed	O
spike	O
proteins	O
of	O
infectious	O
bronchitis	O
virus	O
onto	O
formalin	O
-	O
fixed	O
tissues	O
allows	O
us	O
to	O
profile	O
the	O
binding	B-FUNC
characteristics	O
of	O
these	O
viral	O
attachment	O
proteins	O
to	O
tissues	O
of	O
various	O
avian	O
species	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
hybridoma	O
cell	O
line	O
secreting	O
monoclonal	O
antibody	B-FUNC
against	O
S	O
protein	O
of	O
a	O
Chinese	O
variant	O
of	O
PEDV	O
.	O

The	O
monoclonal	O
antibody	B-FUNC
2D1	O
may	O
provide	O
a	O
useful	O
tool	O
as	O
a	O
specific	O
diagnostic	O
reagent	O
for	O
detecting	O
S	O
protein	O
of	O
the	O
Chinese	O
variant	O
of	O
PEDV	O
and	O
for	O
further	O
investigation	O
into	O
the	O
virus	O
'	O
pathogenic	O
mechanism	O
.	O

Diagnosis	O
of	O
pulmonary	O
tuberculosis	O
was	O
made	O
10days	O
after	O
admission	O
on	O
examination	O
of	O
cavitary	O
and	O
diffuse	O
infiltrates	O
on	O
a	O
second	O
CT	O
scan	O
,	O
in	O
addition	O
to	O
presence	O
of	O
acid	O
-	O
fast	B-FUNC
bacilli	O
on	O
smear	O
examination	O
of	O
bronchial	O
aspirates	O
.	O

Herein	O
,	O
we	O
report	O
that	O
purified	O
MERS	O
-	O
CoV	O
E	O
protein	O
,	O
like	O
SARS	O
-	O
CoV	O
E	O
protein	O
,	O
is	O
almost	O
fully	O
α	O
-	O
helical	O
,	O
has	O
a	O
single	O
α	O
-	O
helical	O
transmembrane	O
domain	O
,	O
and	O
forms	O
pentameric	O
ion	B-FUNC
channels	I-FUNC
in	O
lipid	O
bilayers	O
.	O

ABSTRACT	O
:	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)	O
is	O
still	O
an	O
extremely	O
attractive	O
pharmaceutical	O
target	O
for	O
the	O
identification	O
of	O
new	O
inhibitors	O
possibly	O
active	O
on	O
drug	O
resistant	O
strains	O
.	O

Among	O
the	O
S	O
.	O
chinensis	O
fruit	O
lignans	O
,	O
Schisandrin	O
B	O
and	O
Deoxyschizandrin	O
selectively	O
inhibited	O
the	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
DNA	B-FUNC
polymerase	I-FUNC
activity	I-FUNC
.	O

The	O
diagnosis	O
of	O
ARDS	O
,	O
HIV	O
infection	O
and	O
MDR	B-FUNC
bacterial	O
and	O
fungal	O
VAP	O
was	O
made	O
.	O

Mode	O
of	O
inhibition	O
studies	O
by	O
enzyme	O
kinetics	O
and	O
competition	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
analyses	O
suggested	O
that	O
this	O
compound	O
acts	O
as	O
a	O
competitive	O
inhibitor	O
with	O
an	O
IC50	O
of	O
6	O
μM	O
against	O
MERS	O
-	O
CoV	O
PLpro	O
,	O
indicating	O
that	O
it	O
binds	B-FUNC
to	O
the	O
active	O
site	O
,	O
whereas	O
it	O
acts	O
as	O
an	O
allosteric	O
inhibitor	O
against	O
SARS	O
-	O
CoV	O
PLpro	O
with	O
an	O
IC50	O
of	O
11	O
μM	O
.	O
These	O
results	O
raised	O
the	O
possibility	O
that	O
inhibitor	O
recognition	O
specificity	O
of	O
MERS	O
-	O
CoV	O
PLpro	O
may	O
differ	O
from	O
that	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
.	O

The	O
GAIT	O
element	O
is	O
involved	O
in	O
the	O
translation	O
silencing	O
of	O
these	O
mRNAs	O
through	O
its	O
interaction	O
with	O
the	O
GAIT	O
complex	O
(	O
EPRS	O
,	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
Q	O
,	O
ribosomal	B-FUNC
protein	I-FUNC
L13a	O
,	O
and	O
glyceraldehyde	O
3	O
-	O
phosphate	O
dehydrogenase	O
)	O
to	O
favor	O
the	O
resolution	O
of	O
inflammation	O
.	O

Most	O
of	O
these	O
viruses	O
are	O
genetically	O
simple	O
and	O
rely	O
heavily	O
on	O
co	O
-	O
opting	O
cellular	O
proteins	O
,	O
particularly	O
cellular	O
RNA	O
-	O
binding	B-FUNC
proteins	O
,	O
into	O
new	O
roles	O
for	O
support	O
of	O
virus	O
infection	O
at	O
the	O
level	O
of	O
virus	O
-	O
specific	O
translation	O
,	O
and	O
building	O
RNA	O
replication	O
complexes	O
.	O

The	O
posttraumatic	O
lung	O
injury	O
group	O
demonstrated	O
significantly	O
higher	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
when	O
compared	O
with	O
HS	O
group	O
(	O
744	O
.	O
8	O
±	O
104	O
versus	O
297	O
.	O
7	O
±	O
134	O
pg	O
/	O
mL	O
;	O
P	O
=	O
0	O
.	O
004	O
).	O

ARDS	O
was	O
defined	O
by	O
the	O
Berlin	O
definition	O
and	O
lung	O
injury	O
score	O
(	O
LIS	B-FUNC
).	O

When	O
the	O
Berlin	O
or	O
LIS	B-FUNC
category	O
increased	O
,	O
albumin	O
levels	O
decreased	O
≥	O
1	O
g	O
/	O
L	O
(	O
AUROC	O
0	O
.	O
72	O
-	O
0	O
.	O
77	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
CRP	O
increased	O
≥	O
104	O
mg	O
/	O
L	O
(	O
only	O
significant	O
for	O
Berlin	O
,	O
AUROC	O
0	O
.	O
69	O
,	O
P	O
=	O
0	O
.	O
04	O
).	O

RESULTS	O
:	O
At	O
baseline	O
,	O
48	O
patients	O
had	O
mild	O
to	O
severe	O
ARDS	O
according	O
to	O
Berlin	O
and	O
87	O
according	O
to	O
LIS	B-FUNC
(	O
Rs	O
=	O
0	O
.	O
54	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Molecular	O
modeling	O
and	O
competitive	O
S	O
-	O
adenosyl	O
-	O
l	O
-	O
methionine	O
(	O
SAM	O
)	O
binding	B-FUNC
assay	O
suggest	O
that	O
these	O
compounds	O
likely	O
confer	O
antiviral	O
activity	O
via	O
binding	B-FUNC
to	O
methyltransferase	O
(	O
MTase	O
).	O

A	O
total	O
of	O
360	O
chicken	O
flocks	O
suspected	O
of	O
being	O
infected	O
by	O
IBV	O
were	O
screened	O
for	O
the	O
IBV	O
N	O
gene	O
using	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

In	O
this	O
study	O
,	O
we	O
examined	O
binding	B-FUNC
of	O
the	O
S1	O
domain	O
of	O
hCoV	O
-	O
HKU1	O
spike	O
to	O
a	O
panel	O
of	O
cells	O
and	O
found	O
that	O
the	O
S1	O
could	O
specifically	O
bind	B-FUNC
on	O
the	O
cell	O
surface	O
of	O
a	O
human	O
rhabdomyosarcoma	O
cell	O
line	O
,	O
RD	O
.	O

The	O
stability	O
of	O
the	O
ligand	B-FUNC
was	O
subsequently	O
confirmed	O
by	O
molecular	O
dynamics	O
.	O

Recent	O
advances	O
in	O
recombinant	O
DNA	O
technology	O
have	O
resulted	O
in	O
experimental	O
IB	O
vaccines	O
that	O
show	O
promise	O
in	O
antibody	B-FUNC
and	O
T	O
-	O
cells	O
responses	O
,	O
comparable	O
to	O
live	O
attenuated	O
vaccines	O
.	O

TITLE	O
:	O
In	O
vivo	O
assessment	O
of	O
equine	O
arteritis	O
virus	O
vaccine	O
improvement	O
by	O
disabling	O
the	O
deubiquitinase	B-FUNC
activity	O
of	O
papain	O
-	O
like	O
protease	O
2	O
.	O

After	O
that	O
,	O
she	O
continued	O
to	O
improve	O
with	O
intravenous	O
immunoglobulin	B-FUNC
dosed	O
every	O
3	O
-	O
4	O
weeks	O
.	O

The	O
unique	O
lung	O
recruitment	O
by	O
HFOV	O
can	O
be	O
a	O
useful	O
therapeutic	O
option	O
for	O
severe	O
ARDS	O
patients	O
when	O
combined	O
with	O
sufficient	O
lung	O
rest	B-FUNC
provided	O
by	O
ECMO	O
.	O

Recently	O
,	O
TGF	O
-	O
α	O
/	O
EGFR	B-FUNC
signaling	O
has	O
also	O
been	O
shown	O
to	O
regulate	O
innate	O
immune	O
responses	O
in	O
bronchial	O
epithelial	O
cells	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
whether	O
HGF	O
/	O
c	O
-	O
Met	O
signaling	O
alters	O
the	O
innate	O
immune	O
responses	O
and	O
whether	O
the	O
innate	O
immune	O
responses	O
in	O
AECs	O
are	O
regulated	O
by	O
HGF	O
/	O
c	O
-	O
Met	O
and	O
TGF	O
-	O
α	O
/	O
EGFR	B-FUNC
.	O

TITLE	O
:	O
Host	O
tissue	O
and	O
glycan	O
binding	B-FUNC
specificities	O
of	O
avian	O
viral	O
attachment	O
proteins	O
using	O
novel	O
avian	O
tissue	O
microarrays	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
in	O
the	O
spike	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
a	O
key	O
target	O
for	O
the	O
development	O
of	O
SARS	O
vaccines	O
.	O

The	O
channel	B-FUNC
activity	I-FUNC
and	O
structure	O
of	O
some	O
representative	O
members	O
of	O
these	O
viroporins	O
have	O
been	O
recently	O
characterized	O
in	O
some	O
detail	O
.	O

We	O
profiled	O
the	O
binding	B-FUNC
of	O
recombinantly	O
expressed	O
S1	O
proteins	O
of	O
TCoV	O
,	O
GfCoV	O
,	O
and	O
QCoV	O
to	O
tissues	O
of	O
their	O
respective	O
hosts	O
.	O

We	O
and	O
other	O
investigators	O
demonstrated	O
that	O
MVs	O
released	O
by	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	B-FUNC
)	O
were	O
as	O
effective	O
as	O
the	O
cells	O
themselves	O
in	O
inflammatory	O
injuries	O
,	O
such	O
as	O
after	O
endotoxin	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

MVs	O
derived	O
from	O
human	O
MSCs	B-FUNC
were	O
as	O
effective	O
as	O
the	O
parent	O
stem	O
cells	O
in	O
severe	O
bacterial	O
pneumonia	O
.	O

Here	O
we	O
reported	O
that	O
ET	O
-	O
1	O
stimulated	O
expression	O
of	O
VCAM	O
-	O
1	O
gene	O
on	O
HTSMCs	O
,	O
which	O
was	O
blocked	O
by	O
pretreatment	O
with	O
the	O
inhibitors	O
of	O
ET	O
receptors	O
,	O
Src	O
,	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
),	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
(	O
EGFR	B-FUNC
),	O
platelet	B-FUNC
-	I-FUNC
derived	I-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
(	O
PDGFR	O
),	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	B-FUNC
),	O
AKT	O
,	O
MEK1	B-FUNC
/	O
2	O
,	O
and	O
p300	O
,	O
suggesting	O
the	O
participation	O
of	O
these	O
signaling	O
components	O
in	O
ET	O
-	O
1	O
-	O
regulated	O
HTSMC	O
responses	O
.	O

Adhesion	O
assay	O
revealed	O
that	O
the	O
adhesion	O
of	O
THP	O
-	O
1	O
to	O
HTSMCs	O
challenged	O
with	O
ET	O
-	O
1	O
was	O
increased	O
,	O
which	O
was	O
attenuated	O
by	O
the	O
inhibitors	O
of	O
ET	O
receptors	O
,	O
Src	O
,	O
MMPs	O
,	O
EGFR	B-FUNC
,	O
PDGFR	O
,	O
PI3K	B-FUNC
,	O
AKT	O
,	O
p42	O
/	O
p44	O
MAPK	B-FUNC
,	O
and	O
p300	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggested	O
that	O
ET	O
-	O
1	O
promotes	O
occurrence	O
and	O
amplification	O
of	O
pathology	O
-	O
related	O
airway	O
inflammation	O
via	O
enhancing	O
VCAM	O
-	O
1	O
expression	O
in	O
an	O
ET	O
receptor	O
/	O
Src	O
/	O
MMP	O
/	O
EGFR	B-FUNC
,	O
PDGFR	O
/	O
PI3K	B-FUNC
/	O
AKT	O
/	O
p42	O
/	O
p44	O
MAPK	B-FUNC
/	O
Elk	O
-	O
1	O
/	O
p300	O
pathway	O
in	O
HTSMCs	O
.	O

Mouse	O
hepatitis	O
virus	O
,	O
a	O
β	O
-	O
CoV	O
in	O
group	O
A	O
,	O
uses	O
the	O
galectin	O
-	O
like	O
NTD	O
in	O
its	O
spike	O
protein	O
to	O
bind	B-FUNC
its	O
receptor	O
protein	O
,	O
while	O
HCoV	O
-	O
OC43	O
,	O
another	O
β	O
-	O
CoV	O
in	O
group	O
A	O
,	O
uses	O
the	O
NTD	O
to	O
bind	B-FUNC
to	O
its	O
sialic	O
-	O
acid	O
containing	O
receptor	O
.	O

Thus	O
,	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
HKU1	O
spike	O
glycoprotein	O
is	O
located	O
in	O
the	O
C	O
domain	O
.	O

TGFβ1	O
activated	O
p38	B-FUNC
MAPK	B-FUNC
and	O
SMAD3	O
,	O
but	O
not	O
p42	O
/	O
p44	O
MAPK	B-FUNC
in	O
HLF	O
cells	O
.	O

RESULTS	O
:	O
PDGF	B-FUNC
activated	O
p38	B-FUNC
MAPK	B-FUNC
and	O
p42	O
/	O
p44	O
MAPK	B-FUNC
,	O
but	O
not	O
SMAD3	O
in	O
HLF	O
cells	O
.	O

Among	O
them	O
,	O
seven	O
positive	O
selection	O
sites	O
were	O
chronologically	O
traced	O
in	O
the	O
temporal	O
evolution	O
routes	O
of	O
genotype	O
D	O
,	O
and	O
six	O
were	O
located	O
around	O
the	O
critical	O
sugar	B-FUNC
binding	I-FUNC
region	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
S	O
protein	O
,	O
an	O
important	O
sugar	B-FUNC
binding	I-FUNC
domain	O
of	O
CoV	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
genetic	O
drift	O
of	O
the	O
S	O
gene	O
may	O
play	O
an	O
important	O
role	O
in	O
genotype	O
persistence	O
in	O
human	O
populations	O
,	O
providing	O
insights	O
into	O
the	O
mechanisms	O
of	O
HCoV	O
-	O
OC43	O
adaptive	O
evolution	O
.	O

A	O
codon	O
-	O
optimized	O
PEDV	O
S1	O
gene	O
consisting	O
of	O
amino	O
acid	O
residues	O
25	O
-	O
749	O
was	O
synthesized	O
and	O
used	O
to	O
establish	O
a	O
stable	O
porcine	O
cell	O
line	O
constitutively	O
expressing	O
a	O
recombinant	O
PEDV	O
S1	O
protein	O
containing	O
the	O
chicken	O
immunoglobulin	B-FUNC
Fc	O
fragment	O
at	O
its	O
C	O
-	O
terminus	O
.	O

Clinical	O
disease	O
was	O
severe	O
and	O
developed	O
rapidly	O
following	O
infection	O
with	O
an	O
original	O
North	O
American	O
PEDV	O
isolate	O
,	O
with	O
lesions	O
,	O
viremia	O
,	O
and	O
antigen	O
detection	O
possible	O
by	O
12	O
hpi	B-FUNC
.	O

These	O
findings	O
indicate	O
that	O
the	O
ERK	B-FUNC
signaling	O
pathway	O
plays	O
an	O
important	O
role	O
in	O
the	O
PEDV	O
life	O
cycle	O
and	O
beneficially	O
contributes	O
to	O
viral	O
infection	O
.	O

Antibodies	O
against	O
M	O
.	O
pneumoniae	O
were	O
detected	O
in	O
all	O
patients	O
and	O
were	O
found	O
to	O
be	O
intrathecally	O
synthesised	O
in	O
two	O
cases	O
(	O
GBS	O
and	O
BBE	B-FUNC
),	O
which	O
proves	O
intrathecal	O
infection	O
.	O

Expanding	O
lesions	O
in	O
the	O
absence	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
are	O
characterized	O
by	O
sustained	O
microglial	O
activation	O
and	O
partial	O
loss	O
of	O
macrophage	O
/	O
microglia	O
exhibiting	O
an	O
acquired	O
deactivation	O
phenotype	O
.	O

The	O
ubiquitin	B-FUNC
-	O
proteasome	O
,	O
autophagy	O
,	O
and	O
calpain	O
-	O
caspase	O
pathways	O
have	O
all	O
been	O
implicated	O
in	O
early	O
-	O
phase	O
muscle	O
dysfunction	O
.	O

TITLE	O
:	O
A	O
G	O
-	O
quadruplex	O
-	O
binding	B-FUNC
macrodomain	O
within	O
the	O
""""	O
SARS	O
-	O
unique	O
domain	O
""""	O
is	O
essential	O
for	O
the	O
activity	O
of	O
the	O
SARS	O
-	O
coronavirus	O
replication	O
-	O
transcription	O
complex	O
.	O

The	O
region	O
of	O
the	O
enzyme	O
that	O
directly	O
interacts	O
with	O
viral	O
RNA	O
,	O
the	O
RNA	O
-	O
binding	B-FUNC
domain	O
,	O
contains	O
a	O
number	O
of	O
polymorphisms	O
likely	O
to	O
affect	O
the	O
RNA	O
-	O
binding	B-FUNC
affinity	O
of	O
OAS1	O
.	O

This	O
strongly	O
suggests	O
that	O
pathogen	O
-	O
driven	O
balancing	O
selection	O
acting	O
on	O
the	O
RNA	O
-	O
binding	B-FUNC
domain	O
of	O
OAS1	O
is	O
maintaining	O
variation	O
at	O
this	O
locus	O
.	O

RESULTS	O
:	O
Binding	B-FUNC
of	O
HAdV	O
-	O
B14p1	O
to	O
the	O
apical	O
surface	O
of	O
differentiated	O
human	O
bronchial	O
epithelial	O
cells	O
and	O
subsequent	O
internalization	O
of	O
HAdV	O
DNA	O
was	O
10	O
fold	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
compared	O
to	O
the	O
less	O
-	O
pneumotropic	O
HAdV	O
-	O
C5	O
one	O
hour	O
after	O
infection	O
.	O

Some	O
serological	O
assays	O
for	O
PEDV	O
have	O
been	O
previously	O
described	O
,	O
but	O
few	O
were	O
readily	O
available	O
in	O
the	O
U	O
.	O
S	O
.	O
Several	O
U	O
.	O
S	O
.	O
laboratories	O
quickly	O
developed	O
indirect	O
fluorescent	O
antibody	B-FUNC
(	O
IFA	O
)	O
assays	O
for	O
the	O
detection	O
of	O
antibodies	O
to	O
PEDV	O
in	O
swine	O
serum	O
,	O
indicating	O
prior	O
exposure	O
.	O

The	O
disordered	O
NS3pro	O
appears	O
to	O
be	O
needed	O
for	O
binding	B-FUNC
a	O
human	O
host	O
factor	O
to	O
trigger	O
the	O
membrane	O
remodeling	O
.	O

The	O
multi	O
-	O
fragment	O
antigen	O
(	O
BE	O
)	O
may	O
represent	O
a	O
promising	O
alternative	O
to	O
the	O
whole	O
virus	O
without	O
safety	O
problems	O
,	O
and	O
this	O
newly	O
established	O
ELISA	O
provides	O
an	O
effective	O
method	O
for	O
anti	O
-	O
IBV	O
antibody	B-FUNC
detection	O
.	O

The	O
attenuated	O
strain	O
also	O
had	O
relatively	O
low	O
tissue	O
replication	O
rates	O
and	O
higher	O
antibody	B-FUNC
levels	O
.	O

We	O
previously	O
reported	O
two	O
human	O
monoclonal	O
antibodies	O
that	O
target	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
and	O
exhibit	O
strong	O
neutralization	O
activity	O
against	O
live	O
and	O
pesudotyped	O
MERS	O
-	O
CoV	O
infection	O
.	O

Here	O
we	O
determined	O
the	O
crystal	O
structure	O
of	O
MERS	O
-	O
CoV	O
RBD	O
bound	O
to	O
the	O
Fab	O
fragment	O
of	O
MERS	O
-	O
27	O
antibody	B-FUNC
at	O
3	O
.	O
20	O
Å	O
resolution	O
.	O

One	O
of	O
the	O
residues	O
,	O
Trp535	O
,	O
was	O
found	O
to	O
function	O
as	O
an	O
anchor	O
residue	O
at	O
the	O
binding	B-FUNC
interface	O
with	O
MERS	O
-	O
27	O
.	O

This	O
concept	O
,	O
however	O
,	O
went	O
against	O
years	O
of	O
enzyme	O
-	O
substrate	O
binding	B-FUNC
theory	O
.	O

In	O
the	O
upstream	O
of	O
IRF	O
-	O
3	O
,	O
TANK	O
-	O
binding	B-FUNC
kinase	O
1	O
(	O
TBK1	B-FUNC
)-	O
or	O
inhibitor	O
of	O
κB	O
kinase	O
-	O
ε	O
(	O
IKKε	O
)-	O
mediated	O
IFN	O
-	O
β	O
production	O
was	O
not	O
blocked	O
by	O
PEDV	O
,	O
while	O
RIG	O
-	O
I	O
-	O
and	O
its	O
adapter	O
molecule	O
IFN	O
-	O
β	O
promoter	O
stimulator	O
1	O
(	O
IPS	O
-	O
1	O
)-	O
mediated	O
IFN	O
-	O
β	O
production	O
were	O
completely	O
inhibited	O
after	O
PEDV	O
infection	O
.	O

Despite	O
the	O
numerous	O
functional	O
studies	O
on	O
MHV	O
and	O
its	O
nsp3	O
domain	O
,	O
the	O
structure	O
of	O
only	O
one	O
domain	O
in	O
nsp3	O
,	O
the	O
small	O
ubiquitin	B-FUNC
-	O
like	O
domain	O
1	O
(	O
Ubl1	O
),	O
has	O
been	O
determined	O
.	O

We	O
report	O
here	O
the	O
x	O
-	O
ray	O
structure	O
of	O
three	O
tandemly	O
linked	O
domains	O
of	O
MHV	O
nsp3	O
,	O
including	O
the	O
papain	O
-	O
like	O
protease	O
2	O
(	O
PLP2	O
)	O
catalytic	O
domain	O
,	O
the	O
ubiquitin	B-FUNC
-	O
like	O
domain	O
2	O
(	O
Ubl2	O
),	O
and	O
a	O
third	O
domain	O
that	O
we	O
call	O
the	O
DPUP	O
(	O
domain	O
preceding	O
Ubl2	O
and	O
PLP2	O
)	O
domain	O
.	O

A	O
computationally	O
derived	O
model	O
of	O
MHV	O
PLP2	O
bound	O
to	O
ubiquitin	B-FUNC
was	O
generated	O
,	O
and	O
the	O
potential	O
interactions	O
between	O
ubiquitin	B-FUNC
and	O
PLP2	O
were	O
probed	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

A	O
virus	O
neutralization	O
test	O
with	O
sera	B-FUNC
of	O
7	O
different	O
OD	O
values	O
showed	O
a	O
positive	O
correlation	O
between	O
the	O
OD	O
values	O
and	O
virus	O
neutralization	O
.	O

The	O
target	O
gene	O
regions	O
selected	O
in	O
our	O
study	O
(	O
UpE	O
,	O
ORF1a	O
,	O
ORF1b	O
,	O
N	O
and	O
RdRp	B-FUNC
)	O
which	O
were	O
also	O
recommended	O
by	O
WHO	O
,	O
shown	O
to	O
have	O
high	O
specificity	O
and	O
sensitivity	O
for	O
the	O
diagnosis	O
and	O
confirmation	O
of	O
MERS	O
-	O
CoV	O
,	O
and	O
also	O
recommended	O
by	O
WHO	O
.	O

ABSTRACT	O
:	O
Replication	O
of	O
coronaviruses	O
is	O
inhibited	O
in	O
vitro	O
by	O
cyclosporin	O
A	O
,	O
a	O
well	O
-	O
known	O
immunosuppressive	O
drug	O
which	O
binds	B-FUNC
to	O
cellular	O
cyclophilins	O
thus	O
inactivating	O
their	O
enzymatic	O
cis	O
-	O
trans	O
peptidyl	O
-	O
prolyl	O
isomerase	O
function	O
.	O

In	O
affected	O
glomeruli	O
,	O
glomerular	O
capillary	O
walls	O
and	O
mesangial	O
areas	O
were	O
positive	O
for	O
anti	O
-	O
ferret	O
immunoglobulin	B-FUNC
G	O
.	O
By	O
electron	O
microscopy	O
,	O
subepithelial	O
and	O
mesangial	O
electron	O
-	O
dense	O
deposits	O
were	O
observed	O
consistent	O
with	O
immune	O
complex	O
deposition	O
.	O

After	O
the	O
fifth	O
round	O
of	O
biopanning	O
with	O
Escherichia	O
coli	O
-	O
synthesized	O
ORF6	O
-	O
His	O
tagged	O
protein	O
,	O
the	O
relative	O
binding	B-FUNC
affinity	O
of	O
phage	O
clones	O
to	O
ORF6	O
was	O
determined	O
using	O
direct	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Here	O
,	O
we	O
show	O
that	O
m336	O
,	O
an	O
exceptionally	O
potent	O
human	O
anti	O
-	O
MERS	O
-	O
CoV	O
antibody	B-FUNC
,	O
is	O
almost	O
germline	O
with	O
only	O
one	O
somatic	O
mutation	O
in	O
the	O
heavy	O
chain	O
.	O

Neutralizing	O
antibody	B-FUNC
titers	O
were	O
detected	O
using	O
the	O
serum	O
neutralization	O
test	O
(	O
SN50	O
).	O

In	O
the	O
present	O
study	O
we	O
aimed	O
at	O
assessing	O
NDV	O
and	O
IBV	O
prevalences	O
in	O
Ivory	O
-	O
Coast	O
by	O
molecular	O
screening	O
of	O
>	O
22	O
,	O
000	O
avian	O
swabs	O
by	O
nested	O
PCR	O
and	O
by	O
serology	O
testing	O
of	O
close	O
to	O
2000	O
avian	O
sera	B-FUNC
from	O
2010	O
through	O
2012	O
.	O

No	O
difference	O
in	O
complications	O
and	O
outcome	O
is	O
found	O
in	O
treatment	O
regimens	O
of	O
intravenous	O
immunoglobulin	B-FUNC
(	O
IVIG	O
)	O
and	O
plasma	O
exchange	O
.	O

Integrating	O
phenotypic	O
and	O
genetic	O
data	O
narrowed	O
this	O
region	O
to	O
a	O
single	O
gene	O
,	O
Trim55	O
,	O
an	O
E3	O
ubiquitin	B-FUNC
ligase	O
with	O
a	O
role	O
in	O
muscle	O
fiber	O
maintenance	O
.	O

Bleeding	O
from	O
the	O
chest	O
tube	O
site	O
was	O
reported	O
in	O
13	O
.	O
5	O
%	O
of	O
prone	O
positioning	O
maneuvers	O
in	O
1	O
study	O
,	O
and	O
the	O
rest	B-FUNC
of	O
the	O
studies	O
reported	O
no	O
evidence	O
of	O
chest	O
tube	O
site	O
bleeding	O
.	O

Furthermore	O
,	O
all	O
of	O
the	O
three	O
MAbs	O
reacted	O
with	O
PEDV	O
in	O
the	O
fluorescent	O
antibody	B-FUNC
assay	O
.	O

ABSTRACT	O
:	O
All	O
RNA	O
viruses	O
encode	O
an	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
),	O
which	O
in	O
arteriviruses	O
is	O
expressed	O
as	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
nonstructural	O
protein	O
9	O
(	O
nsp9	O
).	O

METHODS	O
:	O
Overall	O
,	O
149	O
subjects	O
with	O
ACS	B-FUNC
(	O
namely	O
,	O
acute	O
myocardial	O
infarct	O
with	O
or	O
without	O
ST	O
-	O
segment	O
elevation	O
or	O
unstable	O
angina	O
),	O
with	O
no	O
previous	O
history	O
of	O
CHD	O
,	O
admitted	O
to	O
three	O
cardiac	O
intensive	O
care	O
units	O
were	O
included	O
and	O
evaluated	O
by	O
the	O
Structured	O
Clinical	O
Interview	O
for	O
Complicated	O
Grief	O
(	O
SCI	O
-	O
CG	O
),	O
Hamilton	O
Depression	O
Rating	O
Scale	O
,	O
Hamilton	O
Anxiety	O
Rating	O
Scale	O
,	O
and	O
the	O
36	O
-	O
item	O
Short	O
-	O
Form	O
Health	O
Survey	O
(	O
MOS	O
-	O
SF	O
-	O
36	O
).	O

These	O
targeted	O
liposomes	O
showed	O
binding	B-FUNC
to	O
alphavbeta5	O
integrin	O
receptors	O
expressed	O
on	O
alveolar	O
cells	O
.	O

To	O
these	O
eight	O
complexes	O
,	O
the	O
structural	O
basis	O
for	O
inhibitor	O
binding	B-FUNC
was	O
analyzed	O
by	O
the	O
COMBINE	O
method	O
,	O
which	O
is	O
a	O
chemometrical	O
analysis	O
optimized	O
for	O
the	O
protein	O
-	O
ligand	B-FUNC
complex	O
.	O

The	O
substantial	O
contribution	O
of	O
this	O
side	O
chain	O
(∼	O
10	O
%)	O
for	O
the	O
explanation	O
of	O
pIC50	O
s	O
was	O
dependent	O
on	O
stereochemistry	O
and	O
the	O
chemical	O
structure	O
of	O
the	O
ligand	B-FUNC
adapted	O
to	O
the	O
S2	O
pocket	O
of	O
the	O
protease	O
.	O

Using	O
hemi	O
-	O
nested	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
PCR	O
amplification	O
of	O
fragments	O
within	O
the	O
highly	O
conserved	O
regions	O
of	O
the	O
respective	O
RNA	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
genes	O
,	O
we	O
detected	O
astrovirus	O
sequences	O
at	O
an	O
overall	O
detection	O
rate	O
of	O
25	O
.	O
8	O
%	O
of	O
the	O
analysed	O
animals	O
,	O
with	O
a	O
maximum	O
of	O
65	O
%	O
in	O
local	O
populations	O
.	O

Finally	O
,	O
a	O
combination	O
of	O
SCS	B-FUNC
-	O
MP2	O
and	O
B3LYP	O
or	O
M06	O
-	O
2X	O
allows	O
reliable	O
estimates	O
about	O
remaining	O
errors	O
.	O

Analysis	O
of	O
the	O
Receptor	B-FUNC
Binding	I-FUNC
Domains	O
in	O
the	O
spike	O
gene	O
revealed	O
a	O
limited	O
number	O
of	O
amino	O
acid	O
substitutions	O
in	O
US	O
strains	O
compared	O
to	O
Asian	O
strains	O
.	O

We	O
will	O
also	O
examine	O
the	O
pharmacokinetics	O
of	O
the	O
MERS	O
-	O
CoV	O
antibody	B-FUNC
response	O
and	O
viral	O
load	O
over	O
the	O
course	O
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

We	O
previously	O
showed	O
that	O
the	O
tyrosine	O
kinase	B-FUNC
inhibitor	I-FUNC
imatinib	O
increases	O
lung	O
endothelial	O
antioxidant	O
enzymes	O
and	O
protects	O
against	O
pulmonary	O
endothelial	O
antioxidant	O
injury	O
.	O

We	O
herein	O
report	O
of	O
evaluating	O
a	O
recombinant	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
rRBD	O
)	O
protein	O
vaccine	O
in	O
a	O
rhesus	O
macaque	O
model	O
.	O

CONCLUSIONS	O
:	O
Robust	O
and	O
sustained	O
immunological	O
responses	O
(	O
including	O
neutralisation	O
antibody	B-FUNC
)	O
were	O
elicited	O
by	O
the	O
rRBD	O
vaccination	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
detected	O
by	O
monoclonal	O
antibody	B-FUNC
-	O
based	O
nucleocapsid	O
protein	O
-	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
RNA	O
detection	O
,	O
and	O
viral	O
culture	O
from	O
the	O
nasal	O
sample	O
of	O
a	O
1	O
-	O
month	O
-	O
old	O
dromedary	O
calf	O
in	O
Dubai	O
with	O
sudden	O
death	O
.	O

PEDV	O
specific	O
B	O
cell	O
response	O
in	O
the	O
intestine	O
and	O
spleen	O
of	O
infected	O
sows	O
decline	O
by	O
6	O
months	O
,	O
and	O
this	O
associates	O
with	O
specific	O
antibody	B-FUNC
levels	O
in	O
the	O
plasma	O
and	O
oral	O
fluid	O
samples	O
;	O
but	O
the	O
virus	O
neutralization	O
titers	O
in	O
plasma	O
remains	O
high	O
beyond	O
6	O
months	O
post	O
-	O
infection	O
.	O

MERS	O
-	O
CoV	O
RNA	O
was	O
detected	O
in	O
14	O
(	O
11	O
%)	O
of	O
132	O
nasal	O
swabs	O
and	O
antibody	B-FUNC
in	O
126	O
(	O
96	O
%)	O
of	O
131	O
serum	O
samples	O
.	O

Here	O
we	O
describe	O
the	O
clinical	O
signs	O
,	O
pathologic	O
findings	O
,	O
and	O
diagnosis	O
by	O
immunohistochemistry	O
using	O
an	O
FIPV3	O
-	O
70	O
monoclonal	O
antibody	B-FUNC
of	O
systemic	O
coronaviral	O
disease	O
in	O
5	O
ferrets	O
,	O
2	O
of	O
which	O
were	O
strictly	O
laboratory	O
-	O
housed	O
;	O
the	O
remaining	O
3	O
were	O
referred	O
from	O
veterinary	O
private	O
practices	O
.	O

Treatment	O
of	O
G6PD	O
-	O
knockdown	O
cells	O
with	O
siRNA	O
against	O
HSCARG	O
enhanced	O
the	O
DNA	B-FUNC
binding	I-FUNC
activity	O
of	O
NF	O
-	O
κB	O
and	O
the	O
expression	O
of	O
TNF	O
-	O
α	O
and	O
MX1	O
,	O
but	O
suppressed	O
the	O
expression	O
of	O
viral	O
genes	O
;	O
however	O
,	O
the	O
overexpression	O
of	O
HSCARG	O
inhibited	O
the	O
antiviral	O
response	O
.	O

We	O
found	O
that	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
level	O
was	O
elevated	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
of	O
ALI	O
mice	O
.	O

ABSTRACT	O
:	O
Membrane	O
-	O
wrapped	O
nanoparticles	O
represent	O
a	O
versatile	O
platform	O
for	O
utilizing	O
specific	O
lipid	O
-	O
receptor	O
interactions	O
,	O
such	O
as	O
siallyllactose	O
-	O
mediated	O
binding	B-FUNC
of	O
the	O
ganglioside	O
GM3	O
to	O
Siglec1	O
(	O
CD169	O
),	O
for	O
targeting	O
purposes	O
.	O

TITLE	O
:	O
Macro	O
Domain	O
from	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
Is	O
an	O
Efficient	O
ADP	B-FUNC
-	I-FUNC
ribose	I-FUNC
Binding	I-FUNC
Module	O
:	O
CRYSTAL	O
STRUCTURE	O
AND	O
BIOCHEMICAL	O
STUDIES	O
.	O

Using	O
differential	O
scanning	O
fluorimetry	O
and	O
isothermal	O
titration	O
calorimetry	O
,	O
we	O
characterized	O
the	O
MERS	O
-	O
CoV	O
macro	O
domain	O
as	O
a	O
more	O
efficient	O
adenosine	O
diphosphate	O
(	O
ADP	O
)-	O
ribose	O
binding	B-FUNC
module	O
than	O
macro	O
domains	O
from	O
other	O
CoVs	O
.	O

After	O
logistic	O
regression	O
analysis	O
,	O
only	O
age	O
,	O
the	O
presence	O
of	O
septic	O
shock	O
at	O
admission	O
,	O
Ppl	B-FUNC
>	O
30	O
cmH2O	O
,	O
and	O
major	O
co	O
-	O
morbidities	O
were	O
independently	O
associated	O
with	O
hospital	O
outcome	O
.	O

Knowledge	O
and	O
appreciation	O
of	O
the	O
circuit	O
,	O
cannulae	O
,	O
and	O
the	O
physiology	O
of	O
gas	O
exchange	O
with	O
ECMO	O
are	O
necessary	O
to	O
ensure	O
lung	O
rest	B-FUNC
,	O
efficiency	O
of	O
oxygenation	O
,	O
and	O
ventilation	O
as	O
well	O
as	O
troubleshooting	O
problems	O
.	O

This	O
study	O
was	O
based	O
on	O
in	O
vitro	O
microfluidic	O
assays	O
using	O
patient	O
sera	B-FUNC
.	O

We	O
compared	O
the	O
properties	O
of	O
cells	O
incubated	O
with	O
the	O
sera	B-FUNC
of	O
healthy	O
volunteers	O
(	O
n	O
=	O
5	O
),	O
patients	O
presenting	O
with	O
acute	O
cardiogenic	O
pulmonary	O
edema	O
(	O
ACPE	O
;	O
n	O
=	O
6	O
),	O
and	O
patients	O
with	O
ARDS	O
(	O
n	O
=	O
22	O
),	O
of	O
whom	O
13	O
were	O
classified	O
as	O
having	O
moderate	O
to	O
severe	O
disease	O
and	O
the	O
remaining	O
9	O
as	O
having	O
mild	O
disease	O
.	O

TITLE	O
:	O
Comparison	O
of	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
serum	O
and	O
cell	O
-	O
free	O
body	O
cavity	O
effusion	O
for	O
the	O
diagnosis	O
of	O
feline	O
infectious	O
peritonitis	O
.	O

However	O
,	O
despite	O
diminished	O
germinal	O
center	O
B	O
cells	O
and	O
follicular	O
helper	O
T	O
cells	O
in	O
draining	O
lymph	O
nodes	O
,	O
ASC	O
in	O
bone	O
marrow	O
and	O
antiviral	O
serum	O
antibody	B-FUNC
were	O
intact	O
in	O
the	O
absence	O
of	O
CXCL13	O
.	O

Enzymatic	O
studies	O
showed	O
that	O
RMNC6	O
interferes	O
with	O
efavirenz	O
(	O
an	O
approved	O
NNRTI	O
)	O
in	O
its	O
binding	B-FUNC
to	O
the	O
RT	O
polymerase	O
domain	O
,	O
although	O
NNRTI	O
resistance	O
-	O
associated	O
mutations	O
such	O
as	O
K103N	O
,	O
Y181C	O
and	O
Y188L	O
had	O
a	O
minor	O
impact	O
on	O
RT	O
susceptibility	O
to	O
RMNC6	O
.	O

Mutagenesis	O
studies	O
showed	O
that	O
RT	O
RNase	O
H	O
domain	O
residues	O
Asn474	O
and	O
Tyr501	O
,	O
and	O
in	O
a	O
lesser	O
extent	O
Ala502	O
and	O
Ala508	O
,	O
are	O
critical	O
for	O
RMNC6	O
inhibition	O
of	O
the	O
endonuclease	B-FUNC
activity	I-FUNC
of	O
the	O
RT	O
,	O
without	O
affecting	O
its	O
DNA	O
polymerization	O
activity	O
.	O

There	O
are	O
four	O
major	O
epitope	O
regions	O
in	O
the	O
spike	O
glycoprotein	O
:	O
a	O
CO	O
-	O
26K	O
equivalent	O
(	O
COE	O
)	O
domain	O
,	O
SS2	O
and	O
SS6	O
epitopes	O
,	O
and	O
an	O
epitope	O
region	O
recognized	O
by	O
the	O
2C10	O
monoclonal	O
antibody	B-FUNC
.	O

Among	O
the	O
50	O
positive	O
specimens	O
,	O
thirteen	O
gave	O
rise	O
to	O
CoV	O
full	O
-	O
length	O
RdRP	B-FUNC
gene	O
amplification	O
for	O
further	O
sequence	O
comparison	O
,	O
of	O
which	O
three	O
divergent	O
sequences	O
(	O
two	O
from	O
a	O
unreported	O
province	O
)	O
were	O
subjected	O
to	O
full	O
genome	O
sequencing	O
.	O

The	O
median	O
(	O
interquartile	O
range	O
)	O
days	O
before	O
the	O
AST	O
and	O
ALT	B-FUNC
levels	O
returned	O
to	O
lower	O
than	O
200	O
U	O
/	O
L	O
after	O
the	O
ALF	O
were	O
10	O
.	O
5	O
(	O
8	O
.	O
8	O
,	O
12	O
.	O
8	O
)	O
and	O
10	O
.	O
5	O
(	O
7	O
.	O
8	O
,	O
14	O
.	O
0	O
)	O
days	O
,	O
respectively	O
.	O

The	O
formed	O
corona	O
is	O
dominated	O
by	O
complement	O
proteins	O
and	O
immunoglobulins	O
,	O
the	O
binding	B-FUNC
of	O
which	O
can	O
be	O
reduced	O
by	O
PEGylating	O
the	O
VNP	O
surface	O
.	O

TITLE	O
:	O
Hepatitis	O
C	O
Virus	O
Resistance	O
to	O
Carbohydrate	O
-	O
Binding	B-FUNC
Agents	O
.	O

For	O
the	O
M	O
protein	O
,	O
this	O
is	O
the	O
first	O
description	O
of	O
production	O
in	O
plants	O
,	O
while	O
for	O
plant	O
-	O
derived	O
N	O
protein	O
we	O
demonstrate	O
that	O
it	O
is	O
recognized	O
by	O
sera	B-FUNC
of	O
patients	O
from	O
the	O
SARS	O
outbreak	O
in	O
Hong	O
Kong	O
in	O
2003	O
.	O

Understanding	O
the	O
differences	O
in	O
receptor	B-FUNC
binding	I-FUNC
between	O
the	O
prototype	O
and	O
the	O
variant	O
strains	O
may	O
provide	O
insight	O
into	O
PEDV	O
pathogenesis	O
.	O

After	O
binding	B-FUNC
viral	O
particles	O
through	O
viral	O
surface	O
glycoproteins	O
,	O
P9	O
entered	O
into	O
cells	O
together	O
with	O
the	O
viruses	O
via	O
endocytosis	O
and	O
prevented	O
endosomal	O
acidification	O
,	O
which	O
blocked	O
membrane	O
fusion	O
and	O
subsequent	O
viral	O
RNA	O
release	O
.	O

The	O
mean	O
C	O
(	O
T	O
)	O
value	O
for	O
each	O
concentration	O
was	O
different	O
depending	O
on	O
which	O
commercial	O
kit	B-FUNC
was	O
used	O
for	O
the	O
assay	O
.	O

Among	O
the	O
three	O
commonly	O
used	O
kits	O
,	O
PowerChek	O
MERS	O
Real	O
-	O
Time	O
PCR	O
kit	B-FUNC
(	O
KogeneBiotech	O
,	O
Korea	O
)	O
showed	O
the	O
lowest	O
C	O
(	O
T	O
)	O
values	O
at	O
all	O
concentrations	O
of	O
upE	O
and	O
most	O
concentrations	O
of	O
ORF1a	O
.	O

Endothelial	O
activation	O
biomarkers	O
(	O
soluble	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
[	O
sVCAM	O
-	O
1	O
],	O
soluble	O
endothelial	O
selectin	B-FUNC
[	O
sESEL	O
],	O
angiopoietin	O
-	O
1	O
[	O
Ang	O
-	O
1	O
]	O
and	O
angiopoietin	O
-	O
2	O
[	O
Ang	O
-	O
2	O
])	O
were	O
measured	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

By	O
sequencing	O
PCR	O
products	O
of	O
the	O
coronavirus	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
gene	O
(	O
RdRp	B-FUNC
),	O
we	O
found	O
a	O
high	O
frequency	O
of	O
infection	O
by	O
a	O
diverse	O
group	O
of	O
coronaviruses	O
in	O
different	O
bat	O
species	O
in	O
the	O
mineshaft	O
.	O

Cell	O
tropism	O
and	O
host	O
range	O
is	O
determined	O
in	O
part	O
by	O
the	O
coronavirus	O
spike	O
(	O
S	O
)	O
protein	O
,	O
which	O
binds	B-FUNC
cellular	O
receptors	O
and	O
mediates	O
membrane	O
fusion	O
.	O

These	O
features	O
,	O
along	O
with	O
the	O
location	O
of	O
the	O
two	O
protease	O
sites	O
known	O
to	O
be	O
important	O
for	O
coronavirus	O
entry	O
,	O
provide	O
a	O
structural	O
basis	O
to	O
support	O
a	O
model	O
of	O
membrane	O
fusion	O
mediated	O
by	O
progressive	O
S	O
protein	O
destabilization	O
through	O
receptor	B-FUNC
binding	I-FUNC
and	O
proteolytic	O
cleavage	O
.	O

We	O
examined	O
the	O
in	O
vivo	O
efficacy	O
of	O
the	O
human	O
monoclonal	O
antibody	B-FUNC
m336	O
,	O
which	O
has	O
high	O
neutralizing	O
activity	O
against	O
MERS	O
-	O
CoV	O
in	O
vitro	O
.	O

m336	O
was	O
administered	O
to	O
rabbits	O
intravenously	O
or	O
intranasally	O
before	O
infection	O
with	O
MERS	O
-	O
CoV	O
.	O
Prophylaxis	O
with	O
m336	O
resulted	O
in	O
a	O
reduction	O
of	O
pulmonary	O
viral	O
RNA	O
titers	O
by	O
40	O
-	O
9000	O
-	O
fold	O
,	O
compared	O
with	O
an	O
irrelevant	O
control	O
antibody	B-FUNC
with	O
little	O
to	O
no	O
inflammation	O
or	O
viral	O
antigen	O
detected	O
.	O

ABSTRACT	O
:	O
Because	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
is	O
an	O
enzyme	O
whose	O
catalytic	B-FUNC
activity	I-FUNC
depends	O
on	O
its	O
heterodimeric	O
structure	O
,	O
this	O
system	O
could	O
be	O
a	O
target	O
for	O
inhibitors	O
that	O
perturb	O
the	O
interactions	O
between	O
the	O
protein	O
subunits	O
,	O
p51	O
and	O
p66	O
.	O

ABSTRACT	O
:	O
A	O
large	O
number	O
of	O
viruses	O
,	O
including	O
many	O
human	O
pathogens	O
,	O
bind	B-FUNC
cell	O
-	O
surface	O
glycans	O
during	O
the	O
initial	O
steps	O
of	O
infection	O
.	O

An	O
autopsy	O
revealed	O
multiple	O
foci	O
of	O
air	O
-	O
space	O
pneumonia	O
containing	O
numerous	O
acid	O
-	O
fast	B-FUNC
bacilli	O
without	O
granuloma	O
formation	O
,	O
accompanied	O
by	O
diffuse	O
alveolar	O
damage	O
.	O

Though	O
AI	O
-	O
H9N2	O
viruses	O
showed	O
low	O
rate	O
of	O
evolution	O
in	O
comparison	O
to	O
recent	O
strains	O
,	O
few	O
amino	O
acid	O
substitutions	O
indicative	O
of	O
antibody	B-FUNC
selection	O
pressure	O
were	O
observed	O
in	O
the	O
HA	O
gene	O
.	O

Here	O
we	O
show	O
that	O
in	O
multi	O
-	O
site	O
systems	O
like	O
ion	B-FUNC
channels	I-FUNC
the	O
application	O
of	O
the	O
Hill	O
formalism	O
could	O
require	O
a	O
combination	O
of	O
different	O
experiments	O
,	O
even	O
involving	O
site	O
-	O
directed	O
mutagenesis	O
,	O
to	O
identify	O
the	O
different	O
sources	O
of	O
cooperativity	O
and	O
to	O
discriminate	O
between	O
genuine	O
and	O
apparent	O
cooperativity	O
.	O

Cellular	O
therapy	O
by	O
reinfusing	O
autologous	O
bone	O
marrow	O
-	O
derived	O
MSCs	B-FUNC
into	O
MDR	B-FUNC
/	O
XDR	O
-	O
TB	O
patients	O
shows	O
promise	O
,	O
whereas	O
adjunctive	O
T	O
cell	O
-	O
based	O
therapies	O
are	O
considered	O
.	O

Cytotoxic	O
therapy	O
using	O
etoposide	O
,	O
a	O
topoisomerase	B-FUNC
II	I-FUNC
-	O
inhibiting	O
anticancer	O
drug	O
extends	O
survival	O
of	O
patients	O
with	O
severe	O
influenza	O
H1N1	O
infection	O
-	O
induced	O
hemophagocytic	O
lymphohistiocytosis	O
.	O

ABSTRACT	O
:	O
On	O
the	O
basis	O
of	O
structure	O
-	O
based	O
bioisosteric	O
replacement	O
and	O
molecular	O
hybridization	O
strategy	O
,	O
a	O
series	O
of	O
novel	O
dual	O
structural	O
-	O
conformation	O
inhibitors	O
targeting	O
the	O
""""	O
entrance	O
channel	O
""""	O
of	O
HIV	O
-	O
1	O
NNRTIs	O
binding	B-FUNC
pocket	O
(	O
NNIBP	O
)	O
were	O
designed	O
and	O
synthesized	O
.	O

Serum	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
was	O
raised	O
>	O
3	O
-	O
fold	O
in	O
17	O
.	O
16	O
%	O
and	O
serum	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
in	O
4	O
.	O
47	O
%	O
cases	O
.	O

Serum	O
bilirubin	O
,	O
AST	O
and	O
ALT	B-FUNC
levels	O
were	O
higher	O
while	O
age	O
was	O
lower	O
in	O
both	O
overall	O
(	O
p	O
<	O
0	O
.	O
05	O
each	O
)	O
and	O
falciparum	O
malaria	O
cases	O
with	O
hepatopathy	O
than	O
without	O
hepatopathy	O
(	O
p	O
<	O
0	O
.	O
05	O
each	O
).	O

Like	O
murine	O
coronavirus	O
NS2	O
,	O
a	O
previously	O
characterized	O
PDE	B-FUNC
,	O
MERS	O
NS4b	O
,	O
can	O
antagonize	O
activation	O
of	O
the	O
OAS	O
-	O
RNase	O
L	O
pathway	O
,	O
an	O
interferon	O
-	O
induced	O
potent	O
antiviral	O
activity	O
.	O

Rhesus	O
macaques	O
inoculated	O
with	O
MERS	O
-	O
CoV	O
VLPs	O
and	O
Alum	O
adjuvant	O
induced	O
virus	O
-	O
neutralizing	O
antibodies	O
titers	O
up	O
to	O
1	O
:	O
40	O
and	O
induced	O
specific	O
IgG	O
antibodies	O
against	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
),	O
with	O
endpoint	O
titers	O
reaching	O
1	O
:	O
1	O
,	O
280	O
.	O

Specifically	O
,	O
antibody	B-FUNC
-	O
positive	O
groups	O
returned	O
to	O
normal	O
body	O
temperature	O
faster	O
and	O
demonstrated	O
a	O
higher	O
rate	O
of	O
survivability	O
than	O
piglets	O
without	O
PEDV	O
antibody	B-FUNC
.	O

This	O
study	O
shows	O
that	O
positive	O
BAC	O
in	O
TBI	O
patients	O
is	O
associated	O
with	O
lower	O
systemic	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
and	O
leukocyte	O
numbers	O
,	O
indicating	O
that	O
positive	O
BAC	O
may	O
have	O
immunosuppressive	O
effects	O
in	O
this	O
cohort	O
of	O
patients	O
compared	O
with	O
TBI	O
patients	O
who	O
were	O
not	O
alcohol	O
intoxicated	O
.	O

The	O
extension	O
of	O
two	O
fragments	O
allowed	O
us	O
to	O
classify	O
our	O
sequences	O
within	O
the	O
RdRp	B-FUNC
Group	O
Unit	O
defined	O
for	O
Kenyan	O
Betacoronavirus	O
from	O
the	O
same	O
host	O
species	O
.	O

We	O
describe	O
the	O
prevalence	O
,	O
clinical	O
characteristics	O
,	O
outcomes	O
,	O
and	O
risk	O
factors	O
associated	O
with	O
CAP	O
resulting	O
from	O
multidrug	O
-	O
resistant	O
(	O
MDR	B-FUNC
)	O
and	O
non	O
-	O
MDR	B-FUNC
P	O
aeruginosa	O
.	O

TITLE	O
:	O
Platelets	O
are	O
dispensable	O
for	O
antibody	B-FUNC
-	O
mediated	O
transfusion	O
-	O
related	O
acute	O
lung	O
injury	O
in	O
the	O
mouse	O
.	O

TITLE	O
:	O
Diminished	O
COX	O
-	O
2	O
/	O
PGE2	O
-	O
Mediated	O
Antiviral	O
Response	O
Due	O
to	O
Impaired	O
NOX	O
/	O
MAPK	B-FUNC
Signaling	O
in	O
G6PD	O
-	O
Knockdown	O
Lung	O
Epithelial	O
Cells	O
.	O

TITLE	O
:	O
Rapid	O
generation	O
of	O
a	O
human	O
monoclonal	O
antibody	B-FUNC
to	O
combat	O
Middle	O
East	O
respiratory	O
syndrome	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
a	O
method	O
for	O
the	O
swift	O
generation	O
of	O
a	O
human	O
-	O
derived	O
monoclonal	O
antibody	B-FUNC
,	O
known	O
as	O
LCA60	O
,	O
as	O
a	O
treatment	O
for	O
MERS	O
infections	O
.	O

Currently	O
,	O
the	O
LCA60	O
antibody	B-FUNC
is	O
being	O
considered	O
for	O
clinical	O
development	O
,	O
which	O
includes	O
prophylaxis	O
in	O
individuals	O
at	O
risk	O
and	O
a	O
treatment	O
for	O
severe	O
MERS	O
-	O
CoV	O
infections	O
.	O

Scientists	O
are	O
looking	O
to	O
implement	O
viral	O
sequencing	O
on	O
all	O
negative	O
samples	O
by	O
RT	O
-	O
PCR	O
and	O
they	O
beleive	O
that	O
can	O
be	O
exposed	O
to	O
another	O
level	O
of	O
testing	O
using	O
sequencing	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
gene	O
or	O
N	O
gene	O
and	O
in	O
this	O
case	O
a	O
positive	O
result	O
is	O
diagnostic	O
.	O

Moreover	O
,	O
no	O
seroconversion	O
was	O
found	O
among	O
53	O
close	O
contacts	O
by	O
anti	O
-	O
MERS	O
IgG	O
antibody	B-FUNC
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
of	O
paired	O
serum	O
samples	O
.	O

Purified	O
proteins	O
were	O
detected	O
by	O
western	O
blot	O
using	O
mouse	O
anti	O
-	O
GST	O
mAb	O
and	O
pig	O
anti	O
-	O
PEDV	O
immune	O
sera	B-FUNC
.	O

Finally	O
,	O
immunization	O
of	O
mice	O
with	O
10	O
μg	O
of	O
purified	O
proteins	O
elicited	O
highly	O
potent	O
serum	O
IgG	O
and	O
serum	O
neutralizing	O
antibody	B-FUNC
titers	O
.	O

Nanotrap	O
particles	O
are	O
hydrogel	O
particles	O
that	O
are	O
coupled	O
to	O
chemical	O
dye	O
affinity	O
baits	O
that	O
bind	B-FUNC
a	O
broad	O
range	O
of	O
proteins	O
and	O
virions	O
.	O

The	O
determination	O
of	O
the	O
interaction	O
spectra	O
of	O
the	O
protein	O
residues	O
involved	O
in	O
inhibitor	O
binding	B-FUNC
highlighted	O
amino	O
acids	O
R295	O
and	O
Y674	O
as	O
the	O
two	O
fundamental	O
H	O
-	O
bond	O
donors	O
,	O
while	O
two	O
hydrophobic	O
cavities	O
HC1	O
(	O
residues	O
A221	O
,	O
I261	O
,	O
I287	O
,	O
and	O
Y289	O
)	O
and	O
HC2	O
(	O
residues	O
V216	O
,	O
Y303	O
,	O
V306	O
,	O
K307	O
,	O
P408	O
,	O
and	O
A412	O
)	O
fulfill	O
the	O
third	O
pharmacophoric	O
requirement	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
papain	O
-	O
like	O
protease	O
induces	O
Egr	O
-	O
1	O
-	O
dependent	O
up	O
-	O
regulation	O
of	O
TGF	O
-	O
β1	O
via	O
ROS	O
/	O
p38	B-FUNC
MAPK	B-FUNC
/	O
STAT3	O
pathway	O
.	O

Furthermore	O
,	O
the	O
inhibitors	O
for	O
ROS	O
(	O
YCG063	O
),	O
p38	B-FUNC
MAPK	B-FUNC
(	O
SB203580	O
),	O
and	O
STAT3	O
(	O
Stattic	O
)	O
revealed	O
ROS	O
/	O
p38	B-FUNC
MAPK	B-FUNC
/	O
STAT3	O
pathway	O
involving	O
in	O
Egr	O
-	O
1	O
dependent	O
activation	O
of	O
TGF	O
-	O
β1	O
promoter	O
induced	O
by	O
PLpro	O
.	O

Overall	O
,	O
QF	O
regulated	O
the	O
PI3K	B-FUNC
/	O
AKT	O
and	O
Ras	O
/	O
MAPK	B-FUNC
pathways	O
to	O
inhibit	O
pathogenic	O
bacterial	O
infections	O
effectively	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
an	O
affinity	O
purification	O
/	O
mass	O
spectrometry	O
approach	O
to	O
demonstrate	O
that	O
a	O
bat	O
MHC	O
class	O
I	O
molecule	O
,	O
Ptal	O
-	O
N	O
*	O
01	O
:	O
01	O
,	O
binds	B-FUNC
antigenic	O
peptides	O
and	O
associates	O
with	O
peptide	O
-	O
loading	O
complex	O
components	O
.	O

ABSTRACT	O
:	O
We	O
studied	O
antibody	B-FUNC
response	O
in	O
9	O
healthcare	O
workers	O
in	O
Jeddah	O
,	O
Saudi	O
Arabia	O
,	O
who	O
survived	O
Middle	O
East	O
respiratory	O
syndrome	O
,	O
by	O
using	O
serial	O
ELISA	O
and	O
indirect	O
immunofluorescence	O
assay	O
testing	O
.	O

TITLE	O
:	O
Recognition	O
of	O
Lys48	O
-	O
Linked	O
Di	O
-	O
ubiquitin	B-FUNC
and	O
Deubiquitinating	O
Activities	O
of	O
the	O
SARS	O
Coronavirus	O
Papain	O
-	O
like	O
Protease	O
.	O

ARDS	O
episodes	O
were	O
assigned	O
to	O
ACS	B-FUNC
-	O
ARDS	O
or	O
nonACS	O
-	O
ARDS	O
group	O
according	O
to	O
whether	O
the	O
clinical	O
insult	O
was	O
ACS	B-FUNC
or	O
not	O
,	O
respectively	O
.	O

In	O
summary	O
,	O
our	O
data	O
demonstrated	O
critical	O
roles	O
of	O
the	O
p38	B-FUNC
and	O
JNK1	O
/	O
2	O
signaling	O
pathways	O
in	O
facilitating	O
successful	O
viral	O
infection	O
during	O
the	O
post	O
-	O
entry	O
steps	O
of	O
the	O
PEDV	O
life	O
cycle	O
.	O

We	O
developed	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
targeting	O
antibodies	O
to	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
EqCoV	O
and	O
validated	O
its	O
use	O
,	O
using	O
acute	O
and	O
convalescent	O
sera	B-FUNC
from	O
83	O
adult	O
horses	O
involved	O
in	O
6	O
outbreaks	O
.	O

Ubiquitin	B-FUNC
binding	I-FUNC
by	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	O
)	O
involves	O
remarkable	O
differences	O
compared	O
to	O
the	O
corresponding	O
complex	O
with	O
SARS	O
-	O
CoV	O
PL	O
(	O
pro	O
).	O

Neutralizing	O
antibody	B-FUNC
was	O
induced	O
by	O
vaccine	O
with	O
and	O
without	O
adjuvant	O
and	O
lung	O
virus	O
was	O
reduced	O
in	O
vaccinated	O
mice	O
after	O
challenge	O
.	O

Nevertheless	O
,	O
BufCoV	O
HKU26	O
possessed	O
distinct	O
accessory	O
proteins	O
between	O
spike	O
and	O
envelope	O
compared	O
to	O
BCoV	O
.	O
Sugar	O
-	O
binding	B-FUNC
residues	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
S	O
protein	O
in	O
BCoV	O
are	O
conserved	O
in	O
BufCoV	O
HKU26	O
.	O

The	O
nucleoprotein	O
of	O
PDCoV	O
was	O
expressed	O
as	O
a	O
recombinant	O
protein	O
and	O
purified	O
for	O
use	O
as	O
an	O
antigen	O
to	O
immunize	O
mice	O
for	O
polyclonal	O
,	O
hyperimmune	O
sera	B-FUNC
and	O
monoclonal	O
antibody	B-FUNC
(	O
mAb	O
)	O
production	O
.	O

The	O
same	O
antigen	O
was	O
used	O
to	O
develop	O
serological	O
tests	O
to	O
detect	O
the	O
antibody	B-FUNC
response	O
to	O
PDCoV	O
in	O
pigs	O
following	O
infection	O
.	O

This	O
report	O
shows	O
that	O
the	O
CoV	O
RdRp	B-FUNC
(	O
nsp12	O
)	O
likely	O
functions	O
in	O
replication	O
fidelity	O
;	O
that	O
residue	O
determinants	O
of	O
CoV	O
RdRp	B-FUNC
nucleotide	O
selectivity	O
map	O
to	O
similar	O
structural	O
regions	O
of	O
other	O
,	O
unrelated	O
RNA	O
viral	O
polymerases	O
;	O
and	O
that	O
for	O
CoVs	O
,	O
the	O
proofreading	O
activity	O
of	O
the	O
nsp14	O
-	O
ExoN	O
is	O
epistatic	O
to	O
the	O
function	O
of	O
the	O
RdRp	B-FUNC
in	O
fidelity	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
detection	O
and	O
antibody	B-FUNC
response	O
in	O
commercial	O
growing	O
pigs	O
.	O

Nine	O
polypeptides	O
with	O
high	O
scores	O
were	O
synthesized	O
and	O
linked	O
to	O
keyhole	O
limpet	O
hemocyanin	B-FUNC
(	O
KLH	O
).	O

Here	O
,	O
we	O
generated	O
a	O
humanized	O
monoclonal	O
antibody	B-FUNC
(	O
mAb	O
),	O
designated	O
hMS	O
-	O
1	O
,	O
which	O
targeted	O
the	O
MERS	O
-	O
CoV	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
with	O
high	O
affinity	O
.	O

Remarkable	O
beneficial	O
effects	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
blockade	O
therapy	O
using	O
a	O
humanized	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
receptor	O
antibody	B-FUNC
,	O
tocilizumab	O
were	O
recently	O
observed	O
in	O
patients	O
with	O
cytokine	O
release	O
syndrome	O
complicated	O
by	O
T	O
-	O
cell	O
engaged	O
therapy	O
.	O

ABSTRACT	O
:	O
Stiff	O
-	O
person	O
syndrome	O
(	O
SPS	B-FUNC
)	O
is	O
a	O
rare	O
disorder	O
characterized	O
by	O
progressive	O
muscle	O
stiffness	O
,	O
rigidity	O
,	O
and	O
spasms	O
involving	O
the	O
axial	O
muscles	O
.	O

Birds	O
fed	O
YDC	O
showed	O
higher	O
specific	O
antibody	B-FUNC
response	O
against	O
IBV	O
in	O
wk	O
4	O
,	O
while	O
both	O
diets	O
containing	O
YDC	O
and	O
SNB	O
decreased	O
antibody	B-FUNC
response	O
to	O
IBV	O
in	O
wk	O
6	O
.	O

Compared	O
with	O
nonobese	O
women	O
,	O
super	O
obese	O
women	O
had	O
twofold	O
odds	O
of	O
acute	O
(	O
5	O
vs	O
.	O
10	O
%;	O
adjusted	O
odds	O
ratio	O
[	O
aOR	B-FUNC
]:	O
1	O
.	O
81	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]:	O
1	O
.	O
59	O
-	O
2	O
.	O
73	O
)	O
and	O
severe	O
(	O
3	O
vs	O
.	O
6	O
%;	O
aOR	B-FUNC
:	O
2	O
.	O
08	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
59	O
-	O
2	O
.	O
73	O
)	O
neonatal	O
morbidity	O
.	O

However	O
,	O
post	O
-	O
admission	O
decreases	O
in	O
the	O
serum	O
levels	O
of	O
interleukin	O
(	O
IL	O
)-	O
17	O
,	O
IL	B-FUNC
-	I-FUNC
7	I-FUNC
,	O
and	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
were	O
significantly	O
greater	O
in	O
the	O
SLEDf	O
group	O
.	O

Spike	O
glycoprotein	O
of	O
coronavirus	O
is	O
responsible	O
for	O
induction	O
of	O
neutralizing	O
antibody	B-FUNC
response	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
proteins	O
of	O
coronaviruses	O
are	O
capable	O
of	O
binding	B-FUNC
to	O
a	O
wide	O
range	O
of	O
cellular	O
targets	O
,	O
which	O
contributes	O
to	O
the	O
broad	O
species	O
tropism	O
of	O
coronaviruses	O
.	O

The	O
identification	O
of	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	O
molecule	O
5	O
(	O
CEACAM5	O
)	O
as	O
a	O
novel	O
cell	B-FUNC
surface	I-FUNC
binding	I-FUNC
target	O
of	O
MERS	O
-	O
CoV	O
advanced	O
our	O
knowledge	O
on	O
the	O
cell	O
binding	B-FUNC
biology	O
of	O
MERS	O
-	O
CoV	O
.	O
Importantly	O
,	O
CEACAM5	O
could	O
potentiate	O
the	O
entry	O
of	O
MERS	O
-	O
CoV	O
by	O
functioning	O
as	O
an	O
attachment	O
factor	O
.	O

Antibodies	O
in	O
human	O
sera	B-FUNC
neutralized	O
dromedary	O
-	O
derived	O
viruses	O
,	O
suggesting	O
population	O
immunity	O
against	O
dromedary	O
viruses	O
.	O

Orthovanadate	O
,	O
a	O
protein	O
tyrosine	O
phosphatase	B-FUNC
inhibitor	O
,	O
and	O
Resveratrol	O
(	O
Resv	O
),	O
an	O
antioxidant	O
agent	O
,	O
protected	O
FAK	O
and	O
ERK1	B-FUNC
/	O
2	O
from	O
dephosphorylation	O
and	O
HUVEC	O
from	O
ROS	O
-	O
induced	O
loss	O
of	O
adhesion	O
.	O

In	O
addition	O
,	O
R	O
-	O
H120	O
-	O
Beaudette	O
-	O
p65	O
(	O
S	O
)	O
could	O
induce	O
a	O
similar	O
antibody	B-FUNC
titre	O
and	O
provide	O
up	O
to	O
80	O
%	O
immune	O
protection	O
in	O
chickens	O
challenged	O
with	O
the	O
M41	O
strain	O
.	O

Using	O
Western	O
blot	O
under	O
denaturing	O
conditions	O
,	O
ArkDPI	O
serotype	O
-	O
specific	O
sera	B-FUNC
did	O
not	O
bind	B-FUNC
to	O
S1	O
proteins	O
with	O
∆	O
344	O
,	O
suggesting	O
that	O
∆	O
344	O
alters	O
antigenicity	O
of	O
S1	O
.	O

The	O
study	O
was	O
a	O
secondary	O
analysis	O
of	O
the	O
safety	O
of	O
a	O
randomized	O
trial	O
of	O
erythropoietin	B-FUNC
and	O
transfusion	O
threshold	O
in	O
patients	O
with	O
severe	O
TBI	O
.	O

And	O
out	O
of	O
all	O
the	O
investigations	O
WBC	O
,	O
neutrophil	O
counts	O
,	O
AST	O
and	O
ALT	B-FUNC
values	O
have	O
some	O
predictive	O
utility	O
.	O

Via	O
comparison	O
of	O
the	O
available	O
RBD	O
structures	O
,	O
we	O
further	O
proposed	O
a	O
homologous	O
intersubdomain	O
binding	B-FUNC
mode	O
in	O
betaCoV	O
RBDs	O
that	O
anchors	O
the	O
external	O
subdomain	O
to	O
the	O
core	O
subdomain	O
.	O

We	O
speculate	O
that	O
low	O
immunity	O
due	O
to	O
decreased	O
immunoglobulin	B-FUNC
in	O
patients	O
with	O
OHSS	O
makes	O
them	O
prone	O
to	O
SBP	O
.	O

Several	O
strategies	O
focusing	O
on	O
the	O
binding	B-FUNC
grooves	O
of	O
the	O
NHR	O
trimer	O
have	O
been	O
adopted	O
to	O
increase	O
the	O
antiviral	O
activity	O
of	O
the	O
CHR	O
peptides	O
.	O

We	O
solved	O
the	O
crystal	O
structure	O
of	O
the	O
6	O
-	O
HB	O
formed	O
by	O
MT	O
-	O
WQ	O
-	O
IDL	O
and	O
N46	O
and	O
found	O
that	O
,	O
besides	O
the	O
N	O
-	O
terminal	O
MT	O
hook	O
tail	O
,	O
the	O
IDL	O
tail	O
anchor	O
of	O
MT	O
-	O
WQ	O
-	O
IDL	O
also	O
binds	B-FUNC
with	O
the	O
shallow	O
hydrophobic	O
pocket	O
outside	O
the	O
groove	O
of	O
the	O
NHR	O
trimer	O
,	O
resulting	O
in	O
enhanced	O
inhibition	O
of	O
HIV	O
-	O
1	O
fusion	O
with	O
the	O
target	O
cell	O
.	O

In	O
this	O
study	O
,	O
a	O
simple	O
way	O
to	O
conjugate	O
antigens	O
to	O
the	O
S	O
.	O
aureus	O
nanobioparticles	O
was	O
developed	O
by	O
utilizing	O
a	O
cell	O
wall	O
binding	B-FUNC
domain	O
(	O
CBD	O
)	O
from	O
a	O
bacteriophage	O
lysin	O
PlyV12	O
.	O

Both	O
stable	O
(	O
n	O
=	O
177	O
)	O
and	O
acute	O
(	O
n	O
=	O
78	O
)	O
asthmatics	O
were	O
recruited	O
and	O
categorized	O
into	O
lean	O
(	O
n	O
=	O
77	O
and	O
39	O
respectively	O
),	O
overweight	O
(	O
n	O
=	O
41	O
and	O
17	O
respectively	O
)	O
and	O
obese	O
(	O
n	O
=	O
59	O
and	O
22	O
respectively	O
)	O
groups	O
and	O
compared	O
for	O
clinical	O
characteristics	O
,	O
including	O
sputum	O
and	O
plasma	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
protein	O
concentrations	O
,	O
sputum	O
cellularity	O
,	O
spirometry	O
and	O
comorbidities	O
.	O

ESR	O
showed	O
that	O
both	O
FPs	B-FUNC
increase	O
lipid	O
packing	O
and	O
head	O
group	O
ordering	O
as	O
well	O
as	O
reduce	O
the	O
intramembrane	O
water	O
content	O
for	O
anionic	O
membranes	O
.	O

A	O
surface	O
spike	O
(	O
S	O
)	O
protein	O
guides	O
MERS	O
-	O
CoV	O
entry	O
into	O
host	O
cells	O
by	O
binding	B-FUNC
to	O
cellular	O
receptor	O
dipeptidyl	O
peptidase	O
-	O
4	O
(	O
DPP4	O
),	O
followed	O
by	O
fusion	O
between	O
virus	O
and	O
host	O
cell	O
membranes	O
.	O

TITLE	O
:	O
Quantifying	O
the	O
effect	O
of	O
lactogenic	O
antibody	B-FUNC
on	O
porcine	O
epidemic	O
diarrhea	O
virus	O
infection	O
in	O
neonatal	O
piglets	O
.	O

Pregnant	O
multiparous	O
sows	O
and	O
their	O
litters	O
were	O
allocated	O
to	O
one	O
of	O
3	O
treatment	O
groups	O
:	O
Group	O
1	O
-	O
6	O
serum	O
antibody	B-FUNC
-	O
negative	O
sows	O
and	O
a	O
subset	O
(	O
n	O
=	O
11	O
)	O
of	O
their	O
piglets	O
.	O

TITLE	O
:	O
Association	O
of	O
Heme	O
Oxygenase	B-FUNC
1	O
with	O
Lung	O
Protection	O
in	O
Malaria	O
-	O
Associated	O
ALI	O
/	O
ARDS	O
.	O

The	O
conformation	O
1	O
determined	O
at	O
4	O
.	O
3	O
Å	O
resolution	O
is	O
three	O
-	O
fold	O
symmetric	O
and	O
has	O
all	O
the	O
three	O
receptor	O
-	O
binding	B-FUNC
C	O
-	O
terminal	O
domain	O
1	O
(	O
CTD1s	O
)	O
of	O
the	O
S1	O
subunits	O
in	O
""""	O
down	O
""""	O
positions	O
.	O

This	O
phenomenon	O
could	O
be	O
extended	O
to	O
other	O
betacoronaviruses	O
utilizing	O
CTD1	O
of	O
the	O
S1	O
subunit	O
for	O
receptor	B-FUNC
binding	I-FUNC
,	O
which	O
provides	O
new	O
insights	O
into	O
the	O
intermediate	O
states	O
of	O
coronavirus	O
pre	O
-	O
fusion	O
spike	O
trimer	O
during	O
infection	O
.	O

Maternal	O
antibodies	O
titers	O
were	O
very	O
low	O
in	O
calves	O
regardless	O
of	O
the	O
antibody	B-FUNC
titers	O
of	O
the	O
mothers	O
.	O

TITLE	O
:	O
Roles	O
of	O
regulatory	O
T	O
cells	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
in	O
virus	O
-	O
induced	O
demyelination	O
.	O

Regulatory	O
T	O
cells	O
,	O
especially	O
those	O
that	O
are	O
specific	O
for	O
antigens	O
recognized	O
by	O
pathogenic	O
T	O
cells	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
are	O
two	O
anti	O
-	O
inflammatory	O
/	O
pro	O
-	O
resolution	O
factors	O
that	O
demonstrate	O
efficacy	O
in	O
experimental	O
models	O
of	O
virus	O
-	O
induced	O
demyelination	O
and	O
may	O
be	O
useful	O
in	O
patients	O
infected	O
with	O
viruses	O
that	O
cause	O
demyelination	O
.	O

ABSTRACT	O
:	O
Pulmonary	O
exposure	O
to	O
the	O
plant	O
toxin	O
ricin	B-FUNC
leads	O
to	O
respiratory	O
insufficiency	O
and	O
death	O
.	O

Strips	O
run	O
in	O
buffer	O
or	O
pure	B-FUNC
solutions	O
of	O
bovine	O
serum	O
albumin	O
exhibited	O
false	O
positives	O
,	O
but	O
those	O
run	O
in	O
human	O
serum	O
did	O
not	O
.	O

In	O
patients	O
with	O
CoV	O
-	O
CNS	O
infection	O
,	O
the	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
MCP	B-FUNC
-	O
1	O
,	O
and	O
GM	O
-	O
CSF	O
were	O
significantly	O
higher	O
in	O
their	O
cerebrospinal	O
fluid	O
samples	O
than	O
in	O
matched	O
serum	O
samples	O
.	O

However	O
,	O
TMPRSS2	O
overexpression	O
decreased	O
MHV	O
structural	O
protein	O
expression	O
,	O
release	O
of	O
infectious	O
particles	O
,	O
and	O
syncytium	O
formation	O
,	O
and	O
endogenous	O
serine	B-FUNC
protease	I-FUNC
activity	I-FUNC
did	O
not	O
contribute	O
greatly	O
to	O
infection	O
.	O

The	O
arteriviruses	O
have	O
significantly	O
smaller	O
genomes	O
and	O
form	O
an	O
intriguing	O
package	O
with	O
the	O
coronaviruses	O
to	O
analyse	O
viral	O
RdRp	B-FUNC
evolution	O
and	O
function	O
.	O

Understanding	O
RdRp	B-FUNC
behaviour	O
and	O
interactions	O
during	O
RNA	O
synthesis	O
and	O
subsequent	O
processing	O
will	O
be	O
key	O
to	O
rationalising	O
the	O
evolutionary	O
success	O
of	O
nidoviruses	O
and	O
the	O
development	O
of	O
antiviral	O
strategies	O
.	O

Herein	O
,	O
an	O
alternative	O
indirect	O
ELISA	O
for	O
detection	O
of	O
IBV	O
antibody	B-FUNC
was	O
developed	O
with	O
IBV	O
nonstructural	O
protein	O
5	O
(	O
nsp5	O
)	O
produced	O
by	O
Escherichia	O
coli	O
.	O

TITLE	O
:	O
Heat	O
shock	O
protein	O
70	O
in	O
lung	O
and	O
kidney	O
of	O
specific	O
-	O
pathogen	O
-	O
free	O
chickens	O
is	O
a	O
receptor	O
-	O
associated	O
protein	O
that	O
interacts	O
with	O
the	O
binding	B-FUNC
domain	O
of	O
the	O
spike	O
protein	O
of	O
infectious	O
bronchitis	O
virus	O
.	O

The	O
levels	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
-	O
α	O
),	O
interleukin	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
in	O
serum	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
measured	O
using	O
the	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

There	O
were	O
marked	O
changes	O
in	O
the	O
root	O
-	O
mean	O
-	O
square	O
deviation	O
(	O
RMSD	O
)	O
in	O
the	O
ubiquitin	B-FUNC
like	O
domain	O
(	O
Ubl	O
)	O
and	O
the	O
fingers	O
subdomain	O
of	O
the	O
catalytic	O
domain	O
of	O
Plpro	O
.	O

TITLE	O
:	O
Structure	O
of	O
human	O
IFIT1	O
with	O
capped	O
RNA	O
reveals	O
adaptable	O
mRNA	B-FUNC
binding	I-FUNC
and	O
mechanisms	O
for	O
sensing	O
N1	O
and	O
N2	O
ribose	O
2	O
'-	O
O	O
methylations	O
.	O

Clinical	O
and	O
high	O
-	O
resolution	O
CT	O
of	O
229	O
patients	O
including	O
123	O
pure	B-FUNC
COPD	O
patients	O
and	O
106	O
ACOS	O
patients	O
were	O
included	O
.	O

Among	O
them	O
,	O
nsp9	O
plays	O
an	O
essential	O
role	O
in	O
viral	O
replication	O
by	O
forming	O
a	O
homodimer	O
that	O
binds	B-FUNC
single	O
-	O
stranded	O
RNA	O
.	O

Internationally	O
,	O
there	O
is	O
a	O
strong	O
trend	O
towards	O
less	O
invasive	O
surgical	O
approach	O
to	O
PTA	B-FUNC
treatment	O
with	O
avoidance	O
of	O
acute	O
tonsillectomy	O
,	O
needle	O
aspiration	O
instead	O
of	O
ID	O
,	O
and	O
in	O
some	O
cases	O
even	O
antibiotic	O
treatment	O
without	O
surgical	O
drainage	O
.	O

As	O
clinicians	O
,	O
we	O
noticed	O
that	O
FN	O
was	O
recovered	O
from	O
PTA	B-FUNC
patients	O
with	O
increasing	O
frequency	O
and	O
that	O
patients	O
infected	O
with	O
Fusobacterium	O
necrophorum	O
(	O
FN	O
)	O
seemed	O
to	O
be	O
more	O
severely	O
affected	O
than	O
patients	O
infected	O
with	O
other	O
bacteria	O
.	O

To	O
explore	O
the	O
microbiology	O
of	O
PTA	B-FUNC
with	O
a	O
special	O
attention	O
to	O
Fusobacterium	O
necrophorum	O
(	O
FN	O
).	O

We	O
also	O
analysed	O
sera	B-FUNC
taken	O
acutely	O
and	O
at	O
least	O
two	O
weeks	O
after	O
surgery	O
for	O
the	O
presence	O
of	O
anti	O
-	O
FN	O
antibodies	O
.	O

Significantly	O
higher	O
inflammatory	O
markers	O
in	O
FN	O
-	O
positive	O
patients	O
compared	O
to	O
PTA	B-FUNC
patients	O
infected	O
with	O
other	O
bacteria	O
.	O

However	O
,	O
the	O
microbiology	O
of	O
PTA	B-FUNC
fluctuated	O
with	O
seasons	O
:	O
GAS	O
-	O
positive	O
PTA	B-FUNC
cases	O
were	O
significantly	O
more	O
prevalent	O
in	O
the	O
winter	O
and	O
spring	O
compared	O
to	O
the	O
summer	O
,	O
while	O
FN	O
-	O
positive	O
PTA	B-FUNC
patients	O
exhibited	O
a	O
more	O
even	O
distribution	O
over	O
the	O
year	O
,	O
but	O
with	O
a	O
trend	O
towards	O
higher	O
prevalence	O
in	O
the	O
summer	O
than	O
in	O
the	O
winter	O
.	O

Based	O
on	O
our	O
findings	O
suggesting	O
that	O
FN	O
is	O
a	O
frequent	O
pathogen	O
in	O
PTA	B-FUNC
,	O
we	O
recommend	O
clindamycin	O
instead	O
of	O
a	O
macrolide	O
in	O
penicillin	O
-	O
allergic	O
patients	O
with	O
PTA	B-FUNC
.	O

Comparative	O
microbiology	O
between	O
PTA	B-FUNC
patients	O
and	O
""""	O
normal	O
tonsils	O
"""."	O

Antibody	B-FUNC
responses	O
in	O
serum	O
,	O
colostrum	O
,	O
and	O
milk	O
samples	O
were	O
measured	O
by	O
IgG	O
/	O
IgA	O
ELISA	O
and	O
virus	O
neutralization	O
assay	O
(	O
VN	O
).	O

Compared	O
with	O
one	O
dose	O
and	O
2	O
doses	O
at	O
1	O
-,	O
2	O
-,	O
and	O
3	O
-	O
week	O
intervals	O
,	O
a	O
regimen	O
of	O
2	O
doses	O
of	O
this	O
protein	O
separated	O
by	O
an	O
interval	O
of	O
4	O
weeks	O
induced	O
the	O
strongest	O
antibody	B-FUNC
response	O
and	O
neutralizing	O
antibodies	O
against	O
MERS	O
-	O
CoV	O
infection	O
,	O
and	O
maintained	O
at	O
a	O
high	O
level	O
during	O
the	O
detection	O
period	O
.	O

We	O
carried	O
out	O
RT	O
-	O
PCR	O
on	O
306	O
nasal	O
and	O
315	O
rectal	O
swabs	O
and	O
tested	O
243	O
sera	B-FUNC
for	O
antibodies	O
to	O
detect	O
coronavirus	O
infections	O
in	O
apparently	O
healthy	O
horses	O
in	O
Saudi	O
Arabia	O
and	O
Oman	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
IBV	O
exhibits	O
strong	O
global	O
DUB	O
activity	O
with	O
significant	O
reductions	O
of	O
the	O
levels	O
of	O
ubiquitin	B-FUNC
(	O
Ub	O
)-,	O
K48	O
-,	O
and	O
K63	O
-	O
conjugated	O
proteins	O
.	O

The	O
significant	O
antiviral	O
activity	O
of	O
IL	B-FUNC
-	I-FUNC
22	I-FUNC
to	O
curtail	O
multiple	O
enteric	O
diarrhea	O
viruses	O
in	O
vitro	O
suggests	O
that	O
pIL	O
-	O
22	O
could	O
be	O
a	O
novel	O
therapeutic	O
against	O
devastating	O
viral	O
diarrhea	O
in	O
piglets	O
.	O

Based	O
on	O
our	O
structure	O
of	O
NTD	O
solved	O
here	O
,	O
we	O
proposed	O
and	O
experimentally	O
evaluated	O
a	O
model	O
of	O
RNA	B-FUNC
binding	I-FUNC
.	O

Better	O
protection	O
efficiency	O
was	O
observed	O
after	O
a	O
booster	O
vaccination	O
,	O
which	O
resulted	O
in	O
higher	O
antibody	B-FUNC
titers	O
,	O
significantly	O
fewer	O
disease	O
symptoms	O
,	O
and	O
reduced	O
virus	O
replication	O
and	O
shedding	O
.	O

Since	O
publication	O
of	O
the	O
ACR	O
criteria	O
for	O
vasculitis	O
,	O
the	O
sensitivity	O
for	O
each	O
type	O
of	O
vasculitis	O
,	O
except	O
GCA	B-FUNC
,	O
has	O
diminished	O
,	O
although	O
the	O
specificities	O
have	O
remained	O
high	O
,	O
highlighting	O
the	O
need	O
for	O
updated	O
classification	O
criteria	O
.	O

RVA	O
-	O
specific	O
antibodies	O
were	O
detected	O
in	O
10	O
.	O
7	O
%	O
(	O
48	O
/	O
448	O
)	O
of	O
bat	O
sera	B-FUNC
by	O
an	O
indirect	O
immunofluorescence	O
assay	O
(	O
IIFA	O
).	O

Bats	O
in	O
Guangxi	O
and	O
Yunnan	O
had	O
a	O
higher	O
RVA	O
-	O
specific	O
antibody	B-FUNC
prevalence	O
than	O
those	O
from	O
Fujian	O
and	O
Zhejiang	O
provinces	O
.	O

Using	O
mouse	O
models	O
of	O
SARS	O
-	O
CoV	O
pathogenesis	O
,	O
we	O
have	O
identified	O
that	O
the	O
wound	O
repair	O
pathway	O
,	O
controlled	O
by	O
the	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
(	O
EGFR	B-FUNC
),	O
is	O
critical	O
to	O
recovery	O
from	O
SARS	O
-	O
CoV	O
-	O
induced	O
tissue	O
damage	O
.	O

We	O
set	O
out	O
to	O
determine	O
if	O
dyspnea	O
in	O
patients	O
with	O
ENS	O
was	O
associated	O
with	O
hyperventilation	O
syndrome	O
(	O
HVS	B-FUNC
).	O

Previously	O
,	O
we	O
demonstrated	O
that	O
both	O
MERS	O
-	O
CoV	O
and	O
BatCoV	O
HKU4	O
use	O
CD26	O
as	O
a	O
receptor	O
,	O
but	O
how	O
the	O
BatCoVs	O
evolved	O
to	O
bind	B-FUNC
CD26	O
is	O
an	O
intriguing	O
question	O
.	O

Combined	O
with	O
sequence	O
variation	O
in	O
the	O
HKU5	O
-	O
CTD	O
receptor	B-FUNC
binding	I-FUNC
interface	O
,	O
we	O
propose	O
the	O
necessity	O
for	O
surveilling	O
the	O
mutation	O
in	O
BatCoV	O
HKU5	O
spike	O
protein	O
in	O
case	O
of	O
bat	O
-	O
to	O
-	O
human	O
interspecies	O
transmission	O
.	O

It	O
was	O
observed	O
that	O
AG1478	O
and	O
451	O
blocked	O
the	O
activation	O
of	O
EGFR	B-FUNC
signaling	O
in	O
lung	O
tissue	O
and	O
reduced	O
the	O
LPS	O
-	O
induced	O
infiltration	O
of	O
inflammatory	O
cells	O
,	O
inflammatory	O
gene	O
expression	O
,	O
and	O
lung	O
injuries	O
.	O

Furthermore	O
,	O
Hellevad	O
and	O
Hisex	O
chickens	O
were	O
found	O
to	O
have	O
higher	O
levels	O
of	O
humoral	O
innate	O
immunity	O
with	O
regard	O
to	O
sample	O
to	O
positive	O
ratio	O
of	O
natural	O
antibodies	O
in	O
serum	O
and	O
concentration	O
of	O
mannose	O
-	O
binding	B-FUNC
lectin	O
in	O
serum	O
as	O
compared	O
to	O
Bovans	O
.	O

We	O
identify	O
five	O
residues	O
in	O
the	O
insertion	O
subdomain	O
that	O
are	O
critical	O
for	O
binding	B-FUNC
of	O
neutralizing	O
antibodies	O
and	O
two	O
residues	O
essential	O
for	O
receptor	B-FUNC
binding	I-FUNC
.	O

In	O
the	O
present	O
work	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
Uvaria	O
angolensis	O
extracts	O
on	O
the	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
-	O
associated	O
DNA	O
polymerase	O
and	O
ribonuclease	O
H	O
activities	O
.	O

Phosphine	O
is	O
a	O
respiratory	O
toxin	O
that	O
inhibits	O
cytochrome	B-FUNC
C	I-FUNC
oxidase	O
system	O
resulting	O
in	O
renal	O
failure	O
and	O
liver	O
failure	O
.	O

Mutations	O
of	O
these	O
connexin	B-FUNC
(	O
Cx	O
)	O
proteins	O
cause	O
dysmyelinating	O
diseases	O
in	O
humans	O
.	O

TITLE	O
:	O
Rapid	O
Transient	O
Production	O
of	O
a	O
Monoclonal	O
Antibody	B-FUNC
Neutralizing	O
the	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
(	O
PEDV	O
)	O
in	O
Nicotiana	O
benthamiana	O
and	O
Lactuca	O
sativa	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
plant	O
-	O
produced	O
monoclonal	O
antibody	B-FUNC
(	O
mAb	O
)	O
2C10	O
as	O
a	O
prophylactic	O
candidate	O
to	O
prevent	O
the	O
PEDV	O
infection	O
.	O

A	O
single	O
dose	O
of	O
ChAdOx1	O
MERS	O
with	O
tPA	B-FUNC
elicited	O
cellular	O
immune	O
responses	O
as	O
well	O
as	O
neutralising	O
antibodies	O
that	O
were	O
boosted	O
to	O
a	O
significantly	O
higher	O
level	O
by	O
MVA	O
MERS	O
.	O

Here	O
,	O
we	O
described	O
the	O
isolation	O
of	O
a	O
PEDV	O
-	O
neutralizing	O
antibody	B-FUNC
from	O
the	O
B	O
cell	O
of	O
a	O
vaccinated	O
pig	O
.	O

NF	O
-	O
κB	O
activation	O
induced	O
by	O
TGEV	O
infection	O
was	O
found	O
to	O
be	O
associated	O
with	O
two	O
convergent	O
pathways	O
,	O
IKK	B-FUNC
-	O
2_IκBα	O
/	O
p65	O
and	O
JAK2	O
mediated	O
p65	O
phosphorylation	O
,	O
in	O
swine	O
testicular	O
cells	O
.	O

RESULTS	O
:	O
Of	O
the	O
254	O
respiratory	O
specimens	O
,	O
there	O
was	O
total	O
agreement	O
in	O
the	O
results	O
between	O
the	O
xTAG	O
RVP	O
Fast	B-FUNC
v2	O
assay	O
and	O
the	O
other	O
real	O
-	O
time	O
PCR	O
assay	O
in	O
94	O
.	O
1	O
-	O
100	O
%	O
of	O
the	O
specimens	O
.	O

A	O
rapidly	O
deteriorating	O
clinical	O
course	O
in	O
a	O
patient	O
with	O
SCD	O
presenting	O
with	O
ACS	B-FUNC
or	O
severe	O
vaso	O
-	O
occlusive	O
crisis	O
should	O
trigger	O
a	O
high	O
index	O
of	O
suspicion	O
for	O
FES	O
.	O

We	O
report	O
the	O
first	O
case	O
of	O
CHS	B-FUNC
as	O
a	O
complication	O
of	O
lateral	O
medullary	O
infarction	O
after	O
endovascular	O
treatment	O
.	O

After	O
emergent	O
endovascular	O
patent	O
artery	O
occlusion	O
,	O
he	O
developed	O
Wallenberg	O
syndrome	O
and	O
experienced	O
apnea	O
and	O
a	O
conscious	O
disturbance	O
episode	O
due	O
to	O
CHS	B-FUNC
on	O
postoperative	O
days	O
6	O
and	O
16	O
.	O

Patients	O
with	O
ACO	O
showed	O
a	O
higher	O
likelihood	O
of	O
FEV1	O
recovery	O
than	O
those	O
with	O
pure	B-FUNC
COPD	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

Here	O
,	O
we	O
describe	O
a	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)-	O
β	O
-	O
triggered	O
mechanism	O
,	O
in	O
which	O
megalin	O
,	O
the	O
primary	O
mediator	O
of	O
alveolar	O
protein	O
transport	O
,	O
is	O
negatively	O
regulated	O
by	O
glycogen	O
synthase	O
kinase	O
(	O
GSK	B-FUNC
)	O
3β	O
,	O
with	O
protein	O
phosphatase	B-FUNC
1	O
and	O
nuclear	O
inhibitor	O
of	O
protein	O
phosphatase	B-FUNC
1	O
being	O
involved	O
in	O
the	O
signaling	O
cascade	O
.	O

This	O
study	O
was	O
conducted	O
to	O
develop	O
a	O
drug	O
delivery	O
system	O
using	O
lipid	O
-	O
core	O
nanocapsules	O
(	O
LNCs	O
)	O
to	O
improve	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
orally	O
administered	O
α	O
-	O
bis	B-FUNC
.	O

Interestingly	O
,	O
cytoplasmic	O
N	O
molecules	O
of	O
MHV	O
-	O
infected	O
cells	O
constitutively	O
assemble	O
into	O
oligomers	O
through	O
a	O
process	O
that	O
does	O
not	O
require	O
binding	B-FUNC
to	O
genomic	O
RNA	O
.	O

Moreover	O
,	O
mRNA	O
levels	O
of	O
inflammatory	O
cytokines	O
(	O
TNF	O
-	O
α	O
,	O
IL	O
-	O
1β	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
significantly	O
increased	O
with	O
ADE	O
of	O
FIPV	O
79	O
-	O
1146	O
infection	O
in	O
primary	O
feline	O
monocytes	O
,	O
but	O
FECV	O
79	O
-	O
1683	O
did	O
not	O
demonstrate	O
an	O
increase	O
in	O
these	O
levels	O
.	O

The	O
multivariable	O
linear	O
regression	O
analysis	O
of	O
the	O
relationship	O
between	O
peak	O
cTnI	O
value	O
and	O
patient	O
group	O
,	O
age	O
,	O
sex	O
,	O
and	O
type	O
of	O
ACS	B-FUNC
showed	O
that	O
the	O
presence	O
or	O
absence	O
of	O
OSA	O
significantly	O
contributed	O
to	O
the	O
peak	O
cTnI	O
level	O
,	O
which	O
was	O
54	O
%	O
lower	O
in	O
patients	O
with	O
OSA	O
than	O
in	O
those	O
without	O
OSA	O
.	O

We	O
demonstrated	O
that	O
binding	B-FUNC
of	O
nsp4	O
with	O
nsp3	O
is	O
essential	O
for	O
membrane	O
rearrangement	O
and	O
identified	O
amino	O
acid	O
residues	O
in	O
nsp4	O
responsible	O
for	O
the	O
interaction	O
with	O
nsp3	O
.	O

ABSTRACT	O
:	O
One	O
of	O
the	O
most	O
severe	O
types	O
of	O
stroke	O
is	O
locked	O
-	O
in	O
syndrome	O
(	O
LIS	B-FUNC
)	O
due	O
to	O
the	O
loss	O
of	O
almost	O
all	O
voluntary	O
motor	O
functions	O
and	O
a	O
high	O
mortality	O
rate	O
.	O

TITLE	O
:	O
In	O
silico	O
analysis	O
of	O
the	O
cyanobacterial	O
lectin	O
scytovirin	O
:	O
new	O
insights	O
into	O
binding	B-FUNC
properties	O
.	O

Contrary	O
to	O
other	O
reports	O
,	O
binding	B-FUNC
free	O
energy	O
results	O
suggest	O
that	O
Man4	O
can	O
bind	B-FUNC
simultaneously	O
to	O
SD1	O
and	O
SD2	O
binding	B-FUNC
regions	O
,	O
but	O
SD1	O
individually	O
has	O
the	O
best	O
values	O
of	O
energy	O
and	O
the	O
best	O
affinity	O
for	O
Man4	O
.	O

Decomposition	O
of	O
the	O
binding	B-FUNC
free	O
energy	O
showed	O
that	O
the	O
residues	O
that	O
interact	O
with	O
Man4	O
were	O
different	O
in	O
the	O
three	O
systems	O
,	O
suggesting	O
that	O
the	O
binding	B-FUNC
mechanism	O
of	O
Man4	O
varies	O
between	O
full	O
-	O
length	O
protein	O
,	O
SD1	O
and	O
SD2	O
.	O

Furthermore	O
,	O
these	O
cell	O
-	O
adapted	O
strains	O
elicited	O
potent	O
neutralizing	O
antibody	B-FUNC
responses	O
in	O
immunized	O
pigs	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
sensitivity	O
and	O
specificity	O
of	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
specifically	O
designed	O
to	O
detect	O
FCoV	O
spike	O
gene	O
mutations	O
at	O
two	O
nucleotide	O
positions	O
.	O

We	O
obtained	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
/	O
or	O
sera	B-FUNC
from	O
21	O
MERS	O
survivors	O
.	O

Here	O
we	O
use	O
structure	O
-	O
based	O
design	O
to	O
develop	O
a	O
generalizable	O
strategy	O
for	O
retaining	O
coronavirus	O
S	O
proteins	O
in	O
the	O
antigenically	O
optimal	O
prefusion	O
conformation	O
and	O
demonstrate	O
that	O
our	O
engineered	O
immunogen	O
is	O
able	O
to	O
elicit	O
high	O
neutralizing	O
antibody	B-FUNC
titers	O
against	O
MERS	O
-	O
CoV	O
.	O
We	O
also	O
determined	O
high	O
-	O
resolution	O
structures	O
of	O
the	O
trimeric	O
MERS	O
-	O
CoV	O
S	O
ectodomain	O
in	O
complex	O
with	O
G4	O
,	O
a	O
stem	O
-	O
directed	O
neutralizing	O
antibody	B-FUNC
.	O

In	O
this	O
study	O
,	O
we	O
measured	O
the	O
levels	O
of	O
24	O
cytokines	O
/	O
chemokines	O
in	O
the	O
sera	B-FUNC
of	O
healthy	O
controls	O
(	O
HCs	B-FUNC
)	O
(	O
n	O
=	O
34	O
)	O
and	O
patients	O
with	O
asthma	O
(	O
n	O
=	O
77	O
),	O
that	O
were	O
compared	O
among	O
patient	O
groups	O
with	O
different	O
disease	O
activities	O
and	O
characteristics	O
.	O

Otherwise	O
,	O
a	O
novel	O
variation	O
(	O
16	O
-	O
20	O
aa	O
deletion	O
and	O
an	O
L25P	O
mutation	O
)	O
in	O
the	O
transmembrane	O
domain	O
of	O
the	O
E	O
protein	O
affected	O
multiple	O
infection	O
processes	O
,	O
including	O
up	O
-	O
regulation	O
of	O
the	O
production	O
of	O
the	O
ER	O
stress	O
indicator	O
GRP78	O
,	O
improving	O
the	O
expression	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
promoting	O
apoptosis	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
and	O
antiviral	O
evaluation	O
of	O
novel	O
heteroarylcarbothioamide	O
derivatives	O
as	O
dual	O
inhibitors	O
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
-	O
associated	O
RNase	O
H	O
and	O
RDDP	O
functions	O
.	O

The	O
results	O
reveal	O
that	O
the	O
three	O
IBV	O
isolates	O
mainly	O
exhibited	O
mutations	O
in	O
the	O
hypervariable	O
regions	O
(	O
HVRs	O
)	O
of	O
the	O
S1	O
gene	O
and	O
protein	O
,	O
but	O
were	O
phylogenetically	O
and	O
serologically	O
closely	O
related	O
,	O
belonging	O
to	O
lineage	O
11	O
of	O
the	O
GI	O
genotype	O
,	O
the	O
former	O
BR	O
genotype	O
I	O
.	O
All	O
three	O
isolates	O
caused	O
persistent	O
infection	O
in	O
broiler	O
breeders	O
reared	O
in	O
the	O
field	O
,	O
despite	O
high	O
systemic	O
anti	O
-	O
IBV	O
antibody	B-FUNC
titres	O
,	O
and	O
exhibited	O
tropism	O
and	O
pathogenicity	O
for	O
the	O
trachea	O
and	O
kidney	O
after	O
experimental	O
infection	O
in	O
SPF	O
chickens	O
and	O
contact	O
birds	O
.	O

To	O
investigate	O
the	O
detection	O
rates	O
of	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
in	O
feces	O
of	O
healthy	O
and	O
diarrheic	O
calves	O
and	O
to	O
describe	O
the	O
usefulness	O
of	O
a	O
pancoronavirus	O
reverse	O
transcriptase	B-FUNC
(	O
RT	B-FUNC
)	O
PCR	O
(	O
PanCoV	O
-	O
RT	B-FUNC
-	O
PCR	O
)	O
assay	O
to	O
identify	O
BCoV	O
in	O
samples	O
of	O
diarrheic	O
calves	O
.	O

However	O
,	O
sera	B-FUNC
from	O
rSPV	O
-	O
St	O
vaccination	O
did	O
not	O
provide	O
any	O
protection	O
against	O
the	O
heterologous	O
virus	O
challenge	O
.	O

The	O
separate	O
sampling	O
of	O
tracheas	O
and	O
kidneys	O
for	O
IBV	O
detection	O
using	O
reverse	O
transcriptase	B-FUNC
PCR	O
was	O
very	O
useful	O
,	O
as	O
different	O
genotypes	O
or	O
significant	O
differences	O
in	O
sequences	O
of	O
the	O
same	O
genotype	O
were	O
detected	O
between	O
both	O
organs	O
.	O

Currently	O
,	O
the	O
only	O
post	O
-	O
exposure	O
measure	O
that	O
is	O
effective	O
against	O
pulmonary	O
ricinosis	O
at	O
clinically	O
relevant	O
time	O
-	O
points	O
following	O
intoxication	O
in	O
pre	O
-	O
clinical	O
studies	O
is	O
passive	O
immunization	O
with	O
anti	O
-	O
ricin	B-FUNC
neutralizing	O
antibodies	O
.	O

TITLE	O
:	O
Early	O
Antibody	B-FUNC
Response	O
Contributes	O
to	O
the	O
Virus	O
Eradication	O
and	O
Clinical	O
Recovery	O
of	O
H7N9	O
Influenza	O
Infection	O
.	O

ABSTRACT	O
:	O
CD59	O
protein	O
functions	O
as	O
a	O
negative	O
regulator	O
of	O
the	O
terminal	O
pathway	O
of	O
the	O
complement	O
system	O
by	O
binding	B-FUNC
to	O
the	O
C8	O
/	O
C9	O
factors	O
.	O

The	O
trimeric	O
protein	O
contains	O
three	O
receptor	O
-	O
binding	B-FUNC
S1	O
subunits	O
that	O
tightly	O
pack	O
into	O
a	O
crown	O
-	O
like	O
structure	O
and	O
three	O
membrane	O
fusion	O
S2	O
subunits	O
that	O
form	O
a	O
stalk	O
.	O

PdCoV	O
spike	O
possesses	O
several	O
structural	O
features	O
that	O
may	O
facilitate	O
immune	O
evasion	O
by	O
the	O
virus	O
,	O
such	O
as	O
its	O
compact	O
structure	O
,	O
concealed	O
receptor	O
-	O
binding	B-FUNC
sites	O
,	O
and	O
shielded	O
critical	O
epitopes	O
.	O

In	O
the	O
combined	O
data	O
set	O
of	O
IBV	O
challenged	O
shell	O
gland	O
samples	O
,	O
the	O
comprehensive	O
ranking	O
showed	O
TATA	O
-	O
box	O
binding	B-FUNC
protein	O
(	O
TBP	O
)	O
and	O
tyrosine	O
3	O
-	O
monooxygenase	O
/	O
tryptophan	O
5	O
-	O
monooxygenase	O
activation	O
protein	O
zeta	O
(	O
YWHAZ	O
)	O
as	O
the	O
two	O
most	O
stable	O
,	O
and	O
succinate	O
dehydrogenase	O
complex	O
flavoprotein	O
subunit	O
A	O
(	O
SDHA	O
)	O
and	O
albumin	O
(	O
ALB	O
)	O
as	O
the	O
two	O
least	O
stable	O
reference	O
genes	O
.	O

In	O
viral	O
infections	O
,	O
viruses	O
exploit	O
receptor	O
-	O
ligand	B-FUNC
interactions	O
to	O
latch	O
onto	O
cellular	O
exterior	O
prior	O
to	O
subsequent	O
entry	O
and	O
invasion	O
.	O

Additionally	O
,	O
cytokine	O
levels	O
(	O
IL	O
-	O
1β	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
TNF	O
-	O
α	O
)	O
in	O
coinfected	O
cells	O
are	O
lower	O
than	O
cells	O
infected	O
by	O
TGEV	O
alone	O
,	O
and	O
higher	O
than	O
cells	O
infected	O
by	O
ETEC	O
K88	O
alone	O
.	O

Complete	O
genomic	O
sequencing	O
and	O
analyses	O
of	O
SeACoV	O
indicated	O
that	O
the	O
extreme	O
amino	O
-	O
terminal	O
domain	O
of	O
the	O
SeACoV	O
spike	O
(	O
S	O
)	O
glycoprotein	O
structurally	O
similar	O
to	O
the	O
domain	O
0	O
of	O
the	O
alphacoronavirus	O
NL63	O
,	O
whereas	O
the	O
rest	B-FUNC
part	O
of	O
S	O
structurally	O
resembles	O
domains	O
B	O
to	O
D	O
of	O
the	O
betacoronavirus	O
.	O

PEDV	O
-	O
specific	O
IgG	O
and	O
IgA	O
antibody	B-FUNC
titers	O
were	O
enhanced	O
in	O
pregnant	O
sows	O
immunized	O
with	O
PLGA	O
-	O
KAg	O
relative	O
to	O
the	O
titers	O
in	O
sows	O
inoculated	O
with	O
KAg	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
compared	O
the	O
efficiency	O
of	O
two	O
sequence	O
-	O
independent	O
approaches	O
[	O
sequence	O
-	O
independent	O
single	O
primer	O
amplification	O
(	O
SISPA	O
)	O
and	O
single	O
primer	O
isothermal	O
amplification	O
(	O
SPIA	O
,	O
represented	O
by	O
the	O
Ovation	O
kit	B-FUNC
)]	O
coupled	O
with	O
high	O
-	O
throughput	O
sequencing	O
to	O
generate	O
the	O
full	O
-	O
length	O
genome	O
of	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
from	O
a	O
nasal	O
swab	O
.	O

In	O
5	O
effusions	O
there	O
was	O
no	O
evidence	O
for	O
either	O
FCoV	O
RNA	O
or	O
antibodies	O
,	O
51	O
and	O
52	O
specimens	O
tested	O
positive	O
by	O
IIF	O
and	O
qRT	O
-	O
PCR	O
,	O
respectively	O
,	O
although	O
antibody	B-FUNC
titres	O
≥	O
1	O
:	O
1600	O
,	O
which	O
are	O
considered	O
highly	O
suggestive	O
of	O
FIP	O
,	O
were	O
detected	O
only	O
in	O
37	O
effusions	O
.	O

Interestingly	O
,	O
by	O
days	O
7	O
and	O
14	O
after	O
the	O
booster	O
immunization	O
,	O
pBH	O
-	O
S1	O
-	O
TM	O
-	O
1	O
-	O
EGFP	O
-	O
induced	O
antibody	B-FUNC
titre	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
compared	O
to	O
attenuated	O
commercial	O
IBV	O
vaccine	O
;	O
however	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
pBH	O
-	O
S1	O
-	O
TM	O
-	O
1	O
-	O
EGFP	O
and	O
attenuated	O
commercial	O
MG	O
vaccine	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

Consumption	O
of	O
antipyretic	O
medication	O
before	O
the	O
consultation	O
seemed	O
to	O
reduce	O
the	O
risk	O
of	O
developing	O
GI	O
symptoms	O
for	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
influenza	O
(	O
aOR	B-FUNC
=	O
0	O
.	O
3	O
;	O
[	O
0	O
.	O
1	O
-	O
0	O
.	O
6	O
];	O
p	O
=	O
0	O
.	O
002	O
).	O

Phylogenetic	O
analysis	O
shows	O
that	O
the	O
natural	O
HCoV	O
-	O
229E	O
receptor	O
-	O
binding	B-FUNC
loop	O
variation	O
observed	O
defines	O
six	O
RBD	O
classes	O
whose	O
viruses	O
have	O
successively	O
replaced	O
each	O
other	O
in	O
the	O
human	O
population	O
over	O
the	O
past	O
50	O
years	O
.	O

Mice	O
(	O
C57BL	O
/	O
6	O
)	O
had	O
50	O
×	O
10	O
BAL	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
as	O
well	O
as	O
plasma	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
were	O
significantly	O
lower	O
in	O
the	O
animals	O
administered	O
VPA	O
within	O
3	O
h	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
but	O
not	O
when	O
administered	O
later	O
(	O
4	O
,	O
6	O
,	O
9	O
h	O
).	O

The	O
immune	O
response	O
to	O
the	O
vaccine	O
was	O
estimated	O
by	O
measurement	O
of	O
the	O
antibody	B-FUNC
(	O
IgY	O
)	O
response	O
to	O
the	O
vaccine	O
at	O
d	O
21	O
.	O
The	O
antibody	B-FUNC
titer	O
was	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
higher	O
in	O
the	O
vaccinated	O
group	O
at	O
21	O
d	O
PV	O
,	O
confirming	O
stimulation	O
of	O
the	O
immune	O
system	O
.	O

The	O
areas	O
under	O
the	O
curve	O
of	O
the	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curves	O
for	O
discriminating	O
between	O
IPS	O
and	O
unaffected	O
controls	O
at	O
day	O
7	O
post	O
-	O
HCT	O
were	O
.	O
8	O
for	O
ST2	O
,	O
.	O
75	O
for	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
.	O
68	O
for	O
TNFR1	O
.	O

We	O
observed	O
a	O
significant	O
increase	O
in	O
serum	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
CINC	O
-	O
1	O
,	O
uric	O
acid	O
and	O
circulating	O
,	O
but	O
not	O
bone	O
marrow	O
,	O
leukocyte	O
numbers	O
.	O

Treatment	O
with	O
17β	O
-	O
estradiol	O
before	O
the	O
induction	O
of	O
intestinal	O
IR	O
prevented	O
the	O
systemic	O
release	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
CINC	O
-	O
1	O
,	O
and	O
uric	O
acid	O
,	O
but	O
it	O
did	O
not	O
affect	O
the	O
leukocytosis	O
.	O

Taken	O
together	O
,	O
JNK	B-FUNC
constitutes	O
an	O
important	O
aspect	O
of	O
coronavirus	O
-	O
host	O
interaction	O
,	O
along	O
with	O
other	O
MAPKs	O
.	O

The	O
S	O
protein	O
efficiently	O
incorporated	O
into	O
the	O
viral	O
envelope	O
and	O
mediated	O
cell	O
entry	O
through	O
binding	B-FUNC
its	O
receptor	O
,	O
human	O
DPP4	O
.	O

ACS	B-FUNC
in	O
SCD	O
is	O
defined	O
as	O
the	O
presence	O
of	O
fever	O
and	O
/	O
or	O
new	O
respiratory	O
symptoms	O
accompanied	O
by	O
the	O
presence	O
of	O
a	O
new	O
pulmonary	O
infiltrate	O
on	O
chest	O
X	O
-	O
ray	O
.	O

Positive	O
hybridoma	O
cells	O
are	O
stained	O
using	O
a	O
fluorescently	O
labeled	O
anti	O
-	O
mouse	O
IgG	O
-	O
Fc	O
antibody	B-FUNC
.	O

As	O
the	O
main	O
hormones	O
during	O
sepsis	O
,	O
catecholamines	O
(	O
CA	O
),	O
including	O
epinephrine	O
and	O
NE	O
,	O
could	O
bind	B-FUNC
to	O
adrenergic	O
receptor	O
(	O
AR	O
).	O

In	O
contrast	O
,	O
high	O
PEEP	O
minimized	O
lung	O
injury	O
by	O
more	O
uniformly	O
distributing	O
negative	O
Ppl	B-FUNC
,	O
and	O
lowering	O
the	O
magnitude	O
of	O
spontaneous	O
effort	O
(	O
i	O
.	O
e	O
.,	O
deflection	O
in	O
esophageal	O
pressure	O
observed	O
in	O
rabbits	O
,	O
pigs	O
,	O
and	O
patients	O
).	O

We	O
investigated	O
NET	O
production	O
in	O
plasma	O
and	O
supernatant	O
of	O
cultured	O
neutrophils	O
by	O
measuring	O
cell	O
-	O
free	O
deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
and	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)-	O
DNA	O
complexes	O
with	O
PicoGreen	O
dye	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
methods	O
,	O
respectively	O
.	O

The	O
FCoV	O
spike	O
(	O
S	O
)	O
protein	O
is	O
considered	O
the	O
viral	O
regulator	O
for	O
binding	B-FUNC
and	O
entry	O
to	O
the	O
cell	O
.	O

Neither	O
antibody	B-FUNC
titers	O
against	O
viruses	O
nor	O
lymphoid	O
tissues	O
weight	O
were	O
affected	O
by	O
RP	O
and	O
/	O
or	O
VE	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
treatments	O
.	O

Our	O
findings	O
support	O
a	O
bat	O
origin	O
of	O
MERS	O
-	O
CoV	O
and	O
suggest	O
that	O
bat	O
CoV	O
spike	O
proteins	O
may	O
have	O
evolved	O
in	O
a	O
stepwise	O
manner	O
for	O
binding	B-FUNC
to	O
hDPP4	O
.	O

Case	O
reports	O
were	O
only	O
included	O
if	O
the	O
diagnostic	O
criteria	O
for	O
AEP	O
or	O
CEP	B-FUNC
were	O
fulfilled	O
.	O

AEP	O
is	O
a	O
much	O
more	O
fulminant	O
and	O
severe	O
disease	O
than	O
the	O
gradual	O
onset	O
and	O
slowly	O
progressive	O
nature	O
of	O
CEP	B-FUNC
.	O

Methods	O
MERS	O
-	O
CoV	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
recombinant	O
protein	O
was	O
used	O
to	O
immunize	O
alpaca	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
PEDV	O
infection	O
stimulated	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
(	O
EGFR	B-FUNC
)	O
activation	O
,	O
which	O
has	O
been	O
linked	O
to	O
not	O
only	O
anticancer	O
therapeutics	O
,	O
but	O
also	O
antiviral	O
signaling	O
.	O

The	O
data	O
showed	O
that	O
EGFR	B-FUNC
activation	O
enhanced	O
virus	O
replication	O
in	O
both	O
cases	O
.	O

IL	B-FUNC
-	I-FUNC
12	I-FUNC
expression	O
levels	O
showed	O
no	O
difference	O
between	O
patients	O
with	O
MERS	O
-	O
CoV	O
infection	O
and	O
the	O
healthy	O
controls	O
despite	O
the	O
significantly	O
increased	O
levels	O
of	O
IFN	O
-	O
α2	O
and	O
IFN	O
-	O
γ	O
(	O
P	O
<	O
.	O
01	O
).	O

Moreover	O
,	O
in	O
response	O
to	O
restimulation	O
with	O
the	O
PEDV	O
COE	O
antigen	O
in	O
vitro	O
,	O
a	O
significant	O
difference	O
in	O
splenocyte	O
proliferation	O
response	O
and	O
Th2	O
-	O
associated	O
cytokine	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
level	O
was	O
observed	O
in	O
the	O
group	O
of	O
mice	O
orally	O
immunized	O
with	O
pPG	O
-	O
COE	O
-	O
Col	O
-	O
DCpep	O
/	O
L393	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
compared	O
to	O
the	O
groups	O
of	O
mice	O
that	O
received	O
pPG	O
-	O
COE	O
-	O
Col	O
/	O
L393	O
and	O
pPG	O
-	O
COE	O
-	O
DCpep	O
/	O
L393	O
,	O
respectively	O
.	O

COE	O
fused	O
to	O
the	O
flanking	O
C	O
'/	O
N	O
'	O
terminal	O
of	O
rSF	O
yielded	O
rSF	O
-	O
COE	O
-	O
C	O
and	O
rSF	O
-	O
COE	O
-	O
N	O
.	O
As	O
a	O
result	O
,	O
rSF	O
-	O
COE	O
-	O
3D	O
could	O
significantly	O
improve	O
COE	O
specific	O
antibody	B-FUNC
production	O
including	O
serum	O
IgG	O
,	O
serum	O
IgA	O
,	O
mucosal	O
IgA	O
and	O
PEDV	O
neutralizing	O
antibody	B-FUNC
.	O

This	O
is	O
an	O
ancillary	O
study	O
of	O
the	O
ISAACC	O
study	O
,	O
which	O
is	O
a	O
multicentre	O
,	O
prospective	O
,	O
open	O
-	O
label	O
,	O
parallel	O
,	O
randomized	O
,	O
and	O
controlled	O
trial	O
(	O
NCT01335087	O
)	O
in	O
patients	O
with	O
hospital	O
admission	O
for	O
ACS	B-FUNC
.	O

Nested	O
RT	O
-	O
PCR	O
of	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
gene	O
from	O
rectal	O
swabs	O
was	O
used	O
for	O
CoV	O
detection	O
.	O

Phylogenetic	O
analysis	O
of	O
conserved	O
RdRp	B-FUNC
gene	O
revealed	O
that	O
the	O
detected	O
CoVs	O
belonged	O
to	O
group	O
D	O
betacoronavirus	O
(	O
n	O
=	O
64	O
)	O
and	O
alphacoronavirus	O
(	O
n	O
=	O
4	O
).	O

Phylogenetic	O
analysis	O
of	O
conserved	O
RdRp	B-FUNC
gene	O
revealed	O
that	O
the	O
detected	O
CoVs	O
belonged	O
to	O
group	O
D	O
betacoronavirus	O
(	O
n	O
=	O
64	O
)	O
and	O
alphacoronavirus	O
(	O
n	O
=	O
4	O
).	O

Linear	O
regression	O
models	O
(	O
for	O
BVDV	O
,	O
BPI3V	O
,	O
BHV	O
-	O
1	O
,	O
BHV	O
-	O
4	O
,	O
BCoV	O
and	O
H	O
.	O
somni	O
)	O
and	O
a	O
single	O
mixed	O
effect	O
random	O
variable	O
model	O
(	O
for	O
BRSV	O
)	O
were	O
used	O
to	O
identify	O
risk	O
factors	O
for	O
changes	O
in	O
antibody	B-FUNC
levels	O
to	O
these	O
pathogens	O
.	O

TITLE	O
:	O
Engineering	O
a	O
stable	O
CHO	B-FUNC
cell	O
line	O
for	O
the	O
expression	O
of	O
a	O
MERS	O
-	O
coronavirus	O
vaccine	O
antigen	O
.	O

In	O
this	O
study	O
,	O
we	O
designed	O
a	O
new	O
primer	O
set	O
to	O
amplify	O
a	O
668	O
bp	O
-	O
region	O
within	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRP	B-FUNC
)	O
gene	O
that	O
encodes	O
the	O
most	O
conserved	O
protein	O
domain	O
of	O
α	O
-,	O
β	O
-,	O
γ	O
-,	O
and	O
δ	O
-	O
CoVs	O
.	O

The	O
highest	O
antibody	B-FUNC
levels	O
were	O
also	O
detected	O
in	O
the	O
group	O
infected	O
with	O
an	O
isolate	O
from	O
the	O
pigeon	O
.	O

After	O
adjusting	O
for	O
baseline	O
differences	O
,	O
each	O
day	O
of	O
NMB	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
SP	O
-	O
D	O
(-	O
23	O
.	O
7	O
ng	O
/	O
ml	O
/	O
day	O
,	O
p	O
=	O
0	O
.	O
029	O
),	O
VWF	O
(-	O
33	O
.	O
5	O
%	O
of	O
control	O
/	O
day	O
,	O
p	O
=	O
0	O
.	O
015	O
),	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
(-	O
362	O
.	O
6	O
pg	O
/	O
ml	O
/	O
day	O
,	O
p	O
=	O
0	O
.	O
030	O
)	O
in	O
patients	O
with	O
an	O
initial	O
P	O
/	O
F	O
less	O
than	O
or	O
equal	O
to	O
120	O
and	O
receiving	O
low	O
tidal	O
volume	O
ventilation	O
.	O

Two	O
reaction	O
mixtures	O
(	O
Isothermal	O
Mastermix	O
,	O
OptiGene	O
Ltd	O
.	O
and	O
PCRun	O
™	O
Molecular	O
Detection	O
Mix	O
,	O
Biogal	O
)	O
were	O
tested	O
using	O
the	O
same	O
primers	O
,	O
which	O
were	O
designed	O
to	O
bind	B-FUNC
to	O
a	O
conserved	O
region	O
of	O
the	O
FCoV	O
membrane	O
protein	O
gene	O
.	O

MERS	O
-	O
CoV	O
3CL	O
protease	O
is	O
essential	O
for	O
viral	O
replication	O
;	O
consequently	O
,	O
it	O
is	O
an	O
attractive	O
target	O
that	O
provides	O
a	O
potentially	O
effective	O
means	O
of	O
developing	O
small	O
molecule	O
therapeutics	O
for	O
combatting	O
MERS	O
-	O
CoV	O
.	O
We	O
describe	O
herein	O
the	O
structure	O
-	O
guided	O
design	O
and	O
evaluation	O
of	O
a	O
novel	O
class	O
of	O
inhibitors	O
of	O
MERS	O
-	O
CoV	O
3CL	O
protease	O
that	O
embody	O
a	O
piperidine	O
moiety	O
as	O
a	O
design	O
element	O
that	O
is	O
well	O
-	O
suited	O
to	O
exploiting	O
favorable	O
subsite	O
binding	B-FUNC
interactions	O
to	O
attain	O
optimal	O
pharmacological	O
activity	O
and	O
PK	O
properties	O
.	O

The	O
model	O
included	O
male	O
sex	O
,	O
contact	O
with	O
a	O
sick	O
patient	O
or	O
camel	O
,	O
diabetes	O
,	O
severe	O
illness	O
,	O
low	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
count	O
,	O
low	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
),	O
and	O
high	O
aspartate	O
aminotransferase	O
(	O
AST	O
).	O

EV	O
-	O
D68	O
proteases	O
cleave	O
a	O
major	O
autophagic	O
cargo	O
adaptor	O
and	O
the	O
autophagic	O
SNARE	B-FUNC
SNAP29	O
,	O
which	O
reportedly	O
regulates	O
fusion	O
between	O
autophagosome	O
to	O
amphisome	O
/	O
autolysosome	O
.	O

ABSTRACT	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
female	O
with	O
sickle	O
cell	O
anemia	O
presented	O
with	O
respiratory	O
failure	O
due	O
to	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-FUNC
).	O

Finally	O
,	O
hepatocyte	B-FUNC
growth	I-FUNC
factor	I-FUNC
and	O
soluble	O
form	O
of	O
CD163	O
concentrations	O
expressed	O
relatively	O
to	O
macrophage	O
count	O
were	O
higher	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
from	O
acute	O
respiratory	O
distress	O
syndrome	O
survivors	O
.	O

TITLE	O
:	O
A	O
novel	O
mechanism	O
of	O
RNase	O
L	O
inhibition	O
:	O
Theiler	O
'	O
s	O
virus	O
L	O
*	O
protein	O
prevents	O
2	O
-	O
5A	O
from	O
binding	B-FUNC
to	O
RNase	O
L	O
.	O
ABSTRACT	O
:	O
The	O
OAS	O
/	O
RNase	O
L	O
pathway	O
is	O
one	O
of	O
the	O
best	O
-	O
characterized	O
effector	O
pathways	O
of	O
the	O
IFN	O
antiviral	O
response	O
.	O

APOBEC3	O
-	O
mediated	O
restriction	O
was	O
partially	O
dependent	O
on	O
enzyme	B-FUNC
activity	I-FUNC
,	O
and	O
was	O
reduced	O
by	O
the	O
use	O
of	O
enzymatically	O
inactive	O
APOBEC3	O
.	O

Lactate	O
levels	O
and	O
mitochondrial	O
respiratory	O
chain	O
enzyme	B-FUNC
activity	I-FUNC
in	O
muscle	O
,	O
liver	O
and	O
fibroblasts	O
were	O
normal	O
.	O

One	O
hundred	O
seventy	O
one	O
(	O
171	O
)	O
serum	O
samples	O
were	O
collected	O
from	O
healthy	O
dromedary	O
camels	O
with	O
different	O
ages	O
and	O
genders	O
in	O
Tabuk	O
city	O
and	O
tested	O
for	O
specific	O
serum	O
IgG	O
by	O
ELISA	O
using	O
the	O
receptor	O
-	O
binding	B-FUNC
S1	O
subunits	O
of	O
spike	O
proteins	O
of	O
MERS	O
-	O
CoV	O
.	O
144	O
(	O
84	O
,	O
21	O
%)	O
of	O
the	O
total	O
camel	O
sera	B-FUNC
shown	O
the	O
presence	O
of	O
protein	O
-	O
specific	O
antibodies	O
against	O
MERS	O
-	O
CoV	O
.	O
These	O
results	O
may	O
provide	O
evidence	O
that	O
MERS	O
-	O
CoV	O
has	O
previously	O
infected	O
dromedary	O
camels	O
in	O
Tabuk	O
and	O
may	O
support	O
the	O
possible	O
role	O
of	O
camels	O
in	O
the	O
human	O
infection	O
.	O

Substantial	O
saturation	O
of	O
the	O
binding	B-FUNC
resins	O
was	O
detected	O
within	O
the	O
first	O
treatment	O
hour	O
.	O

Further	O
analyses	O
revealed	O
that	O
NS6	O
is	O
not	O
an	O
RNA	O
-	O
binding	B-FUNC
protein	O
;	O
however	O
,	O
it	O
interacts	O
with	O
RIG	O
-	O
I	O
/	O
MDA5	O
.	O

The	O
secondary	O
objectives	O
included	O
measuring	O
the	O
effect	O
of	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
antibodies	O
on	O
calf	O
health	O
,	O
performance	O
,	O
and	O
shedding	O
of	O
less	O
common	O
diarrheal	O
pathogens	O
.	O

Total	O
health	O
score	O
,	O
diarrhea	O
days	O
,	O
average	O
respiratory	O
score	O
,	O
packed	O
cell	O
volume	O
,	O
and	O
serum	O
total	O
protein	O
were	O
not	O
affected	O
by	O
feeding	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
egg	O
antibodies	O
.	O

In	O
summary	O
,	O
feeding	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
antibodies	O
was	O
associated	O
with	O
increased	O
fecal	O
pH	O
,	O
reduced	O
risk	O
of	O
respiratory	O
disease	O
later	O
in	O
the	O
preweaning	O
period	O
,	O
and	O
decreased	O
antibiotic	O
usage	O
despite	O
higher	O
rotavirus	O
infection	O
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
identification	O
of	O
a	O
putative	O
self	O
-	O
binding	B-FUNC
β	O
-	O
zipper	O
-	O
forming	O
peptide	O
within	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
spike	O
(	O
S	O
)	O
protein	O
and	O
its	O
application	O
in	O
viral	O
detection	O
.	O

Our	O
data	O
provide	O
new	O
insights	O
into	O
the	O
specific	O
antibody	B-FUNC
repertoires	O
and	O
the	O
molecular	O
determinants	O
of	O
neutralization	O
during	O
natural	O
MERS	O
-	O
CoV	O
infection	O
in	O
humans	O
.	O

MERS	O
-	O
CoV	O
neutralizing	O
antibodies	O
were	O
detectable	O
in	O
51	O
(	O
71	O
.	O
8	O
%)	O
camel	O
sera	B-FUNC
,	O
and	O
no	O
association	O
was	O
observed	O
between	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
and	O
camel	O
age	O
or	O
gender	O
.	O

Furthermore	O
APN	O
and	O
EGFR	B-FUNC
synergistically	O
stimulate	O
PI3K	B-FUNC
/	O
AKT	O
as	O
well	O
as	O
MEK	O
/	O
ERK1	B-FUNC
/	O
2	O
endocytosis	O
signaling	O
pathways	O
.	O

ACGs	O
reduced	O
the	O
pulmonary	O
edema	O
and	O
microvascular	O
permeability	O
,	O
demonstrating	O
a	O
dose	O
-	O
dependent	O
down	O
-	O
regulation	O
of	O
LPS	O
-	O
induced	O
TNF	O
-	O
α	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	O
-	O
1β	O
expression	O
in	O
lung	O
tissue	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
along	O
with	O
reduced	O
apoptosis	O
.	O

Moreover	O
,	O
metabolic	O
profiling	O
of	O
mice	O
serum	O
and	O
subsequent	O
Ingenuity	O
Pathway	O
Analysis	O
suggested	O
that	O
ACGs	O
activated	O
protective	O
protein	O
networks	O
and	O
pathways	O
involving	O
inflammatory	O
regulators	O
and	O
apoptosis	O
-	O
related	O
factors	O
,	O
such	O
as	O
JNK	B-FUNC
,	O
ERK1	B-FUNC
/	O
2	O
and	O
caspase	O
-	O
3	O
/	O
7	O
,	O
suggesting	O
that	O
ACGs	O
-	O
dependent	O
effects	O
were	O
related	O
to	O
MAPKs	O
and	O
mitochondrial	O
apoptosis	O
pathways	O
.	O

These	O
results	O
were	O
further	O
supported	O
by	O
evaluation	O
of	O
protein	O
expression	O
,	O
showing	O
that	O
ACGs	O
blocked	O
LPS	O
-	O
activated	O
phosphorylation	O
of	O
p38	B-FUNC
,	O
ERK1	B-FUNC
/	O
2	O
and	O
JNK	B-FUNC
on	O
the	O
MAPKs	O
signaling	O
,	O
and	O
significantly	O
upregulated	O
the	O
expression	O
of	O
Bcl	O
-	O
2	O
whilst	O
down	O
-	O
regulated	O
Bax	O
and	O
cleaved	O
caspase	O
-	O
3	O
.	O

Although	O
ADRP	O
activity	O
has	O
not	O
been	O
formally	O
demonstrated	O
for	O
IBV	O
nsp	O
3	O
,	O
Beaudette	O
fails	O
to	O
bind	B-FUNC
ADP	O
-	O
ribose	O
.	O

Sixty	O
patients	O
had	O
severe	O
LIS	B-FUNC
,	O
out	O
of	O
which	O
45	O
(	O
75	O
%)	O
patients	O
expired	O
,	O
as	O
compared	O
to	O
56	O
patients	O
with	O
moderate	O
LIS	B-FUNC
out	O
of	O
which	O
22	O
(	O
39	O
.	O
3	O
%)	O
expired	O
.	O

Sera	B-FUNC
were	O
screened	O
by	O
MERS	O
-	O
CoV	O
nucleocapsid	O
protein	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
indirect	O
immunofluorescence	O
,	O
with	O
results	O
confirmed	O
by	O
microneutralization	O
assay	O
.	O

Sera	B-FUNC
were	O
tested	O
for	O
CRCoV	O
antibody	B-FUNC
using	O
competitive	O
ELISA	O
and	O
results	O
expressed	O
as	O
percent	O
of	O
inhibition	O
(	O
POI	O
).	O

Quantitative	O
real	O
-	O
time	O
PCR	O
was	O
used	O
to	O
analyse	O
intratonsillar	O
gene	O
expressions	O
of	O
IFN	O
-	O
α	O
,	O
IFN	O
-	O
β	O
,	O
IFN	O
-	O
γ	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
28	I-FUNC
,	O
IL	O
-	O
29	O
,	O
IL	O
-	O
37	O
,	O
TGF	O
-	O
β	O
,	O
FOXP3	O
,	O
GATA3	O
,	O
RORC2	O
and	O
Tbet	O
.	O

Group	O
2	O
exhibited	O
higher	O
IBV	O
antibody	B-FUNC
titer	O
at	O
day	O
17	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
furthermore	O
,	O
groups	O
2	O
to	O
4	O
reached	O
the	O
effective	O
levels	O
1	O
wk	O
earlier	O
than	O
control	O
group	O
.	O

IAP	O
was	O
measured	O
in	O
301	O
patients	O
(	O
80	O
·	O
5	O
per	O
cent	O
),	O
of	O
whom	O
274	O
(	O
91	O
·	O
0	O
per	O
cent	O
)	O
had	O
IAH	B-FUNC
and	O
103	O
(	O
34	O
·	O
2	O
per	O
cent	O
)	O
acute	O
compartment	O
syndrome	O
.	O

Compared	O
with	O
grade	O
I	O
IAH	B-FUNC
,	O
patients	O
with	O
grade	O
IV	O
had	O
more	O
infected	O
necrosis	O
(	O
16	O
versus	O
28	O
per	O
cent	O
;	O
P	O
=	O
0	O
·	O
005	O
),	O
need	O
for	O
surgery	O
(	O
27	O
versus	O
50	O
per	O
cent	O
;	O
P	O
=	O
0	O
·	O
006	O
),	O
mechanical	O
ventilation	O
(	O
53	O
versus	O
84	O
per	O
cent	O
;	O
P	O
=	O
0	O
·	O
007	O
)	O
and	O
requirement	O
for	O
CRRT	O
(	O
22	O
versus	O
66	O
per	O
cent	O
;	O
P	O
<	O
0	O
·	O
001	O
).	O

Lead	O
like	O
compounds	O
and	O
drug	O
molecules	O
which	O
are	O
capable	O
of	O
inhibiting	O
3C	O
-	O
like	O
protease	O
was	O
identified	O
by	O
structure	O
-	O
based	O
virtual	O
screening	O
and	O
ligand	B-FUNC
-	O
based	O
virtual	O
screening	O
method	O
.	O

All	O
the	O
compounds	O
are	O
not	O
a	O
substrate	O
of	O
P	B-FUNC
-	I-FUNC
glycoprotein	I-FUNC
.	O

On	O
day	O
28	O
,	O
serum	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
A	O
and	O
IgG	O
were	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
6	O
%	O
FVW	O
group	O
than	O
in	O
the	O
control	O
and	O
antibiotic	O
fed	O
groups	O
.	O

Serum	O
cytokine	O
interleukin	O
(	O
IL	O
)-	O
2	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
α	O
concentrations	O
were	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
both	O
the	O
4	O
%	O
and	O
6	O
%	O
FVW	O
grousp	O
than	O
in	O
the	O
control	O
and	O
antibiotic	O
groups	O
;	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
was	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
FVW	O
groups	O
than	O
in	O
the	O
control	O
group	O
;	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
was	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
6	O
%	O
FVW	O
group	O
than	O
in	O
the	O
control	O
and	O
antibiotic	O
groups	O
.	O

Finally	O
,	O
we	O
show	O
that	O
HA	O
activation	O
by	O
the	O
TMPRSS11A	O
-	O
related	O
enzymes	O
human	O
airway	O
tryptase	O
and	O
DESC1	O
,	O
but	O
not	O
TMPRSS11A	O
itself	O
,	O
is	O
blocked	O
by	O
the	O
cellular	O
serine	O
protease	O
inhibitor	O
hepatocyte	B-FUNC
growth	I-FUNC
factor	I-FUNC
activator	O
inhibitor	O
type	O
-	O
1	O
(	O
HAI	O
-	O
1	O
).	O

These	O
data	O
reveal	O
a	O
link	O
between	O
the	O
gut	O
flora	O
composition	O
and	O
the	O
development	O
of	O
antibody	B-FUNC
-	O
mediated	O
TRALI	O
in	O
mice	O
.	O

The	O
PPIase	B-FUNC
activity	I-FUNC
of	O
most	O
Cyps	O
is	O
inhibited	O
by	O
the	O
immunosuppressive	O
drug	O
cyclosporin	O
A	O
and	O
several	O
of	O
its	O
non	O
-	O
immunosuppressive	O
analogs	O
,	O
which	O
can	O
also	O
block	O
the	O
replication	O
of	O
nidoviruses	O
(	O
arteriviruses	O
and	O
coronaviruses	O
).	O

CAPN5	O
and	O
CBLB	O
were	O
required	O
for	O
a	O
post	O
-	O
binding	B-FUNC
and	O
pre	O
-	O
replication	O
step	O
in	O
the	O
HCV	O
life	O
cycle	O
.	O

The	O
transcriptional	O
activity	O
of	O
ISRE	O
,	O
IFN	O
-	O
β	O
promoter	O
,	O
and	O
NF	O
-	O
κB	O
-	O
RE	O
was	O
significantly	O
reduced	O
in	O
the	O
presence	O
of	O
HCoV	O
-	O
OC43	O
ns2a	O
,	O
ns5a	O
,	O
M	O
,	O
or	O
N	O
protein	O
,	O
following	O
the	O
challenge	O
of	O
cells	O
with	O
Sendai	O
virus	O
,	O
IFN	O
-	O
α	O
or	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
α	O
.	O

Distinctively	O
high	O
frequencies	O
of	O
MERS	O
coronavirus	O
-	O
reactive	O
CD8	O
+	O
T	O
cells	O
were	O
also	O
observed	O
in	O
patients	O
with	O
severe	O
/	O
moderate	O
illness	O
,	O
whereas	O
antibody	B-FUNC
and	O
CD4	O
+	O
T	O
-	O
cell	O
responses	O
were	O
minimally	O
detected	O
at	O
this	O
stage	O
.	O

TITLE	O
:	O
The	O
Accessory	O
Protein	O
ORF3	O
Contributes	O
to	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Replication	O
by	O
Direct	O
Binding	B-FUNC
to	O
the	O
Spike	O
Protein	O
.	O

We	O
also	O
demonstrated	O
that	O
both	O
full	O
-	O
length	O
and	O
naturally	O
truncated	O
ORF3	O
proteins	O
could	O
interact	O
with	O
the	O
S	O
protein	O
but	O
with	O
different	O
binding	B-FUNC
affinity	O
,	O
which	O
correlate	O
with	O
the	O
ability	O
of	O
the	O
protein	O
to	O
regulate	O
virus	O
replication	O
in	O
cell	O
culture	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
probability	O
of	O
freedom	O
(	O
PostPFree	O
)	O
from	O
BRSV	O
and	O
BCV	O
antibodies	O
over	O
time	O
by	O
use	O
of	O
bulk	O
tank	O
milk	O
(	O
BTM	O
)	O
antibody	B-FUNC
-	O
testing	O
,	O
geographic	O
information	O
and	O
animal	O
movement	O
data	O
,	O
and	O
to	O
validate	O
the	O
herd	O
-	O
level	O
estimates	O
against	O
subsequent	O
BTM	O
testing	O
.	O

Moreover	O
,	O
the	O
inter	O
-	O
day	O
precision	O
and	O
sensitivity	O
were	O
adequate	O
for	O
use	O
as	O
a	O
diagnostic	O
kit	B-FUNC
.	O

Mutations	O
of	O
residues	O
residing	O
on	O
the	O
oligomerization	O
interfaces	O
that	O
distort	O
hexamerization	O
,	O
namely	O
,	O
N38A	O
,	O
Y58A	O
,	O
and	O
N157A	O
,	O
decrease	O
thermostability	O
,	O
decrease	O
affinity	O
of	O
binding	B-FUNC
with	O
RNA	O
,	O
and	O
reduce	O
the	O
NendoU	O
activity	O
of	O
Nsp15	O
.	O

Synthesized	O
QDs	O
was	O
further	O
conjugated	O
with	O
anti	O
-	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
antibodies	O
of	O
coronavirus	O
to	O
form	O
an	O
immunolink	O
at	O
the	O
presence	O
of	O
the	O
target	O
analyte	O
and	O
anti	O
-	O
IBV	O
antibody	B-FUNC
-	O
conjugated	O
magneto	O
-	O
plasmonic	O
nanoparticles	O
(	O
MPNPs	O
).	O

Compared	O
with	O
the	O
IDEXX	O
IBV	O
Ab	O
Test	O
kit	B-FUNC
,	O
CIT	O
and	O
RDT	O
have	O
a	O
sensitivity	O
and	O
specificity	O
of	O
at	O
least	O
98	O
.	O
88	O
%	O
and	O
91	O
.	O
67	O
%,	O
respectively	O
.	O

On	O
30th	O
day	O
after	O
the	O
second	O
immunization	O
,	O
sera	B-FUNC
samples	O
were	O
collected	O
from	O
the	O
immunized	O
mice	O
to	O
measure	O
PEDV	O
-	O
specific	O
IgG	O
and	O
IgG	O
subclasses	O
levels	O
,	O
and	O
lymphocytes	O
were	O
isolated	O
to	O
detect	O
T	O
cell	O
subtype	O
and	O
intracellular	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
cytokine	O
productions	O
,	O
and	O
the	O
expressions	O
of	O
co	O
-	O
stimulatory	O
molecule	O
on	O
dendritic	O
cells	O
in	O
the	O
immunized	O
mice	O
.	O

Moreover	O
,	O
our	O
findings	O
verified	O
the	O
significantly	O
enhanced	O
PEDV	O
-	O
specific	O
IgA	O
antibody	B-FUNC
titers	O
in	O
small	O
intestinal	O
and	O
lung	O
in	O
the	O
mice	O
immunized	O
with	O
PEDV	O
vaccine	O
and	O
CVC1303	O
.	O

In	O
addition	O
,	O
Caerin1	O
.	O
1	O
showed	O
powerful	O
antiviral	O
activity	O
without	O
interfering	O
with	O
the	O
binding	B-FUNC
progress	O
between	O
PEDV	O
and	O
the	O
receptor	O
of	O
the	O
cells	O
,	O
therefore	O
,	O
it	O
could	O
be	O
used	O
as	O
a	O
potential	O
antiviral	O
drug	O
or	O
as	O
a	O
microbicide	O
compound	O
for	O
prevention	O
and	O
control	O
of	O
PEDV	O
.	O

Further	O
studies	O
revealed	O
that	O
TA	O
-	O
dampened	O
inflammatory	O
responses	O
by	O
downregulating	O
the	O
LPS	O
-	O
induced	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)	O
expression	O
and	O
inhibiting	O
extracellular	O
-	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	B-FUNC
)	O
1	O
/	O
2	O
and	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
)	O
activation	O
.	O

ABSTRACT	O
:	O
Inhalation	O
of	O
ricin	B-FUNC
toxin	O
is	O
associated	O
with	O
the	O
onset	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
characterized	O
by	O
hemorrhage	O
,	O
inflammatory	O
exudates	O
,	O
and	O
tissue	O
edema	O
,	O
as	O
well	O
as	O
the	O
nearly	O
complete	O
destruction	O
of	O
the	O
lung	O
epithelium	O
.	O

Here	O
we	O
report	O
that	O
the	O
Calu	O
-	O
3	O
human	O
airway	O
epithelial	O
cell	O
line	O
is	O
relatively	O
impervious	O
to	O
the	O
effects	O
of	O
ricin	B-FUNC
,	O
with	O
little	O
evidence	O
of	O
cell	O
death	O
even	O
upon	O
exposure	O
to	O
microgram	O
amounts	O
of	O
toxin	O
.	O

ORF	O
3b	O
is	O
also	O
predicted	O
to	O
contain	O
DNA	O
-	O
binding	B-FUNC
and	O
activator	O
domains	O
,	O
and	O
was	O
found	O
to	O
localise	O
in	O
the	O
mitochondrion	O
.	O

The	O
Anyplex	O
II	O
RV16	O
detection	O
kit	B-FUNC
(	O
Seegene	O
,	O
Seoul	O
,	O
Korea	O
)	O
and	O
Filmarray	O
Respiratory	O
Panel	O
(	O
BioFire	O
Diagnostics	O
,	O
Inc	O
.,	O
Salt	O
Lake	O
City	O
,	O
UT	O
,	O
USA	O
)	O
were	O
used	O
for	O
the	O
routine	O
and	O
rapid	O
tests	O
,	O
respectively	O
.	O

Sera	B-FUNC
were	O
evaluated	O
by	O
nucleocapsid	O
and	O
spike	O
protein	O
enzyme	O
immunoassays	O
and	O
microneutralization	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggested	O
that	O
NF	O
-	O
κB	O
activation	O
was	O
a	O
major	O
contributor	O
to	O
TGEV	O
infection	O
-	O
induced	O
inflammation	O
,	O
and	O
that	O
Nsp2	O
was	O
the	O
key	O
viral	O
protein	O
involved	O
in	O
the	O
regulation	O
of	O
inflammation	O
,	O
with	O
amino	O
acids	O
1	O
-	O
120	O
playing	O
a	O
critical	O
role	O
in	O
activating	O
NF	O
-	O
κB	O
.	O
Abbreviations	O
:	O
TCID50	O
:	O
50	O
%	O
tissue	O
culture	O
infectious	O
dose	O
;	O
DMEM	O
:	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
Medium	O
;	O
eNOS	O
:	O
Endothelial	O
nitric	O
oxide	O
synthase	O
;	O
FBS	O
:	O
fetal	O
bovine	O
serum	O
;	O
IFA	O
:	O
Indirect	O
immunofluorescence	O
;	O
IκB	O
:	O
inhibitor	O
of	O
nuclear	O
factor	O
kappa	O
-	O
B	O
;	O
IL	O
:	O
interleukin	O
;	O
IPEC	O
-	O
J2	O
:	O
intestinal	O
epithelial	O
cell	O
lines	O
J2	O
;	O
IKK	B-FUNC
:	O
IκB	O
kinase	O
;	O
Luc	O
:	O
luciferase	O
reporter	O
gene	O
;	O
mAbs	O
:	O
monoclonal	O
antibodies	O
;	O
MOI	O
:	O
multiple	O
of	O
infection	O
;	O
Nsp	O
:	O
nonstructural	O
protein	O
;	O
NF	O
-	O
κB	O
:	O
nuclear	O
factor	O
-	O
kappa	O
;	O
ORFs	O
:	O
open	O
reading	O
frames	O
;	O
PBS	O
:	O
phosphate	O
-	O
buffered	O
saline	O
;	O
p65	O
p	O
-	O
p65	O
:	O
phosphorylated	O
;	O
RT	O
-	O
PCR	O
:	O
reverse	O
transcription	O
PC	O
;	O
SeV	O
:	O
Sendai	O
virus	O
;	O
ST	O
:	O
swine	O
testicular	O
;	O
TGEV	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
;	O
TNF	O
-	O
α	O
:	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
α	O
;	O
UV	O
-	O
TGEV	O
:	O
Ultraviolet	O
light	O
-	O
inactivated	O
TGEV	O
;	O
ZnF	O
:	O
zinc	O
finger	O
.	O

ABSTRACT	O
:	O
Humoral	O
responses	O
within	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
are	O
common	O
to	O
many	O
neurotropic	O
viral	O
infections	O
,	O
with	O
antibody	B-FUNC
(	O
Ab	O
)-	O
secreting	O
cells	O
(	O
ASC	O
)	O
contributing	O
to	O
local	O
protection	O
.	O

Reduced	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
was	O
distinctly	O
limited	O
to	O
virally	O
infected	O
cells	O
in	O
vivo	O
and	O
not	O
bystander	O
uninfected	O
lung	O
epithelium	O
.	O

Furthermore	O
,	O
the	O
506	O
-	O
2G10G5	O
monoclonal	O
antibody	B-FUNC
significantly	O
reduced	O
plaque	O
formation	O
in	O
MERS	O
-	O
CoV	O
infected	O
Vero	O
cells	O
compared	O
to	O
normal	O
mouse	O
IgG	O
and	O
492	O
-	O
1G10E4E2	O
.	O

Moreover	O
,	O
this	O
competitive	O
ELISA	O
method	O
has	O
other	O
properties	O
,	O
such	O
as	O
high	O
feasibility	O
of	O
testing	O
sera	B-FUNC
without	O
pre	O
-	O
treatment	O
and	O
automatic	O
and	O
instrument	O
-	O
mediated	O
revealing	O
,	O
that	O
makes	O
it	O
appropriate	O
for	O
large	O
-	O
scale	O
screenings	O
of	O
affected	O
pig	O
farms	O
in	O
endemic	O
regions	O
or	O
for	O
monitoring	O
plans	O
in	O
PEDV	O
-	O
free	O
areas	O
.	O

The	O
increased	O
concentration	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
indicates	O
that	O
the	O
injected	O
preparations	O
are	O
stimulatory	O
to	O
cellular	O
immunity	O
.	O

Immunization	O
with	O
the	O
TGEV	O
antigen	O
conjugated	O
to	O
GNPs	O
as	O
a	O
carrier	O
activates	O
the	O
respiratory	O
activity	O
of	O
lymphoid	O
cells	O
and	O
peritoneal	O
macrophages	O
,	O
which	O
is	O
directly	O
related	O
to	O
their	O
transforming	O
activity	O
and	O
to	O
the	O
activation	O
of	O
antibody	B-FUNC
generation	O
.	O

At	O
baseline	O
,	O
the	O
MSC	O
group	O
had	O
numerically	O
higher	O
mean	O
scores	O
than	O
the	O
placebo	O
group	O
for	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
III	O
(	O
APACHE	O
III	O
;	O
104	O
[	O
SD	O
31	O
]	O
vs	O
89	O
[	O
33	O
]),	O
minute	O
ventilation	O
(	O
11	O
·	O
1	O
[	O
3	O
·	O
2	O
]	O
vs	O
9	O
·	O
6	O
[	O
2	O
·	O
4	O
]	O
L	O
/	O
min	O
),	O
and	O
PEEP	O
(	O
12	O
·	O
4	O
[	O
3	O
·	O
7	O
]	O
vs	O
10	O
·	O
8	O
[	O
2	O
·	O
6	O
]	O
cm	O
H	O
One	O
dose	O
of	O
intravenous	O
MSCs	B-FUNC
was	O
safe	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	O
.	O

S	O
is	O
the	O
primary	O
target	O
for	O
MERS	O
-	O
CoV	O
vaccine	O
and	O
antibody	B-FUNC
development	O
,	O
and	O
it	O
has	O
become	O
increasingly	O
important	O
to	O
understand	O
MERS	O
-	O
CoV	O
antibody	B-FUNC
binding	B-FUNC
specificity	O
and	O
function	O
.	O

Furthermore	O
,	O
two	O
recent	O
clinical	O
randomized	O
,	O
placebo	O
-	O
controlled	O
pilot	O
studies	O
demonstrated	O
that	O
treatment	O
of	O
ARDS	O
with	O
MSCs	B-FUNC
appears	O
to	O
be	O
safe	O
and	O
feasible	O
.	O

ABSTRACT	O
:	O
Bordetella	O
pertussis	O
can	O
cause	O
fatal	O
illness	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
pulmonary	O
hypertension	O
(	O
PHT	B-FUNC
).	O

ABSTRACT	O
:	O
Pulmonary	O
veno	O
-	O
occlusive	O
disease	O
(	O
PVOD	O
)	O
is	O
a	O
rare	O
cause	O
of	O
pulmonary	O
arterial	O
hypertension	O
(	O
PAH	B-FUNC
)	O
in	O
humans	O
and	O
can	O
be	O
classified	O
in	O
idiopathic	O
,	O
heritable	O
,	O
drug	O
and	O
radiation	O
-	O
induced	O
,	O
and	O
associated	O
with	O
connective	O
tissue	O
disease	O
or	O
human	O
immunodeficiency	O
virus	O
infection	O
.	O

In	O
dogs	O
,	O
PAH	B-FUNC
is	O
poorly	O
characterized	O
and	O
is	O
generally	O
considered	O
to	O
be	O
idiopathic	O
or	O
secondary	O
to	O
(	O
for	O
example	O
)	O
congenital	O
left	O
-	O
to	O
right	O
cardiovascular	O
shunts	O
or	O
heartworm	O
disease	O
.	O

No	O
causal	O
variants	O
were	O
found	O
in	O
the	O
genes	O
that	O
are	O
known	O
to	O
be	O
involved	O
in	O
human	O
PVOD	O
and	O
PAH	B-FUNC
.	O

Furthermore	O
,	O
TRIM8	O
knockdown	O
evidently	O
improved	O
nuclear	O
factor	O
-	O
erythroid	O
2	O
related	O
factor	O
2	O
(	O
Nrf2	O
)	O
and	O
heme	O
oxygenase	B-FUNC
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
expressions	O
in	O
lung	O
of	O
LPS	O
-	O
treated	O
mice	O
.	O

The	O
results	O
of	O
the	O
ELISA	O
-	O
rN	O
were	O
compared	O
to	O
the	O
commercial	O
kit	B-FUNC
results	O
using	O
receiver	O
-	O
operating	O
characteristics	O
curves	O
,	O
area	O
under	O
the	O
curve	O
,	O
and	O
confidence	O
intervals	O
with	O
the	O
software	O
GraphPad	O
Prism	O
version	O
6	O
.	O
0	O
for	O
Windows	O
(	O
GraphPad	O
Software	O
,	O
USA	O
).	O

This	O
variant	O
was	O
located	O
in	O
the	O
C3b	O
-	O
binding	B-FUNC
site	O
and	O
functional	O
tests	O
revealed	O
that	O
it	O
perturbed	O
the	O
regulatory	O
activity	O
of	O
factor	O
H	O
.	O
This	O
case	O
suggests	O
that	O
pertussis	O
is	O
a	O
strong	O
trigger	O
of	O
HUS	O
and	O
that	O
complement	O
investigations	O
are	O
necessary	O
to	O
guide	O
treatment	O
and	O
understand	O
the	O
pathophysiology	O
.	O

In	O
Vero	O
and	O
IPEC	O
-	O
DQ	O
cells	O
,	O
certain	O
concentrations	O
of	O
BM	O
,	O
PGM	B-FUNC
,	O
bile	O
and	O
bile	O
acids	O
increased	O
significantly	O
the	O
infectivity	O
of	O
icPC22A	O
but	O
had	O
no	O
or	O
negative	O
effects	O
on	O
icPC22A	O
-	O
S1Δ197	O
.	O

TITLE	O
:	O
Porcine	O
deltacoronavirus	O
induces	O
TLR3	O
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
,	O
IFN	O
-	O
α	O
,	O
IFN	O
-	O
β	O
and	O
PKR	O
mRNA	O
expression	O
in	O
infected	O
Peyer	O
'	O
s	O
patches	O
in	O
vivo	O
.	O

Blood	O
samples	O
were	O
collected	O
at	O
7	O
,	O
14	O
,	O
21	O
days	O
post	O
infection	O
(	O
dpi	O
)	O
and	O
subjected	O
for	O
the	O
analyses	O
of	O
serum	O
antibody	B-FUNC
production	O
,	O
T	O
cell	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
frequencies	O
,	O
NK	O
cytotoxicity	O
and	O
serum	O
cytokine	O
levels	O
.	O

Using	O
click	O
chemistry	O
,	O
the	O
overexpressed	O
sterol	O
regulatory	O
element	O
binding	B-FUNC
protein	O
(	O
SREBP	O
)	O
is	O
shown	O
to	O
interact	O
with	O
AM580	O
,	O
which	O
accounts	O
for	O
its	O
broad	O
-	O
spectrum	O
antiviral	O
activity	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
L	O
.	O
acidophilus	O
S	O
-	O
layer	O
protein	O
plays	O
an	O
inhibitory	O
role	O
during	O
PEDV	O
infection	O
of	O
Vero	O
cells	O
,	O
and	O
that	O
the	O
antagonistic	O
activity	O
of	O
the	O
protein	O
is	O
not	O
via	O
competition	O
with	O
PEDV	O
for	O
binding	B-FUNC
sites	O
.	O

A	O
total	O
of	O
120	O
14	O
-	O
d	O
-	O
old	O
broiler	O
chickens	O
(	O
Cobb	B-FUNC
500	O
)	O
were	O
equally	O
divided	O
into	O
4	O
groups	O
for	O
experimental	O
infection	O
in	O
a	O
complete	O
randomized	O
design	O
.	O

Accordingly	O
,	O
the	O
full	O
genome	O
sequence	O
was	O
retrieved	O
from	O
the	O
UK	O
rat	O
coronavirus	O
,	O
along	O
with	O
partial	O
genome	O
sequences	O
from	O
the	O
UK	O
field	O
vole	O
and	O
Poland	O
-	O
resident	O
bank	O
vole	O
CoVs	O
,	O
and	O
a	O
short	O
conserved	O
ORF1b	O
fragment	O
from	O
the	O
French	O
rabbit	O
CoV	O
.	O
Genome	O
and	O
phylogenetic	O
analysis	O
showed	O
that	O
despite	O
their	O
diverse	O
geographic	O
origins	O
,	O
all	O
rodent	O
alpha	O
-	O
CoVs	O
formed	O
a	O
single	O
monophyletic	O
group	O
and	O
shared	O
similar	O
features	O
,	O
such	O
as	O
the	O
same	O
gene	O
constellations	O
,	O
a	O
recombinant	O
beta	O
-	O
CoV	O
spike	O
gene	O
,	O
and	O
similar	O
core	O
transcriptional	O
regulatory	O
sequences	O
(	O
TRS	B-FUNC
).	O

An	O
in	O
vitro	O
model	O
was	O
used	O
to	O
analyze	O
the	O
effect	O
of	O
miR	O
‑	O
223	O
downregulation	O
on	O
an	O
ALI	O
model	O
,	O
which	O
increased	O
inflammation	O
,	O
and	O
induced	O
the	O
activation	O
of	O
the	O
NACHT	O
,	O
LRR	O
and	O
PYD	O
domains	O
‑	O
containing	O
protein	O
3	O
(	O
NLRP3	O
)	O
inflammasome	O
and	O
Toll	O
‑	O
like	O
receptor	O
4	O
(	O
TLR4	O
)/	O
nuclear	O
factor	O
(	O
NF	O
)‑	O
κB	O
signaling	O
pathway	O
via	O
rho	O
‑	O
related	O
GTP	B-FUNC
‑	I-FUNC
binding	I-FUNC
protein	O
RhoB	O
(	O
RHOB	O
).	O

While	O
cells	O
uninfected	O
or	O
infected	O
with	O
a	O
lentivirus	O
expressing	O
a	O
3a	O
protein	O
defective	O
in	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
expressed	O
NLRP3	O
uniformly	O
throughout	O
the	O
cytoplasm	O
,	O
NLRP3	O
was	O
redistributed	O
to	O
the	O
perinuclear	O
space	O
in	O
cells	O
infected	O
with	O
a	O
lentivirus	O
expressing	O
the	O
3a	O
protein	O
.	O

We	O
generated	O
two	O
oligomeric	O
Nbs	O
by	O
linking	O
two	O
or	O
three	O
monomeric	O
Nbs	O
(	O
Mono	O
-	O
Nbs	O
)	O
targeting	O
the	O
MERS	O
-	O
CoV	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
),	O
and	O
compared	O
their	O
RBD	O
-	O
binding	B-FUNC
affinity	O
,	O
RBD	B-FUNC
⁻	I-FUNC
receptor	I-FUNC
binding	I-FUNC
inhibition	O
,	O
stability	O
,	O
and	O
neutralizing	O
and	O
cross	O
-	O
neutralizing	O
activity	O
against	O
MERS	O
-	O
CoV	O
.	O
Relative	O
to	O
Mono	O
-	O
Nb	O
,	O
dimeric	O
Nb	O
(	O
Di	O
-	O
Nb	O
)	O
and	O
trimeric	O
Nb	O
(	O
Tri	O
-	O
Nb	O
)	O
had	O
significantly	O
greater	O
ability	O
to	O
bind	B-FUNC
MERS	O
-	O
CoV	O
RBD	O
proteins	O
with	O
or	O
without	O
mutations	O
in	O
the	O
RBD	O
,	O
thereby	O
potently	O
blocking	O
RBD	O
⁻	O
MERS	O
-	O
CoV	O
receptor	B-FUNC
binding	I-FUNC
.	O

Moreover	O
,	O
CMV	O
re	O
-	O
activation	O
was	O
confirmed	O
by	O
CMV	O
antibody	B-FUNC
detection	O
,	O
and	O
we	O
administered	O
gancyclovir	O
and	O
thymosin	O
α1	O
but	O
reduced	O
the	O
strength	O
of	O
the	O
immunosuppressive	O
drugs	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Infection	O
Dynamics	O
and	O
Antibody	B-FUNC
Responses	O
among	O
Clinically	O
Diverse	O
Patients	O
,	O
Saudi	O
Arabia	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aims	O
to	O
explore	O
the	O
dynamic	O
changes	O
of	O
pulmonary	O
arterial	O
pressure	O
(	O
PAP	B-FUNC
)	O
and	O
its	O
clinical	O
significance	O
in	O
prenatal	O
neonates	O
with	O
pulmonary	O
and	O
extra	O
-	O
pulmonary	O
acute	O
lung	O
injury	O
/	O
respiratory	O
distress	O
syndrome	O
(	O
ALI	O
/	O
ARDS	O
).	O
A	O
prospective	O
study	O
was	O
conducted	O
in	O
the	O
Neonate	O
Intensive	O
Care	O
Unit	O
(	O
NICU	O
)	O
between	O
May	O
2015	O
and	O
April	O
2017	O
.	O

PAP	B-FUNC
in	O
perinatal	O
neonates	O
with	O
ALI	O
/	O
ARDS	O
increases	O
in	O
varying	O
degrees	O
,	O
and	O
its	O
extent	O
was	O
related	O
to	O
the	O
severity	O
of	O
the	O
illness	O
.	O

Efforts	O
to	O
develop	O
antibody	B-FUNC
-	O
based	O
therapies	O
have	O
focused	O
on	O
neutralizing	O
antibodies	O
that	O
target	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
of	O
the	O
viral	O
spike	O
protein	O
thereby	O
blocking	O
receptor	B-FUNC
binding	I-FUNC
.	O

In	O
infected	O
cells	O
,	O
nsp1	O
engages	O
in	O
a	O
multipronged	O
mechanism	O
to	O
inhibit	O
host	O
gene	O
expression	O
by	O
binding	B-FUNC
to	O
the	O
40S	O
ribosome	O
to	O
block	O
the	O
assembly	O
of	O
translationally	O
competent	O
ribosome	O
,	O
and	O
then	O
inducing	O
endonucleolytic	O
cleavage	O
and	O
the	O
degradation	O
of	O
host	O
mRNAs	O
.	O

Consistent	O
with	O
its	O
role	O
in	O
host	O
shutoff	O
,	O
nsp1	O
alters	O
the	O
nuclear	O
-	O
cytoplasmic	O
distribution	O
of	O
an	O
RNA	B-FUNC
binding	I-FUNC
protein	O
,	O
nucleolin	O
.	O

The	O
overall	O
MERS	O
-	O
CoV	O
antibody	B-FUNC
seroprevalence	O
was	O
80	O
.	O
5	O
%,	O
whereas	O
the	O
overall	O
viral	O
RNA	O
prevalence	O
was	O
2	O
.	O
4	O
%.	O

ABSTRACT	O
:	O
Antibody	B-FUNC
phage	O
display	O
has	O
been	O
pivotal	O
in	O
the	O
quest	O
to	O
generate	O
human	O
monoclonal	O
antibodies	O
for	O
biomedical	O
and	O
research	O
applications	O
.	O

At	O
the	O
same	O
time	O
,	O
in	O
the	O
PPAR	O
pathway	O
genes	O
of	O
fatty	O
acid	O
-	O
binding	B-FUNC
protein	O
(	O
FABP	O
)	O
family	O
members	O
were	O
observed	O
with	O
remarkably	O
differential	O
expressions	O
.	O

S1	O
is	O
one	O
of	O
two	O
protein	O
domains	O
in	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
and	O
is	O
responsible	O
for	O
enteric	O
tropism	O
,	O
sialic	O
acid	O
recognition	O
,	O
and	O
host	O
receptor	B-FUNC
binding	I-FUNC
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
infections	O
induce	O
apoptosis	O
in	O
Vero	O
cells	O
via	O
a	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)/	O
p53	O
,	O
but	O
not	O
p38	B-FUNC
MAPK	B-FUNC
and	O
SAPK	B-FUNC
/	O
JNK	B-FUNC
signalling	O
pathways	O
.	O

In	O
addition	O
,	O
we	O
also	O
found	O
that	O
p38	B-FUNC
MAPK	B-FUNC
and	O
SAPK	B-FUNC
/	O
JNK	B-FUNC
were	O
activated	O
in	O
PEDV	O
-	O
infected	O
Vero	O
cells	O
.	O

The	O
BCoV	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
an	O
RNA	O
-	O
binding	B-FUNC
protein	O
,	O
was	O
therefore	O
tested	O
as	O
a	O
candidate	O
.	O

The	O
relationship	O
among	O
the	O
number	O
and	O
type	O
of	O
comorbidities	O
,	O
Charlson	O
comorbidity	O
index	O
(	O
CCI	O
),	O
clinical	O
characteristics	O
and	O
the	O
levels	O
of	O
plasma	O
inflammatory	O
markers	O
[	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
high	O
sensitivity	O
C	O
-	O
reaction	O
protein	O
(	O
hs	O
-	O
CRP	O
),	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
α	O
(	O
TNF	O
-	O
α	O
),	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
]	O
were	O
studied	O
.	O

TITLE	O
:	O
Differential	O
recognition	O
of	O
peptides	O
within	O
feline	O
coronavirus	O
polyprotein	O
1	O
ab	O
by	O
sera	B-FUNC
from	O
healthy	O
cats	O
and	O
cats	O
with	O
feline	O
infectious	O
peritonitis	O
.	O

The	O
most	O
common	O
use	O
of	O
this	O
tool	O
is	O
to	O
determine	O
whether	O
acute	O
coronary	O
syndrome	O
(	O
ACS	B-FUNC
)	O
is	O
occurring	O
,	O
but	O
other	O
differentials	O
include	O
cardiomyopathy	O
,	O
pulmonary	O
embolism	O
,	O
and	O
even	O
acute	O
heart	O
failure	O
.	O

Several	O
viral	O
families	O
,	O
including	O
Coronaviridae	O
,	O
Togaviridae	O
,	O
and	O
Hepeviridae	O
,	O
encode	O
for	O
macrodomain	O
proteins	O
that	O
bind	B-FUNC
to	O
and	O
hydrolyze	O
ADP	O
-	O
ribose	O
from	O
proteins	O
and	O
are	O
critical	O
for	O
optimal	O
replication	O
and	O
virulence	O
.	O

Binary	O
Logistic	O
regression	O
analysis	O
showed	O
that	O
neutral	O
red	O
phagocytosis	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
0	O
.	O
596	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
)	O
=	O
0	O
.	O
212	O
-	O
0	O
.	O
997	O
]	O
and	O
alkaline	B-FUNC
phosphatase	I-FUNC
activity	I-FUNC
(	O
OR	O
=	O
0	O
.	O
573	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
339	O
-	O
0	O
.	O
968	O
)	O
were	O
the	O
influencing	O
factors	O
of	O
prognosis	O
(	O
both	O
P	O
<	O
0	O
.	O
05	O
).	O

However	O
,	O
PDCoV	O
N	O
protein	O
restrained	O
the	O
pRiplet	O
binding	B-FUNC
pRIG	O
-	O
I	O
to	O
inhibit	O
pRIG	O
-	O
I	O
K63	O
-	O
linked	O
polyubiquitination	O
.	O

Among	O
all	O
the	O
potential	O
targets	O
of	O
MERS	O
-	O
CoV	O
,	O
the	O
spike	O
glycoprotein	O
(	O
S	O
)	O
has	O
been	O
the	O
most	O
well	O
-	O
studied	O
due	O
to	O
its	O
critical	O
role	O
in	O
mediating	O
viral	O
entry	O
and	O
in	O
inducing	O
a	O
protective	O
antibody	B-FUNC
response	O
in	O
infected	O
individuals	O
.	O

Meanwhile	O
,	O
serological	O
investigation	O
of	O
sows	O
'	O
sera	B-FUNC
implied	O
that	O
SADS	O
-	O
CoV	O
has	O
existed	O
in	O
the	O
farm	O
and	O
PEDV	O
antibody	B-FUNC
may	O
not	O
directly	O
contribute	O
to	O
the	O
amplification	O
of	O
SADS	O
-	O
CoV	O
.	O
Homology	O
and	O
phylogenetic	O
analysis	O
of	O
the	O
whole	O
genome	O
showed	O
that	O
the	O
re	O
-	O
emerging	O
SADS	O
-	O
CoV	O
strain	O
shared	O
high	O
sequence	O
identities	O
with	O
existing	O
SADS	O
-	O
CoV	O
strains	O
and	O
all	O
strains	O
clustered	O
together	O
in	O
Alpha	O
coronavirus	O
.	O

In	O
contrast	O
to	O
the	O
continued	O
rise	O
of	O
systemic	O
antibodies	O
after	O
booster	O
vaccination	O
,	O
the	O
levels	O
of	O
mucosal	O
IBV	O
-	O
specific	O
immunoglobulin	B-FUNC
A	O
decreased	O
after	O
booster	O
vaccination	O
.	O

A	O
fully	O
human	O
polyclonal	O
IgG	O
antibody	B-FUNC
(	O
SAB	O
-	O
301	O
)	O
was	O
safe	O
and	O
well	O
tolerated	O
in	O
healthy	O
individuals	O
and	O
this	O
agent	O
may	O
deserve	O
further	O
testing	O
for	O
efficacy	O
.	O

Treatment	O
for	O
RSV	O
is	O
mainly	O
supportive	O
since	O
the	O
only	O
approved	O
therapy	O
,	O
a	O
monoclonal	O
antibody	B-FUNC
,	O
is	O
recommended	O
for	O
prophylactic	O
use	O
in	O
high	O
-	O
risk	O
patients	O
.	O

Endocan	O
is	O
a	O
circulating	O
proteoglycan	O
that	O
binds	B-FUNC
to	O
the	O
leukocyte	O
integrin	O
leukocyte	O
functional	O
antigen	O
-	O
1	O
and	O
blocks	O
its	O
interaction	O
with	O
its	O
endothelial	O
ligand	B-FUNC
,	O
ICAM	O
-	O
1	O
.	O

Here	O
we	O
report	O
the	O
monoclonal	O
antibody	B-FUNC
7D10	O
that	O
binds	B-FUNC
to	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
the	O
spike	O
glycoprotein	O
and	O
inhibits	O
the	O
cell	O
entry	O
of	O
MERS	O
-	O
CoV	O
with	O
high	O
potency	O
.	O

Further	O
experiments	O
indicate	O
that	O
the	O
neutralization	O
by	O
7D10	O
is	O
not	O
solely	O
dependent	O
on	O
the	O
inhibition	O
of	O
DPP4	O
binding	B-FUNC
,	O
but	O
also	O
acts	O
after	O
viral	O
cell	O
attachment	O
,	O
inhibiting	O
the	O
pre	O
-	O
fusion	O
to	O
post	O
-	O
fusion	O
conformational	O
change	O
of	O
the	O
spike	O
.	O

Additionally	O
,	O
anti	O
-	O
canine	O
respiratory	O
coronavirus	O
antibody	B-FUNC
concentrations	O
were	O
measured	O
in	O
paired	O
blood	O
samples	O
from	O
30	O
acutely	O
diseased	O
dogs	O
.	O

Recent	O
studies	O
indicated	O
that	O
Cxc	O
chemokine	O
ligand	B-FUNC
5	O
(	O
CXCL5	O
),	O
an	O
inflammatory	O
chemokine	O
,	O
was	O
associated	O
with	O
tumorigenesis	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
performed	O
to	O
determine	O
the	O
expression	O
levels	O
of	O
CXCL5	O
and	O
inflammatory	O
factors	O
(	O
IL	O
-	O
1ß	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
TNF	O
-	O
alpha	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
)	O
in	O
serum	O
.	O

Using	O
viruslike	O
particles	O
lacking	O
the	O
spike	O
(	O
S	O
)	O
protein	O
,	O
we	O
demonstrate	O
that	O
binding	B-FUNC
to	O
the	O
cell	O
is	O
not	O
S	O
protein	O
dependent	O
.	O

TITLE	O
:	O
Patchy	O
Amphiphilic	O
Dendrimers	O
Bind	B-FUNC
Adenovirus	O
and	O
Control	O
Its	O
Host	O
Interactions	O
and	O
in	O
Vivo	O
Distribution	O
.	O

The	O
surface	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
MERS	O
-	O
CoV	O
,	O
which	O
binds	B-FUNC
to	O
the	O
cellular	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
),	O
is	O
considered	O
as	O
a	O
major	O
target	O
for	O
MERS	O
-	O
CoV	O
vaccine	O
development	O
.	O

HLH	O
is	O
increasingly	O
recognized	O
in	O
dengue	O
infection	O
and	O
maybe	O
considered	O
as	O
a	O
differential	O
diagnosis	O
in	O
children	O
with	O
lower	O
hemoglobin	O
,	O
hypoalbuminemia	O
,	O
elevated	O
ALT	B-FUNC
and	O
severe	O
organ	O
dysfunction	O
.	O

As	O
a	O
result	O
,	O
we	O
identified	O
a	O
list	O
of	O
putative	O
AMPs	O
which	O
binds	B-FUNC
to	O
the	O
spike	O
protein	O
of	O
MERS	O
-	O
CoV	O
,	O
which	O
may	O
be	O
crucial	O
in	O
providing	O
the	O
inhibitory	O
action	O
.	O

We	O
speculate	O
that	O
this	O
inhibitory	O
effect	O
is	O
likely	O
to	O
be	O
related	O
to	O
the	O
structure	O
of	O
PLP2	O
with	O
deubiquitinating	B-FUNC
enzyme	I-FUNC
activity	I-FUNC
of	O
the	O
amino	O
acid	O
residues	O
at	O
positions	O
590	O
-	O
1	O
,	O
215	O
in	O
Nsp3	O
.	O

This	O
work	O
not	O
only	O
provides	O
some	O
new	O
findings	O
for	O
the	O
biological	O
function	O
of	O
the	O
PEDV	O
ORF3	O
protein	O
,	O
but	O
also	O
help	O
us	O
for	O
the	O
further	O
understanding	O
the	O
molecular	B-FUNC
interaction	I-FUNC
between	O
PEDV	O
ORF3	O
protein	O
and	O
cells	O
.	O

These	O
patients	O
also	O
experienced	O
shorter	O
hospital	O
length	O
of	O
stay	O
and	O
shorter	O
wound	O
healing	O
times	O
,	O
as	O
well	O
as	O
lower	O
spleen	O
and	O
kidney	O
weights	O
,	O
lower	O
urinary	O
nitrogen	O
losses	O
,	O
improved	O
nitrogen	O
balance	O
,	O
higher	O
insulin	O
levels	O
,	O
higher	O
insulin	B-FUNC
-	I-FUNC
like	I-FUNC
growth	I-FUNC
factor	I-FUNC
-	O
1	O
,	O
lower	O
cortisol	O
,	O
and	O
less	O
muscle	O
protein	O
breakdown	O
.	O

Coumarin	O
-	O
based	O
molecules	O
already	O
proved	O
to	O
act	O
as	O
HIV	O
-	O
1	O
Protease	O
(	O
PR	O
)	O
or	O
Integrase	O
(	O
IN	O
)	O
inhibitors	O
and	O
also	O
to	O
target	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
),	O
blocking	O
the	O
DNA	O
-	O
dependent	O
DNA	O
-	O
polymerase	O
activity	O
or	O
the	O
RNA	O
-	O
dependent	O
DNA	O
-	O
polymerase	O
activity	O
working	O
as	O
common	O
NNRTIs	O
.	O

TITLE	O
:	O
Porcine	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
plasmid	O
as	O
an	O
adjuvant	O
improves	O
the	O
cellular	O
and	O
humoral	O
immune	O
responses	O
of	O
DNA	O
vaccine	O
targeting	O
transmissible	O
gastroenteritis	O
virus	O
spike	O
gene	O
in	O
a	O
mouse	O
model	O
.	O

In	O
that	O
regard	O
,	O
flexible	O
nucleoside	O
analogues	O
known	O
as	O
""""	O
fleximers	O
""""	O
have	O
garnered	O
attention	O
over	O
the	O
years	O
due	O
to	O
their	O
ability	O
to	O
survey	O
different	O
amino	O
acids	O
in	O
enzyme	B-FUNC
binding	I-FUNC
sites	O
,	O
thus	O
overcoming	O
the	O
potential	O
development	O
of	O
antiviral	O
resistance	O
.	O

Ras	O
-	O
GTPase	O
-	O
activating	O
protein	O
(	O
SH3	O
domain	O
)	O
binding	B-FUNC
protein	O
1	O
(	O
G3BP1	O
)	O
is	O
a	O
key	O
stress	O
granule	O
-	O
resident	O
protein	O
that	O
nucleates	O
stress	O
granule	O
assembly	O
.	O

Management	O
of	O
ACS	B-FUNC
is	O
complex	O
and	O
may	O
necessitate	O
mechanical	O
ventilation	O
and	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
VV	O
-	O
ECMO	O
)	O
therapy	O
in	O
the	O
more	O
severe	O
cases	O
.	O

The	O
most	O
intense	O
immunoreaction	O
was	O
detected	O
using	O
a	O
neutralizing	O
antibody	B-FUNC
directed	O
against	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
S1B	O
of	O
the	O
MERS	O
-	O
S	O
protein	O
,	O
which	O
produced	O
an	O
immunosignal	O
in	O
the	O
cytoplasm	O
of	O
ciliated	O
respiratory	O
epithelium	O
and	O
along	O
the	O
apical	O
membranous	O
region	O
.	O

Potently	O
neutralizing	O
antibodies	O
targeting	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
on	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
have	O
been	O
characterized	O
,	O
but	O
much	O
less	O
is	O
known	O
about	O
antibodies	O
targeting	O
non	O
-	O
RBD	O
epitopes	O
.	O

Here	O
,	O
we	O
report	O
the	O
structural	O
and	O
functional	O
characterization	O
of	O
G2	O
,	O
a	O
neutralizing	O
antibody	B-FUNC
targeting	O
the	O
MERS	O
-	O
CoV	O
S1	O
N	O
-	O
terminal	O
domain	O
(	O
S1	O
-	O
NTD	O
).	O

These	O
results	O
advance	O
our	O
understanding	O
of	O
antibody	B-FUNC
-	O
mediated	O
neutralization	O
of	O
coronaviruses	O
and	O
should	O
facilitate	O
the	O
development	O
of	O
immunotherapeutics	O
and	O
vaccines	O
against	O
MERS	O
-	O
CoV	O
.	O

The	O
potential	O
signaling	O
pathways	O
were	O
manipulated	O
individually	O
by	O
pharmacological	O
inhibition	O
,	O
small	O
interfering	O
ribonucleic	O
acid	O
(	O
siRNA	O
)	O
depletion	O
,	O
and	O
antibody	B-FUNC
blocking	O
.	O

ABSTRACT	O
:	O
Growth	B-FUNC
Hormone	I-FUNC
-	O
Releasing	O
Hormone	O
(	O
GHRH	O
)	O
regulates	O
the	O
release	O
of	O
growth	B-FUNC
hormone	I-FUNC
from	O
the	O
anterior	O
pituitary	O
gland	O
.	O

Silencing	O
HK2	B-FUNC
enhanced	O
TGEV	O
-	O
induced	O
mPTP	O
opening	O
,	O
while	O
no	O
effect	O
on	O
NF	O
-	O
κB	O
pathway	O
.	O

For	O
syndromic	O
diagnosis	O
,	O
several	O
multiplex	O
nucleic	O
acid	O
amplification	O
tests	O
have	O
been	O
developed	O
for	O
clinics	O
,	O
of	O
which	O
SureX	O
13	O
Respiratory	O
Pathogen	O
Multiplex	O
Kit	B-FUNC
(	O
ResP	O
)	O
can	O
simultaneously	O
detect	O
13	O
pathogens	O
directly	O
from	O
airway	O
secretion	O
specimens	O
.	O

Here	O
we	O
demonstrate	O
the	O
interaction	O
between	O
the	O
N	O
protein	O
of	O
HCoV	O
-	O
229E	O
and	O
cyclophilin	B-FUNC
A	O
,	O
not	O
cyclophilin	B-FUNC
B	O
.	O
Cyclophilin	B-FUNC
inhibitors	O
abolish	O
this	O
interaction	O
.	O

In	O
HCoV	O
-	O
229E	O
,	O
its	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
shows	O
extensive	O
sequence	O
variation	O
but	O
how	O
S	O
-	O
protein	O
function	O
is	O
maintained	O
is	O
not	O
understood	O
.	O

On	O
day	O
7	O
after	O
treatment	O
,	O
TNF	O
-	O
α	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
CRP	O
and	O
CD8	O
EFR	O
can	O
effectively	O
eliminate	O
inflammatory	O
factors	O
,	O
improve	O
immune	O
function	O
,	O
maintain	O
the	O
stability	O
of	O
blood	O
components	O
,	O
reduce	O
the	O
incidences	O
of	O
ARDS	O
and	O
MODS	O
,	O
and	O
elevate	O
the	O
successful	O
rescue	O
rate	O
in	O
patients	O
with	O
SPF	O
.	O

Here	O
,	O
we	O
describe	O
the	O
generation	O
of	O
antibody	B-FUNC
-	O
peptide	O
bispecific	O
fusion	O
proteins	O
,	O
each	O
of	O
which	O
contains	O
an	O
anti	O
-	O
MERS	O
-	O
CoV	O
single	O
-	O
chain	O
antibody	B-FUNC
m336	O
(	O
or	O
normal	O
human	O
IgG1	O
CH3	O
domain	O
as	O
a	O
control	O
)	O
linked	O
with	O
,	O
or	O
without	O
,	O
a	O
MERS	O
-	O
CoV	O
fusion	O
inhibitory	O
peptide	O
HR2P	O
.	O

In	O
contrast	O
,	O
only	O
QX	O
-	O
RBD	O
binds	B-FUNC
more	O
extensively	O
to	O
cells	O
of	O
the	O
digestive	O
tract	O
,	O
urogenital	O
tract	O
,	O
and	O
kidneys	O
.	O

While	O
removal	O
of	O
sialic	O
acids	O
from	O
tissues	O
prevented	O
binding	B-FUNC
of	O
all	O
proteins	O
to	O
all	O
tissues	O
,	O
binding	B-FUNC
of	O
QX	O
-	O
RBD	O
to	O
trachea	O
and	O
kidney	O
could	O
not	O
be	O
blocked	O
by	O
preincubation	O
with	O
synthetic	O
alpha	O
-	O
2	O
,	O
3	O
-	O
linked	O
sialic	O
acids	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
failure	O
due	O
to	O
Sai	O
-	O
rei	O
-	O
to	O
-	O
induced	O
lung	O
injury	O
successfully	O
treated	O
by	O
multi	O
-	O
modal	O
therapy	O
including	O
immunosuppressive	O
therapy	O
,	O
plasma	O
exchange	O
,	O
and	O
intravenous	O
immunoglobulin	B-FUNC
:	O
A	O
case	O
report	O
.	O

Therefore	O
,	O
we	O
also	O
initiated	O
intravenous	O
immunoglobulin	B-FUNC
(	O
IVIG	O
)	O
therapy	O
for	O
the	O
treatment	O
of	O
potential	O
vasculitis	O
.	O

Further	O
,	O
tests	O
for	O
anti	O
-	O
glomerular	O
basement	O
membrane	O
antibody	B-FUNC
,	O
myeloperoxidase	O
-	O
ANCA	O
,	O
and	O
proteinase	B-FUNC
3	O
-	O
ANCA	O
revealed	O
negative	O
results	O
.	O

In	O
contrast	O
to	O
naïve	O
animals	O
,	O
in	O
-	O
contact	O
vaccinated	O
llamas	O
did	O
not	O
shed	O
infectious	O
virus	O
upon	O
exposure	O
to	O
directly	O
inoculated	O
llamas	O
,	O
consistent	O
with	O
the	O
induction	O
of	O
strong	O
virus	O
neutralizing	O
antibody	B-FUNC
responses	O
.	O

An	O
induced	O
-	O
fit	O
docking	O
analysis	O
indicated	O
that	O
S1	O
,	O
S2	O
and	O
S3	O
'	O
sites	O
are	O
involved	O
in	O
binding	B-FUNC
with	O
flavonoids	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
have	O
utilized	O
steady	O
-	O
state	O
and	O
time	O
-	O
resolved	O
fluorescence	O
spectroscopy	O
in	O
tandem	O
with	O
circular	O
dichroism	O
spectroscopy	O
to	O
elucidate	O
the	O
binding	B-FUNC
,	O
oligomeric	O
status	O
,	O
and	O
secondary	O
structure	O
of	O
the	O
fusion	O
peptide	O
and	O
its	O
impact	O
on	O
the	O
depth	O
-	O
dependent	O
membrane	O
organization	O
and	O
dynamics	O
.	O

High	O
levels	O
of	O
acylcarnitine	O
in	O
the	O
serum	O
confirmed	O
the	O
diagnosis	O
of	O
CPT	B-FUNC
II	O
deficiency	O
.	O

We	O
found	O
that	O
the	O
MHV	O
N	O
protein	O
binds	B-FUNC
exclusively	O
to	O
nsp3	O
and	O
not	O
other	O
RTC	O
components	O
by	O
using	O
a	O
systematic	O
yeast	O
two	O
-	O
hybrid	O
approach	O
,	O
and	O
we	O
identified	O
two	O
distinct	O
regions	O
in	O
the	O
N	O
protein	O
that	O
redundantly	O
mediate	O
this	O
interaction	O
.	O

In	O
this	O
study	O
,	O
an	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
method	O
utilizing	O
ECoV	O
spike	O
S1	O
protein	O
was	O
developed	O
in	O
two	O
formats	O
,	O
and	O
further	O
validated	O
by	O
analyzing	O
27	O
paired	O
serum	O
samples	O
(	O
acute	O
and	O
convalescent	O
sera	B-FUNC
)	O
from	O
horses	O
involved	O
in	O
an	O
ECoV	O
outbreak	O
and	O
1084	O
sera	B-FUNC
of	O
horses	O
with	O
unknown	O
ECoV	O
exposure	O
.	O

ABSTRACT	O
:	O
Traditionally	O
,	O
the	O
emergence	O
of	O
coronaviruses	O
(	O
CoVs	O
)	O
has	O
been	O
attributed	O
to	O
a	O
gain	O
in	O
receptor	B-FUNC
binding	I-FUNC
in	O
a	O
new	O
host	O
.	O

Among	O
the	O
tested	O
compounds	O
,	O
the	O
dihydroxyindole	O
-	O
carboxamide	O
5	O
was	O
able	O
to	O
inhibit	O
in	O
the	O
low	O
micromolar	O
range	O
(	O
1	O
-	O
18	O
μM	O
)	O
multiple	O
functions	O
of	O
IN	O
,	O
including	O
functional	O
IN	O
-	O
IN	O
interactions	O
,	O
IN	O
-	O
LEDGF	O
/	O
p75	O
binding	B-FUNC
and	O
IN	O
catalytic	B-FUNC
activity	I-FUNC
.	O

Early	O
recognition	O
of	O
the	O
complication	O
and	O
application	O
of	O
ventilatory	O
support	O
techniques	O
resulted	O
in	O
fast	B-FUNC
restoration	O
of	O
oxygenation	O
and	O
improvement	O
of	O
treatment	O
efficiency	O
.	O

The	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
:	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
ratio	O
,	O
a	O
marker	O
of	O
the	O
immune	O
system	O
'	O
s	O
inflammatory	O
balance	O
,	O
was	O
skewed	O
towards	O
the	O
pro	O
-	O
inflammatory	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
in	O
the	O
liver	O
of	O
cats	O
with	O
FIP	O
.	O

Both	O
pAPN	O
and	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
domains	O
(	O
aa	O
506	O
-	O
655	O
and	O
145	O
-	O
155	O
,	O
respectively	O
)	O
are	O
necessary	O
but	O
not	O
sufficient	O
for	O
enteric	O
tract	O
infection	O
.	O

The	O
data	O
indicated	O
that	O
U655	O
>	O
G	O
change	O
in	O
S	O
gene	O
(	O
S219A	O
in	O
S	O
protein	O
)	O
was	O
required	O
to	O
confer	O
enteric	O
tropism	O
to	O
a	O
respiratory	O
virus	O
that	O
already	O
contains	O
the	O
pAPN	O
and	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
domains	O
in	O
its	O
S	O
protein	O
.	O

Our	O
data	O
suggest	O
that	O
IL	B-FUNC
-	I-FUNC
11	I-FUNC
is	O
a	O
newfound	O
PEDV	O
-	O
inducible	O
cytokine	O
,	O
and	O
its	O
production	O
enhances	O
the	O
anti	O
-	O
apoptosis	O
ability	O
of	O
epithelial	O
cells	O
against	O
PEDV	O
infection	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
MERS	O
-	O
CoV	O
Neutralizing	O
Antibodies	O
in	O
Sera	B-FUNC
Using	O
Live	O
Virus	O
Microneutralization	O
Assay	O
.	O

Here	O
,	O
four	O
different	O
S	O
subunit	O
proteins	O
,	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
;	O
358	O
-	O
606	O
aa	O
),	O
S1	O
(	O
1	O
-	O
751	O
aa	O
),	O
S2	O
(	O
752	O
-	O
1296	O
aa	O
),	O
and	O
SΔTM	O
(	O
1	O
-	O
1296	O
aa	O
),	O
were	O
generated	O
using	O
the	O
baculoviral	O
system	O
and	O
immunized	O
in	O
mice	O
to	O
develop	O
neutralizing	O
antibodies	O
.	O

Results	O
of	O
hematologic	O
analyses	O
and	O
serum	O
concentrations	O
of	O
intestinal	O
fatty	O
acid	O
-	O
binding	B-FUNC
protein	O
(	O
I	O
-	O
FABP	O
),	O
liver	O
fatty	O
acid	O
-	O
binding	B-FUNC
protein	O
(	O
L	O
-	O
FABP	O
),	O
trefoil	O
factor	O
3	O
(	O
TFF	O
-	O
3	O
),	O
Claudin	O
-	O
3	O
(	O
CLDN	O
-	O
3	O
),	O
γ	O
-	O
enteric	O
smooth	O
muscle	O
actin	O
(	O
ACTG2	O
),	O
intestinal	O
alkaline	O
phosphatase	B-FUNC
(	O
IAP	O
),	O
interleukin	O
-	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
),	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
),	O
and	O
leptin	O
(	O
LP	O
)	O
were	O
compared	O
among	O
calves	O
grouped	O
according	O
to	O
whether	O
they	O
were	O
healthy	O
(	O
control	O
group	O
;	O
G	O
-	O
1	O
)	O
or	O
had	O
diarrhea	O
caused	O
by	O
K99	O
Across	O
the	O
3	O
time	O
points	O
at	O
which	O
blood	O
samples	O
were	O
obtained	O
and	O
evaluated	O
,	O
the	O
groups	O
of	O
calves	O
with	O
diarrhea	O
generally	O
had	O
markedly	O
higher	O
mean	O
serum	O
concentrations	O
of	O
L	O
-	O
FABP	O
,	O
TFF	O
-	O
3	O
,	O
IAP	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
LP	O
,	O
compared	O
with	O
the	O
control	O
group	O
.	O

Serum	O
concentrations	O
of	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	O
)	O
and	O
angiopoietin	O
2	O
(	O
Ang2	O
)	O
were	O
determined	O
.	O

However	O
,	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
tentative	O
receptor	O
-	O
binding	B-FUNC
domain	O
resembles	O
that	O
of	O
SARS	O
-	O
CoV	O
,	O
indicating	O
that	O
these	O
viruses	O
might	O
use	O
the	O
same	O
receptor	O
.	O

CT	O
images	O
showed	O
pure	B-FUNC
ground	O
-	O
glass	O
opacity	O
(	O
GGO	O
)	O
in	O
39	O
of	O
51	O
(	O
77	O
%)	O
patients	O
and	O
GGO	O
with	O
reticular	O
and	O
/	O
or	O
interlobular	O
septal	O
thickening	O
in	O
38	O
of	O
51	O
(	O
75	O
%)	O
patients	O
.	O

Several	O
CoV	O
strains	O
have	O
spike	O
proteins	O
with	O
two	O
receptor	O
-	O
binding	B-FUNC
domains	O
,	O
an	O
S1A	O
that	O
engages	O
host	O
sialic	O
acids	O
and	O
an	O
S1B	O
that	O
recognizes	O
host	O
transmembrane	O
proteins	O
.	O

Overall	O
,	O
these	O
findings	O
reveal	O
roles	O
for	O
sialic	O
acids	O
in	O
virus	O
-	O
cell	O
binding	B-FUNC
,	O
viral	O
spike	O
protein	O
-	O
directed	O
cell	O
-	O
cell	O
fusion	O
,	O
and	O
resultant	O
spread	O
of	O
CoV	O
infections	O
.	O

ABSTRACT	O
:	O
The	O
global	O
spread	O
of	O
the	O
2019	O
-	O
nCoV	O
is	O
continuing	O
and	O
is	O
fast	B-FUNC
moving	O
,	O
as	O
indicated	O
by	O
the	O
WHO	O
raising	O
the	O
risk	O
assessment	O
to	O
high	O
.	O

Here	O
,	O
an	O
indirect	O
anti	O
-	O
PDCoV	O
IgA	O
antibody	B-FUNC
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
PDCoV	O
S1	O
IgA	O
ELISA	O
)	O
using	O
the	O
purified	O
S1	O
portion	O
of	O
S	O
protein	O
as	O
the	O
coating	O
antigen	O
was	O
developed	O
to	O
detect	O
PDCoV	O
IgA	O
antibodies	O
in	O
serum	O
and	O
sow	O
'	O
s	O
milk	O
.	O

Currently	O
the	O
main	O
source	O
of	O
infection	O
is	O
NCP	B-FUNC
patients	O
,	O
and	O
asymptomatic	O
carriers	O
may	O
also	O
be	O
infectious	O
.	O

Strategies	O
for	O
prevention	O
and	O
control	O
of	O
NCP	B-FUNC
include	O
improving	O
epidemic	O
surveillance	O
,	O
quarantining	O
the	O
source	O
of	O
infection	O
,	O
speeding	O
up	O
the	O
diagnosis	O
of	O
suspected	O
cases	O
,	O
optimizing	O
the	O
management	O
of	O
close	O
contacts	O
,	O
tightening	O
prevention	O
and	O
control	O
of	O
cluster	O
outbreaks	O
and	O
hospital	O
infection	O
,	O
preventing	O
possible	O
rebound	O
of	O
the	O
epidemic	O
after	O
people	O
return	O
to	O
work	O
from	O
the	O
Chinese	O
Spring	O
Festival	O
holiday	O
,	O
and	O
strengthening	O
community	O
prevention	O
and	O
control	O
.	O

In	O
order	O
to	O
implement	O
the	O
central	O
government	O
'	O
s	O
decision	O
-	O
making	O
deployment	O
and	O
defeat	O
the	O
NCP	B-FUNC
as	O
soon	O
as	O
possible	O
,	O
we	O
had	O
focused	O
on	O
the	O
key	O
points	O
in	O
the	O
clinical	O
work	O
of	O
general	O
surgery	O
according	O
to	O
latest	O
relevant	O
guidelines	O
,	O
literature	O
and	O
experience	O
in	O
epidemic	O
prevention	O
.	O

Here	O
we	O
suggest	O
renaming	O
2019	O
-	O
nCoV	O
as	O
""""	O
transmissible	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
TARS	O
-	O
CoV	O
")"""	O
and	O
briefly	O
review	O
the	O
advancement	O
of	O
research	O
and	O
development	O
of	O
neutralizing	O
antibodies	O
and	O
vaccines	O
targeting	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
and	O
viral	O
fusion	O
inhibitors	O
targeting	O
the	O
heptad	O
repeat	O
1	O
(	O
HR1	O
)	O
domain	O
in	O
spike	O
protein	O
of	O
2019	O
-	O
nCoV	O
.	O

Specific	O
IgM	O
antibody	B-FUNC
screening	O
for	O
patients	O
whose	O
pharyngeal	O
swab	O
nucleic	O
acid	O
test	O
is	O
negative	O
but	O
with	O
ground	O
glass	O
-	O
like	O
lung	O
lesions	O
is	O
very	O
important	O
for	O
early	O
detection	O
and	O
early	O
isolation	O
.	O

The	O
epitope	O
of	O
CR3022	O
does	O
not	O
overlap	O
with	O
the	O
ACE2	O
binding	B-FUNC
site	O
within	O
2019	O
-	O
nCoV	O
RBD	O
.	O

In	O
addition	O
,	O
to	O
know	O
the	O
timing	O
of	O
TLR	O
ligand	B-FUNC
treatment	O
,	O
six	O
time	O
intervals	O
were	O
analyzed	O
viz	O
.	O

Sera	B-FUNC
were	O
obtained	O
near	O
the	O
onset	O
of	O
RI	O
and	O
3	O
to	O
4	O
weeks	O
later	O
as	O
part	O
of	O
a	O
prospective	O
study	O
of	O
200	O
subjects	O
evaluated	O
for	O
RI	O
from	O
2009	O
to	O
2013	O
.	O

The	O
present	O
study	O
shows	O
that	O
abnormal	O
coagulation	O
results	O
,	O
especially	O
markedly	O
elevated	O
D	O
-	O
dimer	O
and	O
FDP	O
are	O
common	O
in	O
deaths	O
with	O
NCP	B-FUNC
.	O

In	O
this	O
paper	O
,	O
combining	O
with	O
the	O
key	O
clinical	O
problems	O
of	O
prevention	O
and	O
control	O
in	O
hospital	O
during	O
the	O
epidemic	O
period	O
of	O
NCP	B-FUNC
infection	O
,	O
medical	O
evidence	O
,	O
and	O
clinical	O
and	O
management	O
experience	O
,	O
the	O
author	O
formulates	O
prevention	O
and	O
control	O
management	O
strategy	O
of	O
the	O
author	O
'	O
s	O
unit	O
in	O
order	O
to	O
provide	O
reference	O
for	O
prevention	O
and	O
control	O
of	O
burn	O
and	O
wound	O
care	O
ward	O
.	O

TITLE	O
:	O
Structure	O
analysis	O
of	O
the	O
receptor	B-FUNC
binding	I-FUNC
of	O
2019	O
-	O
nCoV	O
.	O
ABSTRACT	O
:	O
2019	O
-	O
nCoV	O
is	O
a	O
newly	O
identified	O
coronavirus	O
with	O
high	O
similarity	O
to	O
SARS	O
-	O
CoV	O
.	O
We	O
performed	O
a	O
structural	O
analysis	O
of	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
spike	O
glycoprotein	O
responsible	O
for	O
entry	O
of	O
coronaviruses	O
into	O
host	O
cells	O
.	O

Structural	O
analysis	O
suggests	O
that	O
ACE2	O
from	O
these	O
animals	O
can	O
potentially	O
bind	B-FUNC
RBD	O
of	O
2019	O
-	O
nCoV	O
,	O
making	O
them	O
all	O
possible	O
natural	O
hosts	O
for	O
the	O
virus	O
.	O

It	O
has	O
been	O
proven	O
that	O
NCP	B-FUNC
can	O
be	O
transmitted	O
from	O
human	O
to	O
human	O
and	O
cause	O
hospital	O
infection	O
,	O
which	O
seriously	O
threatens	O
surgical	O
staffs	O
and	O
inpatients	O
.	O

If	O
the	O
emergent	O
patients	O
(	O
intestinal	O
obstruction	O
)	O
with	O
suspected	O
or	O
confirmed	O
NCP	B-FUNC
,	O
the	O
surgeons	O
must	O
perform	O
emergency	O
surgery	O
,	O
and	O
intestinal	O
decompressive	O
tube	O
through	O
colonoscopy	O
is	O
not	O
recommended	O
.	O

(	O
4	O
)	O
The	O
surgical	O
medical	O
workers	O
who	O
process	O
colorectal	O
cancer	O
patients	O
with	O
NCP	B-FUNC
must	O
be	O
protected	O
by	O
three	O
-	O
level	O
.	O

CONCLUSIONS	O
:	O
We	O
speculate	O
that	O
SARS	O
-	O
CoV	O
-	O
2	O
may	O
be	O
detected	O
in	O
the	O
tears	O
and	O
conjunctival	O
secretions	O
in	O
NCP	B-FUNC
patients	O
with	O
conjunctivitis	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
makes	O
the	O
medical	O
treatment	O
of	O
colorectal	O
cancers	O
difficult	O
.	O

TITLE	O
:	O
Development	O
and	O
Clinical	O
Application	O
of	O
A	O
Rapid	O
IgM	O
-	O
IgG	O
Combined	O
Antibody	B-FUNC
Test	O
for	O
SARS	O
-	O
CoV	O
-	O
2	O
Infection	O
Diagnosis	O
.	O

ABSTRACT	O
:	O
Fast	B-FUNC
point	O
-	O
of	O
-	O
use	O
detection	O
of	O
,	O
for	O
example	O
,	O
early	O
-	O
stage	O
zoonoses	O
,	O
e	O
.	O
g	O
.,	O
Q	O
-	O
fever	O
,	O
bovine	O
tuberculosis	O
,	O
or	O
the	O
Covid	O
-	O
19	O
coronavirus	O
,	O
is	O
beneficial	O
for	O
both	O
humans	O
and	O
animal	O
husbandry	O
as	O
it	O
can	O
save	O
lives	O
and	O
livestock	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
clinical	O
and	O
imaging	O
characteristics	O
of	O
computed	O
tomography	O
(	O
CT	O
)	O
in	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
caused	O
by	O
SARS	O
-	O
CoV	O
-	O
2	O
.	O

Females	O
(	O
adjusted	O
OR	O
(	O
aOR	B-FUNC
)	O
1	O
.	O
72	O
-	O
2	O
.	O
00	O
;	O
95	O
%	O
CI	O
1	O
.	O
14	O
to	O
2	O
.	O
86	O
)	O
and	O
lower	O
self	O
-	O
reported	O
household	O
economic	O
status	O
respondents	O
were	O
more	O
likely	O
to	O
perceive	O
the	O
affective	O
risk	O
.	O

Together	O
these	O
results	O
reveal	O
a	O
new	O
role	O
of	O
receptor	B-FUNC
binding	I-FUNC
in	O
MHV	O
entry	O
:	O
in	O
addition	O
to	O
its	O
well	O
-	O
characterized	O
role	O
in	O
viral	O
attachment	O
to	O
host	O
cells	O
,	O
receptor	B-FUNC
binding	I-FUNC
also	O
induces	O
the	O
conformational	O
change	O
of	O
the	O
spike	O
and	O
hence	O
the	O
fusion	O
of	O
viral	O
and	O
host	O
membranes	O
.	O

We	O
found	O
that	O
assay	O
performance	O
using	O
the	O
same	O
primers	O
and	O
probes	O
with	O
different	O
PCR	O
systems	O
varied	O
and	O
the	O
commercial	O
kit	B-FUNC
performed	O
well	O
.	O

In	O
this	O
study	O
,	O
we	O
screened	O
these	O
chemical	O
structures	O
from	O
traditional	O
Chinese	O
medicinal	O
compounds	O
proven	O
to	O
show	O
antiviral	O
activity	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
the	O
similar	O
chemical	O
structures	O
through	O
a	O
molecular	O
docking	O
study	O
to	O
target	O
RdRp	B-FUNC
of	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
SARS	O
-	O
CoV	O
,	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

Regarding	O
contact	O
modes	O
,	O
hydrophobic	O
interactions	O
contribute	O
significantly	O
in	O
binding	B-FUNC
and	O
additional	O
hydrogen	O
bonds	O
were	O
found	O
between	O
theaflavin	O
and	O
RdRp	B-FUNC
.	O

Our	O
results	O
suggest	O
that	O
theaflavin	O
could	O
be	O
a	O
potential	O
SARS	O
-	O
CoV	O
-	O
2	O
RdRp	B-FUNC
inhibitor	O
for	O
further	O
study	O
.	O

The	O
nucleic	O
acid	O
test	O
or	O
genetic	O
sequencing	O
serves	O
as	O
the	O
gold	O
standard	O
method	O
for	O
confirmation	O
of	O
infection	O
,	O
yet	O
several	O
recent	O
studies	O
have	O
reported	O
false	O
-	O
negative	O
results	O
of	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
rRT	O
-	O
PCR	O
).	O

The	O
case	O
fatality	O
rate	O
was	O
significantly	O
higher	O
in	O
Hubei	O
province	O
than	O
the	O
rest	B-FUNC
of	O
China	O
.	O

TITLE	O
:	O
Composition	O
of	O
human	O
-	O
specific	O
slow	O
codons	O
and	O
slow	O
di	O
-	O
codons	O
in	O
SARS	O
-	O
CoV	O
and	O
2019	O
-	O
nCoV	O
are	O
lower	O
than	O
other	O
coronaviruses	O
suggesting	O
a	O
faster	O
protein	O
synthesis	O
rate	O
of	O
SARS	O
-	O
CoV	O
and	O
2019	O
-	O
nCoV	O
.	O
ABSTRACT	O
:	O
Translation	O
of	O
a	O
genetic	O
codon	O
without	O
a	O
cognate	O
tRNA	B-FUNC
gene	O
is	O
affected	O
by	O
both	O
the	O
cognate	O
tRNA	B-FUNC
availability	O
and	O
the	O
interaction	O
with	O
non	O
-	O
cognate	O
isoacceptor	O
tRNAs	O
.	O

Among	O
the	O
structural	O
proteins	O
,	O
the	O
spike	O
protein	O
(	O
S	O
-	O
protein	O
),	O
the	O
envelope	O
protein	O
(	O
E	O
-	O
protein	O
),	O
and	O
the	O
nucleocapsid	O
protein	O
(	O
N	O
-	O
protein	O
)	O
can	O
be	O
constructed	O
based	O
on	O
the	O
crystal	O
structures	O
of	O
the	O
proteins	O
from	O
SARS	O
-	O
CoV	O
.	O
It	O
is	O
known	O
that	O
PL	O
-	O
Pro	O
,	O
3CL	O
-	O
Pro	O
,	O
and	O
RdRp	B-FUNC
are	O
important	O
targets	O
for	O
design	O
antiviral	O
drugs	O
against	O
2019	O
-	O
nCoV	O
.	O
And	O
S	O
protein	O
is	O
critical	O
target	O
candidate	O
for	O
inhibitor	O
screening	O
or	O
vaccine	O
design	O
against	O
2019	O
-	O
nCoV	O
because	O
coronavirus	O
replication	O
is	O
initiated	O
by	O
the	O
binding	B-FUNC
of	O
S	O
protein	O
to	O
cell	O
surface	O
receptors	O
.	O

The	O
optimal	O
threshold	O
and	O
area	O
under	O
the	O
ROC	O
curve	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
were	O
24	O
.	O
3	O
pg	O
/	O
mL	O
and	O
0	O
.	O
795	O
respectively	O
,	O
while	O
those	O
of	O
D	O
-	O
Dimer	O
were	O
0	O
.	O
28	O
µg	O
/	O
L	O
and	O
0	O
.	O
750	O
,	O
respectively	O
.	O

TITLE	O
:	O
PRESCIENT	O
:	O
platform	O
for	O
the	O
rapid	O
evaluation	O
of	O
antibody	B-FUNC
success	O
using	O
integrated	O
microfluidics	O
enabled	O
technology	O
.	O

SARS	O
-	O
CoV	O
-	O
2	O
RBD	O
exhibited	O
significantly	O
higher	O
binding	B-FUNC
affinity	O
to	O
ACE2	O
receptor	O
than	O
SARS	O
-	O
CoV	O
RBD	O
and	O
could	O
block	O
the	O
binding	B-FUNC
and	O
,	O
hence	O
,	O
attachment	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
RBD	O
and	O
SARS	O
-	O
CoV	O
RBD	O
to	O
ACE2	O
-	O
expressing	O
cells	O
,	O
thus	O
inhibiting	O
their	O
infection	O
to	O
host	O
cells	O
.	O

Two	O
critical	O
cases	O
(	O
8	O
%)	O
were	O
given	O
invasive	O
mechanical	O
ventilation	O
,	O
corticosteroids	O
,	O
and	O
immunoglobulin	B-FUNC
.	O

